## ACADEMIC CURRICULA

Professional Elective Courses

**BIOTECHNOLOGY** 

Regulations - 2018



## SRM INSTITUTE OF SCIENCE AND TECHNOLOGY

(Deemed to be University u/s 3 of UGC Act, 1956) Kattankulathur, Kancheepuram, Tamil Nadu, India

| Cou   |   | 18BTE301T Course Name  | DEVELOPMENTAL E                           | BIOLOGY                            |                           |                      | Course<br>Categor       | _ I                      |                      |                         |                               | Profe             | ssion             | al Elec                      | ctive              |                           |               |                        | L<br>3   | T<br>0 | P<br>0 | C<br>3 |
|---|---|--|---|------------------------------------|---------------------------|----------------------|-------------------------|--------------------------|----------------------|-------------------------|-------------------------------|-------------------|-------------------|------------------------------|--------------------|---------------------------|---------------|------------------------|----------|--------|--------|--------|
| F   | Pre-requis  | ite Courses Nil  | Co-r                                      | equisite Courses   Nil             |                           |                      | Progre                  | essive Co                | urses                | Nil                     |                               |                   |                   |                              |                    |                           |               |                        |          |        |        |        |
|   |   | Department Biotechnology                                     |   | Book / Codes/Standa                |                           | ٨                    |                         | 00110 00                 | arooo                | 1 111                   |                               |                   |                   |                              |                    |                           |               |                        |          |        | -      |        |
| Oddioc  | o norning   | Diotocimology  | Data                                      | Book / Codoo/Clarida               | Ido                       |                      |                         |                          |                      |                         |                               |                   |                   |                              |                    |                           |               |                        |          |        |        |        |
| Course  | e Learning  | g Rationale (CLR): The pur                                   | pose of learning this course is to:       | CUL                                | H                         | Learnii              | ng                      |                          |                      |                         |                               | Progra            | ım Le             | earning                      | Outo               | omes (                    | PLO)          |                        |          |        |        |        |
| CLR-2   | : Disc  | cuss fertilization, gametogenesis and sex det                | t <mark>ermination</mark>                 |                                    |                           | 25                   | =                       |                          |                      |                         |                               |                   |                   |                              |                    |                           |               |                        |          |        |        |        |
| CLR-3   | : Con   | npare developmental patterns among metaz                     | oan, drosophila and zebrafish             |                                    |                           | enc                  | ner                     | 7/                       | S                    |                         |                               | age               | a                 |                              |                    | Ε                         |               |                        | рu       |        |        |        |
| CLR-4   | : Ехр   | lain somites and their derivatives.                          | 41.                                       |                                    | l iğ                      | je<br>je             | aj.                     | 7.                       | lysi                 |                         | igi                           | Us                | Ē                 | જ .                          |                    | ea                        | o             | ox                     | i.E      |        |        |        |
| CLR-5   | : Des   | scribe metamorphosis and organogene <mark>sis</mark>         |   | Thorago Print                      | Thinking                  | Expected Proficiency | Expected Attainment (%) | e g                      | Problem Analysis     | Design &<br>Development | Analysis, Design,<br>Research | Modern Tool Usage | Society & Culture | Environment & Sustainability |                    | Individual & Team<br>Work | Communication | Project Mgt. & Finance | Learning |        |        |        |
| CLR-6   | : Ana   | alyze birth defects and endocrine disr <mark>uptors</mark>   |   | 1                                  | J (                       | ed                   | bed                     | Engineering<br>Knowledge | m/                   | & F                     | is,                           | L                 | ∞ >               | nab<br>lab                   |                    | nal                       | .in           | ě Ĕ                    |          | -      | 2      | -3     |
|   |   |  |   |                                    | Level of (Bloom)          | Sec _                | ) ec                    | gine                     | ple                  | sign                    | alys                          | der               | Siet              | /iro<br>stai                 | Ethics             | ≅₹                        | m L           | Project N<br>Finance   | C        | 0      | Ö      | 0      |
| Course  | e Learning  | g Outcomes (CLO):  At the e                                  | end of this course, learners will be able | to:                                | Le le                     | EX S                 | X X %                   | 교조                       | Prc                  | De                      | An                            | OM<br>Mo          | Soc               | Sus                          | Eth                | Ind<br>Wo                 |               |                        | Life     | PSO.   | - OSd  | PSO.   |
| CLO-1   |   | alyze the mechanisms of cell to <mark>cell comm</mark> un    |   | ALC: YELLOW                        | 1                         | 80                   | 80                      | L                        | Н                    | H                       | Н                             |                   | М                 | L                            | H                  | Н                         | Н             | Н                      | H        | L      | Н      | Η      |
| CLO-2   |   | scribe the fundamental organiz <mark>ation of rep</mark> roc |   | 51/56 11/0                         | 2                         | 85                   | 75                      | М                        | Н                    | Н                       | M                             |                   |                   | М                            | Н                  | L                         | Н             | Н                      | Н        | L      | Н      | Н      |
| CLO-3   |   | lain the concepts and experim <mark>ents in the</mark> ear   |   | mation                             | 2                         | 75                   | 80                      | М                        | Н                    | М                       | Н                             | М                 | М                 |                              | М                  | Н                         | Н             | Н                      | Н        | L      |        | Н      |
| CLO-4   |   | cognize the various pathways <mark>of organo</mark> gene     | esis                                      | 2077 W W W                         | 2                         | 85                   | 80                      | L                        | Н                    | Н                       | H                             |                   |                   | Н                            | L                  | L                         | Н             | Н                      | Н        | М      |        |        |
| CLO-5   |   | cuss about the various endoc <mark>rine recep</mark> tors    | 7.00                                      |                                    | 3                         | 85                   | 75                      | L                        | Н                    | Н                       | М                             |                   | М                 | Н                            | Н                  | Н                         | L             | Н                      | Н        | Н      |        | Η      |
| CLO-6   | : <i>Ехр</i>  | lain the concepts of develop <mark>ment in he</mark> alth a  | nd diseases                               |                                    | 2                         | 80                   | 80                      | M                        | Н                    | Н                       | H                             | L                 | Н                 | М                            | М                  | Н                         | Н             | Н                      | Н        | Н      | Н      | Н      |
|   |   |  | 90.00                                     |                                    |                           |                      | ES ST                   |                          |                      |                         |                               |                   |                   |                              |                    |                           |               |                        |          |        |        |        |
| Durati  | on (hour)   | 9  | 9   |                                    | 9                         |                      |                         |                          |                      |                         | 9                             |                   |                   |                              | 1                  |                           |               | 9                      |          |        |        |        |
| S-1   | SLO-1   | Mechanisms of Developmen <mark>tal Organization</mark>       | Sex determination                         | Early Development Gastrulation and | Axis form                 | nation               |                         | Building                 |                      | mesode                  | erm                           |                   |                   |                              |                    | /elopme                   |               |                        |          |        |        |        |
|   | SLO-2   | The cycle of life  | Chromosomal sex determination             | Developmental Pa<br>Metazoa        | - 4                       |                      |                         | Endode                   | rm                   | y.                      | *                             |                   |                   |                              | Ge                 | netic er                  | rors o        | f huma                 | n dev    | elopn  | nent   |        |
| S-2   | SLO-1   | Epigenesis and cleavage                                      | Mammalian Pattern of sex determination    | Early developmer elegans           | nt in the                 | Nemato               | de C.                   | Organo                   | genes                | is                      |                               |                   |                   |                              | Birt               | h defec                   | ts            |                        |          |        |        |        |
|   | SLO-2   | Evolutionary embryology                                      | Genetic mechanisms                        | Early Drosophila                   | Develop                   | ment                 |                         | Paraxia                  | meso                 | oderm                   |                               |                   |                   |                              | End                | docrine                   | disrur        | otors                  |          |        |        |        |
|   |   | Cell Specification:  | Wnt family and signaling                  | Early Zebrafish D                  |                           |                      |                         | The son                  |                      |                         | r deriva                      | tives             |                   |                              |                    | A and re                  |               |                        | health   |        |        |        |
| S-3   | SLO-2   |  | Hormonal regulation of sexual phenotype   | Early Developmen                   |                           |                      |                         | Intermed                 |                      |                         |                               |                   | derm              | 7                            | Cai                | ncer                      | ,             |                        |          |        |        |        |
| S-4   | SLO-1   | Autonomous and conditional specification                     | Environmental sex determination           | Building with Ecto                 |                           |                      | ebrate                  | Heart, E                 | llood,               | and Kid                 | Ineys                         |                   |                   |                              | Det                | fects in                  | parac         | rine pa                | athway   | 'S     |        |        |
|   | SLO-2   | Cell identities  | Gametogenesis                             | Neural tube forma                  |                           |                      | ning                    | Develop                  | ment                 | of the t                | etr <mark>ap</mark> od        | limb              |                   |                              | Cai                | ncer an                   | d sten        | n cell h               | vpoth    | esis   |        |        |
| 0.5   |   | Differential Gene Expression                                 | Spermatogenesis                           | Brain growth                       |                           | 1                    |                         | The end                  |                      |                         |                               |                   |                   |                              |                    | /elopme                   |               |                        |          |        | t      |        |
| S-5   |   | Mechanisms of Cell Differentiation                           | OOgenesis                                 | Neural crest cells                 |                           |                      |                         | The tub                  | es and               | d organ                 | s for dig                     | estion            |                   |                              | Die                | t-induce                  | ed pol        | ypheni                 | isms     |        |        | -      |
| S-6   | SLO-1   | Differential RNA processing                                  | Fertilization                             | Axonal specificity                 |                           |                      |                         | Organs                   |                      |                         |                               |                   |                   |                              |                    | velopme                   |               |                        |          |        |        |        |
| ა-ხ   | SLO-2   | Cell-to-Cell communication                                   | Structure of gametes                      | Ectodermal Placo                   |                           |                      |                         | Postemi                  |                      |                         |                               |                   |                   |                              | Bio                | tic regu                  | lation        |                        |          |        |        | -      |
| 0.7   | S-7 SLO-1 Juxtacrine signaling Translocation and capacitation Epidermis |  |   |                                    |                           |                      |                         |                          | <u>Metamorphosis</u> |                         |                               |                   |                   |                              | Abiotic regulation |                           |               |                        |          |        |        |        |
| SLO-2 Mechanisms of Morphogenesis Thermotaxis and chemotaxis Cell Signalin      |   |  |   | Cell Signaling                     | The hormonal reactivation |                      |                         |                          | ation ar             | nd dev                  | elopn                         | nent              | Syr               | nbiotic                      | regula             | tion of development       |               |                        |          |        |        |        |
| S SLO-1 Cadherins and cell adhesions Fusion of genetic material Fibroblast grow |   |  |   |                                    | factors                   |                      |                         | Regene                   |                      |                         |                               |                   |                   |                              |                    | /elopme                   |               |                        |          |        |        |        |
| 3-0   | SLO-2   | Stem cells: Their potential and their niches                 | Activation of mammalian egg               | RTK pathway                        |                           |                      |                         | Aging a                  | nd sei               | nescen                  | ce                            |                   |                   |                              | De                 | /elopme                   | ental r       | nechai                 | nisms    |        |        |        |

| Durati | on (hour) | 9                     | 9                      | 9                     | 9   | 9                                  |
|--------|-----------|-----------------------|------------------------|-----------------------|---|------------------------------------|
| S-9    | SLO-1     | Human model systems   | Flowering              | 0 0 ,                 | Differentiation of dermal, ground, and vascular tissues in plants | Evolutionary changes               |
|        | SLO-2     | Development in Plants | Reproduction in Plants | The TGF-β superfamily | Techniques in embryology  | Mechanisms of evolutionary changes |

| Learning  | 1. Scott F. Gilbert, Michael J. F. Barresi. Developmental Biology, Sinauer Associates-Oxford University Press; 11 edition, 2016 |
|-----------|---|
| Resources | 2. JMW Slack Essentials of Developmental Biology 3rd Edition Wiley-Blackwell;.2012  |

| Learning | Assessment        |        |          |        |  |                      | 4/1/     |         |          |                   |                    |
|----------|-------------------|--------|----------|--------|--|----------------------|----------|---------|----------|-------------------|--------------------|
|          | Bloom's           |        |          | Conti  | nuous Learning Asse  | essment (50% weighta | ige)     |         |          | Final Evamination | a (E00/ woightaga) |
|          | Level of Thinking | CLA -  | 1 (10%)  | CLA -  | 2 (15%)  | CLA – 3 (            | (15%)    | CLA – 4 | (10%)#   |                   | n (50% weightage)  |
|          | Level of Thinking | Theory | Practice | Theory | Practice   | Theory               | Practice | Theory  | Practice | Theory            | Practice           |
| Level 1  | Remember          | 40 %   |          | 30%    |  | 30%                  |          | 30%     |          | 30%               |                    |
| Level    | Understand        | 40 %   |          | 30%    |  | 30%                  |          | 30%     |          | 30%               | -                  |
| Level 2  | Apply             | 40 %   |          | 40%    | STATE OF THE STATE | 40%                  |          | 40%     |          | 40%               |                    |
| Level 2  | Analyze           | 40 %   |          | 40%    |  | 40 %                 |          | 4076    |          | 4070              | -                  |
| Level 3  | Evaluate          | 20 %   |          | 30%    | <b>国内科学</b>  | 30%                  |          | 30%     |          | 30%               |                    |
| Level 3  | Create            | 20 %   |          | 30%    |  | 30%                  |          | 30%     |          | 30%               | -                  |
|          | Total             | 10     | 0 %      | 100    | O %  | 100 9                | %        | 100     | 0 %      | 10                | 0 %                |

| Course Designers   |   | 30   |
|--|---|--|
| Experts from Industry  | Experts from Higher Technical Institutions              | Internal Experts                             |
| 1. Dr. G. N. Ramchand, Saksin Life sciences Pvt Ltd, Chennai, ramchand@saksinlife.com  | 1. Prof. K Subramaniam, IITM, Chennai, subbu@iitm.ac.in | 1. Dr <mark>. S.Thyag</mark> aRajan, SRMIST  |
| 2. Dr. Karthik Periyasamy, Scientist I, Auroz <mark>ymes Uni</mark> t, Aurobindo Pharma Limited, Hyderabad, karthikmpk@gmail.com | 2. Prof. R. B. Narayanan, SVCE, Chennai, rbn@svce.ac.in | 2. D <mark>r.R.Vasan</mark> tharekha, SRMIST |

| Cou<br>Co |            | 18BTE302T            | Course Name                              | CELLULAR AND MOLECULAR NEUF                                 | ROSCIENCE                               |                |                          | Cour<br>Categ           |                          | Е                |                         |                               | Pro               | fessi             | onal El                      | ective | )                         |               |                        | L<br>3   | T<br>0 | P 0     | C<br>3 |
|-----------|------------|----------------------|--|---|---|----------------|--------------------------|-------------------------|--------------------------|------------------|-------------------------|-------------------------------|-------------------|-------------------|------------------------------|--------|---------------------------|---------------|------------------------|----------|--------|---------|--------|
|           | re-requis  | site Courses         | Nil                                      | Co-requisite  | Courses                                 | Nil            |                          | Progres                 | ssive Co                 | urses            | Nil                     |                               |                   |                   |                              |        |                           |               |                        |          |        |         |        |
|           |            | Department           | Biotechnology                            | Data Book   |   |                |                          | Nil                     | 30110 00                 | uioco            | 7 477                   |                               |                   |                   |                              |        |                           |               |                        |          |        |         | -      |
| Oddio     | onomig     | рораганона           | Biotodilliology                          | Data Book   | O G G G G G G G G G G G G G G G G G G G | naarao         | ,                        | 1111                    |                          |                  |                         |                               |                   |                   |                              |        |                           |               |                        |          |        |         |        |
| Course    | Learning   | g Rationale (CLF     | R): The                                  | e purpose <mark>of learning this co</mark> urse is to:      |   | 1311           | Learnin                  | q                       |                          |                  |                         |                               | Progi             | am L              | earning                      | a Out  | comes (                   | (PLO)         |                        |          |        |         |        |
| CLR-1     |            |                      | unction from its organizati              |   |   | 1              | 2                        | 3                       | 1                        | 2                | 3                       | 4                             | 5                 | 6                 | 7                            | 8      | 9                         | 10            | 11                     | 12       | 13     | 14      | 15     |
| CLR-2     |            |                      | ar signaling in neurons                  |   |   |                | >                        | =                       |                          |                  |                         |                               |                   |                   |                              |        |                           |               |                        |          |        |         |        |
| CLR-3     | : C        | ompare Neural I      | basis of senses                          |   |   |                | Expected Proficiency (%) | Expected Attainment (%) | 17                       | S                |                         |                               | Modern Tool Usage | a)                |                              |        | E                         |               |                        | g        |        |         |        |
| CLR-4     | : E        | xplain different r   | methods for studying neur                | o <mark>-immune</mark> functions                            |   | ki j           | je<br>je                 | aj.                     |                          | lysi             |                         | igu                           | Us                | ŢŢ.               | ∞ŏ .                         |        | -ea                       | e<br>U        | ٥X                     | Ē        |        |         |        |
| CLR-5     |            | escribethe cortic    | cal structures pertaining to             | emotions and feelings                                       | 200                                     | Thinking       | P                        | Att                     | e g                      | √na              | ent                     | Des                           | 00                | C                 | iity                         |        | ~                         | cati          | gt. 8                  | Learning |        |         |        |
| CLR-6     | : A        | nalyze genetic v     | ariation and inheritance p               | ertaining to nervous system disorders                       | F 19.5                                  | J (c           | ted                      | ted                     | Engineering<br>Knowledge | Problem Analysis | Design &<br>Development | Analysis, Design,<br>Research | L                 | Society & Culture | Environment & Sustainability |        | Individual & Team<br>Work | Communication | Project Mgt. & Finance |          | _      | 7       | ٦3     |
|           |            |                      |  |   |   | evel of Bloom) | oec -                    | Sec _                   | gine                     | plde             | sign                    | alys                          | der               | Siet              | <mark>/iro</mark><br>stai    | Ethics | ≅₹                        | l E           | Project IV<br>Finance  | 2        | 0      | PS0 - 2 | 0      |
| Course    |            | g Outcomes (CL       |  | the end of this course, learners will be able to:           | Sec. 7.                                 | Le<br>Bi       | % EX                     | % E                     | ᇍᅐ                       | Prc              | De                      | An                            | Mo                | Soc               | Sus                          | Eŧ     | Individ<br>Work           | Ö             | Prc<br>Fin             | Life     | PSO    | PS      | PSO.   |
| CLO-1     |            |                      | of genes in brain <mark>developn</mark>  |   | 200                                     | 1              | 80                       | 80                      | L                        | Н                | H                       | H                             |                   | M                 | L                            | Н      | Н                         | Н             | Н                      | Н        | L      | Н       | Н      |
| CLO-2     |            |                      | lamental organi <mark>zation of b</mark> |   | 1000                                    | 2              | 85                       | 75                      | M                        | Н                | Н                       | М                             |                   |                   | М                            | Н      | L                         | Н             | Н                      | Н        | L      |         | Н      |
| CLO-3     |            |                      |  | he ion channels and NEUROTRANSMITTERS                       |   | 2              | 75                       | 80                      | M                        | Н                | М                       | Н                             | М                 | М                 |                              | М      | Н                         | Н             | Н                      | Н        | L      |         | Н      |
| CLO-4     |            |                      | arious pathway <mark>s of sens</mark> or |   | 11.75                                   | 2              | 85                       | 80                      | L                        | Н                | Н                       | Н                             |                   |                   | Н                            | L      | L                         | Н             | Н                      | Н        | М      | Н       | Н      |
| CLO-5     |            |                      |  | endocrine and immune interactions                           | 100                                     | 3              | 85                       | 75                      | L                        | Н                | Н                       | M                             |                   | М                 | Н                            | Н      | Н                         | L             | Н                      | Н        | Н      |         | Н      |
| CLO-6     | : <i>E</i> | xplain the conce     | pts of nervou <mark>s system d</mark> is | sorder and the diseases associated with it                  |   | 2              | 80                       | 80                      | M                        | Н                | Н                       | Н                             | L                 | Н                 | М                            | М      | Н                         | Н             | Н                      | Н        | Н      | Н       | Н      |
| - ·       | 41 \       | 1                    |  |   | Sec. 15.                                | 4-1            |                          | -E-11                   |                          |                  |                         | 1                             |                   |                   |                              |        | 1                         |               |                        | •        |        |         |        |
| Durati    | on (hour)  |                      | 9  | 9   |   |                | 9                        |                         |                          |                  |                         |                               | 9                 |                   |                              |        | D'                        |               |                        | 9        |        |         |        |
| S-1       | SLO-1      | Genetics of ne       | rvous system                             | Electrical signals  | Somatic se                              | ensory sy      | stem-Pa                  | ain                     |                          | Cognit           | ion-Spe                 | ech and                       | l Lang            | ıuage             | 9                            |        | system                    |               | d injuri               | es ot ti | ne ne  | vous    |        |
| 3-1       | SLO-2      | brain                | omics in the a <mark>ssembly o</mark> f  | Long-distance transmission of Electrical signals            | Touch and                               |                |                          | 307.3                   |                          |                  |                         | ortical st                    |                   | es                |                              |        | Alzheii                   | mer's         | disease                | 9        |        |         |        |
|           | SLO-1      | Model organisi       | ms in neurosci <mark>ence</mark>         | The ionic basis of resting membrane potential               | Pain and it                             | s pathwa       | ys                       |                         |                          |                  |                         | kefulnes                      |                   |                   |                              |        |                           |               | disease                |          |        |         |        |
| S-2       | SLO-2      | Development o        | of the nervous sy <mark>stem</mark>      | Voltage-dependent membrane permeability                     | Visual and                              | Vestibul       | ar pathv                 | ays                     |                          |                  | rcadian<br>ılness       | cycle of                      | sleep             | and               |                              |        | gravis                    |               | ılar Dis               |          | •      |         |        |
| S-3       | SLO-1      | Molecular basi       | is of neural induction                   | lon channels and transporters                               | Retinal circ                            | cuitry         |                          |                         | I                        | Emotic           | ns-Mer                  | nory                          |                   |                   |                              |        | Basal (                   |               | ia disor               | ders: F  | Parkin | son's   |        |
| 3-3       | SLO-2      | Initial differenti   | iation of neurons and <mark>glia</mark>  | Diversity of ion channels                                   | Phototrans                              | duction        |                          |                         | ı                        | Early t          | heories                 | of emot                       | ional             | brain             |                              |        | Pharm<br>diseas           |               | gical ta               | rgets o  | of Par | kinson  | ıs     |
| S-4       | SLO-1      | Cellular Composystem | onents of the Nervous                    | Synaptic transmission-Neurotransmitters and their receptors | Motor neur                              |                | ts-Moto                  | neuron o                | control                  | Kluver           | -Bucy s                 | yndr <mark>ome</mark>         | 9                 |                   |                              |        | Spinal                    | Cord          | Injury                 |          |        |         |        |
|           | SLO-2      | Neurons and G        | Glia                                     | Chemical and electrical synapses                            | Motor units                             |                |                          | -10                     |                          | Brain r          | eward o                 | circuitry                     |                   |                   |                              |        | Traum                     | atic B        | rain Inju              | ıry (TE  | 31)    |         |        |
| S-5       | SLO-1      | Organization o       | f nerves                                 | Molecular signaling in neurons                              | The Cortice                             | ospinal a      | nd Cort                  | cobulbar                | Tracts I                 | Learnii          | ng                      |                               |                   |                   |                              |        |                           |               | matic ei               |          |        | thy     |        |
| 3-3       | SLO-2      | Pre synaptic te      | erminals                                 | Activation of signaling pathways                            | Upper mot                               | or neuroi      | าร                       |                         |                          |                  |                         | o <mark>lidatio</mark> n      |                   |                   |                              |        | Stroke                    |               |                        |          |        |         |        |
|           | SLO-1      | Neural Circuits      | 3  | Second messengers   | Disorders of                            |                |                          |                         |                          | Cognit           | ion-Spe                 | ech and                       | Lang              | ıuage             | )                            |        | Blood                     | Suppi         | y to Bra               | ain      |        |         |        |
| S-6       | SLO-2      | Myotactic refle      | x  | Nuclear signaling   | Molecular i<br>synapse fo               |                | sms invo                 | olved in                |                          | Sex ar           | nd Sexu                 | ality                         |                   |                   |                              |        | Transi                    | ent Is        | chemic                 | Attack   | (      |         |        |
|           | SLO-1      | Organization o       | f the Nervous system                     | Synaptic plasticity   | Molecular I                             |                | rophic ii                | nteraction              | s I                      | Neuroa           | anatomi                 | ical basis                    | s for k           | rain              | function                     | าร.    | Acute .                   | stroke        | treatm                 | ent      |        |         |        |
| S-7       |            | Divisons of ne       | •  | Short and long-term synaptic plasticity                     | Construction circuits                   | on and m       | odificati                | on of neu               | ral                      | Hypoth           | nalamus                 | and en                        | docrir            | ne sys            | stem                         |        | Prever                    | ntion (       | of stroke              | 9        |        |         |        |

| Durati | on (hour) | 9  | 9                                | 9                                   | 9   | 9                         |
|--------|-----------|--|----------------------------------|-------------------------------------|---|---------------------------|
| S-8    | SLO-1     | Central nervous system                                   |                                  | system                              | regulation  | Dementia                  |
| 3-0    | SLO-2     | Peripheral nervous system                                | Properties of neurotransmitters  | Hypoxia/Ischemia in mammalian brain | Interactions between neuroendocrine system and immune system    | Mild cognitive impairment |
| S-9    |           | Structural and Functional analysis of the Nervous system | Receptors of neurotransmitters   | Axon Growth after Brain Injury      | Neural-Immune interactions in the periphery                     | Alzheimer's dementia      |
| 3-9    | SLO-2     | Cellular diversity of nervous system                     | Unconventional neurotransmitters | 10-0at prain dissection             | Nervous <mark>-immune syste</mark> m role in health and disease | Prevention and treatment  |

| Learning  | 1. | Dale Purves, George J. Augustine, David Fitzpatrick, William C. Hall, Anthony-Samuel LaMantia, Leonard E. White, "Neuroscience," Sinauer Associates, Inc., 6th Edition, 2017. |
|-----------|----|---|
| Resources | 2. | Eric R. Kandel, James H. <mark>Schwartz,</mark> Thomas M. Jessell, "Principles of Neural Science," McGraw-Hill, 5th Edition, 2012.  |
|           |    |   |

| Learning A | Assessment             |                      |          |         |                    |                    |          |         |          |                                   |                    |  |  |
|------------|------------------------|----------------------|----------|---------|--------------------|--------------------|----------|---------|----------|-----------------------------------|--------------------|--|--|
|            | Bloom's                |                      |          | Conti   | nuous Learning Ass | essment (50% weigl | ntage)   |         |          | Final Evamination                 | n (FOO/ woightogo) |  |  |
|            |                        | CLA –                | 1 (10%)  | CLA – : | 2 (15%)            | CLA -              | 3 (15%)  | CLA – 4 | (10%)#   | Final Examination (50% weightage) |                    |  |  |
|            | Level of Thinking      | Theory               | Practice | Theory  | Practice           | Theory             | Practice | Theory  | Practice | Theory                            | Practice           |  |  |
| Level 1    | Remember<br>Understand | - 40 <mark>%</mark>  | 1500     | 30%     |                    | 30%                | An alle  | 30%     |          | 30%                               | -                  |  |  |
| Level 2    | Apply<br>Analyze       | - 4 <mark>0 %</mark> | 101      | 40%     |                    | 40%                | 1        | 40%     |          | 40%                               | -                  |  |  |
| Level 3    | Evaluate<br>Create     | 2 <mark>0 %</mark>   | 7        | 30%     | 3 755 5            | 30%                | Ver G    | 30%     |          | 30%                               | -                  |  |  |
|            | Total                  | 10                   | 0 %      | 100     | ) %                | 10                 | 0 %      | 100     | %        | 10                                | 00 %               |  |  |

<sup>#</sup> CLA – 4 can be from any combination of these: Assignments, Seminars, Tech Talks, Mini-Projects, Case-Studies, Self-Study, MOOCs, Certifications, Conf. Paper etc.,

| Course Designers   | and the second s |                               |
|--|--|-------------------------------|
| Experts from Industry  | Experts from Higher Technical Institutions   | Internal Experts              |
| 1. Dr. G. N. Ramchand, Saksin Life sci <mark>ences Pvt</mark> Ltd, Chennai, ramchand@saksinlife.com                                    | 1. Prof. K Subramaniam, IITM, Chennai, subbu@iitm.ac.in  | 1. Dr. S.ThyagaRajan, SRMIST  |
| <ol> <li>Dr. Karthik Periyasamy, Scientist I, Aurozymes Unit, Aurobindo Pharma Limited,<br/>Hyderabad, karthikmpk@gmail.com</li> </ol> | 2. Prof. R. B. Narayanan, SVCE, Chennai, rbn@svce.ac.in  | 2. Dr.R.Vasantharekha, SRMIST |

| Course             | 1 18           | BTE303T                       | Course Name   | METABOLIC I   | DISORDERS  |   |  | urse<br>egory           | Е                        |                       |                         | Prof                          | ession                                 | al Elec       | tive     |                           |               | L                         | . T                | P<br>0 | C 3        |
|--------------------|----------------|-------------------------------|---|---|--|---|--|-------------------------|--------------------------|-----------------------|-------------------------|-------------------------------|--|---------------|----------|---------------------------|---------------|---------------------------|--------------------|--------|------------|
| Oodo               |                |                               |   |   |  |   | Odio                                   | gory                    |                          |                       |                         |                               |  |               |          |                           |               | 0                         | 0                  | 1 0    |            |
| Pre                | e-requisite (  | Courses                       | 18BTC101J   | Co-requisi  | te Courses Nil   |   | Pr                                     | ogressi                 | ve Cours                 | es                    | Nil                     |                               |  |               |          |                           |               |                           |                    |        |            |
| Course C           | Offering Dep   | partment                      | Biotechnology                                       |   | Data Book / Codes/Standards  |   | Nil                                    |                         |                          |                       |                         |                               |  |               |          |                           |               |                           |                    |        |            |
|                    |                |                               | T   |   |  |   |  |                         |                          |                       |                         |                               |  |               |          |                           |               |                           |                    |        |            |
|                    |                | tionale (CLR):                |   | pose of learning this course is to:                             |  |   | Learnin                                | Ψ                       |                          |                       |                         |                               |  | Learnir       |          |                           |               | 4.4                       | 40                 |        |            |
| CLR-1:             |                |                               | principles of metabolic                             |   |  | 1   | 2                                      | 3                       | 1                        | 2                     | 3                       | 4                             | 5 6                                    | 7             | 8        | 9                         | 10            | 11                        | 12                 | 13 1   | 4 15       |
| CLR-2 :<br>CLR-3 : |                |                               | tance of genetics in med<br>If enzymes in various m | dici <mark>ne and in met</mark> abolic diseases.                |  |   | Expected Proficiency (%)               | ent                     | 1                        |                       |                         |                               | e<br>Se                                |               |          |                           |               |                           |                    |        |            |
| CLR-3:             |                |                               | diseases in our society                             |   |  | Thinking                                      | ciel                                   | Expected Attainment (%) | 10                       | Sis                   |                         | Analysis, Design,<br>Research | Modern Tool Usage<br>Society & Culture |               |          | Individual & Team<br>Work | _             |                           | Life Long Learning |        |            |
| CLR-5:             |                |                               | reatment strategies o <mark>f m</mark>              |   |  | - <u>                                    </u> | Ju                                     | \tta                    | D                        | Jal)                  | in t                    | esi                           | <u> </u>                               | ± ± 8         | <u>.</u> | ¥.                        | atio          | t. &                      | ear                |        |            |
| CLR-6:             |                |                               | principles of metabolic                             |   | B. SHOTH CO.   | IJĘ ́   | \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\ | pe /                    | erin                     | n A                   | S S                     | S, D                          |  | a like        | 5        | a<br>S                    | nic           | Mg                        | J DL               | _   _  | ر<br>س     |
| 02.10.             | 200111 01      | 00011110 100010               | printerprese or metabolic                           | - Squareri  |  | Level of (Bloom)                              | ecte                                   | ecte                    | Engineering<br>Knowledge | Problem Analysis      | Design &<br>Development | lysi<br>ear                   | Society & (                            | Environment & | S        | غ<br>غ                    | Communication | Project Mgt. &<br>Finance | ١                  | -1     |            |
| Course L           | earning Ou     | itcomes (CLO                  | ): At the e   | <mark>nd</mark> of this course, learners will be al             | ble to:  | B e   | X 8                                    | X ⊗                     |                          | Prol                  | Des                     | Ana<br>Res                    | Soc                                    | ELS (         | Ethics   | ndi<br>Nor                | Sol           | Proj<br>Fine              | <u>i</u>           | 087    | PSO -      |
| CLO-1:             |                |                               | olic principles                                     |   | THE REAL PROPERTY OF   | 2   | 80                                     | 70                      | L                        | M                     | L                       |                               | H H                                    |               |          | H                         | Н             | Н                         |                    |        | 1 L        |
| CLO-2:             | able to s      | solve the meta                | bolic problem <mark>s of spec</mark> ii             | fic nutrients   | The state of the s | 2   | 85                                     | 75                      | L                        | М                     | Н                       | Н                             | Н Н                                    | М             |          | Н                         | Н             | Н                         | Н                  | L N    | <i>1</i> Н |
| CLO-3:             |                |                               | ge in metabo <mark>lic control</mark>               |   |  | 2   | 75                                     | 80                      | L                        | Н                     | М                       |                               | H H                                    |               |          | Н                         | Н             | Н                         |                    |        | H M        |
| CLO-4:             |                |                               |   | and in metabolic diseases.                                      | - 177 mm   | 2   | 85                                     | 80                      | L                        | Н                     | L                       |                               | H H                                    |               |          | Н                         | Н             | Н                         | Н                  |        | 1 L        |
| CLO-5:             |                |                               |   | our society and the reason for it.                              |  | 3   | 85                                     | 80                      | L                        | М                     | L                       |                               | H H                                    |               | М        | Н                         | Н             | Н                         |                    |        | 1 L        |
| CLO-6:             | Underst        | and the variou                | is treatmen <mark>t strategie</mark> s d            | of metabolic disorders  |  | 2   | 80                                     | 75                      | L                        | Н                     | Н                       | Н                             | H H                                    | M             |          | Н                         | Н             | Н                         | Н                  | L   F  | Н          |
| Duratio            | on (hour)      |                               | 15  | 15  | 15   | -   |  | -                       | 1                        |                       | -                       | 15                            |  |               |          |                           |               | 15                        |                    |        |            |
| S-1                | SLO-1<br>SLO-2 | Introduction                  | to metaboli <mark>c disorde</mark> rs               | Carbohydrate metabolic pathways and its associated deficiencies |  |   | ans Am                                 | inoacid                 | Inborn e                 | rror of               |                         |                               | n                                      |               | Disc     | orders o                  | of Fat        |                           | vitam              | ins    |            |
| S-2                | SLO-1          | Principles of<br>Garrod's hyp | metabolic r <mark>egulation</mark> -<br>othesis     | Glycolysis  | Metabolism of branched chain<br>Phenylketonuria, tyrosinemia,<br>syrup urine disease, Alkaptonu  | aminoac<br>nomocys                            | tinuria, ı                             | maple                   | Hyperlip                 | idemia                | a                       | 7                             |  |               | Disc     | orders o                  | of wate       | er solul                  | ole vita           | mins   |            |
|                    | SLO-1          | Regulation o                  | f enzyme activity                                   | V   |  |   |  |                         |                          |                       |                         |                               |  |               |          |                           |               |                           |                    |        |            |
| S-3                | SLO-2          |                               | difications and                                     | Glycogenesis  | Amino acid transport disorders<br>Dicarboxylic aminoaciduria, Ha   |   |  |                         | Hyperch<br>disorder      |                       | rolemia                 | and its                       | associ                                 | ated          | Disc     | orders o                  | of coei       | nzymes                    | 8                  |        |            |
| S<br>4-5           | SLO-1<br>SLO-2 | phosphorylat                  | ion, dephosphor <mark>ylation,</mark>               | Glycogenolysis, Gluconeogenesis                                 | Inborn error of purine metaboli  | sm  |  | - 10                    | Hypolipo                 | protei                | inemia                  |                               |  |               | Disc     | orders o                  | of cofa       | ctors                     |                    |        |            |
| S-6                | SLO-1<br>SLO-2 | adenylation a                 | and disulphide                                      | Congenital disorders of Glycosylation                           | adenylosuccinatelyase deficier<br>monophosphate deaminase de   |   | nosine                                 |                         | Tangier                  | diseas                | se                      |                               |  |               | Biot     | inidase                   | defici        | ency                      |                    |        |            |
| S-7                | SLO-1<br>SLO-2 |                               | inherited metabolic                                 | Galactosaemia Fructosaemia                                      | Nucleotide salvage - Lesch-Ny  |   | drome                                  | H                       | Lipodyst                 | rophy                 |                         |                               |  |               | Hole     | ocarbox                   | ylase         | synthe                    | tase d             | eficie | псу        |
|                    | SLO-1          | aiscase proc                  | 00000   |   | adenine phosphoribosyltransfe  | rase def                                      | iciency -                              |                         | Lipid sto                | rage o                | disorde                 | s: Sphin                      | aolinia                                | loses:        |          |                           |               |                           |                    |        |            |
| S-8                | SLO-2          | Accumulation                  | n of substrate                                      | Lactose intolerance   | Adenosine deaminase deficier<br>Pyrimidine metabolism  |   |  |                         | ganglios<br>sphingos     | id <mark>e-</mark> gi | <mark>lobosi</mark> d   | <mark>e- sphing</mark>        |  |               |          | tothena<br>rodege         |               |                           | sociat             | ∍d     |            |
| S<br>9-10          | SLO-1<br>SLO-2 | Accumulation                  | n of minor metabolites                              | Glycogen storage diseases                                       | Inborn error of pyrimidine meta  | bolism:                                       | Oroticad                               | ciduria                 | Fatty-ac                 |                       |                         |                               | rs, bio                                | tinidase      | Met      | hylmalo                   | onic ad       | cademi                    | а                  |        |            |
| S-11               | SLO-1<br>SLO-2 | Deficiency of<br>metabolic ph | product, Secondary enomena                          | Insulin, glucose homeostasis and diabetes mellitus              | Miller syndrome, Dihydropyrim deficiency   | idi <mark>ne del</mark>                       | nydroger                               | nase                    | Sjögren-                 | -Larss                | son syn                 | drome                         |  |               | Fan      | nilial isc                | lated         | vitamir                   | E def              | icienc | у          |
| S-12               | SLO-1          | Introduction                  | to metabolic disorders                              |   |  |   |  |                         | Inborn e                 | rror of               | f lipid m               | etabolisi                     | n                                      |               | Disc     | orders o                  | of Fat        | soluble                   | vitam              | ins    |            |

| Duratio | on (hour) | 15                                  | 15                              | 15  | 15                                      | 15                                  |
|---------|-----------|-------------------------------------|---------------------------------|---|---|-------------------------------------|
|         | SLO-2     |                                     | Carbohydrate metabolic pathways | Nitrogen metabolism and its target organs Aminoacid |   |                                     |
|         | 3LU-2     |                                     | and its associated deficiencies | synthesis transport and storage                     |   |                                     |
|         | SLO-1     | Principles of metabolic regulation- |                                 | Metabolism of branched chain aminoacids             |   |                                     |
| S-13    |           | Garrod's hypothesis                 | Glycolysis                      | Phenylketonuria, tyrosinemia, homocystinuria, maple | <u>Hyperlipidemia</u>                   | Disorders of water soluble vitamins |
|         | 3LU-2     | Garrou's hypothesis                 |                                 | syrup urine disease, Alkaptonuria, Albinism         |   |                                     |
| ٠ ـ     | SLO-1     | Regulation of enzyme activity       |                                 | Amino acid transport disorders: Cystinuria,         | Hypercholesterolemia and its associated |                                     |
| 14-15   | SLO-2     | Covalent modifications and          |                                 |   | disorders                               | Disorders of coenzymes              |
| 14-13   | JLU-Z     | reversible modifications            |                                 | Dicarboxylic aminoaciduma, Hartiidp disease         | uisoruers                               |                                     |

Learning Resources

Robert K. Murray, Darryl K. Granner, Peter A. Mayes, Harper's Illustrated Biochemistry 30th Edition, 2003
 Enid Gilbert-Barness, Lewis A. Barness, Philip M. Farrell." Metabolic Diseases: Foundations of Clinical Management, Genetics, and Pathology", IOS Press BV, Netherlands, Second Edition, 2017

| Learning A | Assessment                   |               |          |               |                       | 1000             |           | -       |          |                                   |                  |  |
|------------|------------------------------|---------------|----------|---------------|-----------------------|------------------|-----------|---------|----------|-----------------------------------|------------------|--|
|            | Dloom's                      |               |          | Conti         | nuous Learning Asse   | ssment (50% weig | htage)    |         |          | Final Evamination                 | (E00/ woightogo) |  |
|            | Bloom's<br>Level of Thinking | CLA – 1 (10%) |          | CLA – 2 (15%) |                       | CLA -            | 3 (15%)   | CLA – 4 | (10%)#   | Final Examination (50% weightage) |                  |  |
|            | Level of Thinking            | Theory        | Practice | Theory        | Practice              | Theory           | Practice  | Theory  | Practice | Theory                            | Practice         |  |
| Laval 1    | Remember                     | 40 %          |          | 30%           |                       | 30%              |           | 200/    |          | 30%                               |                  |  |
| Level 1    | Understand                   | 40 %          |          | 30%           | Carried Wall          | 30%              |           | 30%     |          | 30%                               | -                |  |
| Level 2    | Apply                        | 40 %          | 1        | 40%           | 7 1 1 1 1 1 1 1 1 1 1 | 40%              | A 100 CO  | 40%     |          | 40%                               |                  |  |
| Level 2    | Analyze                      | 40 %          |          | 40%           |                       | 40%              |           | 40%     |          | 40%                               | -                |  |
| Level 3    | Evaluate                     | 20 %          |          | 30%           | CONTRACTOR            | 30%              |           | 30%     |          | 30%                               |                  |  |
| Level 3    | Create                       | 20 %          |          | 30%           |                       | 30%              | THE PLANT | 30%     |          | 30%                               | -                |  |
|            | Total                        | 10            | 0 %      | 100           | 0 %                   | 10               | 0 %       | 100     | %        | 10                                | 0 %              |  |

| Course Designers   |   |                               |
|--|---|-------------------------------|
| Experts from Industry  | Experts from Higher Technical Institutions                        | Internal Experts              |
| 1. Dr. Giridharan Appaswamy, Lifecell International (P) Limited, Chennai, giridharan.a@lifecell.in | 1. Prof. Karunagaran D, IITM, Chennai, karuna@iitm.ac.in          | 1. Dr. K.M. Ramkumar, SRMIST  |
| 2. Dr. Karthik Periyasamy, Aurobindo Pharma Limited, Hyderabad, karthikmpk@gmail.com               | 2. Dr. Sib Sankar Roy, CSIR-IICB, Kolkatta, sibsankar@iicb.res.in | 2. Dr. Koustav Sarkar, SRMIST |

| Cou<br>Co      |            | 18BTE304T                        | Course Name                                  | INFECTIOUS DISEAS   | SES                   |                            | Cou<br>Cate         | ırse<br>gory | Е  |          |                         | Р                 | rofess              | sional Ele                   | ective                                |              |               |                | 3                  | T<br>0   | P<br>0 | C<br>3 |
|----------------|------------|----------------------------------|--|---|-----------------------|----------------------------|---------------------|--------------|--|----------|-------------------------|-------------------|---------------------|------------------------------|---------------------------------------|--------------|---------------|----------------|--------------------|----------|--------|--------|
|                | Pre-regu   | isite Courses                    | Nil  | Co-requisite Courses  | Nil                   |                            | Progre              | essive       | Courses  | Nil      |                         |                   |                     |                              |                                       |              |               |                |                    |          |        |        |
| Course         |            | Department                       | Biotechnology                                | Data Boo  | ok / Codes/Standards  |                            | Nil                 |              |  |          |                         |                   |                     |                              |                                       |              |               |                |                    |          |        |        |
|                |            |                                  |  |   | 1 2 3 3 3             | 7                          |                     |              |  |          |                         |                   |                     |                              |                                       |              |               |                |                    |          |        |        |
|                |            | g Rationale (CLR                 |  | The purpose of learning this course is to:                                    |                       | Lear                       | ning                |              |  |          |                         | Pro               | gram                | Learning                     | g Outc                                | comes        |               | )              |                    |          |        |        |
| CLR-1          |            |                                  | lifferent infections and infe                |   | W                     | 1 2                        | 2 3                 |              | 1 2  | 3        | 4                       | 5                 | 6                   | 7                            | 8                                     | 9            | 10            | 11             | 12                 | 13       | 14     | 15     |
| CLR-2          |            |                                  | bacterial infections and bac                 |   |                       | 2                          | e E                 |              | 100  |          |                         | (I)               |                     |                              |                                       |              |               |                |                    |          |        |        |
| CLR-3          |            |                                  | al infections, viral disease <mark>s</mark>  |   |                       | g                          | me                  |              | <u>.v</u>  |          | c                       | gag               | உ                   |                              |                                       |              |               |                | ing                |          |        |        |
| CLR-4          |            |                                  |  | s and diseases associated with them   |                       | of Thinking                | tai                 |              | alys   | +        | Design,                 | ž                 | 킕                   | ± 5<br>∞ >                   |                                       | Team         | tion          | ∞ర             | l g                |          |        |        |
| CLR-5          |            |                                  |  | mon infectious diseases and the impact of i                                   | ntectious diseases.   | Tiel P                     | ₹                   | ing          | Ang B  | 1 2      | ے ر                     | 8                 | Ö                   | per jii                      |                                       | ~~           | ica           | √gt.           | Le                 |          |        |        |
| CLR-6          | :  Ide     | entify newer appro               | paches/alternative method                    | s for controlling infectious diseases   |                       | Level of Thinking (Bloom)  | Expected Attainment | Engineering  | Knowledge<br>Problem Analysis  | Design & | Analysis, E<br>Research | Modern Tool Usage | Society & Culture   | Environment & Sustainability | (0                                    | Individual & | Communication | Project Mgt. & | Life Long Learning | <u> </u> | -2     | - 3    |
| 0              | . 1        | Out (OL 0                        | 2).  | 1 A 4 4   | h I - 4               | -evel                      | b é                 | ]   je       | do ldo   | esig     | ese                     | ode               | ocie                | nvir<br>Jesta                | H Ethics                              | di Ş         | JIII          | oje i          | fe L               | PSO      | PSO    | PSO    |
| Course         | e Learning | g Outcomes (CLC                  | )):<br>-                                     | At the end of this course, learners will be a                                 | able to:              |                            |                     |              |  | ع د      |                         | Ž                 |                     | <u>ந</u> ்ல                  | 山山                                    |              |               | Δ i            |                    | ď        | ă      | ă,     |
| CLO-1<br>CLO-2 |            |                                  |  | tious diseases and their causative agents ackle different bacterial diseases. | 100000                |                            | 0 80<br>5 75        |              | H H  | H        | H                       |                   | М                   | M                            | Н                                     | H            | H             | Н              | H                  | H        | H      | H      |
| CLO-2          |            |                                  | fections, vacci <mark>ne develo</mark> pm    |   | i Distilla            | 2 7                        |                     |              | л <u>п</u>   | М        | Н                       | М                 | М                   | IVI                          | М                                     | Н            | Н             | Н              | Н                  | Н        | Н      | Н      |
| CLO-3          |            |                                  |  | ions and methods to combat them   | Total Wall Pro-       |                            | 5 80                |              | и п<br>Н Н   | Н        | Н                       | IVI               | IVI                 | Н                            | L                                     | Н            | Н             | Н              | Н                  | Н        | Н      | Н      |
| CLO-5          |            |                                  | ctious diseas <mark>es and the</mark> ir s   |   |                       |                            | 5 75                |              | 1 H  | H        | Н                       |                   | М                   | Н                            | Н                                     | H            | 1             | Н              | Н                  | Н        | Н      | H      |
| CLO-6          |            |                                  | erging infecti <mark>ons and th</mark> eir o |   | THE PARTY OF          |                            | 0 80                |              | H H  | Н        | Н                       | L                 | M                   | M                            | М                                     | Н            | Н             | Н              | Н                  | Н        | Н      | H      |
| 020 0          | .  7.07    | aryzo aro rominio                | rging imoduone and their c                   | SOLITO I  | North Colonia         |                            | 0   00              |              |  |          |                         |                   | 101                 | 101                          | 141                                   | 1            |               |                | 1                  |          |        |        |
| Durati         | on (hour)  |                                  | 9  | 9   | - 144.50              | 9                          |                     | E.           |  |          |                         | 9                 |                     |                              |                                       |              |               |                | 9                  |          |        |        |
| S-1            | SLO-1      | Origin of Infection              | on   | Introduction to pathogenic and non pathogenic bacteria                        | History of viral infe | ections                    | ŭ,                  | Æ            | Introdu  | ıction   | to Protoz               | zoan E            | iseas               | ses                          | An                                    | tibacte      | erial: A      | ntibio         | otics              |          |        |        |
|                | SLO-2      | Evolution of infe                | ectious disea <mark>ses</mark>               | Common bacterial diseases in humans   | Different Viral dise  | eases                      | 100                 | 41.          | Differe  | nt pro   | tozoan a                | lisease           | es                  |                              | Мо                                    | de of        | action        | s of a         | antibio            | tics     |        |        |
| 0.0            | SLO-1      | Concept of Infe                  | ction: Immunit <mark>y</mark>                | Basic mechanism of Bacterial pathogenesis                                     | Viral pathogenesis    | s                          | No.                 |              | Severi   | ty of p  | r <mark>otoz</mark> oar | n disea           | ses                 |                              | An                                    | tibiotic     | resis         | tance          | )                  |          |        |        |
| S-2            | SLO-2      | Immune surveili                  | lance  | Bacterial survival in host cells-Quoram sensing                               | Viral life cycle      |                            |                     |              | Genera   | al mod   | le of acti              | ion of            | orotoz              | oa                           | ME                                    | DR and       | d XDR         | ? strai        | ns                 |          |        |        |
| 0.0            | SLO-1      | Concept of Infe                  | ction: Virulence                             | Bacterial virulence factors: Microbial structures                             | Virus genomes an      | nd structure               | 9                   |              | Pathog<br>study:   | ,        |                         | ozoan             | disea               | i <mark>ses:</mark> Cas      | se An                                 | tivirals     | : Vac         | cines          |                    |          |        |        |
| S-3            | SLO-2      | Concept of Path                  | nogenesis                                    | Bacterial virulence factors: Microbial structures: Toxins                     | Host –virus intera    | ctions                     |                     |              | Host re  | espon    | se to Pro               | zoan              |                     |                              | lmį                                   | pact o       | f vacc        | ine in         | viral o            | diseas   | e con  | trol   |
| S-4            | SLO-1      | Virus                            | ts of infectious diseases-                   | Host response to Bacterial infection  | Host Immune read      | ction again                | st viruse           | es           | 100  |          | gnaling <mark>a</mark>  |                   |                     |                              | Challenges in viral vaccine developme |              |               | ents           |                    |          |        |        |
| 3-4            | SLO-2      | Bacteria                         | ts of infectious diseases-                   | Molecular cell signaling involved in Bacterial diseases                       | Viral evasion of ho   | f host immune surveillance |                     |              | Hypersensitivity and autoimmunity associated with Protozoan infections |          |                         |                   | Antiviral compounds |                              |                                       |              |               |                |                    |          |        |        |
| 0.5            | SLO-1      | Causative agen<br>Protozoa and P | ts of infectious diseases-<br>arasites       | Host Immune response to bacteria  | Antiviral pathways    |                            |                     |              | Antimalarial drug development  |          |                         |                   |                     |                              |                                       |              |               |                |                    |          |        |        |

Mutations in viral genome

Viral diseases and antibody response

Mode of action of fungal diseases

Immune response against fungal infection

Mode of action of antimalarial drugs

Development of Vaccine for Malaria

SLO-1 Disease epidemiology

Causative agents of infectious diseases-Other causative agents

Bacterial immune evasion: Molecular

Strategies for antibacterial therapy:

Antibiotics

S-5

S-6

SLO-2

| Durati | on (hour) | 9  | 9   | 9  | 9   | 9  |
|--------|-----------|--|---|--|---|--|
|        |           | Steps involved in epidemiology   | Other antibacterial compounds               |  | II ace ciliu/, i audidiacie               | Challenges for the development of antimalarial drugs |
|        | SLO-1     | Epidemiological case studies-Bacteria                                    | Gut bacteria and their role in pathogenesis | Antivirals compounds for viral infections                | Infection caused by Yeast                 | Infectious diseases and life style                   |
| S-7    |           | Epidemiological case studies-Bacteria                                    | Bacterial vaccines                          | Challenges in vaccine production against certain virtues | Mode of action of Yeast infection         | Beneficial gut microflora                            |
| S-8    | SLO-1     | Epidemiological case studies-Virus<br>Epidemiological case studies-Virus | Case study: E. Coli infection               | Case study: Influenza                                    |   | Neglected diseases                                   |
| 3-0    | SLO-2     | Epidemiological case studies-Virus                                       | Case study: Tuberculosis                    | Case study: Dengue                                       | Strategies to combat Protozoan infections | Reemerging infectious diseases                       |
| 2      | SLO-1     | Trends in Current epidemiology-Bacterial infections                      | Case study: Pneumonia                       |  |   | Sexually transmitted diseases and awareness          |
| S-9    | SLO-2     | Trends in Current epidemiology-Viral infections                          | Case study: Helicobacter and gastric cancer | Case study: HIV and AIDS                                 | Zoonotic diseases                         | Infectious disease and social issues                 |

| Learning<br>Resources | <ol> <li>Brenda A. Wilson, Abigail A. Salyers, Dixie D. Whitt, Malcolm E. Winkler, "Bacterial pathogenesis: a molecular approach". 3<sup>rd</sup> Edition- ASM Press, 2011.</li> <li>Alan Cann, "Principles of Molecular Virology": 6<sup>th</sup> Edition-Academic Press, 2015</li> <li>Vincent Racaniello, "Principles of Virology": 4<sup>th</sup> Edition- ASM Press, 2015</li> </ol> | 4. Tracey Lamb, "Immunity to Parasitic Infections": Willy Blackwell, 2012. 5. Malcolm D. Richardson, David W. Warnock, "Fungal Infection: Diagnosis and Management": 4th Edition- Willy Blackwell, 2012. |
|-----------------------|---|--|
|-----------------------|---|--|

| Learning / | Assessment        |                    |  |               | Tilly at White | Jones St. | The second   |         |                      |                                   |          |  |
|------------|-------------------|--------------------|--|---------------|----------------|-----------|--------------|---------|----------------------|-----------------------------------|----------|--|
| _          | Dlaam'a           |                    | Continuous Learning Assessment (50% weightage) |               |                |           |              |         |                      |                                   |          |  |
|            | Bloom's           | CLA – 1 (10%)      |  | CLA – 2 (15%) |                | CLA -     | 3 (15%)      | CLA – 4 | (10 <mark>%)#</mark> | Final Examination (50% weightage) |          |  |
|            | Level of Thinking | Theory             | Practice                                       | Theory        | Practice       | Theory    | Practice     | Theory  | Practice             | Theory                            | Practice |  |
| Lovol 1    | Remember          | 40 %               |  | 30%           |                | 30%       | The state of | 30%     |                      | 30%                               |          |  |
| Level 1    | Understand        | 40 /0              |  | 30%           | 100000         | 30%       |              | 3076    |                      | 30%                               | -        |  |
| Level 2    | Apply             | 40 %               |  | 40%           |                | 40%       | 200          | 40%     |                      | 40%                               |          |  |
| Level 2    | Analyze           | 40 /0              |  | 40 /0         |                | 4070      |              | 4070    |                      | 40 /0                             | -        |  |
| Level 3    | Evaluate          | 2 <mark>0 %</mark> | 100  | 30%           |                | 30%       | - 1000       | 30%     |                      | 30%                               |          |  |
| Level 3    | Create            | 20 /0              | and the same                                   | 3078          |                | 30 /0     |              | 3070    |                      | 30 /0                             | -        |  |
|            | Total             | 10                 | 0 %  | 100           | %              | 10        | 0 %          | 100     | ) %                  | 10                                | 0 %      |  |

<sup>#</sup> CLA – 4 can be from any combination of these: Assignments, Seminars, Tech Talks, Mini-Projects, Case-Studies, Self-Study, MOOCs, Certifications, Conf. Paper etc.,

| Course Designers  |  |                       |
|---|--|-----------------------|
| Experts from Industry   | Experts from Higher Technical Institutions                             | Internal Experts      |
| Dr. G. N. Ramchand, Saksin Life sciences Pvt Ltd, Chennai, ramchand@saksinlife.com  | Prof. K Subramaniam, IITM, Chennai,     suubu@iitm.ac.in               | 1. Dr Suvankar Ghorai |
| 2. Dr. Karthik Periyasamy, Scientist I, Aurozymes <mark>Unit, Auro</mark> bindo Pharma Limited, Hyderabad, karthikmpk@gmail.com | 2. Dr. Saumya Raychaudhuri, IMTECH, Chandigarh<br>Saumya@imtech.res.in | 2. Dr. Koustav Sarkar |

| Cou     |   | 18BTE401T                     | Course Name                                   | CANCER BIOLOGY   |             |                     |                          |                         | ourse                    | Е                |                          |                               | Pi                | rofess                       | sional E                     | lectiv   | / <u>P</u>                |               |                           | L                 | Т      | Р        | С             |
|---------|---|-------------------------------|---|--|-------------|---------------------|--------------------------|-------------------------|--------------------------|------------------|--------------------------|-------------------------------|-------------------|------------------------------|------------------------------|--|---------------------------|---------------|---------------------------|-------------------|--------|----------|---------------|
| Co      | de  | TOBTETOTT                     | Course Harrie                                 | C/MOEIT BIOECCT  |             |                     |                          | Ca                      | ategory                  |                  |                          |                               |                   | 101000                       | nonai L                      | .10011   |                           |               |                           | 3                 | 0      | 0        | 3             |
|         | ro roquis   | site Courses                  | Nil   | Co-requisite Cours   | 00          | Nil                 |                          |                         | Progres                  | ecivo C          | `oureoe                  |                               | Nil               |                              |                              |  |                           |               |                           |                   |        |          | —             |
|         |   | Department                    | Biotechnology                                 | Data Book  |             |                     | \$                       | Nil                     | Flogres                  | SIVE             | ourses                   | /                             | VII               |                              |                              |  |                           |               |                           |                   |        |          |               |
| Course  | Oncing  | Dopartinont                   | Dioteorificiogy                               | Data Book  | 7 00000070  | taridara            |                          | 7411                    |                          |                  |                          |                               |                   |                              |                              |  |                           |               |                           |                   |        |          |               |
| Course  | Learning  | g Rationale (CLR              | R): The purpose of                            | learning this course is to:  |             |                     | Learnin                  | a                       |                          |                  |                          |                               | Prog              | ram L                        | earning                      | Outo   | comes (                   | PLO)          |                           |                   |        |          |               |
| CLR-1   | : D   | escribe the gene              | s, risk factors in tumor progi                | ression  |             | 1                   | 2                        | 3                       | 1                        | 2                | 3                        | 4                             | 5                 | 6                            | 7                            | 8  | 9                         | 10            | 11                        | 12                | 13     | 14       | 15            |
| CLR-2   | : D   | )iscuss epigeneti             | ics, DNA damage and repair                    | ri <mark>n cancer</mark>   |             |                     | >                        | ±                       | 171                      |                  |                          |                               |                   |                              |                              |  |                           |               |                           |                   |        |          |               |
| CLR-3   |   |                               | lar signaling mechanisms i <mark>n</mark>     |  |             |                     | euc                      | ner                     |                          | S                |                          |                               | age               | a)                           |                              |  | E                         |               |                           | ng                |        |          |               |
| CLR-4   | E   | xplain different m            | nethods for studying neuro-ir                 | mmune functions  |             | ki j                | je<br>je                 | ainr                    |                          | JSi              |                          | igi                           | Usi               | ŢŢ.                          | ≪ .                          |  | ea_                       | o<br>U        | ~X                        | arni              |        |          |               |
| CLR-5   |   | escribe the role o            | of stem cells in cance <mark>r treatr</mark>  | nent   | 104711      | Ę                   | P.                       | Atta                    | ng e                     | √na              | ent                      | Des                           | 00                | S                            | ent<br>ijt                   |  | ~                         | cati          | gt. å                     | Learning          |        |          |               |
| CLR-6   | Ai  | nalyze the role o             | f nuclear medicine a <mark>nd alkal</mark>    | <mark>loids in cancer</mark>   | 100         | of Thinking<br>m)   | ted                      | ted                     | edg                      | E                | % r                      | rch<br>rch                    | T                 | ∞<br>>                       | na de l                      |  | na                        | E             | E M                       | bud               | _      | 7        | က္            |
|         |   |                               |   |  |             | Level of<br>(Bloom) | Expected Proficiency (%) | Expected Attainment (%) | Engineering<br>Knowledge | Problem Analysis | Design &<br>Development  | Analysis, Design,<br>Research | Modern Tool Usage | Society & Culture            | Environment & Sustainability | Ethics   | Individual & Team<br>Work | Communication | Project Mgt. &<br>Finance | Life Long         | Ö      | 0        | 0             |
|         |   | g Outcomes (CL0               |   | is course, learners will be able to:   |             | e e                 |                          |                         | 민주                       |                  |                          | Re A                          | Mo                |                              | SU SU                        |  | P N                       |               | Pro<br>Fin                | Life              | PSO    | PSO      | PSO           |
| CLO-1   |   |                               | f diet in different <mark>forms of c</mark> a |  | 100         | 1                   | 80                       | 80                      | L                        | Н                | Н                        | Н                             |                   | М                            | L                            | Н  | Н                         | Н             | Η                         | Н                 | L      |          | Н             |
| CLO-2   |   |                               | amental assay <mark>s in hazard</mark> ide    |  | TOTAL S     | 2                   | 85                       | 75                      | M                        | Н                | Н                        | М                             |                   |                              | М                            | Н  | L                         | Н             | Н                         | Н                 | L      |          | Н             |
|         | CLO-3 : Explain the concepts and experiments in cancer development  |                               |   |  |             | 2                   | 75                       | 80                      | M                        | Н                | М                        | Н                             | М                 | М                            |                              | М  | Н                         | Н             | Н                         | Н                 | L      | Н        | Н             |
| CLO-4   |   |                               | rious pathway <mark>s of canc</mark> er an    |  |             | 2                   | 85                       | 80                      | L                        | Н                | Н                        | Н                             |                   |                              | Н                            | L  | L                         | Н             | Н                         | Н                 | М      | Н        | Н             |
| CLO-5   |   |                               |   | docrine and immune interactions in cancer  | -           | 3                   | 85                       | 75                      | L                        | Н                | Н                        | М                             |                   | М                            | Н                            | Н  | Н                         | L             | Н                         | Н                 | Н      |          | Н             |
| CLO-6   | :  E)   | xpıaın tne conce <sub>l</sub> | ots of cancer <mark>detection</mark> and t    | nerapy   | 400         | 2                   | 80                       | 80                      | М                        | Н                | Н                        | Н                             | L                 | Н                            | М                            | М  | Н                         | Н             | Н                         | Н                 | Н      | Η        | Н             |
| Duratio | on (hour)   |                               | 9   | 9  |             | -                   | 9                        |                         |                          |                  |                          |                               | 9                 |                              |                              |  |                           |               | ç                         | )                 |        |          | $\overline{}$ |
| Darati  |   | Basic concents                | of cancer: Oncogenes and                      |  |             |                     |                          |                         |                          |                  |                          |                               |                   |                              |                              |  | _                         |               |                           |                   |        |          |               |
|         | SLO-1   | tumor suppress                |   | DNA structure and stability  | Signal tra  | ansductio           | on                       | -                       |                          | Stem             | cells ar                 | nd cance                      | er                |                              |                              |  | Cancer t                  | herap         | y and d                   | etectic           | on     |          |               |
| S-1     | 01.0.0  |                               | athogenesis, treatment and                    | 0 4 200  | 0 " (       | -                   |                          | C 10                    |                          | Self-            | renewa                   | and its                       | moled             | cular                        |                              |  |                           |               |                           | ,                 |        |          |               |
|         | SLO-2   | future prospect               |   | Spontaneous DNA damage   | Growth fa   | actors ar           | na recep                 | otors                   |                          | mechanisms       |                          |                               |                   | /                            | Modalities of treatment      |  |                           |               |                           |                   |        |          |               |
|         | SLO-1   | The cell cycle                |   | DNA repair   | EGF grov    | wth facto           | or recept                | tor signal              | ling                     | Hedg             | ehog si                  | gnaling <sub>l</sub>          | oathw             | ay                           |                              | 1  | Vuclear                   | medic         | ine                       |                   |        |          |               |
| S-2     | SLO-2   | cyclin and cycli              | n dependent kinases                           | Clinical applications of DNA repair  | Ras activ   | otion               |                          |                         |                          |                  |                          | oup prot                      |                   |                              |                              | 1  | Chemotl                   | horon         | outic oa                  | onto              |        |          |               |
|         |   |                               |   | biomarkers   |             |                     |                          |                         |                          | Fulyo            | omb gr                   | σαρ ρισι                      | ellis             |                              |                              |  |                           |               |                           | <del>J</del> IIIS |        |          |               |
| S-3     |   | Mechanisms of                 |   | Epigenetics  | Activation  |                     | PK path                  | ways                    |                          |                  |                          | strategie                     |                   |                              |                              |  | Plant alk                 |               | 3                         |                   |        |          |               |
| 0-3     |   | Tumor suppres                 |   | Epigenome and its implications   | Oncogen     |                     |                          |                         |                          |                  |                          | environ                       |                   |                              |                              |  | Antibiotic                |               |                           |                   |        |          |               |
| S-4     |   | Knudson's two-                |   | Carcinogenesis   | Immune .    |                     | 1                        |                         |                          |                  |                          | s and tui                     |                   | rogres                       | ssion                        |  | Hormona                   |               |                           |                   |        |          |               |
| Ŭ .     | SLO-2   | P53 and contro                | l of cell cycle                               | Causes of cancer   | Effector r  | nechani             | sms in c                 | ancer im                | munity                   | SMA              | D signa                  | ing cent                      | ers               |                              |                              |  | Biologica                 |               |                           |                   |        |          |               |
|         | SLO-1   | Molecular path                | ways of p53                                   | Cancer risk factors  | NF-KB si    | analina i           | pathway                  | /                       |                          | Invas            | ion and                  | metasta                       | sis               |                              |                              |  | mmuno                     | therap        | y and h                   | emato             | poiet  | ic gro   | wth           |
| S-5     |   | ,                             |   | Control of the Contro |             |                     |                          |                         |                          |                  |                          |                               |                   |                              |                              |  | actors                    |               |                           |                   |        |          |               |
|         |   | Myc transcription             |   | Types of carcinogens   | JAK/STA     |                     |                          |                         |                          |                  |                          | n molecu                      | ıles              |                              |                              |  | Cancer <u>j</u>           |               |                           |                   |        |          |               |
| S-6     | S-6 SLO-1 Powers of Myc oncoprotein Bacteria and cancer SLO-2 Role of myc oncoprotein in regulating pRb Hormones and cancer |                               |   | Neuroen  |             |                     | DOD :                    | P.                      |                          | ogenesis         |                          |                               |                   |                              |                              | Screening techniques and diagnostic tests Imaging and cancer |                           |               |                           |                   |        |          |               |
|         |   |                               |   | Hormones and cancer  | Neurotra    |                     |                          |                         | naiing                   |                  |                          | genesis                       |                   | eovas                        | sculatur                     |  |                           |               |                           | 1! - !            |        |          |               |
| 0.7     | SLU-1   | TGF role in car               | ncer  | Ecogenetics and cancer risk  | Estrogen    |                     |                          |                         |                          | VEG              | - signal                 | <u>trans</u> du               | ction             |                              |                              |  | K-Ray C                   | ı, Mh         | kı, and r                 | adio ir           | nagın  | <u>g</u> |               |
| S-7     | SLO-2   | pRb's role in ca              | ancer   | Mutations  | Growth fa   |                     | rıa grow                 | ıııı tactor             |                          | Angio            | o <mark>geni</mark> c ii | hibitors                      |                   |                              |                              |  | Optical i                 | magin         | g                         |                   |        |          |               |
|         | SI O-1  | Tumor suppres                 | sor gangs                                     | red  |             | receptors           |                          |                         | Vascular targets         |                  |                          |                               | -1.               | Tumor vasculature metabolism |                              |  |                           |               |                           |                   |        |          |               |
| S-8     |   |                               | _   |  |             |                     |                          |                         |                          |                  |                          |                               |                   |                              |                              |  | Contrast                  |               |                           |                   |        | ılar     | $\dashv$      |
|         | SLO-2   | Cell cycle and o              | cancer  | Biotransformation and cancer risk  | Implication | ons in ca           | ncer the                 | erapy                   |                          | Pain             | and phy                  | siology                       | of pail           | n perd                       | ception                      |  | maaina                    | •             | io iii oai                | 1001 11           | 101000 | ıuı      |               |

| Dura | ion (hour) | 9                         | 9                            | 9                    | 9                       | 9                                      |
|------|------------|---------------------------|------------------------------|----------------------|-------------------------|--|
| S_0  | SLO-1      | Different forms of cancer | Cancer prevention            | Apoptosis and Cancer | Neuropathic cancer pain | Bioinformatics for pathway interaction |
| 3-9  | SLO-2      | Diet and cancer           | Hazard identification assays | Bcl-2 and cancer     | Pain therapy            | Population screening challenge         |

| Learning<br>Resources | 1.<br>2. | Lauren Pecorino, Molecular Biology of Cancer: Mechanisms, Targets, and Therapeutics, Oxford University Press; 4th edition, 2016 Robert A. Weinberg, The Biology of Cance <mark>r Garland Science</mark> ; 2nd edition, 2013 | 3. John Mendelsohn, Peter M. Howley, Mark A. Israel, Joe W. Gray, Craig B. Thompson. The Molecular Basis of Cancer, Saunders; 4 edition, 2014 |
|-----------------------|----------|---|---|
|-----------------------|----------|---|---|

| Learning A | Assessment        |        |                   | 178.        |                     |                      | 1/1/     |         |          |                                  |                    |  |
|------------|-------------------|--------|-------------------|-------------|---------------------|----------------------|----------|---------|----------|----------------------------------|--------------------|--|
|            | Bloom's           |        |                   | Conti       | nuous Learning Asse | essment (50% weighta | ige)     |         |          | Final Evamination                | a (EOO) waightaga) |  |
|            | Level of Thinking | CLA -  | - 1 (10%) CLA     |             | 2 (15%)             | CLA – 3 (15%)        |          | CLA – 4 | l (10%)# | Final Examination (50% weightage |                    |  |
|            | Level of Thinking | Theory | Practice Practice | Theory      | Practice            | Theory               | Practice | Theory  | Practice | Theory                           | Practice           |  |
| Lovel 1    | Remember          | 40 %   |                   | 30%         | 1000                | 30%                  |          | 30%     |          | 30%                              |                    |  |
| Level 1    | Understand        | 40 %   |                   | 30%         |                     | 30%                  |          | 30%     |          | 30%                              | -                  |  |
| Level 2    | Apply             | 40 %   |                   | 40%         | HW 25-1             | 40%                  |          | 40%     |          | 40%                              |                    |  |
| Level 2    | Analyze           | 40 /0  | _                 | 4070        |                     | 4070                 |          | 4070    |          | 4070                             | -                  |  |
| Level 3    | Evaluate          | 20 %   |                   | 30%         | 2010年1月1日           | 30%                  |          | 30%     |          | 30%                              |                    |  |
| Level 3    | Create            | 20 %   |                   | 30%         |                     | 30%                  |          | 30%     |          | 30%                              | -                  |  |
|            | Total             | 10     | 0 %               | 100 % 100 % |                     |                      |          |         | 0 %      | 100 %                            |                    |  |

| Course Designers   |   |                                  |
|--|---|----------------------------------|
| Experts from Industry  | Experts from Higher Technical Institutions              | Internal Experts                 |
| Dr. G. N. Ramchand, Saksin Life sciences Pvt Ltd, Chennai, ramchand@saksinlife.com   | 1. Prof K Subramaniam, IITM, Chennai, subbu@iitm.ac.in  | 1. Dr. S.ThyagaRajan,<br>SRMIST  |
| <ol> <li>Dr. Karthik Periyasamy, Scientist I, Aurozymes Unit, Aurobindo Pharma Limited, Hyderabad,<br/>karthikmpk@gmail.com</li> </ol> | 2. Prof. R. B. Narayanan, SVCE, Chennai, rbn@svce.ac.in | 2. Dr.R.Vasantharekha,<br>SRMIST |

| Cou            |             | 18BTE402T               | Course Name                         | PHYSIOLOGY OF STRESS AND ITS N   | MANAGEMI            | ENT            |                          | Cour<br>Categ           |                          | Е                |                         |   | Prof              | essio             | onal Ele                     | ective | !                        |               |                        | L<br>3             | T<br>0 | P (     | 3             |
|----------------|-------------|-------------------------|-------------------------------------|--|---------------------|----------------|--------------------------|-------------------------|--------------------------|------------------|-------------------------|---|-------------------|-------------------|------------------------------|--------|--------------------------|---------------|------------------------|--------------------|--------|---------|---------------|
|                | Pro-roquis  | site Courses            | Nil                                 | Co-requisite Courses   | Nil                 |                |                          | Progre                  | essive C                 | OUITE            | s Nil                   |   |                   |                   |                              |        |                          |               |                        |                    |        |         | $\neg$        |
|                |             | Department              | Biotechnology                       | Data Book /  |                     | ndards         |                          | Nil                     | 233176 0                 | ourses           | 5 IVII                  |   |                   |                   |                              |        |                          |               |                        |                    |        |         | $\dashv$      |
|                |             | •                       |                                     |  | Oodco/Otal          |                |                          |                         |                          |                  |                         |   |                   |                   |                              |        |                          |               |                        |                    |        |         |               |
|                |             | g Rationale (CLR        |                                     | ourpose of learni <mark>ng this course is to:</mark>   |                     | 70.1           | Learning                 |                         |                          |                  |                         |   |                   |                   | earning                      |        | comes (                  |               |                        |                    |        |         |               |
| CLR-1          |             |                         | eostasis and contro                 | systems in stress  |                     | 1              | 2                        | 3                       | 1                        | 2                | 3                       | 4   | 5                 | 6                 | 7                            | 8      | 9                        | 10            | 11                     | 12                 | 13     | 14 ′    | 15            |
| CLR-2          |             | scuss stress neu        |                                     | The last terms of the last ter |                     |                | ठ                        | Ħ                       |                          |                  |                         |   | (D)               |                   |                              |        |                          |               |                        |                    |        |         |               |
| CLR-3          |             |                         | ral response to stre                | SS   |                     | <u>g</u>       | Expected Proficiency (%) | Expected Attainment (%) |                          | .82              |                         | n,  | Modern Tool Usage | ஒ                 |                              |        | яш                       | _             |                        | Life Long Learning |        |         |               |
| CLR-4:         |             |                         | sorders of stress                   |  |                     | l of Thinking  | )jj                      | tain                    |                          | Problem Analysis | =                       | Analysis, Design <mark>,</mark><br>Research | $\tilde{\Xi}$     | Society & Culture | st ≻                         |        | ndividual & Team<br>Nork | Communication | ∞                      | all                |        |         |               |
| CLR-5          |             |                         | of age and emotion                  |  |                     | 虐              | Ā.                       | ¥                       | Engineering<br>Knowledge | A P              | Design &<br>Development | ا ا   | 8                 | Ö                 | Environment & Sustainability |        | 8 =                      | ica           | Project Mgt. & Finance | J Le               |        |         |               |
| CLR-6          | : Ar        | nalyze the role of      | f education I manag                 | ing stress   |                     | g @            | ctec                     | ctec                    | led                      | e u              | n 8<br>Iopr             | sis,<br>arch                                | `⊑                | ty 8              | onu<br>ina                   | "      | qna                      | l I           | e 5 ≥                  | ong                |        | 17      | 33            |
|                | <del></del> | 0 (0)                   | 0) [444                             |  |                     | evel of Bloom) | be (c                    | cbe(                    | ligi wo                  | g                | Design & Developm       | Analysis,<br>Research                       | ode               | Scie              | nvir<br>Ista                 | Ethics | Individ<br>Work          | JE            | Project N<br>Finance   | e.                 | PSO    | PSO     | PSO           |
|                |             | Outcomes (CLC           |                                     | e end of this course, learners will be able to:  |                     |                |                          | ம்⊗                     | 교호                       |                  |                         |   | Ž                 |                   | <u>ய்</u>                    | ш      |                          |               |                        |                    | ř      | ă ì     | <u>:-</u>     |
| CLO-1          |             |                         |                                     | nune system in stress  |                     | 1              | 80                       | 80                      | L                        | Н                | Н                       | Н   |                   | М                 | L                            | Н      | Н                        | Н             | H                      | Н                  | L      |         | <u>H</u>      |
| CLO-2          |             |                         |                                     | ansmitters in stress   |                     | 2              | 85                       | 75                      | M                        | Н                | H                       | M   |                   |                   | M                            | H      | L                        | Н             | Н                      | Н                  | L      |         | <u>H_</u>     |
| CLO-3          |             |                         |                                     | s in stress and stressors  |                     | 2              | 75                       | 80                      | M                        | H                | M                       | H   | М                 | М                 |                              | М      | Н                        | Н             | Н                      | Н                  | L      |         | <u>H_</u>     |
| CLO-4<br>CLO-5 |             |                         |                                     | ress related disorders   | - 7-7-              |                | 85                       | 75                      | L                        |                  | Н                       | M   |                   |                   | H                            | L      | L                        | Н             | Н                      | Н                  | M<br>H |         | Н             |
|                |             |                         |                                     | nanagement of stress   |                     | 3              | 85                       | 80                      | M                        | H                | Н                       | Н   | ,                 | M<br>H            | H                            | H<br>M | H                        | L<br>H        | <u>Н</u><br>Н          | H                  | • •    |         | <u>Н</u><br>Н |
| CLO-6          | : Ex        | cpiain the concep       | ols of alet, ex <mark>ercise</mark> | and life style in managing stress  | -                   |                | 80                       | 80                      | IVI                      | П                | Н                       | н   |                   | П                 | М                            | IVI    | П                        | П             | п                      | П                  | Н      | Η .     | 7             |
| Duration       | on (hour)   |                         | 9                                   | 9  | 1000                | 7              | 9                        | 40.00                   | -7.                      | 7 40             |                         | (   | 9                 |                   |                              |        |                          |               | 9                      |                    |        |         | $\Box$        |
| 0.4            | SLO-1       | Homeostasis ar          | nd control sy <mark>stems</mark>    | Stress neuroendocrinology  | Behavior            | al respo       | nses to s                | stress                  | 771                      | Str              | ess of E                | Boredom                                     |                   |                   |                              | Aи     | arenes                   | s abol        | ut mana                | aging s            | tress. |         |               |
| S-1            |             | Endocrine syste         |                                     | limbic forebrain   | Behavior            | al sourc       | es of stre               | ess                     |                          | An               | xiety dis               | sorders                                     |                   |                   |                              | Ex     | tra role                 | in beł        | navior                 |                    |        |         |               |
| S-2            |             | HPA axis                |                                     | Noradrenergic system   | Impairme            | ent of res     | sponse ir                | hibition                |                          | Pa               | nic diso                | rder  | 4                 |                   |                              | Ма     | naging                   | stress        | s and b                | ehavio             | r      |         |               |
| 3-2            | SLO-2       | Limbic modulati         | ion of HPA a <mark>xis</mark>       | Corticotropin releasing hormone  | lack of m           | otivatior      |                          | 27.1                    | 3                        | So               | cial anx                | iety diso                                   | rder              |                   |                              | Ex     | tra role                 | in edu        | ıcation                | setting            | s      |         |               |
| S-3            | SLO-1       | Nervous system disorder | n and stress                        | CRF family with role in HPA axis   | Aggressi            |                |                          |                         |                          | Со               | gnitive l               | behavior                                    | thera             | ру                |                              | Re     | laxation                 | ١.            |                        |                    |        |         |               |
| 3-3            | SLO-2       | Hippocampus a           | and depression                      | Intracellular signaling mediating external signals of stress   | Physiologresponse   | 9              |                          |                         |                          |                  | st-traum                | natic syn                                   | drome             | es                |                              | Eff    | ective c                 | отті          | unicatio               | n.                 |        |         |               |
| S-4            | SLO-1       | Parasymaptheti          | -                                   | Catecholamines and MAP kinases   | Interaction compone | ents           | H                        | and phys                | siologica                | EV               |                         | and treat                                   | ment              |                   |                              | Inte   | erventic                 | n of c        | aregive                | ers                |        |         |               |
|                | SLO-2       | Fight/flight resp       | onses                               | microRNAs-Telomeres  | Environn            | nental fa      | ctors                    |                         |                          |                  | stress                  |   |                   |                   |                              | Ins    | titutiona                | al care       | )                      |                    |        |         |               |
| S-5            | SLO-1       | Rest/digest res         | ponses                              | Role of micro-RNA in fear conditioning   | Impact o            | f enviror      | mental f                 | actors on               | stress                   |                  | ycholog<br>tress        | ical cond                                   | comita            | nts o             | of                           | Ма     | naging                   | angei         | r and co               | oping v            | ith ai | nxiety. |               |
| 3-3            | SLO-2       | Immune system           | 1                                   | Neural circuitry of stress, fear and anxiety   | Different           | ial expos      | sure                     | . E                     |                          | Ch               | ronic st <mark>ı</mark> | ress.                                       |                   |                   |                              |        | ychoph;<br>rspectiv      |               | gical ar               | nd biolo           | gical  |         |               |
| S-6            | SLO-1       | Innate Immunity         | у                                   | Serotonergic systems modulates anxiety   | Vulnerab            | ility of e     | nvironme                 | ental stres             | ssors                    | Fe               | ar.                     |   |                   |                   |                              | Ме     | ditation                 | mode          | el                     |                    |        |         |               |
| 3-0            | SLO-2       | Adaptive immur          | nity                                | Locus coeruleus facilitate stress  | Psycholo            | ogical str     | essors                   |                         |                          | En               | notional                | <mark>inhi</mark> bitioi                    | <u> </u>          |                   |                              | Ea     | ting beh                 | avior         | and he                 | althy li           | festyl | e       |               |
| S-7            | SLO-1       | Stress and its u        | ınderpinnings                       | Neurons and central autonomic control  | Historica           |                |                          |                         | ons                      | str              | ess.                    | e behavi                                    |                   |                   |                              | inta   | man re:<br>ake           |               |                        |                    |        |         |               |
|                |             | Kinds of stress         |                                     | Stress-Hippocampal neurogenesis.   | Concept             | ual deve       | lopments                 | S                       |                          | Ac               | ute and                 | chronic                                     | stress            | moa               | lels                         | Ме     | chanisi                  | ns rel        | ating st               | ress to            | eatir  | ng      |               |
| S-8            | SLO-1       | Norepinephrine          | in stress                           | Neurons modulate HPA axis  | Methodo             | logical c      | onsidera                 | tions                   |                          | Ag               | ing and                 | psychol                                     | ogical            | stres             | SS                           | Ex     | ercise                   |               |                        |                    |        |         |               |

| Durati | on (hour) | 9                               | 9  | 9                                | 9   | 9   |
|--------|-----------|---------------------------------|--|----------------------------------|---|---|
|        | SLO-2     | Noradrenergic control of stress | Epigenetics and stress and neural network              | Cognition and stress             | Age-related disease                       | Time management and stress reduction plan |
| S-9    | SLO-1     | Allostasis                      | Epigenetics and stress response                        | Cognitive origin of stress       | Stress response and central role of brain | General principles of prevention          |
| 3-9    | SLO-2     | Allostatic load                 | Transgenerational effects of epigenetic stress markers | Cognitive consequences of stress | Job-related stress.                       | Physical and mental well-being            |

| Learning  | 1. | George Fink. Stress: Concepts, Cognition, Emotion, and Behavior: Handbook in Stress. Academic Press. First edition. 2016 |  |
|-----------|----|--|--|
| Resources | 2. | George Fink, Stress: Neuroe <mark>ndocrinology</mark> and neurobiology; Academic Press. First edition. 2017              |  |

| Learning / | Assessment          |                     |          | V 1    | 100000000000000000000000000000000000000 | 1.04              |          |        |          |                   |                     |
|------------|---------------------|---------------------|----------|--------|---|-------------------|----------|--------|----------|-------------------|---------------------|
|            | Bloom's             |                     |          | Cont   | inuous Learning Asse                    | essment (50% weig | htage)   |        |          | Final Evamination | a (EOO) (waightaga) |
|            | Level of Thinking   | CLA –               | 1 (10%)  | CLA –  | 2 (15%)                                 | CLA -             | 3 (15%)  | CLA –  | 4 (10%)# | Final Examinatio  | n (50% weightage)   |
|            | Level of Thinking   | Theory              | Practice | Theory | Practice                                | Theory            | Practice | Theory | Practice | Theory            | Practice            |
| Level 1    | Remember Understand | - 40 %              | 1        | 30%    |   | 30%               |          | 30%    | 4 11-    | 30%               | -                   |
| Level 2    | Apply<br>Analyze    | - 40 <mark>%</mark> |          | 40%    | 10.0                                    | 40%               | Ma alle  | 40%    | -        | 40%               | -                   |
| Level 3    | Evaluate<br>Create  | - 20 <mark>%</mark> | 101      | 30%    |   | 30%               |          | 30%    | -        | 30%               | -                   |
|            | Total               | 10                  | 0 %      | 10     | 0 %                                     | 10                | 0 %      | 10     | 0 %      | 10                | 0 %                 |

<sup>#</sup> CLA – 4 can be from any combination of these: Assignments, Seminars, Tech Talks, Mini-Projects, Case-Studies, Self-Study, MOOCs, Certifications, Conf. Paper etc.,

| Course Designers   |   |                               |
|--|---|-------------------------------|
| Experts from Industry  | Experts from Higher Technical Institutions              | Internal Experts              |
| 1. Dr. G. N. Ramchand, Saksin Life sciences Pvt Ltd, Chennai, ramchand@saksinlife.com  | 1. Prof K Subramaniam, IITM, Chennai, subbu@iitm.ac.in  | 1. Dr. S.ThyagaRajan, SRMIST  |
| <ol> <li>Dr. Karthik Periyasamy, Scientist I, Aurozymes Unit, Aurobindo Pharma Limited, Hyderabad,<br/>karthikmpk@gmail.com</li> </ol> | 2. Prof. R. B. Narayanan, SVCE, Chennai, rbn@svce.ac.in | 2. Dr.R.Vasantharekha, SRMIST |

| Cou              |           | 18BTE305T                          | Course Name                           | PHA                                     | ARMACEUTICAL BIO      | TECHNOLOGY   |                          | (                        | Course<br>Catego        | _                     | E                |                      |                         |                   | Profe                  | ssional E                    | lective | е                |               |                        | L<br>3            | T 0      | P 0      | C<br>3 |
|------------------|-----------|------------------------------------|---------------------------------------|---|-----------------------|--|--------------------------|--------------------------|-------------------------|-----------------------|------------------|----------------------|-------------------------|-------------------|------------------------|------------------------------|---------|------------------|---------------|------------------------|-------------------|----------|----------|--------|
|                  |           |                                    | C101J                                 |   | Co-requisite Courses  |  |                          | _                        | rogres                  | sive C                | ourse            | s N                  | il                      |                   |                        |                              |         |                  |               |                        |                   |          |          |        |
| Course           | Offering  | Department                         | Biotechnology                         |   | Data                  | a Book / Codes/Standards   |                          | Nil                      |                         |                       |                  |                      |                         |                   |                        |                              |         |                  |               |                        |                   |          |          |        |
| Course           | Lograin   | g Rationale                        |                                       |   |                       |  |                          | -                        |                         |                       |                  |                      |                         |                   |                        |                              |         |                  |               |                        |                   |          |          | _      |
| (CLR):           |           | The                                | purpose of learning                   | this course is to:                      |                       | A STATE OF THE PARTY OF THE PAR | L                        | .earnir                  | ng                      |                       |                  |                      |                         | Pro               | gram                   | Learning                     | Outco   | omes (           | PLO)          | )                      |                   |          |          |        |
| CLR-1            |           | oraise the change                  | es the drug and huma                  | ın syste <mark>m undergoes</mark> v     | when consumed         |  | 1                        | 2                        | 3                       | 1                     | 2                | 3                    | 4                       | 5                 | 6                      | 7                            | 8       | 9                | 10            | 11                     | 12                | 13       | 14 ′     | 15     |
| CLR-2            | : Der     | monstrate the par                  | rameters that affect th               | ne act <mark>ion of drug</mark> in hui  | ıman system           |  | (m                       | (%                       | (%                      | Φ                     |                  | t                    |                         |                   |                        |                              |         | ÷                |               |                        |                   |          |          |        |
| CLR-3            |           |                                    |                                       | rea <mark>ctions and d</mark> rug abu   |                       |  | 98                       | 5                        | i t                     | bpe                   | 1                | neu                  |                         | a)                |                        |                              |         | & Team Work      |               | nce                    |                   |          |          |        |
| CLR-4            |           |                                    |                                       | <mark>and uses of</mark> antibiotics    |                       |  | g (E                     | ien                      | me                      | owle                  | <u>.v</u>        | udo                  | Ĺ.                      | age               | ഉ                      |                              |         | E                |               | ina                    | ing               |          |          |        |
| CLR-5            |           |                                    |                                       |   |                       | Indian System of medicine  | iž                       | ofic                     | tain                    | 조                     | alys             | vel                  | Design,                 | S                 | 릒                      | ∞ >                          |         | Les              | ioi           | &<br>F                 | arn               |          |          |        |
| CLR-6            | : Dis     | tinguish various p                 | parameters to be cons                 | <mark>sidered</mark> during drug dis    | scovery process       |  | Ė                        | P.                       | Ι¥                      | ing                   | Ana              | De                   | De                      | 8                 | ರ                      | bilit                        |         | ∞ _              | igat          | lgt.                   | l Le              |          |          |        |
|                  |           |                                    |                                       |   |                       | AND REAL PROPERTY.   | of                       | ted                      | Sted                    | eer                   | E                | n &                  | sis,<br>arch            | Ε                 | t/ 8                   | inal<br>inal                 |         | dua              | Ę             | ıt M                   | buc               | <u>-</u> | 7 '      | က      |
| Course<br>(CLO): |           | g Outcomes At to                   | he end of this c <mark>ourse</mark>   | <mark>, lear</mark> ners will be able t | to:                   | 100000   | evel of Thinking (Bloom) | Expected Proficiency (%) | Expected Attainment (%) | Engineering Knowledge | Problem Analysis | Design & Development | Analysis, E<br>Research | Modern Tool Usage | Society & Culture      | Environment & Sustainability | Ethics  | Individual 8     | Communication | Project Mgt. & Finance | ife Long Learning | PSO.     | PSO.     | PSO.   |
| CLO-1            | . Sel     | ect appropriate ta<br>ameters      | arget, drug-lik <mark>e candid</mark> | <mark>dat</mark> es based on desired    | d pharmacokinetic and | d pharmacodynamic  | 1                        | 80                       | 80                      | М                     | Н                | L                    | Н                       |                   | U)                     | L                            | Н       | L                | L             | L                      | H                 | Н        |          | Н      |
| CLO-2            |           |                                    | f drug to be administe                | ered for individuals                    |                       |  | 2                        | 85                       | 75                      | М                     | Н                | 1                    | Н                       |                   |                        | 1                            | Н       | М                | ,             | Н                      | Н                 | Н        | Н        | -      |
| CLO-3            |           |                                    |                                       | ggest appropriate trea                  | atment                |  | 2                        | 75                       | 80                      | L                     | H                | М                    | Н                       |                   | М                      | _                            | Н       | Н                | Н             | Н                      | Н                 | Н        |          | Н      |
| CLO-4            |           |                                    |                                       | rfection in an individual               |                       |  | 2                        | 85                       | 80                      | H                     | Н                | Н                    | Н                       |                   | 101                    | Н                            | H       | H                | Н             | H                      | H                 | H        |          | Н      |
| CLO-5            |           |                                    |                                       |   |                       | nd sale of drugs in India  | 3                        | 85                       | 75                      | Н                     | Н                | Н                    | Н                       | Н                 | М                      | H                            | Н       | Н                | Н             | Н                      | Н                 | Н        |          | Н      |
| CLO-6            |           |                                    |                                       | igation of drug designi                 |                       |  | 2                        | 80                       | 80                      | Н                     | Н                | Н                    | Н                       | М                 | М                      | М                            | Н       | Н                | Н             | Н                      | Н                 | Н        |          | Н      |
|                  |           | •                                  |                                       |   | The second second     |  |                          | -                        | -                       |                       |                  |                      |                         |                   |                        |                              |         |                  | •             |                        |                   |          |          |        |
| Durati           | on (hour) |                                    | 9                                     |   | 9                     | 9  | -                        |                          |                         |                       |                  |                      |                         | 9                 |                        |                              |         |                  |               |                        | 9                 |          |          |        |
| S-1              | SLO-1     | Basic concepts                     | - 178                                 | Plateau principle                       | V. A.                 | Pharmacovigilance  | и                        |                          |                         |                       | Mecha            | anism                | of action               | of Te             | tracyc                 | lines                        |         | В                |               |                        |                   | -        | hoteryc  | in     |
| 3-1              | SLO-2     | Pharmacopoeia                      | and Essential <mark>Drugs</mark>      | Target level strategy                   | Y 11                  | Casualty assessment  |                          |                          |                         |                       | Uses,<br>Tetrac  |                      | rum of a<br>s           | ctivity           | , toxici               | ty of                        |         | Spect<br>effect: |               |                        |                   |          | erse     |        |
|                  | SLO-1     | Local routes of                    | drug administrat <mark>ion</mark>     | Prolongation of drug                    | action                | Side, secondary and toxic e  | ffects                   | of dru                   | gs                      |                       |                  | nism                 | of action               | of an             | ni <mark>no</mark> gly | <mark>rcos</mark> ide        |         |                  |               |                        |                   |          | eofulvin | ,      |
| S-2              | SLO-2     | Systemic routes administration     | s of drug                             | Target delivery devic                   | ces                   | Accidental overdose of drug  | s and                    | the tre                  | eatmen                  | t                     | Classi           | ficatio              | n, Uses                 | of am             | inogly                 | osides                       |         | Mecha<br>and T   |               |                        |                   |          |          |        |
| 2.0              | SLO-1     | Influence of pH<br>molecules acros |                                       | Principles of drug act                  | tion                  | Drug Intolerance and Drug a  | allergy                  |                          | H                       | Vi.                   | Mecha            | nism                 | of acti <mark>on</mark> | of Ma             | acrolid                | e <mark>a</mark> ntibio      |         | Indian           |               |                        |                   |          |          |        |
| S-3              | SLO-2     |                                    | ort and facilitated                   | Mech <mark>anism of dru</mark> g a      | action on enzymes     | Drug abuse and Treatment   |                          |                          | Εİ                      |                       | Classi           | ficatio              | n <mark>of M</mark> ac  | rolide            | antibi                 | otics                        |         | Drug i           | Regu          | latory                 | body              | - CDS    | CO       |        |
| C 4              | SLO-1     | Absorption of Di                   | rugs                                  | Mechanism of drug a                     |                       | Classification of anti-microbic chemical structure   | ial age                  | ents ba                  | sed or                  | 1                     | Specti           | rum of               | activity                | of Ma             | crolide                | antibioti                    | cs      | Hierai           | rchy a        | at CD                  | sco               |          |          |        |
| S-4              | SLO-2     | Bioavailability                    |                                       | Mechanism of drug a                     |                       | Classification of anti-microbinechanism of action  | ial age                  | ents ba                  | sed or                  | 1                     | Uses a           | and to               | xicity of I             | Macro             | lide ar                | ntibiotics                   |         | Good             | clinic        | al Pra                 | actices           | }        |          |        |
| S-5              | SLO-1     | Distribution and drugs             | Redistribution of                     | Action-Effect sequen                    | ace                   | Drug modification and altera   | ition o                  | f targe                  | t site b                | y                     | Treatn           | nent o               | f Urinary               | tract             | infecti                | ons                          |         | Role o           | of Pha        | armac                  | ists in           | Drug     | regulati | ion    |

| Duratio | n (hour) | 9   | 9  | 9  | 9   | 9  |
|---------|----------|---|--|--|---|--|
|         | SLO-2    | Tissue storage, placental & brain transport | Transducer mechanism   | Reduction in drug accumulation and alteration of metabolic pathway by microorganisms | Structure, adverse effects of Isoniazid                         | Functions of State Drug-Inspectors                                 |
| S-6     | SLO-1    | Biotransformation of drugs and types        | Dose-Response Relationship   | Mechanism of action of Co-trimoxazole  | Mechanism of action of Isoniazid                                | Functions of CDSCO   |
|         | SLO-2    | Cytochrome P450                             | Therapeutic efficiency   | Uses and adverse effects of cotrimoxazole  | Structure, adverse effects of Rifampicin                        | Functions of Central Drug-Inspectors                               |
| 0.7     | SLO-1    | Non-synthetic biotransformation reactions   | Synergystic drug action  | Mechanism of action of Fluoroquinolones  | Mechanism of action of Rifampicin                               | Ayurvedic Formulary of India                                       |
| S-7     | SLO-2    | Synthetic biotransformation of drugs        | Antagonistic drug action   | Classification, Uses and adverse effects of Fluoroquinolones                         | Structure, Mechanism of action, adverse effects of Pyrazinamide | Ayurvedic Dosage Forms   |
| S-8     | SLO-1    | Inhibition of drug metabolism               | Fixed dose combination of drugs  | Structure of beta-lactum antibiotics   | Structure, Mechanism of action, adverse effects of Ethambutol   | Ayurvedic Pharmacopoeia of India                                   |
| 3-0     | SLO-2    | Induction of microsomal enzymes             | Factors modifying drug action  | Classification of beta-lactum antibiotics  | Tuberculosis in pregnant and lactating women                    | Ayurvedic, Unani, Siddha drugs<br>undertaken by British commission |
| S-9     | SLO-1    | I ROUTES OF EXCRETION OF ARUSE              | Pharmacogenetics and Pharmacogenomics                                      | Uses of beta-lactum antibiotics  | Tuberculosis in HIV infected individuals in India               | Indian Government Initiatives to promote Ayurvedic products        |
| 3-9     | SLO-2    |   | Drug dosage in individuals with hepatic, renal, heart and thyroid problems | Adverse effects of beta-lactum antibiotics   | Mycobacterium Avium Compl <mark>ex infectio</mark> ns in India  | Indian Government Initiatives to promote Unani and Siddha products |

| Learning  | 1. Rang and Dale, "Pha <mark>rmacolog</mark> y", Churchill Livingstone, 2007.  | 3. | http://www.cdsco.nic.in/forms/contentpage1.aspx?lid=1888           |
|-----------|--|----|--|
| Resources | 2. Tripathi.K.D, "Essentials of Medical Pharmacology", Jaypee Brothers Medical Publishers, New Delhi, 7th Edition, 2013. | 4. | cdsco.nic.in <mark>/writeread</mark> data/guidance%20documents.pdf |

| Learning | Assessment        |         |          | 25 /51) a VA |                    |                    |                  |         |          |                   |                     |
|----------|-------------------|---------|----------|--------------|--------------------|--------------------|------------------|---------|----------|-------------------|---------------------|
|          | Bloom's           |         |          | Conti        | nuous Learning Ass | essment (50% weigh | ntage)           |         |          | Final Evamination | a (EOO) (waightaga) |
|          |                   | CLA – 1 | 1 (10%)  | CLA – 2      | 2 (15%)            | CLA - 3            | 3 (15%)          | CLA – 4 | (10%)#   |                   | n (50% weightage)   |
|          | Level of Thinking | Theory  | Practice | Theory       | Practice           | Theory             | Practice         | Theory  | Practice | Theory            | Practice            |
| Level 1  | Remember          | 40 %    |          | 30%          |                    | 30%                | Carlotte Control | 30%     |          | 30%               |                     |
| Level I  | Understand        | 40 70   | a fee    | 3076         |                    | 3076               |                  | 30%     |          | 3070              | -                   |
| Level 2  | Apply             | 40 %    |          | 40%          |                    | 40%                |                  | 40%     |          | 40%               | _                   |
| LEVEI Z  | Analyze           | 40 70   | 754      | 4070         |                    | 4070               | -                | 4070    |          | 4070              | _                   |
| Level 3  | Evaluate          | 20 %    |          | 30%          |                    | 30%                |                  | 30%     |          | 30%               |                     |
| Level 3  | Create            | 20 70   |          | 3070         |                    | 3070               | -                | 3076    |          | 3070              | -                   |
|          | Total             | 100     | ) %      | 100          | ) %                | 100                | ) %              | 100     | %        | 10                | 0 %                 |

<sup>#</sup> CLA – 4 can be from any combination of these: Assignments, Seminars, Tech Talks, Mini-Projects, Case-Studies, Self-Study, MOOCs, Certifications, Conf. Paper etc.,

| Course Designers  | CA-LEVP TERM  |                                 |
|---|---|---------------------------------|
| Experts from Industry   | Experts from Higher Technical Institutions              | Internal Experts                |
| 1. Dr. G. N. Ramchand, Saksin Life sciences Pvt Ltd, Chennai, ramchand@saksinlife.com   | 1. Prof. K Subramaniam, IITM, Chennai, suubu@iitm.ac.in | 1. Mr. S. Karthik, SRMIST       |
| 2. Dr. Karthik Periyasamy, Scientist I, Aurozymes Unit, A <mark>urobindo Pha</mark> rma Limited,<br>Hyderabad, karthikmpk@gmail.com | 2. Prof. R. B. Narayanan, SVCE, Chennai, rbn@svce.ac.in | 2. Mr. M. K. Jaganathan, SRMIST |

| Course          | 18BTE306T                                  | Course Name                          | BIOINFORMATICS   |                       |                  |                          | Course                  | e Categor                | v E              |                         |                               | Dr                | fession          | al Elov  | ativo.                    |               |                        | L           | Т      | Р     | С      |
|-----------------|--|--------------------------------------|--|-----------------------|------------------|--------------------------|-------------------------|--------------------------|------------------|-------------------------|-------------------------------|-------------------|------------------|----------|---------------------------|---------------|------------------------|-------------|--------|-------|--------|
| Code            | 100123001                                  | Course maine                         | BIOINFORMATICS   |                       |                  |                          | Course                  | Calegor                  | у С              |                         |                               | FI                | 16221011         | ai Elec  | Clive                     |               |                        | 3           | 0      | 0     | 3      |
| Pre-re          | quisite Courses                            | Nil                                  | Co-requisite Course                                      | s Nil                 |                  |                          |                         | Progres                  | sive C           | Ourses                  |                               | Nil               |                  |          |                           |               |                        |             |        |       | $\neg$ |
|                 | ing Department                             | Biotechnology                        | Data Book /  |                       | ndards           |                          | Nil                     | Trogroo                  | 0110 0           | ourooo                  |                               | 1 111             |                  |          |                           |               |                        |             |        |       |        |
|                 | <b>y</b> = -p                              | , = <b>3 /</b>                       |  | - 10                  |                  | 7                        |                         |                          |                  |                         |                               |                   |                  |          |                           |               |                        |             |        |       |        |
|                 | ning Rationale (CLR                        |                                      | The purpose <mark>of learning this co</mark> urse is to: |                       |                  | Learnin                  |                         |                          |                  |                         |                               |                   |                  |          | utcomes                   |               |                        |             |        |       |        |
|                 |  | ses in bioinformatics                |  |                       | 1                | 2                        | 3                       | 1                        | 2                | 3                       | 4                             | 5                 | 3 7              | 8        | 9                         | 10            | 11                     | 12          | 13     | 14    | 15     |
|                 |  | nment to find similar                |  |                       |                  | Expected Proficiency (%) | ŧ                       | 471                      |                  |                         |                               | Φ                 |                  |          |                           |               |                        |             |        |       |        |
|                 |  | uild hierarchical linea              |  |                       | Б                | Sien                     | Expected Attainment (%) |                          | Sis.             |                         | Analysis, Design,<br>Research | Modern Tool Usage | שַ               |          | Individual & Team<br>Work | _             |                        | Learning    |        |       |        |
|                 | Apply principles of the Analyze motifs and |                                      | d te <mark>rtiary struct</mark> ures of proteins         |                       | Thinking         | rofic                    | ttair                   |                          | aly              | Ħ                       | esiç                          | <u> </u>          | t &              | ≥        | <u>a</u>                  | aţio          | ∞ŏ                     | earr        |        |       |        |
|                 |  |                                      | Bioinformatics applications                              | W-11                  | 본                | РР                       | Αþ                      | liring<br>Age            | A                | a se                    | ),<br>D                       | To T              | aer Jer          | <u> </u> | <u>8</u>                  | 1.25          | Mgt                    | g Le        |        |       | ~      |
| CLIN-0.         | Analyze uses of Fyl                        | ulon programming in                  | Biolition matter applications                            | -                     | Level of (Bloom) | ecte                     | scte                    | Engineering<br>Knowledge | Problem Analysis | Design &<br>Development | ysis<br>earc                  | ern               | Environment &    | alli y   | ĭ ļiģi ↓                  | Communication | Project Mgt. & Finance | Life Long l | -      | PS0-2 | - 3    |
| Course Learn    | ning Outcomes (CLC                         | ))·                                  | At the end of this course, learners will be able to:     |                       | Block            | dx (%                    | × × %                   | ligi.                    | rop              | esi<br>eve              | nal<br>Rese                   | Joh               | iv i             | Sustair  | je                        | Ę             | roje                   | <u>i</u> e  | PSO    | SO    | SO     |
|                 |  |                                      | ics to build databases for universal usage               | 100                   | 1                | 80                       | 80                      | H                        | Н                | Н                       | H                             |                   | л L              | b H      | <u>. = &gt;</u><br>I H    | . <u> </u>    | Н                      | H           | Н      | Н     | H PSO  |
| CLO-2:          |  |                                      | alignment between similar sequences of DNA or F          | Protein               | 2                | 85                       | 75                      | Н                        | Н                | Н                       | Н                             |                   | M                |          |                           | Н             | Н                      | Н           | Н      | Н     | Н      |
| CLO-3:          |  | tern of lineage <mark>s and e</mark> |  |                       | 2                | 80                       | 80                      | М                        | Н                | М                       | Н                             | М                 | 1                | N        |                           | Н             | Н                      | Н           | Н      | Н     | Н      |
| CLO-4:          | Discuss the differen                       | nt methods in the co                 | nstruction the structure of a protein                    | 7.11.75               | 2                | 85                       | 80                      | М                        | Н                | Н                       | Н                             | 7                 | Н                | N        | 1 H                       | Н             | Н                      | Н           | Н      | Н     | Н      |
| CLO-5:          |  |                                      | egions in a molecular sequence                           |                       | 3                | 85                       | 75                      | М                        | Н                | Н                       | Н                             |                   | Л <mark>Н</mark> | N        |                           | L             | Н                      | Н           | Н      | Н     | Н      |
| CLO-6:          | Explain the basic co                       | oncepts and <mark>principle</mark>   | s of Programming in Python for bioinformatics            | 100                   | 3                | 80                       | 80                      | Н                        | Н                | Н                       | Н                             | L                 | 1 M              | N        | 1 H                       | Н             | Н                      | Н           | Н      | Н     | Н      |
|                 | 11   |                                      |  | 4500                  |                  |                          | 100                     | 114.5                    |                  |                         | 76                            |                   |                  |          |                           |               |                        |             |        |       |        |
| Duration (hour) |  | 9                                    | 9  |                       |                  | 9                        |                         |                          |                  |                         | 9                             |                   |                  |          |                           |               | 9                      |             |        |       |        |
|                 | Bioinformatics s                           |                                      | Introduction on databases & biological database          |                       |                  |                          |                         |                          |                  |                         | terns pre                     |                   |                  |          | troductio                 |               | ython an               | d text      | editor | S     |        |
| SLO-2           | 2 Applications of b                        |                                      | Uses of biological databases                             | Global P              |                  |                          | nt Algorit              |                          |                  |                         | motif pr                      |                   |                  |          | tring data                |               |                        |             |        |       |        |
|                 |  |                                      | t Primary sequence databases, Nucleotide                 | Solving p             |                  |                          |                         |                          |                  |                         | patterns                      |                   |                  |          | uples da                  |               |                        |             |        |       |        |
| SLO-2           | Internet Protocol                          | S                                    | Protein sequence database                                | Local Pa              |                  |                          | t Algorith              |                          |                  |                         | tabase S                      |                   |                  |          | sts datat                 |               | ,                      |             |        |       |        |
|                 | HTML script                                |                                      | Primary structure databases                              | Databas               | e searcn         | ıng                      |                         |                          |                  |                         | icture pi                     |                   |                  |          | low contr                 | oi: it e      | ise                    |             |        |       |        |
|                 | 2 Webpage creation                         |                                      | PDB file format  | BLAST                 |                  |                          |                         |                          |                  |                         | ndary sti<br>condary          |                   |                  |          | or loop                   |               |                        |             |        |       |        |
| S-4 SLO-        |  |                                      | Fasta, GCG, VFF etc                                      | FASTA                 | No.              |                          |                         | p                        | redict           | ion                     | 7                             |                   | e                |          | /hile loop                |               |                        |             |        |       |        |
|                 | Uses of human g                            |                                      | Secondary databases                                      | Multiple              |                  |                          |                         |                          |                  |                         | ire predi                     |                   |                  |          | eading a                  |               |                        |             |        |       |        |
| S-5 SLO-        |  | nodel: Introduction                  | secondary sequence databases                             | Progress              |                  |                          |                         |                          |                  |                         | nodelling                     | 1                 |                  |          | lodules ir                | n Pytho       | on                     |             |        |       |        |
|                 | SEQ-lds BIOSEQs and BI                     | IOCEO CET-                           | secondary structure databases                            | Tools for             |                  |                          |                         |                          |                  | modeli                  |                               |                   |                  |          | unctions                  |               | · · · · ·              | .4          |        |       |        |
| S-6 SLO-        | I BIOSEQS and BI                           | IUSEQ-SETS                           | SCOP LINE 1  | tools for             |                  |                          |                         |                          |                  |                         | ertiary <mark>st</mark>       |                   |                  | R        | egular ex                 | kpressi       | ions: Syr              | ntax        |        |       |        |
| SLO-            | SEQ-ANNOT and                              | •                                    | CATH   | Applicati<br>Alignmei | nt               |                          | -                       | Li .                     |                  |                         | lo <mark>gy m</mark> o        |                   |                  |          | egex exa                  | •             |                        |             |        |       |        |
|                 | I Genbank databa                           |                                      | Composite protein databases                              | Databas               |                  |                          | lignment                |                          |                  |                         | ure <mark>val</mark> id       |                   |                  |          | iopython                  |               |                        |             |        |       |        |
| SLO-            | Genbank Flat file                          |                                      | Metabolic databases                                      | Molecula              |                  |                          |                         |                          |                  |                         | alization                     | tools             |                  |          | dvantage                  |               |                        |             |        | cs    |        |
|                 | Sequence submi                             |                                      | SNP databases  | Methods               |                  | geny                     |                         |                          | asmol            |                         |                               |                   |                  |          | omponei                   |               |                        |             | abet   |       |        |
| SLO-7           | Online and offline                         | e tools                              | Whole genome , medelian disease databases                | types of              |                  |                          |                         |                          |                  |                         | ture bui                      |                   |                  |          | eq, Seq                   |               |                        |             |        |       |        |
|                 | 1 Entrez , INSDC                           |                                      | chemical structure databases                             | Tools for             | pnyloge          | eny                      |                         | f                        | ile forr         | nats for                | small m                       | oiecule           | 3                |          | lign and                  |               |                        |             |        |       |        |
| S-9 SLO-2       | Other databases                            | in NCBI                              | bibliographic databases                                  | PAM and               | BLOSU            | JM                       |                         | fi                       | ile forr         | nat con                 | version t                     | ools              |                  |          | LAST Rι<br>iopython       |               | ana Prod               | cessin      | g with |       |        |

| Learning  | 1. Andreas D Baxevanis & B F Francis, "Bioinformatics- A practical guide to analysis of Genes & Proteins", John Wiley, 2002 | 3. | Jin Xiong, "Essential Bioinformatics", Cambridge University Press, 2006    |
|-----------|---|----|--|
| Resources | 2. T K Attwood, D J Parry-Smith," Introduction to Bioinformatics", Pearson Education, 1st Edition, 11th Reprint 2005.       | 4. | Sebastian Bassi, "Python for Bioinformatics", 2nd Edition CRC Press, 2017. |

| Learning / | Assessment             |        |                   |                   |              |        |          |         |          |                   |                     |
|------------|------------------------|--------|-------------------|-------------------|--------------|--------|----------|---------|----------|-------------------|---------------------|
|            | Bloom's                |        | Final Evamination | n (50% weightage) |              |        |          |         |          |                   |                     |
|            | Level of Thinking      | CLA –  | 1 (10%)           | CLA –             | 2 (15%)      | CLA –  | 3 (15%)  | CLA – 4 | 4 (10%)# | Filiai Examinatio | ii (50% weigiilage) |
|            | Level of Thinking      | Theory | Practice          | Theory            | Practice     | Theory | Practice | Theory  | Practice | Theory            | Practice            |
| Level 1    | Remember<br>Understand | 40 %   | -                 | 30%               |              | 30%    | HAVE     | 30%     | -        | 30%               | -                   |
| Level 2    | Apply<br>Analyze       | 40 %   |                   | 40%               | The state of | 40%    | 73       | 40%     | 1        | 40%               | -                   |
| Level 3    | Evaluate<br>Create     | 20 %   |                   | 30%               |              | 30%    | - 1      | 30%     | -        | 30%               | -                   |
|            | Total                  | 100    | ) %               | <b>1</b> 0        | 0 %          | 10     | 0 %      | 10      | 0 %      | 10                | 0 %                 |

| Course Designers   |  |  |
|--|--|--|
| Experts from Industry  | Experts from Higher Technical Institutions                     | Internal Experts   |
| Mr. Raghu R.Schrondinger, raghu <mark>.rangasw</mark> amy@schrodinger.com  | Dr.G. Ramesh kumar, AU-KBC Research Centre, gramesh@au-kbc.org | Dr. Priya Swaminathan, SRM Institute of Science & Technology, priya.s@ktr.srmuniv.ac.in    |
| <ol><li>Dr. Karthik Periyasamy, Scientist I, Aurozymes Unit, Aurobindo Pharma<br/>Limited, Hyderabad, karthikmpk@gmail.com</li></ol> | 2. Prof. R. B. Narayanan, SVCE,Chennai, rbn@svce.ac.in         | Mr. M.K.Jagannathan, SRM Institute of Science & Technology, jaganathan.m@ktr.srmuniv.ac.in |

| Cou<br>Co  |   | 18BTE307T  | Course Name  | ESIGNING   | Cour<br>Categ  |                         | E                                      | Ξ                |                      |                                      |                   | Profe             | ssiona                          | al Elec        | ctive                                   |                             |             |                       | L 1          | -             | P<br>0        | C<br>3 |        |  |                   |  |        |         |       |       |  |
|--|---|--|--|--|--|-------------------------|--|------------------|----------------------|--------------------------------------|-------------------|-------------------|---------------------------------|----------------|---|-----------------------------|-------------|-----------------------|--------------|---------------|---------------|--------|--------|--|-------------------|--|--------|---------|-------|-------|--|
|  | Pre-requis  | site Courses   | Nil  | Co-requisite Cour  | ses Nil  | Prod                    | ares                                   | ssive            | Cours                | ses                                  | Ni                | 7                 |                                 |                |   |                             |             |                       |              |               |               |        | $\neg$ |  |                   |  |        |         |       |       |  |
|  |   | Department   | Biotechnology  |  | / Codes/Standards  |                         | J                                      |                  |                      |                                      |                   |                   |                                 |                |   |                             |             |                       |              |               |               |        |        |  |                   |  |        |         |       |       |  |
|  | _   |  |  |  | 127 2 / 1  |                         |  |                  |                      |                                      |                   |                   |                                 |                |   |                             |             |                       |              |               |               |        |        |  |                   |  |        |         |       |       |  |
| Course<br>(CLR):   |   | g Rationale The  |  | Le   | earnir   | ng                      |  |                  |                      | F                                    | Progra            | m Le              | arning                          | Outco          | mes (P                                  | LO)                         |             |                       |              |               |               |        |        |  |                   |  |        |         |       |       |  |
| CLR-1  |   | the basic concep                                       |  |  | 1  | 2                       | 3                                      | 1                | 2                    | 3                                    | 4                 | 5                 | 6                               | 7              | 8                                       | 9 10                        | ) 11        | 12                    | 13           | 14            | 15            |        |        |  |                   |  |        |         |       |       |  |
| CLR-1 : State the basic concepts of drug discovery and drug design processes  CLR-2 : State the basic concepts of target identification and target characterization    |   |  |  |  |  |                         |  |                  |                      | a                                    |                   |                   |                                 |                |   |                             |             | ㅗ                     |              |               |               |        |        |  |                   |  |        |         |       |       |  |
| CLR-3: Explain about the various computational tools in drug discovery   |   |  |  |  |  |                         |  |                  | )t (                 | gpe                                  |                   | Jeu               |                                 |                |   |                             |             | رة<br>ا               | 1 20         |               |               |        |        |  |                   |  |        |         |       |       |  |
| CLR-4  |   |  | rmacophore Model a                                     |  | and the state of t |                         | g (E                                   | ien              | meı                  | )WE                                  | .00               | ndc               | ر'                              | age            | æ                                       |                             |             | Ē                     | in a         | Learning      |               |        |        |  |                   |  |        |         |       |       |  |
|  | CLR-5: Discuss about the quantum mechanics in drug design, De novo and future developments in drug design |  |  |  |  |                         |  |                  |                      | Ä                                    | alys              | · ke              | Design,<br>۱                    | N <sub>S</sub> | 릨                                       | જ _                         |             | <u>i</u> .   <u>6</u> | %            | arı           |               |        |        |  |                   |  |        |         |       |       |  |
| CLR-6  | : Expl  | ain the basic conc                                     | epts of drug disco <mark>ve</mark>                     | <mark>ry and d</mark> rug design processes and computational to                          | ols used in the drug designing.  |                         | 늘                                      | Pr               | Att                  | ing                                  | Ans               | ا ۵               | De (                            | <u> </u> 8     | ರ                                       | oiit<br>oiit                |             | <u>∞</u>   <u>7</u>   | <u> </u>     | , e           |               |        |        |  |                   |  |        |         |       |       |  |
|  |   |  |  |  | 7.6 2 12507-1  |                         | of J                                   | ted              | ted                  | eer                                  | E                 | ∞ .               | sis,<br>arch                    | Ξ              | £ ∞                                     | inat                        |             | dua                   | ≥            | buc           | _             | . 2    | - 3    |  |                   |  |        |         |       |       |  |
| Course<br>(CLO):   | e Learnino  |  | 8  | Level of Thinking (Bloom)  | Expected Proficiency (%)   | Expected Attainment (%) | Engineering Knowledge                  | Problem Analysis | Design & Development | Analysis, <mark>L</mark><br>Research | Modern Tool Usage | Society & Culture | Environment &<br>Sustainability | Ethics         | Individual & Team Work<br>Communication | Project Mat. & Finance      | Life Long L | PSO.                  | PSO.         | PSO           |               |        |        |  |                   |  |        |         |       |       |  |
| CLO-1  |   |  |  | <mark>ess</mark> es for a various number of drug development so                          | cenarios.  |                         | 1                                      | 85               | 80                   | L                                    | Н                 | Н                 | Н                               | Н              |   | М                           | М           | Н                     |              | Н             | Н             | Н      | Н      |  |                   |  |        |         |       |       |  |
| CLO-2  |   |  |  | ation and target characterization  | A DOWN   |                         | 1                                      | 85               | 80                   | L                                    | Н                 | Н                 | Н                               | Н              |   | Н                           |             | Н                     |              | Н             | Н             | Н      | Н      |  |                   |  |        |         |       |       |  |
| CLO-3  |   |  |  | for drug designing and the computer software used  | in the drug designing.   |                         | 2                                      | 80               | 70                   | М                                    | Н                 | Н                 | Н                               | Н              |   | Н                           |             | Н                     |              | Н             | Н             | Н      | Н      |  |                   |  |        |         |       |       |  |
| CLO-4  |   |  |  | ore Model and QSAR.  | CONTRACTOR OF THE PROPERTY OF  |                         | 1                                      | 80               | 70                   | М                                    | Н                 | Н                 | Н                               | Н              |   | Н                           |             | Н                     |              | Н             | Η             |        |        |  |                   |  |        |         |       |       |  |
| CLO-5  |   |  |  | Mechanics in drug designing and De nova ligand s   |  |                         | 1                                      | 85               | 80                   | М                                    | Н                 | Н                 | Н                               | Н              |   | Н                           |             | Н                     |              | Н             | Н             |        | Н      |  |                   |  |        |         |       |       |  |
| CLO-6  | :  Sum  | marize the basic c                                     | concepts in t <mark>he drug</mark>                     | design process and the computational techniques u  | sed in the drug design process.  |                         | 1                                      | 80               | 70                   | М                                    | Н                 | Н                 | Н                               | Н              |   | Н                           |             | Н                     |              | Н             | Н             | Н      | Н      |  |                   |  |        |         |       |       |  |
| Durati   | on (hour)   |  | 0  | 9  | 9  |                         | ÷                                      |                  | - 44                 |                                      |                   | 9                 |                                 |                |   |                             |             |                       | 9            |               |               |        |        |  |                   |  |        |         |       |       |  |
| Durati   | ` '   | Introduction to the                                    | o drug discovory                                       | Target Identification: Primary Sequence and  | introduction to computational t  | oole in                 | dru                                    | α                |                      |                                      |                   |                   |                                 |                |   | Quantum Mechanics in drug d |             |                       |              |               |               |        | -      |  |                   |  |        |         |       |       |  |
| S-1  | SLO-1   | process  |  | Metabolic Pathway,   | discovery  | )013 III                | uru                                    | 9 и              | /hat is              | a pha                                | rmac              | cophor            | re Mod                          | lel .          |   |                             |             |                       |              |               |               |        |        |  |                   |  |        |         |       |       |  |
|  | SLO-2   | The sequence of<br>in the developme                    | f research act <mark>ivities</mark><br>ent of new drug | Crystallography and 2D NMR, Homology Models and Protein Folding in target identification | Introduction to Homology Mod   | el Build                | ding                                   | C                | Сотро                | nents                                | of a              | Pharm             | nacoph                          | ore M          | odel                                    |                             |             | ntum m<br>ar mec      |              | nics is<br>s? | supe          | erior  |        |  |                   |  |        |         |       |       |  |
| S-2  | SLO-1   | "hits," "leads," "di<br>"drugs,"                       |  | Analysis of Target Mechanism: Kinetics and Crystallography, Automated Crevice Detection, | Importance of sequence similar homology modeling   | rity in                 |  |                  | reatin<br>ctive      |                                      |                   |                   | ore M <mark>o</mark>            | del fro        | m the                                   | Qua                         | ntum I      | Лесhar                | nics A       | lgorithi      | ns            |        |        |  |                   |  |        |         |       |       |  |
| 3-2  | SLO-2   | Criteria that may<br>move a compour<br>lead developmen | nd series onto the                                     | Transition Structures and Reaction Coordinates.  | Steps for Building a Homology  | Model                   | odel                                   |                  | odel                 |                                      | odel              |                   | el                              |                |   |                             | Advantages  |                       | ges of pharm |               | armacophore s |        | ching  |  | ntum I<br>I desig |  | nics S | oftware | e use | ed in |  |
| S-3  | SLO-1   | Homology Model creation                                |  | Homology Model creation  |  |                         | A                                      | ctive .          | Site                 |                                      |                   | ore Mo            |                                 |                | <sup>e</sup> Mod                        | leling s                    | ystem       | s with                | metal        | aton          | าร            |        |        |  |                   |  |        |         |       |       |  |
| SLO-2   Compound Testing: Cell-Based   Molecular dynamics in target characterization   Homology Model va   |   |  |  |  |  |                         |  | tŀ               | xamp<br>ne Act       |                                      |                   | nacopl            | hore M                          | lodel f        | rom                                     | Incre                       | eased       | accura                | су           |               |               |        |        |  |                   |  |        |         |       |       |  |
| S-4  | SLO-1   | Compound Testi   | ng: Animal Testing                                     | Pharmacophore identification   | Molecular Mechanics: Brief Inti<br>Molecular Mechanics   |                         |  | S                | Search               | ing Co                               | ompo              | und D             | atabas                          | es             |   | Con                         | nputing     | reacti                | on pa        | ths           |               |        |        |  |                   |  |        |         |       |       |  |
| J-4  | SLO-2   | alternatives to an                                     | · ·  | Deriving and using 3D pharmacophores   | How molecular mechanics are drug design.   | utilized                | d in                                   | R                | Reliabi              | lity of                              | seard             | ch Res            | sults                           |                | _                                       | Com                         | nputing     | specti                | ra           |               |               |        |        |  |                   |  |        |         |       |       |  |
| S-5 SLO-1 Compound Testing: Human Clinical The Drug Design Process for a Known Protein Target: The Structure-Based Design Process Force Fields for Drug Design Process |   |  |  |  |  |                         | ign QSAR Structure-based De novo Ligan |                  |                      |                                      |                   |                   |                                 | nd s           | ynth                                    | esis                        |             |                       |              |               |               |        |        |  |                   |  |        |         |       |       |  |

| Durat | ion (hour) | 9  | 9   | 9   | 9   | 9   |
|-------|------------|--|---|---|---|---|
|       | SLO-2      | Phases in clinical trials                                  | The Drug Design Process for a Known Protein<br>Target: Initial Hits and Compound Refinement,<br>ADMET | common force fields and their usage                     | Conventional QSAR versus 3D-QSAR                | Example of De novo Ligand synthesis   |
| 0.0   | SLO-1      | Effect of Molecular Structure on Activity                  | What is Drug Resistance   | Introduction to Molecular Docking                       | The QSAR Process                                | Nonquantitative predictions   |
| S-6   | SLO-2      | Effect of Molecular Structure on Bioavailability           | Mechanisms of resistance to the drug  | Search Algorithms in Molecular Docking                  | Descriptors                                     | Quantitative predictions  |
|       | SLO-1      | Drug Side Effects and Toxicity                             | The Drug Design Process for an Unknown Target: The Ligand-Based Design Process                        | The Docking Process: Preparation of Protein and Ligand  | Automated QSAR Programs                         | Future Developments in Drug Design:<br>Individual Patient Genome Sequencing |
| S-7   | SLO-2      | Multiple Drug Interactions                                 | The Drug Design Process for an Unknown Target: Initial Hits and Compound Refinement, ADMET            |   | QSAR versus Other Fitting Methods               | Analysis of the Entire Proteome   |
| c o   | SLO-1      | Metrics for Drug-Likeness                                  | Drug Design for Other Targets   | Docking Options and Running the Docking Calculation     | The 3D-QSAR Process                             | Drugs Customized for Ethnic Group or Individual Patient                     |
| S-8   | SLO-2      | The Lipinski rule of fives                                 | Drug design issues that arise in situations other than competitive inhibition of proteins.            | Analysis of docking Results                             | Criteria are used to construct conformers       | Application of Genetic Manipulation in drug designing                       |
|       | SLO-1      | Exceptions to the Rules                                    | Targets inside cells  | Docking software  | 3D-QSAR Software Packages                       | Cloning and Stem Cells in drug design                                       |
| S-9   | SLO-2      | Examples of successful drugs that do not obey the "rules." | Targets within the central nervous system   | An important criterion for selecting a docking program. | Advantage and disadvantages of 3D-QSAR Software | Longevity   |

|           | 1. | Young, "Computational Drug Design: a Guide for Computational and Medicinal Chemists", Wiley,     |
|-----------|----|--|
| Learning  |    | 2009   |
| Resources | 2. | Andrew Leach, "Molecular Modeling: Principles and applications," 2nd edition, Pearson Education, |
|           |    | 1996   |

- Andrew Leach, "An introduction to Chemoinformatics," Springer, 2007
   Rick NG, "Drugs: From Discovery to Approval," John Wiley & Sons, 2004.
   Paul S Charifson, "Practical Application of Computer-Aided Drug Design," Informa Health Care,

| Learning A | Assessment                   |        |                  | 4 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - |          |        |             |         |                        |                  |                   |
|------------|------------------------------|--------|------------------|---|----------|--------|-------------|---------|------------------------|------------------|-------------------|
| _          | Dia ami'a                    |        | Final Evaminatio | n /EOO/ waightoga)                      |          |        |             |         |                        |                  |                   |
|            | Bloom's<br>Level of Thinking | CLA –  | 1 (10%)          | CLA –                                   | 2 (15%)  | CLA -  | 3 (15%)     | CLA – 4 | 4 (1 <mark>0%)#</mark> | Final Examinatio | n (50% weightage) |
|            | Level of Triinking           | Theory | Practice         | Theory                                  | Practice | Theory | Practice    | Theory  | Practice               | Theory           | Practice          |
| Level 1    | Remember<br>Understand       | 40 %   | 1                | 30%                                     | - 11     | 30%    | - 17        | 30%     |                        | 30%              | -                 |
| Level 2    | Apply<br>Analyze             | 40 %   |                  | 40%                                     |          | 40%    | 135         | 40%     | 811-                   | 40%              | -                 |
| Level 3    | Evaluate<br>Create           | 20 %   | <b>1</b> - 3     | 30%                                     | VD V     | 30%    | in mives of | 30%     | <b>M</b> -             | 30%              | -                 |
|            | Total                        | 100    | ) %              | 10                                      | 00 %     | 10     | 0 %         | 10      | 0 %                    | 10               | 0 %               |

| Course Designers   |  |                                    |
|--|--|------------------------------------|
| Experts from Industry  | Experts from Higher Technical Institutions                               | Internal Experts                   |
| 1. Dr. G. N. Ramchand, Saksin Life sciences Pvt Ltd, Chennai, ramchand@saksinlife.com                          | <ol> <li>Prof. K Subramaniam, IITM, Chennai, suubu@iitm.ac.in</li> </ol> | 1. Mr. Jaganathan. M. K. SRMIST    |
| Dr. Karthik Periyasamy, Scientist I, Aurozymes Unit, Aurobindo Pharma Limited, Hyderabad, karthikmpk@gmail.com | 2. Prof. R. B. Narayanan, SVCE, Chennai, rbn@svce.ac.in                  | 2. Dr. S. Priyaswaminathan. SRMIST |

| Cou<br>Co |   | 18BTE308T Course Name                                  | MARINE BIOTECHNOLO   | OGY                            |  |   | Cou<br>Cate              | irse<br>gory          | Е                          |                               |                         | F                 | rofes                           | sional E      | Electiv                                      | /e                 |                        |                    | L<br>3     | T<br>0 | P C 0 3 |
|-----------|---|--|--|--------------------------------|--|---|--------------------------|-----------------------|----------------------------|-------------------------------|-------------------------|-------------------|---------------------------------|---------------|--|--------------------|------------------------|--------------------|------------|--------|---------|
| F         | Pre-reauis  | ite Courses Nil  | Co-requisite Courses   |                                | Nil  |   |                          | Progres               | sive C                     | ourses                        |                         | Nil               |                                 |               |  |                    |                        |                    |            |        |         |
|           |   | Department Biotechnology                               |  | ok / Codes/Sta                 | andards  |   | Nil                      | g.                    |                            |                               |                         |                   |                                 |               |  |                    |                        |                    |            |        |         |
| Course    | e Learning  | Rationale (CLR):                                       | The purpose of learning this course is to:                       | -11                            |  | Learning  |                          |                       |                            |                               |                         | Prog              | ram L                           | earning.      | Outo   | comes (            | PLO)                   |                    |            |        |         |
| CLR-1     |   | n the knowledge of the living and non-                 |  |                                | 1  | 2   | 3                        | 1                     | 2                          | 3                             | 4                       | 5                 | 6                               | 7             | 8  | 9                  | 10                     | 11                 | 12         | 13     | 14 15   |
| CLR-2     |   | yze the pharmacological potency of to                  |  |                                | >  | ¥   |                          |                       |                            | THE STATE OF                  |                         |                   |                                 |               |  |                    |                        |                    |            |        |         |
| CLR-3     |   | y the biopolymers from various source                  |  |                                | 0  | Expected Proficiency (%)  | Expected Attainment (%)  |                       | S                          |                               | <u> </u>                | Modern Tool Usage | Ð                               |               |  | Ε                  |                        |                    | ng         |        |         |
| CLR-4     |   | erstand the commercialization of marin                 |  |                                | ki<br>King   | ofici   | aj.                      |                       | lysi                       |                               | sign                    | Us                | 草                               | જ ્           |  | ea                 | on                     | ంగ                 | in.        |        |         |
| CLR-5     |   | rol measures of various marine pollution               |  | Ë                              | Pr   | Att   | g o                      | Ina                   | ent                        | Ğ                             | 00                      | C                 | ent                             |               | ~<br>~                                       | cati               | gt.                    | Les                |            |        |         |
| CLR-6     | : Anal  | yze the techniques on the resource ma                  | 4000   | of Thinking<br>n)              | eg   | ted   | eri<br>edg               | m/                    | ∞ rd                       | is,                           | n_T                     | ∞<br>>            | nm<br>nab                       |               | la   | iun                | e E                    | ng                 | _          | 2 %    |         |
|           |   |  | 100  | Level of<br>(Bloom)            | 960  | Dec -   | Engineering<br>Knowledge | Problem Analysis      | Design &<br>Development    | Analysis, Design,<br>Research | der                     | Society & Culture | Environment &<br>Sustainability | Ethics        | Individual & Team<br>Work                    | Communication      | Project Mgt. & Finance | Life Long Learning | PS0 - 1    | PSO -  |         |
| Course    |   |  | <mark>At the end of this course, learners will be able to</mark> |                                | E E  | % E   | ¥ %                      | ᇍᅐ                    |                            | De De                         | An<br>Re                | Mo                | Soc                             | Sug           | 댪  | 일                  |                        |                    | Life       |        |         |
| CLO-1     |   | cribe the economically important <mark>marin</mark>    | e resources and their wealth.                                    | 7 5 5 7 1                      | 1  | 80  | 80                       | М                     | H                          | Н                             | Н                       | Н                 |                                 | Н             | Н  | Н                  | Н                      | Н                  | Н          | Н      | H H     |
| CLO-2     |   | ain the natural toxins.                                | 一件一  | 100                            | 2  | 85  | 75                       | М                     | Н                          | Н                             | Н                       | Н                 |                                 | Н             | Н  | Н                  | Н                      | Н                  | Н          | Н      | H H     |
| CLO-3     |   | nguish the availability of bioact <mark>ive com</mark> | pounds.  | OR SHEET                       | 2  | 80  | 80                       | Н                     | Н                          | Н                             | Н                       | Н                 |                                 | Н             | Н  | Н                  | Н                      | Н                  | Н          | Н      | H H     |
| CLO-4     |   | yze the useful natural products.                       |  |                                | 2  | 85  | 80                       | М                     | Н                          | M                             | М                       | Н                 |                                 | М             | Н  | Н                  | Н                      | Н                  | Н          | Н      | H H     |
| CLO-5     |   | v the degradation process for <mark>discharg</mark>    |  |                                | 3  | 85  | 75                       | М                     | М                          | Н                             | H                       | Н                 |                                 | Н             | Н  | Н                  | Н                      | Н                  | Н          | Н      | H       |
| CLO-6     | : Expla   | ain the diseases of cultivable <mark>animals a</mark>  | and its controlling measures.                                    | 100                            | 2  | 80  | 80                       | М                     | Н                          | Н                             | Н                       | Н                 |                                 | Н             | Н  | Н                  | Н                      | Н                  | Н          | Н      | H H     |
| Durati    | on (hour)   | 9  | 9  | PARTY.                         |  | 9   |                          | -                     |                            |                               | -6                      | 9                 |                                 |               |  |                    |                        | 9                  |            |        |         |
| Baran     |   | Zonation of the Sea                                    | Toxic marine animals   | Bioactive co.                  | mpounds  |   |                          | 57.                   | C                          | oil spills                    | and acc                 | idents            | 3                               |               | S  | hrimp a            | iseas                  |                    |            |        |         |
| S-1       |   | Motion of the Ocean                                    | Octopus, venomous spines, stings                                 |                                | ionolymers Omega-3 fetty acids Eate of spilled oil |   |                          |                       |                            |                               | N                       | lonodor<br>vcosis |                                 |               | vibrio                                       | sis, la            | irval                  |                    |            |        |         |
|           | SLO-1   | Living resources                                       | Sources of toxins  | Free radicals                  | S  |   | 20                       | 1                     | В                          | Biosurfactants                |                         |                   |                                 | Fish diseases |  |                    |                        |                    |            |        |         |
| S-2       | SLO-2   | Corals, seaweeds and mangroves                         | TTX, conotoxin   | Antioxidant e                  | enzymes,   | , peptide   | s                        |                       | Microbes in biodegradation |                               |                         |                   |                                 |               | Rhabdovirus, erythrodermatitis, gill disease |                    |                        |                    |            |        | ill     |
| 0.0       | SLO-1   | Non-living resources                                   | Various effects of toxin   | Biopolymers                    |  |   |                          |                       | H                          | larmful l                     | blooms                  |                   |                                 |               | Α  | ntibiotic          | s in a                 | quacult            | ure        |        |         |
| S-3       | SLO-2   | Oil, gas and salts                                     | Intoxication, stings   | Collagen, ge                   |  |   |                          |                       | В                          | lue-gree                      | en algal                | bloon             | n, red                          | tides         |  | xytetra            |                        |                    |            | 7      |         |
|           |   | Economically important animals                         | Puffer fish toxins   | Anticoagular                   | nt substa  | nces  |                          |                       |                            |                               | armful b                |                   |                                 |               | lr.  | nmunos             | timula                 | nts                |            |        |         |
| S-4       | SLO-2   | FInfishes  | Tetrodotoxin   | Heparin                        | H.   |   |                          |                       | lr                         | npacts (                      | of bloon                | )                 |                                 |               |  | bjective<br>nmunos |                        |                    | teristic   | cs of  |         |
|           | SLO-1   | Penaeid shrimps  | Intoxication of puffer toxin                                     | Biomaterials                   |  | -   |                          |                       | F                          | esticide                      | pollutio                | n                 |                                 |               | С  | ommon              | immı                   | ınostim            | ulants     |        |         |
| S-5       |   | Penaeus indicus  | Pharmacological effects  | Chitin, Chito                  | san  | 4p  | 1                        | HV.                   | C                          |                               | hlorine,                |                   | ophos                           | sphate        | N  | <b>l</b> uramyl    | dipep                  | tide, lev          | /amisc     | le     |         |
|           | SLO-1   | Non-penaeid shrimps                                    | Molluscan venoms   | Poly unsatur                   | rated fatt   | y acids   |                          |                       |                            |                               | etal poli               | ution             |                                 |               | Τ  | ools to            | diagno                 | se the             | diseas     | se     |         |
| S-6       | SLO-2   | Omega 3-fat  | tty acids  |                                |  |   | ٨                        | linamat               | a diseas                   | e                             |                         |                   | te                              | est           |  |                    |                        | scent              | t antibody |        |         |
| S-7       |   | Marine crabs   | Pharmacology of conotoxin  | Applications                   |  |   |                          |                       | C                          | hemica                        | <mark>l an</mark> d bid | ologica           | al mo                           | dificatio     | n V  |                    |                        |                    |            |        |         |
| 5-1       |   | Portunidae crabs                                       | Clinical effects of conotoxin                                    | Antiinflamma                   | atory, car   | diovasci  | ular, diab               | etes                  |                            |                               | on, facto               |                   | ecting                          | 7             | T  | empera             |                        |                    |            |        |         |
| S-8       |   | Edible Oysters   | Seafood poisoning  | Fat soluble pigments Solid was |  |   |                          | Solid waste pollution |                            |                               |                         |                   | Salinity                        |               |  |                    |                        |                    |            |        |         |
| 3-0       |   |  |  |                                |  | Carotenoids Plastic waste degradation   |                          |                       |                            | Dissolved oxygen, pH          |                         |                   |                                 |               |  |                    |                        |                    |            |        |         |
| S-9       | SLO-1 Pearl Oysters Sources of ciguateratoxin Sources |  |  |                                |  | Sources of carotenoids Microbes for degradation Nutrients                         |                          |                       |                            |                               |                         |                   |                                 |               |  |                    |                        |                    |            |        |         |
| 3-9       |   |  |  |                                |  | Micro algae, sponges, mollusks, crustaceans Factors affecting degradation Ammonia |                          |                       |                            |                               |                         |                   |                                 |               |  |                    |                        |                    |            |        |         |

|           | 1. | Milton Fingerman and Rachakonda Nagabhushanam, "Recent Advances in Marine         |
|-----------|----|---|
| Learning  |    | Biotechnology (Series) Biomaterials and Bioprocessing", Science Publishers, 2009. |
| Resources | 2. | Proksch and Werner E.G.Muller, "Frontiers in Marine Biotechnology", Horizon       |
|           |    | Bioscience, 2006.   |

- Le Gal, Y., Ulber, R, "Marine Biotechnology I: Advances in Biochemical Engineering/Biotechnology", (Series editor: T. Scheper) Springer-Verlag Berlin Heidelberg. Vol. 96, 2005.
   Le Gal, Y., Ulber, R "Marine Biotechnology II: Advances in Biochemical engineering/Biotechnology", (Series editor:
- T. Scheper) Springer-Verlag Berlin Heidelberg. Vol. 97, 2005.

| Learning / | Assessment        |         |          |        | -1.11               | NI I              |          |        |                  |                    |                   |
|------------|-------------------|---------|----------|--------|---------------------|-------------------|----------|--------|------------------|--------------------|-------------------|
|            | Dia ami'a         |         |          | Conti  | nuous Learning Asse | essment (50% weig | htage)   |        |                  | Final Evansination | n (FOO) waishtaga |
|            | Bloom's           | CLA – 1 | l (10%)  | CLA -  | 2 (15%)             | CLA –             | 3 (15%)  | CLA –  | 4 (10%)#         | Final Examinatio   | n (50% weightage) |
|            | Level of Thinking | Theory  | Practice | Theory | Practice            | Theory            | Practice | Theory | Practice         | Theory             | Practice          |
| Level 1    | Remember          | 40 %    |          | 30%    |                     | 30%               | 1        | 30%    |                  | 30%                |                   |
| Level      | Understand        | 40 %    |          | 30%    | and the same        | 30%               |          | 30%    |                  | 30%                | -                 |
| Level 2    | Apply             | 40 %    |          | 40%    | 18.1013             | 40%               |          | 40%    |                  | 40%                |                   |
| Level 2    | Analyze           | 40 /0   |          | 40 /0  |                     | 40 /6             |          | 40 /0  | -                | 40 /0              | -                 |
| Level 3    | Evaluate          | 20 %    |          | 30%    | 15 A = 1            | 30%               |          | 30%    |                  | 30%                |                   |
| Level 3    | Create            | 20 %    |          | 30%    | LAC 47 15 C         | 30%               |          | 30%    |                  | 30%                | -                 |
|            | Total             | 100     | %        | 100    | ) %                 | 10                | 0 %      | 10     | 0 <mark>%</mark> | 10                 | 0 %               |

| Course Designers   |   | Z-                        |
|--|---|---------------------------|
| Experts from Industry  | Experts from Higher Technical Institutions              | Internal Experts          |
| Dr. G. N. Ramchand, Saksin Life sciences Pvt Ltd, Chennai, ramchand@saksinlife.com   | 1. Prof. K Subramaniam, IITM, Chennai, subbu@iitm.ac.in | 1. Dr.R.A.Nazeer, SRMIST  |
| <ol> <li>Dr. Karthik Periyasamy, Scientist I, Aurozymes Unit, Aurobindo Pharma Limited,<br/>Hyderabad, karthikmpk@gmail.com</li> </ol> | 2. Prof. R. B. Narayanan, SVCE, Chennai, rbn@svce.ac.in | 2. Dr.R.Jaiganesh, SRMIST |

| Cour     | se Code  | 18BTE403T                              | Course Nan                                       | ne VACCINE BIOTECH  | INOLOGY                  |  |                          |                  | Course<br>ategory       |                               | Е                                |                       |                               | Pr                    | ofessio                   | nal Ele          | ective                    |                      |                         |        | L T    | P 0    |        |
|----------|--|--|--|---|--------------------------|--|--------------------------|------------------|-------------------------|-------------------------------|----------------------------------|-----------------------|-------------------------------|-----------------------|---------------------------|------------------|---------------------------|----------------------|-------------------------|--------|--------|--------|--------|
| Course   |  |  | 18BTC106J<br>Biotechnology                       | Co-requisite Courses  | Nil<br>ook / Codes/S     | Standar  | do                       | Nil              | Pro                     | ogress                        | sive Cou                         | ırses                 |                               | Nil                   |                           |                  |                           |                      |                         |        |        |        |        |
| Course   | Offering   | Department                             | biolecimology                                    | Data Bu   | ok / Codes/s             | otanuan  | JS                       | IVII             |                         |                               |                                  |                       |                               |                       |                           |                  |                           |                      |                         |        |        |        |        |
| Course   | Learning   | Rationale (CLR):                       |  | The purpose of learning this course is to:                      |                          |  | Learnin                  | a                |                         |                               |                                  |                       | Proc                          | nram I                | earnin                    | a Outa           | comes (                   | PI ()                |                         |        |        |        | $\neg$ |
| CLR-1    |  | derstand the convention                | al strategies ir                                 |   |                          | 1  | 2                        | 3                | 1                       | 2                             | 3                                | 4                     | 5                             | 6                     | 7                         | 8                | 9                         | 10                   | 11                      | 12     | 13     | 14     | 15     |
| CLR-2    |  | velop an understanding                 |  |   |                          |  | _                        |                  |                         | Ī.                            |                                  |                       | Ŭ                             |                       |                           |                  |                           | 10                   |                         |        | ,,,    |        |        |
| CLR-3    |  | tegorise the types of vac              | productive or in quee                            |   |                          | lo Co  | Jen                      |                  | 1                       |                               |                                  | ge                    |                               |                       |                           | _                |                           |                      | g                       |        |        |        |        |
| CLR-4    |  | alyze different methods o              |  | ing   | ficie                    | ini  |                          | ysis             |                         | g                             | Jsa                              | ture                  | ంగ                            |                       | ear                       | E                | _                         | Тİ                   |                         |        |        |        |        |
| CLR-5    | Col  | mprehend the guidelines                | 110047   | Thinking  | Expected Proficiency (%) | Expected Attainment (%)  | D 0                      | Problem Analysis | Design &<br>Development | Analysis, Design,<br>Research | Modern Tool Usage                | Culture               | Environment & Sustainability  |                       | Individual & Team<br>Work | Communication    | Project Mgt. &<br>Finance | Learning             |                         |        |        |        |        |
| CLR-6    | Ana  | alyze the immunization of              |  | ÷ (   | Pa                       | pe /   | Engineering<br>Knowledge | ٩u               | ∞ E                     | S, C                          | Ţ                                | Society & (           | Environment<br>Sustainability |                       | <u>a</u>                  | ij               | ω MG                      | Life Long L          | _                       | 2      | က      |        |        |
|          |  |  |  | evel of Bloom)  | ect                      | ect  | ine                      | bler             | e ga                    | lysi                          | derr                             | iety                  | iror                          | SS                    | 을<br>수                    |                  | ect                       | Ē                    |                         |        | 1      |        |        |
| Course   | Learning   | Outcomes (CLO):                        | At the end of this course, learners will be able | to:   | Level of<br>(Bloom)      | d %  | dxi(%)                   | 155              | 20                      | Design &<br>Developm          | Ana                              | Moc                   | 300                           | Sus                   | Ethics                    | i je je          | 등                         | Project №<br>Finance | -ife                    | PSO    | PSO    | PSO    |        |
| CLO-1    |  |  | dge on c <mark>onve</mark> n                     | ntional strategies in vaccine production                        | 1.44.0                   | 1  | 80                       | 80               | Н                       | Н                             | H                                | Н                     |                               | M                     | L                         | Н                | H                         | Н                    | Н                       | Н      | Н      | Н      | Н      |
| CLO-2    |  | emplify the students with              |  |   | 10000                    | 2  | 85                       | 75               | Н                       | Н                             | Н                                | Н                     | М                             |                       | М                         | Н                | Н                         | Н                    | Н                       | Н      | Н      | Н      | Н      |
| CLO-3    |  | stinguish various types o              |  |   |                          | 2  | 75                       | 80               | М                       | Н                             | М                                | Н                     | М                             | М                     |                           | М                | Н                         | Н                    | Н                       | Н      | Н      | Н      | Н      |
| CLO-4    | : De   | vise various methods fo                | r vacc <mark>ine deliv</mark>                    | very  | 77.00                    | 2  | 85                       | 80               | Н                       | Н                             | Н                                | Н                     | М                             |                       | Н                         | L                | Н                         | Н                    | Н                       | Н      | Н      | Н      | Н      |
| CLO-5    |  | plain the guidelines for v             | /accin <mark>e produ</mark>                      | ction and delivery  |                          | 3  | 85                       | 75               | Н                       | Н                             | Н                                | Н                     |                               | М                     | Н                         | Н                | Н                         | L                    | Н                       | Н      | Н      | Н      | Н      |
| CLO-6    | : Illus  | strate the basic concept:              | s of v <mark>accinatio</mark>                    | n and prophylaxis   |                          | 2  | - 80                     | 80               | Н                       | Н                             | Н                                | Н                     | L                             | M                     | М                         | М                | Н                         | Н                    | Н                       | Н      | Н      | Н      | Н      |
|          |  |  |  | 121 140 172   | 4000                     | 60.0   | -77                      | 100              | 1100                    |                               |                                  |                       |                               |                       |                           |                  |                           |                      |                         |        |        |        |        |
| Duration | on (hour)  | 9                                      |  | 9   | 1000                     | - 22   | 9                        |                  | 15.5                    |                               |                                  | 9                     | )                             |                       |                           |                  |                           |                      | 9                       |        |        |        |        |
| S-1      | SLO-1  | History of vaccine deve                | elopm <mark>ent</mark>                           | Technology related to monitoring seed lot for better production | Types of va              |  |                          |                  |                         |                               | uidelines for vaccine management |                       |                               |                       |                           |                  |                           |                      |                         |        |        |        |        |
|          | SLO-2  | Types of Immunity                      | - 19   | Temperature Monitoring  | Vaccine eff              | icacy  | 1                        | E                | , Ju                    |                               | ovative<br>munoge                | method<br>ns          | s of de                       | eliverir              | ng                        | Regul            | latory is                 | sues ir              | n vaccin                | e dev  | elopn  | nent   |        |
| S-2      | SLO-1  | Conventional strategies<br>improvement | s for v <mark>accine</mark>                      | Sterilization   | Inactivated              | toxins   |                          |                  |                         | '                             | osomes                           |                       |                               |                       |                           | Regul            | latory bo                 | odies f              | or vacci                | ne ma  | anage  | ment   |        |
|          | SLO-2  | Current development ir                 | n vaccin <mark>es</mark>                         | Environmental strategies for better production                  | Inactivated              | whole b  | acteria                  |                  |                         | Ме                            | chanisi                          | n of lipo             | some                          | form <mark>a</mark> i | tion                      | Enviro           | onmenta                   | al effec             | ts of re                | combi  | nant v | /accin | es     |
| S-3      | SLO-1  | Types of vaccines                      |  | quality assurance and related areas in vaccine production       | Inactivated              | whole v  | virus                    |                  |                         | Cla                           | assificat                        | ion of lip            | osom                          | es                    |                           | Disea            | se secu                   | rity an              | d biose                 | curity | princi | ples   |        |
|          | SLO-2  | Live vaccine                           |  | Analysis of vaccine efficiency                                  | Live attenua             | ated bad   | cteria                   |                  |                         | Me                            | thods o                          | f liposor             | nes pr                        | epara                 | tion                      | Asses            | sing an                   | d Mon                | itoring S               | Safety | of Va  | ccine  | S      |
|          | SLO-1  | Attenuated vaccine                     |  | Vaccine Production techniques                                   | Live attenua             | ated viru  | uses                     |                  |                         | Ch                            | aracten                          | sation o              | f lipos                       | omes                  |                           | OIE -            | structu                   | re and               | mission                 | 1      |        |        |        |
| S-4      |  |  |  |   |                          | ccines   | 110                      | 0                | H                       |                               | erapeut<br>osomes                | ic applic             | ations                        | of                    |                           | OIE g            | uideline                  | s for v              | accine                  | seed l | ot ma  | nager  | nent   |
| 9.5      | SLO-1 Peptide vaccine Steps involved in vaccine production       |  |  |   |                          | ride vad   | ccines                   |                  | G.L.                    | vac                           | ccines                           | som <mark>es</mark> i |                               |                       |                           | OIE g<br>produ   | uideline<br>ction         | s for tl             | he meth                 | od of  | vaccii | те     |        |
| 3-3      | SLO-2 killed vaccine Selecting the strain for vaccine production |  |  |   |                          | l vaccine  |                          |                  |                         |                               | vantage<br>o <mark>somes</mark>  | s & disa              | <mark>dv</mark> ant           | ages (                |                           |                  |                           |                      | for Production facility |        |        |        |        |
|          | SLO-1  | Types of adjuvants                     |  | Culturing bacteria  | Recombina                |  |                          |                  |                         | Mic                           | crosphe                          | res                   |                               |                       |                           |                  | mentatio                  |                      |                         |        |        |        |        |
| S-6      | SLO-2 Mode of action of adjulyants - L'ulturing virus            |  |  |   |                          | betweint vaccir  |                          | ional and        |                         | Types of microspheres         |                                  |                       |                               |                       | Guide<br>exam             | elines fo<br>ple | r manı                    | ıfacture             | of va                   | ccine  | with a | n      |        |
| S-7      |  |  |  |   |                          | Edible vaccines Methods of preparing microspheres In process control and |                          |                  |                         |                               |                                  | nd batc               | batch control                 |                       |                           |                  |                           |                      |                         |        |        |        |        |

| Durati | on (hour) | 9   | 9   | 9                                 | 9   | 9                                     |
|--------|-----------|---|---|-----------------------------------|---|---------------------------------------|
|        | SLO-2     | Methods to access vaccine efficacy              | Inactivation of Microorganism                         | Plasma derived vaccines           | Characterisation and applications of microspheres | organization and responsibilities     |
| S-8    |           | Quality control in vaccine production           |   |                                   | ISCOMS-Properties of ISCOM based vaccines         | documentation and evaluation of data  |
| 3-0    | SLO-2     | Preservation of industrially important microbes | Preservation of industrially important microorganisms | HPV L1 VLP vaccine                | Types of ISCOM                                    | Test on final products                |
|        | SLO-1     | monitoring of microorganisms                    | Preservation using low temperature                    | Nanoparticles in vaccine delivery | components of ISCOM                               | General manufacturing recommendations |
| S-9    | SLO-2     | Seed lot systems                                | freez <mark>e drying</mark>                           |                                   | Induction of antibody responses by ISCOMs         | Final product release tests           |

| Learning<br>Resources | <ol> <li>Ronald W. Ellis, "New Vaccine Technologies", Landes Bioscience, 2001.</li> <li>Noel Mowat, "Vaccine manual: The production and quality control of veterinary vaccines for use in developing countries", Daya books, 1999.</li> </ol> | 3. Cheryl Barton, "Advances in Vaccine Technology and Delivery", Espicom Business Intelligence, 2009. |
|-----------------------|---|---|
|-----------------------|---|---|

| Learning A | Assessment         |               |            |               | 11. 45 15 15   | THE PARTY OF       |  |         |                        |                                   |                    |  |  |
|------------|--------------------|---------------|------------|---------------|--|--------------------|--|---------|------------------------|-----------------------------------|--------------------|--|--|
|            | Bloom's            |               |            | Conti         | nuous Learning Ass   | sessment (50% weig | ghtage)  |         |                        | Final Evamination                 | o (EOO/ woightogo) |  |  |
|            | Level of Thinking  | CLA – 1 (10%) |            | CLA – 2 (15%) |  | CLA –              | 3 (15%)  | CLA – 4 | 1 ( <mark>10%)#</mark> | Final Examination (50% weightage) |                    |  |  |
|            | Level of Thirtking | Theory        | Practice   | Theory        | Practice   | Theory             | Practice   | Theory  | Practice               | Theory                            | Practice           |  |  |
| Level 1    | Remember           | 40 %          |            | 30%           |  | 30%                | - 15 TO 10 T | 30%     |                        | 30%                               |                    |  |  |
| Level I    | Understand         | 40 /0         | - P. S. L. | 30 /6         | ALCOHOL:   | 30 //              | 100  | 30%     |                        | 30 /0                             | -                  |  |  |
| Level 2    | Apply              | 40 %          | - III      | 40%           | 100 to 10 | 40%                | HAROL MA   | 40%     |                        | 40%                               |                    |  |  |
| Level 2    | Analyze            | 40 /0         |            | 40 /0         | 1407   | 4070               | RESERVE TO THE   |         |                        | 40 /0                             | -                  |  |  |
| Level 3    | Evaluate           | 20 %          |            | 30%           |  | 30%                | - 1 S - 1 S - 1  | 30%     |                        | 30%                               |                    |  |  |
| revel 2    | Create             | 20 70         |            | 30 /6         |  | 3070               |  | 3070    |                        | 3070                              | -                  |  |  |
|            | Total              | 10            | 00 %       | 10            | 0 %  | 10                 | 0 %  | 10      | 0 %                    | 10                                | 0 %                |  |  |

<sup>#</sup> CLA – 4 can be from any combination of these: Assignments, Seminars, Tech Talks, Mini-Projects, Case-Studies, Self-Study, MOOCs, Certifications, Conf. Paper etc.,

| Course Designers  |   |                                |  |  |  |  |  |
|---|---|--------------------------------|--|--|--|--|--|
| Experts from Industry   | Experts from Higher Technical Institutions              | Internal Experts               |  |  |  |  |  |
| 1. Dr. G. N. Ramchand, Saksin Life sciences Pvt Ltd, Chennai, ramchand@saksinlife.com   | 1. Prof. K Subramaniam, IITM, Chennai, subbu@iitm.ac.in | 1. Dr. S.Sujatha, SRMIST       |  |  |  |  |  |
| 2. Dr. Karthik Periyasamy, Scientist I, Au <mark>rozymes U</mark> nit, Aurobindo Pharma Limited, Hyderaba, karthikmpk@gmail.com | 2. Prof. R. B. Narayanan, SVCE, Chennai, rbn@svce.ac.in | 2. Dr. Suvankar Ghorai, SRMIST |  |  |  |  |  |

| Cour<br>Cod      |        | 18BTE404T                                | Course Name  | MOLECULAR B   | ASIS OF DRU    | IG ACTION  |                               |                          |                         | urse<br>egory                                | E                |                      |  |                     | Profes                 | sional E                               | lective | )                      |   |                        | <u>L</u>             | T<br>0 | P<br>0  | C<br>3   |
|------------------|--------|--|--|---|----------------|--|-------------------------------|--------------------------|-------------------------|--|------------------|----------------------|--|---------------------|------------------------|--|---------|------------------------|---|------------------------|----------------------|--------|---------|----------|
| Р                | re-rea | uisite Courses                           | Nil  | Co-requisite Courses                                      | Nil            |  |                               |                          |                         | Progre                                       | essive           | Cours                | es                                       | Nil                 |                        |  |         |                        |   |                        |                      |        |         |          |
|                  |        | ng Department                            | Biotechnology  |   |                | ok / Codes/Standar   | rds                           |                          |                         | . regic                                      |                  | 0000                 |  | 1                   |                        |  |         |                        |   |                        |                      |        |         |          |
|                  |        |  |  |   |                | - 1 T. A   |                               |                          |                         |  |                  |                      |  |                     |                        |  |         |                        |   |                        |                      |        |         |          |
| Course<br>(CLR): | Learn  | ing Rationale T                          | he purpose of learning thi                                     | s course is to:   |                | C'IL   | 1                             | _earnii                  | ng                      |  |                  |                      |  | Pro                 | gram l                 | Learning                               | g Outo  | omes                   | (PLO)   |                        |                      |        |         |          |
| CLR-1            | St     | tate the basic kno                       | wledge of drug targets an                                      | d m <mark>olecular clonin</mark> g of these targ          | jets.          |  | 1                             | 2                        | 3                       | 1  | 2                | 3                    | 4  | 5                   | 6                      | 7                                      | 8       | 9                      | 10  | 11                     | 12                   | 13     | 14      | 15       |
| CLR-2            |        |  |  | om <mark>ent in human</mark> drug target : G-p            |                | d receptors.   | E E                           | %                        | (%                      | Φ  |                  |                      |  |                     |                        |  |         | ×                      |   | <b>a</b> >             |                      |        |         |          |
| CLR-3            |        |  |  | o <mark>ment in hu</mark> man drug target : ion           |                |  | l<br>evel of Thinking (Bloom) | Expected Proficiency (%) | Expected Attainment (%) | Engineering Knowledge                        | 7.0              | Design & Development |  | (D)                 |                        |  |         | Individual & Team Work |   | Project Mgt. & Finance |                      |        |         |          |
| CLR-4:           |        |  |  | <mark>oment in h</mark> uman drug target : tran           |                | ns   | 9                             | ie.                      | l me                    | NO N   | <u>.v</u>        | opr                  | c'                                       | ⊤ Modern Tool Usage | ഉ                      |  |         | E                      |   | i.                     | ⊥ Life Long Learning |        |         |          |
| CLR-5:           |        |  |  | <mark>nfluence</mark> s their response to therap          | peutic drugs.  | No. 10 176   | iž                            | ofic                     | tain                    | 조  | Problem Analysis | see.                 | Design,                                  | ñ                   | Society & Culture      | Environment & Sustainability           |         | l e                    | Communication                                       | ∞                      | ä                    |        |         |          |
| CLR-6:           | Di     | iscuss about the c                       | drug targets and thei <mark>r role l</mark>                    | i <mark>n he</mark> alth and disease.                     |                |  | 喜                             | 7                        | ¥                       | ing  | Ang              | ۵                    | ا ل                                      | 8                   | Ō                      | el iii                                 |         | ∞                      | ica   | ¶gt.                   | Fe                   |        |         |          |
| -                |        |  |  |   |                | N. P. S. 1999  | <u>م</u>                      | ctec                     | stec                    | ee   | E H              | ∞<br>⊑               | sis                                      | Ē                   | Ę.                     | nina ani                               | (0      | enp                    | nu  | t<br>t                 | on o                 | Τ.     | - 2     | - 3      |
|                  | Learn  | ing Outcomes A                           | t the end of this c <mark>ourse, le</mark>                     | earners will be able to:                                  | 1000           |  | skel                          | (pe                      | Kpe                     | jē.  | lqo.             | esic                 | Analysis, E<br>Research                  | ode                 | ocie                   | Jyir                                   | Ethics  | iĕ                     | omr.  | oje                    | e<br>L               | PSO    | OSd     | H PSO    |
| (CLO):           |        |  |  |   |                | Checkly  |                               |                          | Û 00                    | <u>ū</u>                                     |                  | ă                    | A  | Ž                   | Ϋ́                     | <u>ш х</u>                             |         | =                      | ŭ   | ᇫ                      | <u>:</u>             | ď      |         | <u>ď</u> |
| CLO-1<br>CLO-2   |        |  | he drug targets <mark>and metho</mark>                         | a to clone arug targets.                                  |                |  | 1                             | 85                       | 80<br>70                | L  | H                | H                    | H  | Н                   |                        | M<br>H                                 | М       | H                      |   |                        | Н                    | H      | H       | Н        |
| CLO-2            |        | xplain about G pro<br>xplain about vario | otein coupled receptors.                                       |   |                |  | 1                             | 80                       | 75                      | L  | Н                | Н                    | Н  | Н                   |                        | Н                                      |         | Н                      |   |                        | Н                    | Н      | Н       | Н        |
| CLO-4            |        | xplain about vario<br>xplain about vario |  |   |                | The second   | 1                             | 85                       | 80                      |  | Н                | Н                    | Н  | H                   |                        | Н                                      |         | Н                      |   |                        | Н                    | H      | Н       | Н        |
| CLO-5            |        |  |  | nfluences their response to thera                         | neutic drugs   | A STATE OF THE STA | 1                             | 80                       | 70                      | ī  | Н                | Н                    | Н  | Н                   |                        | Н                                      | Н       | Н                      |   |                        | H                    | H      | H       | Н        |
| CLO-6            |        |  | he drug targets <mark>and thei</mark> r r                      |   | ipcuiic drugs. | 77777  | 2                             | 85                       | 80                      | Ī  | Н                | Н                    | H  | М                   |                        | Н                                      | M       | Н                      |   |                        | Н                    | H      | Н       | Н        |
| 020 0            | . 100  | anninance accat ti                       | to arag targete and their re                                   | sie in nearth and dicedes.                                |                |  |                               | 1 00                     | 00                      | L-   |                  |                      |  | 101                 |                        | - ''                                   |         |                        |   |                        |                      | •      |         |          |
| Dura             | tion   |  | 9  | 9   |                |  | 9                             | 7 1                      | -                       | -  | -                | -                    |  | 9                   |                        |  |         |                        |   |                        | 9                    |        |         |          |
| (ho              | ır)    |  | Э  |   | - 10.33        |  | 9                             |                          |                         |  |                  |                      |  | 9                   |                        |  |         |                        |   |                        | 9                    |        |         |          |
| SI               | .0-1   |  | nolecular pharm <mark>acology</mark>                           | Introduction to GPCRs and H<br>G-protein                  | leterotrimeric | introduction to io   | n chan                        | nels                     | Tr.                     |  | intro            | ductio               | Transpo                                  | orter pr            | roteins                |  | Ту      | pes o                  | f gene  | tic van                | iation               |        |         |          |
| S-1<br>SI        | .0-2   |  | ular pharmacolo <mark>gy based</mark><br>d to interrogate drug | molecular structure of GPCR                               |                | Classification of  | ion cha                       | annels                   |                         |  | class            | sificatio            | on of Trai                               | nsporte             | er pr <mark>ote</mark> | eins                                   |         | niopuri<br>ardiac      |   |                        |                      |        |         |          |
| S-2              | .0-1   | Molecular pharm pharmacology             | nacology vs traditional  | Classification of GPCR                                    | 2              | introduction to Ve   | oltage-                       | gated                    | ion cha                 | nnels  | Tran<br>inter    |                      | r families                               | of pha              | armacc                 | ological                               |         | olymor                 |   |                        | •                    |        |         |          |
|                  | .0-2   | Importance of m                          | olecular pharmacology.   | Activation of GPCR  | AT AT          | structure of Volta   |                               | 200                      |                         |  | The              | major                | facilitator                              | super               | family                 | (MFS)                                  | afi     | fferent<br>fecting     | drug .  | metab                  | olism                |        | norphi  | sms      |
| S-3              | .0-1   | Nature of the Dr                         | ug targets   | Signal transduction pathways phospholipase C and adenyly  | yl cyclase     | Voltage-gated io disease   |                               | 11                       |                         | and  | MFS              | in hea               | alth                                     |                     |                        |  | ро      | ethods<br>lymor        | ohism   | S                      |                      |        |         |          |
|                  | .0-2   | Future drug targ                         |  | Measurement of phospholipa<br>adenylyl cyclase activation |                | Voltage-gated ion neurotransmission  | on                            |                          |                         |  |                  |                      | n diseas                                 |                     |                        |  |         | CR-RF<br>nalysis       |   | alysis                 | and L                | arge-s | scale S | SNP      |
| S-4              | .0-1   | DNA to drug disc                         |  | Desensitization and down-reg<br>GPCR signalling           |                | Voltage-gated ion contraction  | n chan                        | nels a                   | nd mus                  | The neurotransmitter: sodium symporter (NSS) |                  |                      |  |                     | mporter                | Genetic variation in drug transporters |         |                        |   |                        |                      |        |         |          |
|                  | .0-2   | The relevance o                          | f recombinant DNA<br>narmacology/drug discove                  | Role of GPCR phosphorylation desensitisation              | on in          | Voltage-gated Ca   | a2+ ch                        | annels                   | 3                       |  | Gltpl            | n trans              | porters                                  |                     |                        |  |         |                        | Multi-drug resistance protein MDR1 (P-glycoprotein) |                        |                      |        |         |          |
|                  |        | j., ,                                    | <u> </u>   |   |                |  |                               |                          |                         |  |                  |                      | Multi-drug resistance associated protein |                     |                        |  |         |                        |   |                        |                      |        |         |          |

Voltage-gated Na+ channels

S-5 SLO-1

The 'cloning' of drug targets

Constitutive GPCR activity

(MRP) transporters

Leucine Transporter(LeuTAa)

Multi-drug resistance associated protein

| Duration<br>(hour) | 9   | 9   | 9  | 9   | 9  |
|--------------------|---|---|--|---|--|
| SLO-2              | Cloning using peptide sequence(s)   | Promiscuous G-protein coupling                                    | otein coupling Voltage-gated K+ channels NSS in health and disease |   | Organic anion-transporting polypeptide (OATP) transporters |
| SLO-1              | Synthesis of cDNA, and construction of a cDNA library   | Agonist-directed signalling                                       | Other types of voltage-gated ion channels                          | Sodium antiporters                            | Genetic variation in G protein coupled receptors           |
|                    | screening of a cDNA library   | Allosteric modulators of GPCR function                            | CatSper channels   | NhaA Na+:H+ antiporter (NhaA) family          | Genetic variation within the adrenergic receptor family    |
| SLO-1              | Cloning using a specific antibody, a functional assay and Polymerase chain reaction.  | Pharmacological chaperones for GPCRs                              | Ligand-gated ion channels  | The cell penetrating peptides (CPP)           | β1-adrenergic receptor single nucleotide polymorphisms     |
| SLO-2              | What information can DNA cloning provide?   | Some key examples of GPCR mutations and their associated disease  | Pentameric ligand-gated ion channel family                         | CPP in health and disease                     | Are β1AR SNPs risk factors for heart failure?              |
| SLO-1              | Pharmacologic profile of the 'cloned' and the 'native' drug target  | GPCR dimerisation   | Nicotinic acetylcholine receptors                                  | ATPase transporters                           | β2AR SNPs and asthma                                       |
| SLO-2              | 'cloned' and the 'native' drug target   | Methods to study GPCR dimerisation                                | 5-HT3 receptor channels and GABAA receptors                        | ATPase transporters in health and disease     | β2AR SNPs and cardiovascular function                      |
| SLO-1              | Reverse pharmacology  | GPCR splice variants 1  | P2X receptor structure, signalling and pharmacology                | Role of transporters in drug pharmacokinetics | Functional consequences of the Trp64Arg<br>SNP             |
| SLO-2              | Reverse pharmacology illustrat <mark>ed on orphan GPCRs and the control of the control </mark> | Clinical and pathophysiological relevance of GPCR splice variants | Therapeutic potential of P2X receptors                             | Role of transporters in cellular homeostasis  | β3AR Trp64Arg SNP: disease associations                    |

| Learning  |
|-----------|
| Resources |

- Chris Lloyd Mills, Fi<mark>ona Free</mark>man, Christian Thode, Shiva Sivasubramaniam, John Dickenson, "Molecular pharmacology: from DNA to drug discovery ", Wiley-Blackwell, 2012.

  2. Michael Palmer, Alice Chan, Thorsten Dieckmann, John Honek, "Biochemical Pharmacology", Wiley, 2012.

- Terry Kenakin, "Pharmacology in drug discovery: understanding drug response", Mica Haley, 2016.
  Rang and Dale, "Pharmacology", Churchill Livingstone, 2007.

| Learning / | Assessment                   |        | 100      |        |                       | 450               | 1.00     |         |                        |                                   |                      |  |  |
|------------|------------------------------|--------|----------|--------|-----------------------|-------------------|----------|---------|------------------------|-----------------------------------|----------------------|--|--|
|            | Diagrafia                    |        |          | Con    | tinuous Learning Asse | essment (50% weig | htage)   |         |                        | Final Evansination                | · (EOO) ···oimbtomo) |  |  |
|            | Bloom's<br>Level of Thinking | CLA –  | 1 (10%)  | CLA -  | - 2 (15%)             | CLA -             | 3 (15%)  | CLA – 4 | 4 (10 <mark>%)#</mark> | Final Examination (50% weightage) |                      |  |  |
|            | Level of Thinking            | Theory | Practice | Theory | Practice              | Theory            | Practice | Theory  | Practice               | Theory                            | Practice             |  |  |
| Level 1    | Remember<br>Understand       | 40 %   |          | 30%    | - 1                   | 30%               | - 1,37   | 30%     |                        | 30%                               | -                    |  |  |
| Level 2    | Apply<br>Analyze             | 40 %   |          | 40%    | -34                   | 40%               |          | 40%     | # 11 -                 | 40%                               | -                    |  |  |
| Level 3    | Evaluate<br>Create           | 20 %   |          | 30%    | M.Y.                  | 30%               | FHAN     | 30%     | -                      | 30%                               | -                    |  |  |
|            | Total                        | 10     | 0 %      | 10     | 00 %                  | 10                | 0 %      | 10      | 0 %                    | 10                                | 0 %                  |  |  |

<sup>#</sup> CLA - 4 can be from any combination of these: Assignments, Seminars, Tech Talks, Mini-Projects, Case-Studies, Self-Study, MOOCs, Certifications, Conf. Paper etc.,

| Course Designers  |   |                                 |
|---|---|---------------------------------|
| Experts from Industry   | Experts from Higher Technical Institutions              | Internal Experts                |
| 1. Dr. G. N. Ramchand, Saksin Life sciences Pvt Ltd, Chennai, ramchand@saksinlife.com                             | 1. Prof K Subramaniam, IITM, Chennai, suubu@iitm.ac.in  | 1. Mr. Jaganathan. M. K. SRMIST |
| 2. Dr. Karthik Periyasamy, Scientist I, Aurozymes Unit, Aurobindo Pharma Limited, Hyderabad, karthikmpk@gmail.com | 2. Prof. R. B. Narayanan, SVCE, Chennai, rbn@svce.ac.in | 2. Mr. S. karthik. SRMIST       |

| Cou<br>Co      |           | 18BTE309T          | Course Name                              | PLANT NUTRITION AND   | PHYSIOLOGY  |                  |                          | Cou<br>Cate             |   | Е                            |                         |                               | Pro               | ofessio     | onal Ele   | ective |                           |               |              | L<br>3    | T<br>0 | P<br>0 | C<br>3 |
|----------------|-----------|--------------------|--|---|---|------------------|--------------------------|-------------------------|---|------------------------------|-------------------------|-------------------------------|-------------------|-------------|--|--------|---------------------------|---------------|--------------|-----------|--------|--------|--------|
| F              | re-requis | ite Courses        | Nil                                      | Co-requisite Courses Nil  |   |                  |                          | Pı                      | ogressiv  | e Cou                        | irses                   | Nil                           |                   |             |  |        |                           |               |              |           |        |        |        |
|                |           | Department         | Biotechnology                            |   | Book / Codes/S  | tandards         |                          | Nil                     | og. coc.  |                              |                         | 1                             |                   |             |  |        |                           |               |              |           |        |        |        |
|                |           |                    |  |   | 1000  |                  | <i>e</i>                 |                         |   |                              |                         |                               |                   |             |  |        |                           |               |              |           |        |        |        |
|                |           | Rationale (CLR     |  | The purpose of learning this course is to:  |   |                  | Learning                 | ,                       |   |                              |                         |                               |                   |             |  |        | mes (P                    | LO)           |              |           |        |        |        |
| CLR-1          |           |                    |  | mited by the availability of fresh water and n                                    | utrients  | 1                | 2                        | 3                       | 1   | 2                            | 3                       | 4                             | 5                 | 6           | 7  | 8      | 9                         | 10            | 11           | 12        | 13     | 14     | 15     |
| CLR-2          |           |                    | f proton pumps in plan                   |   |   |                  | ıcy                      | art .                   | V. W  |                              |                         |                               | 9                 |             |  |        |                           |               |              | _         |        |        |        |
| CLR-3<br>CLR-4 |           |                    |  | trien <mark>ts from soil</mark> into the plant body<br>macronutrient deficiencies |   | Б                | Expected Proficiency (%) | Expected Attainment (%) |   | Sis                          |                         | Analysis, Design,<br>Research | Modern Tool Usage | Culture     |  |        | Individual & Team<br>Work | _             |              | Learning  |        |        |        |
| CLR-4          |           |                    |  | es on global nutrient cycles  |   | Thinking         | Jol                      | ıttai                   | CD.   | Problem Analysis             | Ę                       | esić                          |                   | Jultu       | Environment & Sustainability                                 |        | E Te                      | Communication | ∞ઇ<br>.:     | earı      |        |        |        |
| CLR-6          |           |                    |  | y, limitation and a toxic level of a micronutrie                                  | ent   | Ę                | B<br>T                   | ν p <sub>o</sub>        | arin dge  | ٦A۲                          | s eme                   | ري<br>دي ک                    | To                | 8<br>O      | mer<br>abil  |        | al 8                      | nic           | Mg           | g L       |        | 2      | 3      |
| OLITO          |           | torprot tiro piane | respondes to denoising                   | y, miniation and a toxic forci of a micronation                                   |   | Level of (Bloom) | ecte                     | ecte                    | Engineering<br>Knowledge  | olen                         | Design &<br>Development | lysi                          | lern              | Society & ( | iron<br>tain   | SS     | vidu<br>k                 | JML           | Project Mgt. | Life Long | -      | `.`    | 1      |
| Course         | Learning  | Outcomes (CLC      | O):                                      | At the end of this course, learners will be al                                    | ole to:   | evel             | <b>₩</b>                 | x %                     | E &   | Prof                         | Dev<br>Dev              | Ana<br>Res                    | Moc               | Soc         | Sus  | Ethics | Individ<br>Work           | Son           | Proj         | <u>i</u>  | PSO    | PSO    | PSO.   |
| CLO-1          |           |                    | -water relations, <mark>uptak</mark>     |   | 40.00   | 1                | 80                       | 80                      | M   | Н                            | Н                       | Н                             | M                 | Н           | Н  | Н      | H                         | Н             | Н            | H         | Н      | H      | Н      |
| CLO-2          |           | xplain the contrib | butions of two <mark>different</mark>    | transporters to plant salinity tolerance  | 5456600   | 2                | 85                       | 75                      | М   | М                            | Н                       | Н                             | -                 | Н           | Н  | Н      | Н                         | Н             | Н            | Н         | Н      | Н      | Н      |
| CLO-3          |           |                    |  | pacts of the use of chemically synthesized fe                                     | rtilizers   | 2                | 75                       | 80                      | М   | -                            | М                       | Н                             | М                 | Н           | Н  | -      | Н                         | Н             | Н            | Н         | Н      |        | Н      |
| CLO-4          |           |                    | ent ways to ca <mark>lculate N</mark>    |   | 2010/00/00  | 2                | 85                       | 80                      | 15.   | Н                            | Н                       | Н                             | -                 | Н           | Н  | L      | Н                         | Н             | Н            | Н         | Н      |        | Н      |
| CLO-5          |           |                    | ant of influx a <mark>nd efflux</mark>   |   |   | 3                | 85                       | 75                      | М   | Н                            | Н                       | Н                             | Н                 | Н           | Н  | -      | Н                         | М             | Н            | Н         | Н      |        | Н      |
| CLO-6          | : G       | ain knowledge al   | bout the biolo <mark>gical fund</mark>   | ctions of each of the micronutrients  |   | 2                | 80                       | 80                      | М   | М                            | Н                       | Н                             | -                 | Н           | Н  | М      | Н                         | М             | Η            | Н         | Н      | Н      | Η      |
| Durati         | on (hour) |                    | 9  | 9   | 771-17  |                  | )                        | -57-1                   |   | -                            |                         | 9                             |                   |             |  |        |                           |               | 9            |           |        |        |        |
|                |           | Plant Nutrition    | 9  | Nutrient uptake and transport   | Overview  |                  | 9                        |                         |   | Potass                       | ium                     | 9                             | _                 |             |  | Intr   | oductio                   | n             | 9            |           |        |        |        |
| S-1            |           | Water & minera     | al nutrients                             | Overview  | Plant nutrient r  | requireme        | nts and                  | fertilizers             |   |                              | shes in th              | e not n                       | otast             | ,           |  |        | ronutrie                  |               | nd Me        | tals      |        |        | -      |
|                |           | Mineral nutrient   |  | Energizing the membrane   | Macronutrients  |                  |                          |                         |   |                              | sium upta               |                               |                   |             | ion  |        | rients n                  |               |              | laio      |        |        | -      |
| S-2            |           |                    |  |   |   |                  |                          |                         |   |                              |                         |                               |                   |             |  |        | аро- а                    |               |              | t & me    | embra  | ne     |        |
|                | SLO-2     | Macronutrients     | & micronutrie <mark>nts</mark>           | Plasma membrane proton ATPases  | The most abur   | ndant min        | eral elen                | nent in a               | plant   l   | Biphas                       | sic uptak               | e respor                      | ise               |             |  |        | sporter                   |               |              |           |        |        |        |
|                | SLO-1     | Water uptake a     | nd transport                             | Vacuolar pumps  | Nitrogen metal  | bolism           |                          |                         | į.  | Sulfur                       |                         |                               |                   |             |  | Iror   | 1                         |               |              |           |        |        |        |
| S-3            | SLO-2     | Physical laws      |  | Vacuolar H+-ATPase and Vacuolar H+-<br>PPase                                      | Uptake, assim   | ilation and      | d remobi                 | lization                | (   | Global                       | cycles a                | nd cells                      |                   |             |  | Αbι    | ındant,                   | impor         | tant, a      | and lar   | gely i | nsolul | ble    |
|                | SLO-1     | Membrane-hou       | nd water channels                        | Potassium Uptake  | Nitrogen regula   | ation            |                          |                         | 1.  | Sulfur                       | uptake                  |                               |                   |             |  | Cor    | per                       |               |              |           |        |        | -      |
| S-4            |           | Aquaporins         | Ta trater enamere                        | Uptake & response   | Nitrogen sensi  |                  | ling and                 | deficit                 |   |                              | R transpo               | orters                        |                   |             |  |        | ical for                  | aerob         | ic life      |           |        |        |        |
| 0.5            | SLO-1     | Movement of w      | ater                                     | Potassium Transport   | Strategies to m   |                  |                          | nmental                 | HV  | Sulfur -                     | – metab                 | olic <mark>reg</mark> u       | ılatior           | 1           | Ī  | Zin    | С                         |               |              |           |        |        |        |
| S-5            | SLO-2     |                    | nrough Soil – Plant –<br>ontinuum (SPAC) | Co-transporters, channels, The guard cell model                                   | Field-based pr  |                  |                          | ling                    | ,   | Addres                       | ssing S <mark>-c</mark> | l <mark>eficienc</mark>       | y in p            | olants      |  | Def    | ficiency                  | comm          | on in        | plants    | and    | people | е      |
|                | SLO-1     | Water uptake ir    | roots                                    | Potassium Homeostasis   | The most diver  | rse set of       | function                 | S                       | 1   | Magne                        | sium                    |                               |                   |             |  | Mai    | nganes                    | е             |              |           |        |        |        |
| S-6            | SLO-2     | From soil to ste   | le                                       | K+ mobilization is critical for K+ homeostasis                                    | Phosphorus  |                  |                          |                         |   | Magnesium in rocks and cells |                         |                               |                   |             | Central to the water-splitting, oxygen-<br>evolving reaction |        |                           |               |              |           |        |        |        |
| S-7            | SLO-1     | SPAC               |  | Sodium Toxicity, Transport, and Tolerance   | Phosphate acquisition Mg - Uptake and assimilation Zingle |                  |                          |                         | Zinc: Deficiency common in plants and people, Nickel: Necessary but rarely limiting |                              |                         |                               |                   |             |  |        |                           |               |              |           |        |        |        |

| Durat | ion (hour) | 9                               | 9  | 9  | 9                            | 9   |
|-------|------------|---------------------------------|--|--|------------------------------|---|
|       | SLO-2      | Flow of water through the xylem | The challenges of soil salinization      | Mining & foraging                            | MRS/ MGT family              | Manganese: Central to the water-splitting,<br>oxygen-evolving reaction. Metal tolerance<br>and metal hyper accumulation |
| S-8   | SLO-1      | SPAC                            | Sodium toxicity and tolerance            | Phosphate uptake & transport                 | Calcium                      | Toxic metals and metalloids   |
| 3-0   | SLO-2      | From leaf to air                | Halophytes and salt-tolerant plants      | PHT1 family                                  | Low free cytosolic levels    | Arsenic, Cadmium, Aluminum  |
| S-9   | SLO-1      | Water deficit                   | Ion pumps <mark>, channels</mark>        | Strategies                                   | Calcium uptake and transport | Essential micronutrient   |
| 3-9   | SLO-2      | Plant responses                 | Transporters contribute to Na+ tolerance | Improve crop plant phosphorus use efficiency | Calcium signaling            | Boron, Silicon, Chlorine, Selenium  |

| Learning  | 1. | Lincoln Taiz and Eduardo Zeig <mark>er, "Plant Ph</mark> ysiology", Third edition. Panima Publishing Corporation, 2003.               |
|-----------|----|---|
| Resources | 2. | Teaching Tools in Plant Biology: Lecture Notes. The Plant Cell (online) http://www.plantcell.org/content/teaching-tools-plant-biology |
|           |    |   |

| Learning . | Assessment                   |         |          |           | P Ref Guly   |                     |                   |         |          |                  |                    |
|------------|------------------------------|---------|----------|-----------|--|---------------------|-------------------|---------|----------|------------------|--------------------|
|            | Dlaam'a                      |         |          | Continuou | s Learning Asses   | sment (50% weightag | ge)               | #7/L    |          | Final Evaminatio | n /EOO/ woightogo) |
|            | Bloom's<br>Level of Thinking | CLA - 1 | (10%)    | CLA – 2   | (15%)  | CLA - 3             | 3 (15%)           | CLA – 4 | l (10%)# |                  | n (50% weightage)  |
|            | Level of Thinking            | Theory  | Practice | Theory    | Practice   | Theory              | Practice          | Theory  | Practice | Theory           | Practice           |
| Level 1    | Remember                     | 40 %    |          | 30%       | State of the state | 30%                 | and the same      | 30%     |          | 30%              | _                  |
| Level I    | Understand                   | 70 /0   |          | 3070      |  | 3070                |                   | 3070    |          | 3070             | _                  |
| Level 2    | Apply                        | 40 %    |          | 40%       | 1770   | 40%                 |                   | 40%     |          | 40%              | _                  |
| LCVCI Z    | Analyze                      | 40 70   |          | 4070      |  | 4070                | A 1 TO 100 Sec. 1 | 4070    |          | 4070             |                    |
| Level 3    | Evaluate                     | 20 %    | 1        | 30%       |  | 30%                 |                   | 30%     |          | 30%              | _                  |
| revel 2    | Create                       | 20 /0   |          | 3070      | 1 (000) (4   | 3070                |                   | 30 /0   |          | 3070             | -                  |
|            | Total                        | 100 9   | %        | 100       | %  | 100                 | ) %               | 10      | 0 %      | 10               | 00 %               |

| Course Designers  |  |                               |
|---|--|-------------------------------|
| Experts from Industry   | Experts from Higher Technical Institutions                             | Internal Experts              |
| 1. Dr. Senthil, EID Parry, Chennai, parrynutraceuticals@parry.murugappa.com | 1. Prof .Usha Vijayraghavan. IISc, Bangalore, uvr@mcbl.iisc.ernet.in   | 1. Dr. R. Pachaiappan, SRMIST |
| 2. Dr. G. N. Ramchand, Saksin Life sciences Pvt Ltd, Chennai,               | 2. Prof. Akhilesh. S. Raghubanshi, Banaras Hindu University, Varanasi, | 2 Dr. D.V.I. Carada CDMICT    |
| ramchand@saksinlife.com   | asr@bhu.ac.in  | 2. Dr. D.V.L. Sarada, SRMIST  |

| Cours  | e Code        | 18BTE310T Course Name   | PLANT HORMONES AND SIGNA   | ALING  | Cour                     |                          | Е                       |                                 |                  |                      | Pro   | ofessio             | onal E            | Elective                     |   |                        |                                      | L<br>3                                    | T<br>0   |         | 3      |
|--------|---------------|---|--|--|--------------------------|--------------------------|-------------------------|---------------------------------|------------------|----------------------|---|---------------------|-------------------|------------------------------|---|------------------------|--------------------------------------|---|----------|---------|--------|
|        |               | Ivaille   |  |  | Cale                     | JOLY                     |                         |                                 |                  |                      |   |                     |                   |                              |   |                        |                                      | 3   | U        | 0 ,     | ,      |
|        | Pre-rea       | quisite Courses Nil   | Co-requisite Courses   Nil   |  | Proc                     | aressi                   | ive Co                  | urses                           | N                | il                   |   |                     |                   |                              |   | -                      |                                      |   |          |         |        |
| Course |               | Department Biotechnology  |  | Codes/Standards N  |                          |                          |                         |                                 |                  |                      |   |                     |                   |                              |   |                        |                                      |   |          |         | ٦      |
|        |               |   |  | 21 2 / 2   |                          |                          |                         |                                 |                  |                      |   |                     |                   |                              |   |                        |                                      |   |          |         |        |
| Course |               |   | of learning this course is to:                                     | A NEW YORK   | Le                       | earnir                   |                         |                                 |                  |                      |   | Progi               | ram L             | earning                      |   |                        |                                      |   |          |         |        |
| CLR-1  |               |   | eir gro <mark>wth, developm</mark> ent, reproduction and stres     | s responses  | 1                        | 2                        | 3                       | 1                               | 2                | 3                    | 4   | 5                   | 6                 | 7                            | 8   | 9 1                    | 0 1                                  | 1 12                                      | 13       | 14 ′    | 5      |
| CLR-2  |               |   | c m <mark>ovement and m</mark> echanism of actions of auxin        |  | evel of Thinking (Bloom) | Expected Proficiency (%) | (%)                     | <u>e</u>                        |                  | _                    |   |                     |                   |                              |   | 논                      |                                      | ,   |          |         |        |
| CLR-3  |               | rpret the effects of Cytokinin, and its rece  |  |  | 300                      | 5                        | Expected Attainment (%) | Engineering Knowledge           |                  | Design & Development |   | (I)                 |                   |                              |   | Individual & Team Work | Communication  Project Mot & Finance | 3   |          |         |        |
| CLR-4  |               |   | eptors and regulation of physiological functions                   | TO SECURE OF THE | g (F                     | ie.                      | me                      | owl                             | . <u>v</u>       | do                   | Ć.  | T Modern Tool Usage | உ                 |                              |   | E                      | c                                    | H reject mgt. & ring H Life Long Learning | '        |         |        |
| CLR-5  |               |   | <mark>lings mut</mark> ated in ethylene perception, and recons     | struct a genetic pathway from  | liš                      | ofic                     | tain                    | X                               | Problem Analysis | s e                  | Analysis, De <mark>sign,</mark><br>Research | ı Š                 | Society & Culture | Environment & Sustainability |   | <u> </u>               | []<br>[ 2                            | ar   g                                    |          |         |        |
|        | aoui          | ble mutant phenotypes   |  | Service Committee  | ĪĒ                       | P.                       | A                       | ing                             | An               | ۾                    | صّ ر  | 8                   | Ö                 | ner<br>bilit                 |   | ∞ .                    | <u> </u>                             | Le St                                     |          |         |        |
| CLR-6  | :  IIIus      | strate the interactions of the core signaling   | <mark>g for</mark> controlling the functions of Abscisic acid in p | olants   | of.                      | ctec                     | ctec                    | leel                            | em               | 8 LE                 | sis   | Ē                   | ity &             | onn<br>ina                   | (0)   | enp                    | <u> </u>                             |   | <u> </u> | -2      | ی      |
| Carra  | . I a a malia | a Outcomes (CLO):   | this source to among will be able to:                              |  | - se                     | xpe                      | x be                    | ngir                            | go               | esic                 | Analysis, E<br>Resear <mark>ch</mark>       | ode                 | ocie              | nvir<br>usta                 | Ethics  | i∑                     | <u> </u>                             | fe L                                      | PSO - 1  | PSO -   | PSO.   |
| CLO-1  |               | g Outcomes (CLO):  At the end of the same | this course, learners will be able to:                             |  | 1                        | <u>ய்</u><br>80          | 部<br>80                 | L                               | M                | Н                    | ₹ œ<br>H                                    | Σ                   | M<br>M            | <u>ш ю</u>                   | H   | <u>⊆</u> (             | F Communication                      |   | H        | H       | H<br>H |
| CLO-1  | . Ga          | xplain the history, synthesis, tra <mark>nsport an</mark>   | d functions of auxin in plant life                                 | District Control   | 2                        | 85                       | 75                      | M                               | M                |                      | H   | Н                   | Н                 | M                            | Н   |                        | M F                                  |   | H        |         | Н      |
| CLO-3  | · D           | escribe the cytokinin hiosynthetic nathwa   | y, two methods of analyzing and protein kinase o                   | rascade  | 2                        |                          | 80                      | M                               |                  |                      | Н   | M                   | М                 | H                            | M   |                        | M F                                  |   | Н        |         | H      |
| CLO-4  |               |   | umulation of bioactive GAs, role of DELLAs and                     |  | 2                        |                          | 80                      | M                               |                  |                      | Н   | Н                   | M                 | M                            | M   |                        | M F                                  |   | Н        |         | H      |
| CLO-5  |               | ain knowledge the different ph <mark>ysiologic</mark> al  |  | orrysiological responses   | 3                        | 85                       | 75                      | L                               |                  | М                    | H   | М                   | M                 | H                            |   |                        | L F                                  |   |          | H       |        |
| CLO-6  |               | plain the ways that ABA affec <mark>ts develo</mark> pn   |  | OCH THE THE  | 2                        |                          | 80                      | М                               | М                | Н                    | Н   | 1                   | M                 | H                            |   |                        | и н                                  |   |          | H .     |        |
|        |               | ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,   |  |  |                          |                          |                         |                                 |                  |                      |   | -                   |                   |                              | 1   |                        |                                      |   | 1        |         | ·      |
| Durati | on (hour)     | 9   | 9  | 9  |                          | 1                        |                         |                                 |                  |                      | 9   |                     |                   |                              |   |                        |                                      | 9   |          |         |        |
| S-1    | SLO-1         |   | Historical studies of auxin  | Overview   |                          |                          | H                       | listory                         | and o            | vervie               | W   |                     |                   |                              | Abs   | scisic a               | acid                                 |   |          |         |        |
| 3-1    | SLO-2         | 1.71  | Classical studies  | The discovery of cytokinins  | 97                       | 4                        |                         | nhibitor                        |                  |                      |   |                     |                   |                              |   | nt pro                 |                                      |   |          |         |        |
|        | SLO-1         | Overview of hormone action  | Auxin signaling pathway  | Cytokinin homeostasis  |                          |                          | G                       | GA synt                         | hesis            | and h                | omeos                                       | stasis              |                   |                              |   | synthe                 |                                      |   |          |         |        |
| S-2    | SLO-2         | Signaling   | Biosynthesis and homeostasis                                       | Structure of major CKs   |                          |                          | G                       | GA dea                          | ctivat           | ion & t              | ranspo                                      | ort                 |                   |                              |   | axanth<br>CYP70        |                                      | xidase                                    | , NCE    | D, VP1  | 4      |
| S-3    | SLO-1         | Hormones and vegetative development   | Tools in auxin research  | The Agrobacterium tmr gene i<br>biosynthesis gene  | s a Ch                   | <                        | G                       | A perd                          | eptio            | n and                | signali                                     | ing                 |                   |                              | Tra   | nsport                 |                                      |   |          |         |        |
|        | SLO-2         | Auxin & cytokinin   | Experimental evidences   | CYP735A  |                          |                          | G                       | GID1 er                         | code             | s a GA               | 4 re <mark>ce</mark> p                      | otor                |                   |                              | AB.   | A mov                  | emen                                 | !   |          |         |        |
|        | SLO-1         | Vegetative development  | Auxin transport  | Formation of active CKs  |                          |                          | G                       | A-regu                          | ılated           | growt                | th repre                                    | essor               | S                 |                              | Per   | rceptio                | n and                                | signa                                     | ing      |         |        |
| S-4    | SLO-2         | Strigolactones, Gibberellins & Brassinosteroids   | Polar auxin transport  | LONELY GUY, IPT over expre   | ssion                    |                          | D                       | ELLA                            | orote            | ins                  |   |                     |                   |                              | PY  | R/RC                   | 4R                                   |   |          |         |        |
| 0.5    | SLO-1         | Hormonal control of reproductive development  | Chemiosmotic model   | CK inactivation by conjugation degradation   | or                       |                          | G                       | GA's ro                         | es in            | whole                | -plant <sub>l</sub>                         | physic              | ology             |                              |   | I1 enc                 |                                      | PP20                                      | C prote  | ein     |        |
| S-5    | SLO-2         | Transition to flowering, development of flowers and fruits  | Auxin moves through efflux and influx carrier proteins             | Cytokinin oxidase  |                          |                          | F                       | Respon<br>Howe <mark>rir</mark> |                  | salt st              | ress, s                                     | eed g               | ermin             | ation a                      |   | 2C bin<br>ase sir      |                                      | A + re                                    | cepto    | · & SnF | Κ      |
| S-6    | SLO-1         | Reproductive development  | Types of carrier proteins  | CK acts as a paracrine and a signal  | ong-d                    | listan                   | 00                      | thylen                          |                  | gasec                | ous hor                                     | mone                | )                 |                              | Cai   | lcium-c                | depen                                | •   |          | kinases | 3      |
| 3-0    | SLO-2         | Ethylene & Abscisic Acid  | AUX1 / LAX, ABCB family & PIN family                               | PUP and ENT  |                          |                          | 7                       | riple re                        | spon             | se                   |   |                     |                   |                              | ranscription factors are major argets of SnRK2s and CDPKs |                        |                                      |   |          |         |        |
| S-7    | SLO-1         | Hormonal responses to abiotic stress  | Auxin perception - receptors                                       | CK perception and signaling  |                          |                          | E                       | thylen                          | e syn            | thesis               | and ho                                      | omeos               | stasis            |                              |   | A's rol<br>I turgo     |                                      | he coi                                    | itrol o  | guard   |        |

| Durati | on (hour) | 9                                   | 9   | 9   | 9  | 9   |
|--------|-----------|-------------------------------------|---|---|--|---|
|        | SLO-2     | Abscisic Acid                       | ABP1, TIR1 and AFP protein family of F-box proteins | Two-component-like system   | Burg and Thimann's studies, The Yang cycle | SnRK2s and PP2Cs contribute to guard cell responses |
|        | SLO-1     | Hormonal responses to biotic stress | Auxin signaling                                     | Downstream of the receptors   | Ethylene response                          | ABA in whole-plant processes                        |
| S-8    | SLO-2     | Jasmonates & Salicylates            |   | Histidine phosphotransfer proteins (HPTs) and response regulators (RRs) | Receptors and downstream signaling         | drought stress                                      |
| S-9    | SLO-1     | Hormonal crosstalk                  | Auxin action  | CK action in whole-plant processes                                      | Ethylene's roles                           | surviving extreme desiccation                       |
| 3-9    | SLO-2     | Cross-talk in defense signaling     | Whole-plant processes                               | Abiotic and biotic stress responses                                     | Whole-plant processes                      | systemic stress responses                           |

| Learning  | 1. Lincoln Taiz and Eduardo Zeiger, "Plant Physiology", Third edition. Panima Publishing corporation, 2003.  | 3. Teaching Tools in Plant Biology: Lecture Notes. The Plant Cell (online) |
|-----------|--|--|
| Resources | 2. Davies, P. J., "Plant Hormones -Biosynthesis, Signal Transduction, Action", Third Edition, Springer 2010. | http://www.plantcell.org/content/teaching-tools-plant-biology.             |
|           |  |  |

| Learning | Assessment         |        |          | V /     | 11.5   | A CONTRACTOR OF THE PARTY OF TH |   |  |          |                                 |                   |  |
|----------|--------------------|--------|----------|---------|--|--|---|--|----------|---------------------------------|-------------------|--|
|          | Bloom's            |        |          | Conti   | nuous Learning Ass   | essment (50% weigh   | ntage)                                    | ************************************** |          | Final Examination (50% weightag |                   |  |
|          | Level of Thinking  | CLA -  | 1 (10%)  | CLA – : | 2 (15%)  | CLA -  | 3 (15%)                                   | CLA –                                  | 4 (10%)# |                                 | n (50% weightage) |  |
|          | Level of Thirtking | Theory | Practice | Theory  | Practice   | Theory   | Practice                                  | Theory                                 | Practice | Theory                          | Practice          |  |
| Level 1  | Remember           | 40 %   |          | 30%     | ALTERNATION OF THE PARTY OF THE | 30%  | 100                                       | 30%                                    |          | 30%                             |                   |  |
| Level    | Understand         | 40 %   |          | 30%     |  | 30%  |   | 30%                                    |          | 30%                             | -                 |  |
| Level 2  | Apply              | 40 %   |          | 40%     | Carried St.  | 40%  |   | 40%                                    |          | 40%                             |                   |  |
| Level 2  | Analyze            | 40 70  |          | 40%     |  | 40%  | - 2000                                    | 40%                                    |          | 40%                             | -                 |  |
| Level 3  | Evaluate           | 20 %   | 100      | 30%     | Real Control   | 30%  | N. 18. 18. 18. 18. 18. 18. 18. 18. 18. 18 | 30%                                    |          | 30%                             |                   |  |
| Level 3  | Create             | 20 70  |          | 30%     | the New York   | 30%  |   | 30%                                    |          | 30%                             | -                 |  |
|          | Total              | 10     | 0 %      | 100     | ) %  | 10   | 0 %                                       | 10                                     | 0 %      | 10                              | 0 %               |  |

| Course Designers  |  |                               |
|---|--|-------------------------------|
| Experts from Industry   | Experts from Higher Technical Institutions                                       | Internal Experts              |
| 1. Dr. Senthil, EID Parry, Chennai, parrynutraceuticals@parry.murugappa.com | 1. Prof .Usha Vijayraghavan. IISc, Bangalore, uvr@mcbl.iisc.ernet.in             | 1. Dr. R. Pachaiappan, SRMIST |
| 2. Dr. Karthik Periyasamy, Scientist I, Aurozymes Unit, Aurobindo Pharma    | 2. Prof. Santa Ram Joshi., Department of Biotechnology & Bioinformatics          | 2. Dr. D.V.L. Sarada, SRMIST  |
| Limited, Hyderabad, karthikmpk@gmail.com                                    | North Eastern Hill University, Shillong-793022, Meghalaya, srjoshi2006@gmail.com | 2. Dr. D.V.L. Sarada, SKMIST  |

| Course<br>Code                                 | 18BTE311T              | Course Name  | PATHOG   | ENESIS - RELATED PROTEINS IN PL  | ANTS                         |                          |                         | urse<br>egory            | Е                |                         |                               | Pr                | ofess             | ional Ele                       | ective |                           |               |                           | L<br>3             | T   1 | P<br>0 | C<br>3 |
|--|------------------------|--|--|--|------------------------------|--------------------------|-------------------------|--------------------------|------------------|-------------------------|-------------------------------|-------------------|-------------------|---------------------------------|--------|---------------------------|---------------|---------------------------|--------------------|-------|--------|--------|
| Pre-   | requisite Courses      | Nil  | Co-requisite Co  | urses Nil  |                              |                          | Pro                     | gressive                 | Cour             | ses                     | Vil                           |                   |                   |                                 |        |                           |               |                           |                    |       |        |        |
|  | ering Department       |  | Biotechnology  | Data Book / Codes/Stand  | ards                         |                          | Nil                     |                          |                  |                         |                               |                   |                   |                                 |        |                           |               |                           |                    |       |        |        |
|  | arning Rationale (CLR) |  | The purpose of learning  |  | A                            | Learning                 | 9                       |                          |                  |                         |                               |                   |                   | earning                         |        | _ `                       | PLO)          |                           |                    |       |        |        |
| CLR-1:   |                        |  |  | by mode of pathogenicity   | 1                            | 2                        | 3                       | 1                        | 2                | 3                       | 4                             | 5                 | 6                 | 7                               | 8      | 9                         | 10            | 11                        | 12                 | 13    | 14     | 15     |
| CLR-2:<br>CLR-3:<br>CLR-4:<br>CLR-5:<br>CLR-6: | Compare and evalua     | vledge about the strute the plant – insect<br>R-Proteins in physiol<br>plecular responses to | actural, catalytic mecha<br>and other pathogen in<br>ogical and developmen<br>o biotic factors | nism and regulation of PR reactions tal processes in plants rse, learners will be able to: | Level of Thinking<br>(Bloom) | Expected Proficiency (%) | Expected Attainment (%) | Engineering<br>Knowledge | Problem Analysis | Design &<br>Development | Analysis, Design,<br>Research | Modern Tool Usage | Society & Culture | Environment &<br>Sustainability | Ethics | Individual & Team<br>Work | Communication | Project Mgt. &<br>Finance | Life Long Learning |       | ``     | PSO-3  |
| CLO-1:   | Describe the three w   | ays that plants <mark>defe</mark> i  | <mark>nd the</mark> mselves against  | pathogens  | 1                            | 80                       | 80                      | М                        | Н                | Н                       | Н                             | -                 | Н                 | Н                               | М      | Н                         | Н             | Н                         | Н                  | Н     | Н      | Н      |
| CLO-2:   | Explain the physiolog  | gical functions <mark>of pat</mark>  | <mark>hoge</mark> nesis related prote  | eins in plants   | 2                            | 85                       | 75                      | М                        |                  | Н                       | Н                             | -                 | М                 | Н                               | Н      | Н                         | Н             | Н                         | Н                  | Н     | Н      | Н      |
| CLO-3:   | Comprehend the con     | cept of cell w <mark>all deg</mark>  | <mark>rad</mark> ing enzymes produ   | ced from plants as a defence   | 2                            | 75                       | 80                      | Н                        | М                | -                       | Н                             | Н                 | Н                 | Н                               | М      | Н                         | Н             | Н                         | Н                  | Н     | Н      | Н      |
| CLO-4:   | Discuss the different  | ways of resistance t   | <mark>to pathogens at molecu</mark>  | lar level  | 2                            | 85                       | 80                      | F                        | М                | Н                       | Н                             | -                 | Н                 | Н                               | М      | Н                         | Н             | Н                         | Н                  | Н     | Н      | Н      |
| CLO-5:   | Explain the important  | ce of PR-Pro <mark>teins in</mark>   | agriculture crop develo  | ppment   | 3                            | 85                       | 75                      | Н                        | Н                | Н                       | Н                             | Н                 | Н                 | Н                               | -      | Н                         | М             | Н                         | Н                  | Н     | Н      | Н      |
| CLO-6 :  | Gain knowledge about   | ut the signal <mark>s, synth</mark>  | esis, binding to the rec   | eptor and role during plant – pathogen   | 2                            | 80                       | 80                      | Н                        | М                | Н                       | Н                             | 3                 | Н                 | Н                               | М      | Н                         | М             | Н                         | Н                  | Н     | Н      | Н      |

| Durati | ion (hour) | 9   | 9   | 9   | 9  | 9  |
|--------|------------|---|---|---|--|--|
|        | SLO-1      | Pathogens make plants sick  | Introduction  | Plant chitinases  | The PR-6 Family  | PR gene expression   |
| S-1    | SLO-2      | Pathogens include viruses, bacteria, fungi, oomycetes and nematodes | PR- 1 Proteins  | PR-3, 4, 8, 11  | Proteinase Inhibitors in Plant-Microbe and Plant-Insect Interactions | Signals and Putative Receptors that<br>Activate PR Gene Expression           |
|        | SLO-1      | Brief history   | Characterization  | Structure of the Proteins   | Occurrence and Structure   | Receptors  |
| S-2    | SLO-2      | Plant pathology   | Acidic and basic proteins   | PR-3, A Plant-Specific Chitinase Family (Family 19,), Family 18, The Ubiquitous | Plant Proteinase Inhibitors with Potential Defensive Capabilities    | Leucine-rich repeat receptor kinases ,<br>LysM receptor proteins             |
| S-3    | SLO-1      | The disease triangle concept  | Occurrence  | PR-8/Class III Chitinases, PR-11<br>Chitinases                                  | Proteinases and Proteinase Inhibitors                                | Pathogens Activate PR Genes by Different Pathways                            |
| 3-3    | SLO-2      | Pathogen, Host, Environment   | PR - proteins from other organisms & Functions  | Other Related Proteins, The PR-4 Family   | Plant-Microbe Interactions   | Reactive oxygen species (ROS), salicylic acid (SA), ethylene, and jasmonates |
|        | SLO-1      | Strategies of pathogenicity   | Expression of PR-1  | Catalytic Mechanisms and Specificities  | Proteinases and Proteinase Inhibitors                                | Transcriptional Regulation of PR Gene Expression                             |
| S-4    | SLO-2      | necrotrophy and hemibiotrophy                                       | Pathogens/wounds, salicylic acid,<br>ethylene and other hormones, UV light<br>and developmental stimuli | Family 18 & 19 Chitinases   | Plant-Insect Interactions  | W-box, GCC box, MRE-like sequence & G-box                                    |
|        | SLO-1      | Plant immune responses  | PR-1 promoter analysis  | Structure and Regulation of the Genes   | Ribosome inactivating proteins (RIP)                                 | GCC box-binding proteins   |
| S-5    | SLO-2      | Pathogen triggered & Effector triggered                             | Acidic and basic proteins   | Chib (PR-8) and Chic (PR-11) Genes  | Structure  | EREBP-1, EREBP-2, EREBP-3, and EREBP-4                                       |
| S-6    | SLO-1      | Pathogen-recognition receptors                                      | Introduction  | Functions of Plant Chitinases   | RIP  | Genetic studies of PR gene expression  |

| Duration | n (hour) | 9  | 9   | 9  | 9  | 9                                    |
|----------|----------|--|---|--|--|--------------------------------------|
|          | SLO-2    | PTI stimulates production of phytoalexins, reactive oxygen and callose | PR-2 – β-1,3-Glucanases                   | Antifungal and other physiological   | Function, and Engineering                        | SA-inducible promoter-GUS,           |
| S-7      | SLO-1    | Recognition and response to effectors through paired R proteins        | Structural classes                        | PR-5 - Thaumatin-like proteins   | Plant defensins                                  | Transgenic plants                    |
|          | SLO-2    | ETI and biochemical response   | PR-2 Nomenclature                         | Occurrence, Physico-Chemical properties  | Introduction                                     | Over expression of PR proteins       |
|          | SLO-1    | Induction  |   | Biological properties  |  | PR Proteins                          |
| S-8      | SLO-2    | Pathogenesis Related proteins (PR-<br>Proteins)                        | Plant reproductive and defence            | Taste, Antifungal Activity, TLPs as Anti-<br>Freeze Proteins & TLPs as Inhibitors?   | Disulfide-linked cysteine residues               | Antifungal and insecticidal proteins |
|          | SLO-1    | IPRS and PR like proteins  | Regulation of β-1,3-Glucanases expression | Regulation of TLP Expression   | Antimicrobial Activities                         | PR proteins in Rice                  |
| S-9      | SLO-2    | Occurrence, properties and functions                                   | Developmental and hormonal & pathogenic   | Microbial Infection, Osmotic Stress,<br>Abscisic Acid and Ethylene, Salicylate,<br>Methyl Jasmonate, and Elicitors,<br>Wounding. | Structure activity relationships, Mode of action | IR72 and IR64                        |

| Learning<br>Resources | 1.<br>2. | Agrios, G.N. (2005). Plant Pathology. (Burlington, MA: Elsevier Academic Press). Schumann, G.L., andand D'Arcy, C.J. (2010). Essential Plant Pathology. (St. Paul, MN: The American Phytopathological Society). | 3. | Swapan K. Datta and Muthukrishnan, "Pathogenesis – Related Proteins in plants", CRC Press, 1999. |  |
|-----------------------|----------|---|----|--|--|
|-----------------------|----------|---|----|--|--|

| Learning | Assessment             |                   |          | THE PARTY OF  | THE RESIDENCE      |                    |          | F 69    |          |                                   |                    |  |
|----------|------------------------|-------------------|----------|---------------|--------------------|--------------------|----------|---------|----------|-----------------------------------|--------------------|--|
|          | Dia amai'a             |                   |          | Conti         | nuous Learning Ass | essment (50% weigl | ntage)   |         |          | Final Evanninatio                 | n (FOO) waishtasa) |  |
|          | Bloom's                | CLA –             | 1 (10%)  | CLA – 2 (15%) |                    | CLA -              | 3 (15%)  | CLA – 4 | (10%)#   | Final Examination (50% weightage) |                    |  |
|          | Level of Thinking      | Theory            | Practice | Theory        | Practice           | Theory             | Practice | Theory  | Practice | Theory                            | Practice           |  |
| Level 1  | Remember<br>Understand | 40 <mark>%</mark> | Tien!    | 30%           |                    | 30%                |          | 30%     | -        | 30%                               | -                  |  |
| Level 2  | Apply<br>Analyze       | 40 <mark>%</mark> | 5        | 40%           |                    | 40%                | -        | 40%     | -        | 40%                               | -                  |  |
| Level 3  | Evaluate<br>Create     | 20 %              | CENT.    | 30%           | - 1                | 30%                | 1 10     | 30%     | 1        | 30%                               | -                  |  |
|          | Total                  | 100               | ) %      | 100           | 0 %                | 10                 | ) %      | 100     | 0 %      | 10                                | 0 %                |  |

<sup>#</sup> CLA – 4 can be from any combination of these: Assignments, Seminars, Tech Talks, Mini-Projects, Case-Studies, Self-Study, MOOCs, Certifications, Conf. Paper etc.,

| Course Designers   | MANAGER TO THE PARTY OF THE PAR |                                 |
|--|--|---------------------------------|
| Experts from Industry  | Experts from Higher Technical Institutions   | Internal Experts                |
| 1. Dr. Senthil, EID Parry, Chennai, parrynutraceuticals@parry.murugappa.com              | <ol> <li>Prof .Usha Vijayraghavan. IISc, Bangalore, uvr@mcbl.iisc.ernet.in</li> </ol>  | 1. Dr. R. Pachaiappan, SRMIST   |
| 2. Dr. G. N. Ramchand, Saksin Life sciences Pvt Ltd, Chennai, ramchand@saksinlife.com    | 2. Prof. Appa Rao Podile, Central University, Hyderabad,   | 2. Dr. D.V.L. Sarada, SRMIST    |
| 2. Dr. G. N. Namichand, Saksin Life Sciences FVI Etd, Offennal, Tamorandu@Saksiniile.com | podilerao@gmail.com  | Z. Dr. D. V.L. Saraua, SINVIIST |

| Cou   | ırse<br>de | 18BTE312T                       | Course Name  | FOOD SCIENCE AND NUTRITION   | )N  |                     |                          | Course                  | Categor                                     | ry E             |                      |                               | Pr                     | ofess             | sional El                    | lectiv  | e   |               |                        | L<br>3      | T 0    | P<br>0 | C<br>3 |
|-------|------------|---------------------------------|--|--|---|---------------------|--------------------------|-------------------------|---|------------------|----------------------|-------------------------------|------------------------|-------------------|------------------------------|---------|---|---------------|------------------------|-------------|--------|--------|--------|
|       |            | site Courses<br>p Department    | Nil<br>Biotechnology   | Co-requisite Courses Data Book / 0   | <i>Nil</i><br>Codes/St                      | andards             |                          | Pro<br>Nil              | gressiv                                     | e Cou            | ırses                | Nil                           |                        |                   |                              |         |   |               | II.                    | -           |        |        |        |
| _     |            |                                 |  | 2.5  |   |                     |                          |                         |   |                  |                      |                               |                        |                   |                              |         |   |               |                        |             |        |        |        |
|       |            | g Rationale (CLF                |  | arning this course is to:  |   |                     | Learning                 | ~                       |   |                  |                      |                               |                        |                   |                              |         | comes (                                     |               |                        |             |        |        |        |
| CLR-1 |            |                                 |  | ation of the existing food sources   |   | 1                   | 2                        | 3                       | 1   | 2                | 3                    | 4                             | 5                      | 6                 | 7                            | 8       | 9   | 10            | 11                     | 12          | 13     | 14     | 15     |
| CLR-2 |            |                                 | onal quality and nutritional requi                               | rement   |   |                     | )C                       | aut .                   | 7.10  |                  |                      |                               | e                      |                   |                              |         |   |               |                        | _           |        |        | ı      |
| CLR-3 |            |                                 | rgy requirements of the body<br>v trends in nutrition            |  |   | <u>B</u>            | cie                      | Ĕ                       |   | Sis              |                      | Ľ,                            | sac                    | <u>e</u>          |                              |         | am  | _             |                        | nin         |        |        | ı      |
| CLR-5 |            | rign balanced m                 |  |  |   | Thinking            | Jo                       | ıttai                   | CD.   | laly             | Ħ                    | esić                          |                        | 芸                 | nt &<br>ity                  |         | <u> </u>                                    | atio          | ≪ઇ<br>.:               | Learning    |        |        | ı      |
| CLR-6 |            |                                 | nal factors in food  | 1 1  |   | 돈                   | В<br>П                   | ρ                       | dge   | ٦Ā               | &<br>ome             | ر<br>ان ج                     | To                     | ∞ ∞               | me<br>abil                   |         | a<br>8                                      | nica          | ₩.                     | g L         |        |        | 3      |
| OLIT  | . paon     | iny antinatrition               | ar ladiore in 100a   |  |   | Level of<br>(Bloom) | Expected Proficiency (%) | Expected Attainment (%) | Engineering<br>Knowledge                    | Problem Analysis | Design & Development | Analysis, Design,<br>Research | Modern Tool Usage      | Society & Culture | Environment & Sustainability | S       | Individual & Team<br>Work                   | Communication | Project Mgt. & Finance | Life Long L | -1     | )-2    |        |
| Cours | e Learnin  | g Outcomes (CL                  | O): At the end of this   | course, learners will be able to:  |   | evel<br>Bloor       | XIX<br>%                 | å (%                    | ing   | Job<br>Job       | )es<br>)ev           | Ana                           | γoγ                    | Soci              | invi<br>Sust                 | Ethics  | ng<br>Vor                                   | Son           | roj<br>Fina            | -iĘe        | PSO    | PSO    | PSO    |
| CLO-1 |            |                                 | pts of Food and Nutrition  |  | F 23 T                                      | 2                   | 80                       | 70                      | ш х   | H                | Н                    | 4 11                          | _                      | Н                 | шо                           | H       | H   | 0             | <u> </u>               | _           | H      | H      | H      |
| CLO-2 |            |                                 | n daily dietary all <mark>owances</mark>                         | - 14 3 4 4 4 1   | 4110  | 2                   | 80                       | 70                      |   | Н                | Н                    |                               |                        |                   | Н                            |         |   |               |                        |             | Н      | Н      | Н      |
| CLO-3 | : Iden     | ntify the scope a               | and prospects o <mark>f food sci</mark> ence ir                  | food industries  |   | 2                   | 80                       | 70                      | М   | Н                | Н                    | М                             | Н                      |                   | М                            |         | Н   |               | Н                      |             | Н      | Н      | Н      |
| CLO-4 |            |                                 | ng to energy re <mark>quiremen</mark> ts of the                  |  |   | 2                   | 80                       | 70                      | Н   |                  | Н                    |                               | Н                      |                   | М                            |         | Н   |               | Н                      |             | Н      | Н      | Н      |
| CLO-5 |            |                                 | rent age group <mark>and for p</mark> eople ui                   | nder diseased condition  |   | 3                   | 80                       | 70                      | Н   | Н                | Н                    | Н                             | Н                      |                   | М                            |         | Н   |               | Η                      |             | Н      | Н      | Н      |
| CLO-6 | : Eva      | luate food const                | tituents and it <mark>s_importa</mark> nce                       |  | 100   | 2                   | 80                       | 70                      | Н   | Н                | Н                    | H                             | Н                      |                   | Н                            | Н       | Н   |               | Н                      | Н           | Н      | Н      | Н      |
| -     |            |                                 |  | THE STATE OF THE STATE OF  | -   |                     |                          | 100                     | -   |                  |                      | - 1                           |                        |                   |                              |         |   |               |                        |             |        |        |        |
| Durat | on (hour)  | )                               | 9  | 9  | 0 1 1                                       |                     | 9                        |                         |   |                  |                      |                               | 9                      |                   |                              |         |   | , .           | 9                      |             | . ,    |        |        |
| S-1   | SLO-1      | Food as a soul                  | rce of energy  | Functions of protein, fat and carbohydrates and their dietary requirements | and fur                                     | ctions,             | deficiend                | cy in diet              |   |                  |                      | daily int                     |                        |                   |                              | fa      | lew trer<br>ast food                        |               |                        |             | onai   | /alue  | Of     |
|       | SLO-2      | Macro and mic                   | cro nutrients  | Sources of Carbohydrates   | carboh                                      | ydrates             |                          |                         |   | Daily<br>water   |                      | body wa                       | ter an                 | d defi            | iciency (                    | of F    | Probiotic                                   | s and         | prebiot                | ics         |        |        |        |
| S-2   | SLO-1      | Carbohydrate,                   | Fat and Protein  | Classification of Carbohydrates  | Digestion of carb                           |                     |                          | and absor               | rption                                      | Sourc            | es of vi             | tamins                        |                        |                   |                              | 4       | Antioxida                                   | ants          |                        |             |        |        |        |
|       | SLO-2      | Food requirem                   | ent in human bo <mark>dy</mark>                                  | Polysaccharides –Starch and dietary fibers                                 | Nutritio                                    | nal sign            | ificance                 | of protein              |   |                  |                      | tamins -                      |                        |                   |                              | ٨       | lutraceι                                    | ıticals       |                        |             |        |        |        |
| S-3   | SLO-1      |                                 | nced diets to meet <mark>the</mark><br>of different age groups   | Chemical composition of cereals  | Animal                                      | sources             | s of prote               | ein                     |   |                  | ins, Ane             | e Vitamii<br>emia –pr         |                        |                   |                              | and F   | ortificat                                   | ion           |                        |             |        |        |        |
|       | SLO-2      | Solving Proble                  | ems-   | Nutritional value of cereals   | Digestion of protest                        |                     | abolism                  | and abso                | rption                                      | Effec            | t of cool            | king on v                     | r <mark>itam</mark> ir | ıs                |                              | S       | Significa                                   | nce o         | nutritio               | nal lai     | beling | ı      |        |
| S-4   | SLO-1      | Energy require                  | Protein- dietary requirements, functions, and deficiency in diet | Nutritio   | nal sign                                    | ificance            | of lipids                |                         | stabil                                      | ity of vit       | amin du              | ring fo                       | od pr                  | ocessin           | g 7                          | rans fa | ty aci                                      | ds            |                        |             |        |        |        |
| 3-4   | SLO-2      | Calculations of proximate princ | Sources of Protein   | Classifi   | cation c                                    |                     | toxicity due to vitamins |                         |   |                  |                      | Role of photochemical         |                        |                   |                              |         |   |               |                        |             |        |        |        |
| S-5   | SLO-1      | affecting BMR                   |  | Ch <mark>emical composition of pulses (grams and dhal)</mark>              | Plant Sources of Tavol                      |                     |                          |                         |   |                  |                      | of vitan                      |                        |                   |                              |         | Naturally occurring food toxicants in foods |               |                        |             |        |        |        |
|       | SLO-2      |                                 | energy requirements  | Nutritional value of pulses  | Marine and animal sour                      |                     |                          |                         | s of fat/oil reasons for losses of vitamins |                  |                      |                               |                        | ns in             | foods                        | p       | rotease                                     | inhib         | itors                  |             |        |        |        |
| S-6   | SLO-1      | Instrumental m                  | nethods to calculate caloric                                     | Antinutritional factors in pulses  | Digestion, metabolism and absorption of fat |                     |                          |                         | Role  | of these         | constitu             | ients i                       | n foo                  | d indust          | try h                        | emaggl  | utinin                                      | 5             |                        |             |        |        |        |
|       | SLO-2      | RDS's for spec                  | cific nutrients  | Chemical composition of oil seeds  | The food pyramid Mineral in food goitrogens |                     |                          |                         |   |                  | goitrogens           |                               |                        |                   |                              |         |   |               |                        |             |        |        |        |

| Durati | on (hour) | 9                                 | 9   | 9   | 9                                    | 9   |
|--------|-----------|-----------------------------------|---|---|--------------------------------------|---|
| S-7    | SLO-1     | Dietary allowances fixed by FAO   | effect of processing on the nutritional value of food grains (cereals and pulses) | Therapeutic diets – A brief account.                      | Classification of minerals           | lathyrogens   |
|        | SLO-2     | Dietary allowances fixed by WHO   | Chemical composition of cereals   | Planning of balanced meal                                 | Sources of minerals in food          | toxic amino acids                                       |
| S-8    | SLU-1     | tixed by ICMR                     | Inutritional value of cereals   | Dietary requirement for different Age group               | stability status of minerals in food | naturally occurring carcinogens in food                 |
|        | SLO-2     |                                   |   | Dietary requirement for women at different stages of life | INITITIONAL VAIDE OF ITHIS           | Carcinogens produced during food processing and storage |
| S-9    | SLO-1     | Modifying energy content of meals |   | Meal frequency pattern and variety in balanced diet       | Nutritional value of vegetables      | Acrylamide formation in food                            |
|        | SLO-2     | Under weight/,overweight/obesity  | Antinutritional factors in pulses   | Calculating nutritional value of a recipe                 | Nutritional value of biverages       | furan formation in food                                 |

| Lograina              | 1. | Sunetra Roday. "Food science and nutrition". 2016, Oxford university Press                         | 3. | Ahuja, K.J, Nath Prem and K.R.M Swamy Food and Nutrition, 2010. Studium Press Pvt. Ltd., New Delhi., |  |
|-----------------------|----|--|----|--|--|
| Learning<br>Resources | 2. | Swaminathan, M. (5 <sup>th</sup> Edi <mark>tion). "Han</mark> d Book of food and Nutrition", 2015. | 4. | Shakuntala Manay and Shadasharasamy "Foods; Facts and principles", 1997.                             |  |
| Resources             |    | The Bangalore Printing a <mark>nd Publish</mark> ing co. Ltd. Bangalore                            |    | New Age international Publishers, New Delhi. ,   |  |
|                       | ļ. | The Bangalore 1 finding and 1 dollaring co. Etc. Bangalore   | 40 | New Age International Fubilishers, New Dollin. ,   |  |

| Learning | Assessment         |        |          |         | 定可能能是的              | 1000              | 50.6 U   |         |          |                   |                   |
|----------|--------------------|--------|----------|---------|---------------------|-------------------|--|---------|----------|-------------------|-------------------|
|          | Bloom's            |        |          | Conti   | nuous Learning Asse | ssment (50% weigh | ntage)   |         |          | Final Examination | n (50% weightage) |
|          | Level of Thinking  | CLA –  | 1 (10%)  | CLA – 2 | 2 (15%)             | CLA -             | 3 (15%)  | CLA – 4 | (10%)#   |                   | i (50% weightage) |
|          | Level of Triinking | Theory | Practice | Theory  | Practice            | Theory            | Practice   | Theory  | Practice | Theory            | Practice          |
| Level 1  | Remember           | 40 %   |          | 30%     | REAL PROPERTY.      | 30%               |  | 30%     |          | 30%               |                   |
| Level I  | Understand         | 40 %   |          | 30%     | The state of        | 30%               | AUG 18   | 30%     |          | 30%               | -                 |
| Level 2  | Apply              | 40 %   |          | 40%     | N. D COLOR II.      | 40%               | THE CO.  | 40%     |          | 40%               |                   |
| Level 2  | Analyze            | 40 %   | -        | 40%     |                     | 40%               |  | 40%     |          | 40%               | -                 |
| Level 3  | Evaluate           | 20 %   |          | 30%     |                     | 30%               | The state of the s | 30%     |          | 30%               |                   |
| Level 3  | Create             | 20 %   |          | 30%     |                     | 30%               |  | 30%     |          | 30%               | -                 |
|          | Total              | 100    | 0 %      | 100     | ) %                 | 10                | 0 %  | 100     | %        | 10                | 0 %               |

<sup>#</sup> CLA – 4 can be from any combination of these: Assignments, Seminars, Tech Talks, Mini-Projects, Case-Studies, Self-Study, MOOCs, Certifications, Conf. Paper etc.,

| Course Designers   | 1/1/2   |                               |
|--|---|-------------------------------|
| Experts from Industry  | Experts from Higher Technical Institutions  | Internal Experts              |
| 1. Dr. S. Sam Gunasekar, Orchid Chemicals and Pharmaceuticals Ltd., sam@orchidpharma.com | Dr. A. Gnanamani, CSIR-Central Leather Research Institute, agmani_2000@yahoomail.com        | 1. Dr. K.A.Athmaselvi, SRMIST |
| 2. Dr. D. Gunaseelan, BIOCON Ltd., guna.sachin@gmail.com                                 | 2. Dr. Anbumani Sadasivam, CSIR-Indian Institute of Toxicology Research,anbumani@itr.res.in | 2. Dr. R.Preetha, SRMIST      |

|                                  | urse<br>ode   | 18BTE405T   | Course Name  | THERAPEUTI   | IC COMPOUNDS I                            | FROM PLANTS                            |                          | Cate                     |  | Е                     |            |                      |  | Profe        | essiona                         | al Elec  | tive           |                  |                     |                        |          | T<br>0  | P<br>0 | 3   |
|----------------------------------|---|---|--|--|---|--|--------------------------|--------------------------|--|-----------------------|------------|----------------------|--|--------------|---------------------------------|----------|----------------|------------------|---------------------|------------------------|----------|---------|--------|-----|
| F                                | re-reguisi  | ite Courses   | Nil  | Co-requisite Courses   |   | Nil                                    |                          | Pr                       | ogress   | sive Cou              | rses       |                      | Vil  |              |                                 |          |                |                  |                     |                        |          |         |        |     |
| _                                |   | g Department  | Biotech  |  | Data Book / C                             | odes/Standards                         | ٨                        |                          | - 9:   |                       |            |                      |  |              |                                 |          |                |                  |                     |                        |          |         |        | -   |
| (CLR                             | :   |   | e purpose of learning this   |  | -05                                       | CHAC                                   | t                        | Learnii                  | 0  |                       |            |                      |  |              |                                 | _earniı  |                |                  | es (PL              | ,                      |          |         |        |     |
| CLR-                             |   |   | istorical uses of plants ar<br>iques involved in Biopros   | d p <mark>lant parts as m</mark> edicines  | s and traditional kr                      | owledge                                | 1                        | 2                        | 3  | 1                     | 2          | 3                    | 4<br>4   | 5            | 6                               | 7        | 8              | 9                | 10                  | 11                     | 12       | 13      | 14     | 15  |
| CLR-:<br>CLR-:<br>CLR-:<br>CLR-: | 3: Unde<br>4: unde<br>5: Gain                             | erstand the majo<br>erstand the struct<br>insight into engii  | r secondary metabolic paures and roles of the managements of the manag | nthways that produce pharm<br>ior classes of photochemic<br>duction of pharmaceuticall<br>pharmaceutically importa | cals with medicinal<br>ly important metab | properties<br>olites i <u>n planta</u> | evel of Thinking (Bloom) | Expected Proficiency (%) | Expected Attainment (%)                                | Engineering Knowledge | lysis      | Design & Development | ≖ <mark>Analysis, Design, Res<mark>earch</mark></mark> | Usage        | Culture                         | ∞ .      |                | Team Work        | ou                  | Project Mgt. & Finance | arning   |         |        |     |
|                                  |   | a Outcomoo  |  | ant compounds in the   | lerapeutics                               | el of Thin                             | ected Pro                | ected Atta               | gineering l  | Problem Analysis      | sign & Dev | alysis, Des          | Modern Tool Usage                                      | Society & Cu | Environment &<br>Sustainability | ics      | Individual & T | Communication    | ject Mgt. 8         | Life Long Learning     | 0-1      | 0-2     | 0 – 3  |     |
| (CLO                             | ):  | At  | the end of this <mark>course, le</mark>  |  | 5,750,00                                  | n Republic                             |                          | ш                        |  |                       | Pro        |                      | Ans  | Mo           |                                 |          |                |                  |                     |                        |          | PSO     | PSO    | PSO |
| CLO-                             |   |   | ant parts used <mark>as medici</mark> n  |  |   | See As Jones                           | 1                        | 80                       | 80   | L                     |            | М                    |  |              | Н                               | Н        | Н              | Н                | Н                   | Н                      | Н        | Н       | Н      | Н   |
| CLO-                             |   | Apply techniques to screen plants for drugs and medicines  Analyze the secondary metabolic pathways that produce several medicinally import  Deduce structure activity relationship |  |  |   | inounds                                | 2                        | 85<br>75                 | 75<br>80   | H                     | H          | H                    | H  | H            | H<br>M                          | Н        | H<br>M         | H                | H                   | H                      | H        | H       | H      | H   |
| CLO-                             |   |   |  | at produce several medicin   | rany important com                        | pounds                                 | 3                        | 85                       | 80   | H                     | Н          | Н                    | Н  | H            | 101                             | L        | L              | Н                | Н                   | Н                      | Н        | Н       | Н      | Н   |
| CLO-                             | 5: Predi  | ict the metabolic   | branch points that can be  | e targeted for engineering   |   | 7737176                                | 3                        | 85                       | 75   | Н                     | Н          | Н                    | Н  | Н            | Н                               | Н        | L              | Н                | L                   | Н                      | Н        | Н       | Н      | Н   |
| CLO-                             | 6: Expla  | ain the mechanis  | m of action o <mark>f major k</mark> no  | wn pharmaceutically impor  | rtant compounds ir                        | therapeutics                           | 2                        | 80                       | 80   | Н                     | Н          | Н                    | Н  | Н            | М                               | М        | М              | Н                | Η                   | Н                      | Η        | Н       | Η      | Н   |
| Dura                             | ion (hour)  | )   | 9  | 9  |   | 9                                      |                          |                          |  | pri i                 |            |                      | 9  |              |                                 |          |                |                  |                     |                        | 9        |         |        |     |
| S-1                              | SLO-1   | Plants vs Medi  | cinal Plants   | Overview of extraction an<br>Phytoconstituents   | nd purification of                        | Primary vs Secondary Meta              | bolisi                   | n                        | Jan 1  | In vitro              | tages      |                      |  |              |                                 |          |                |                  | ıtic Ap<br>ıstituei |                        | ions o   | f       |        |     |
| 3-1                              | SLO-2   | Medicine  | l validation of H <mark>erbal</mark>   | Extraction Techniques  | 100                                       | Examples of Major Seconda Pathways     | ary M                    | etabolio                 | С  | Omics<br>metho        | ds         |                      |  |              |                                 |          | Pot            | ential           | drugs               | availa                 | able in  | the m   | narkei | t   |
|                                  | SLO-1   | Traditional Indi  | ian Medicine   | Different Types  |   | The Mevalonate Pathway                 |                          |                          |  | Metab                 |            |                      |  |              |                                 |          | Me             | chanis           | sms of              | f Actio                | n        |         |        |     |
| S-2                              | SLO-2   | Traditional Chi   | nese Medicine  | Advantages and Limitatio<br>Techniques   | ons of Extraction                         | Examples                               |                          |                          |  | Altera<br>function    | ons        |                      |  |              |                                 |          |                | •                | c actio             |                        |          | ,       | •      | e)  |
| S-3                              | SLO-1   | Traditional Kno   | owledge  | <mark>Analyti</mark> cal Techniques - S  | Spectrometry                              | The Shikmate Pathway                   |                          |                          |  | Pione plant           | netab      | olites               |  |              |                                 |          | (Pip           | perene           |                     |                        |          |         | loids  |     |
|                                  | SLO-2   | Ethanobotany  |  | Purification   | APVIN                                     | Examples                               | 4                        | E                        |  | Recor<br>micro        |            | on of I              | netab  | olic pa      | athway                          | 's in    |                | i canc<br>rberin | er aci              | tivity c               | of alka  | loids   |        |     |
| S-4                              | SLO-1   | Quality Assura  | nce of Herbal Medicines  | Analytical Techniques – C  | Chromatography                            | The Phenyl Propanoid and Pathway       | the P                    | olyketid                 | de   | Host S                | Select     | ion an               | d Patl   | nway r       | econs                           | titution |                |                  |                     |                        |          |         | oids   |     |
| 3-4                              | SLO-2   | Over the Coun   | ter Herbal Medicines   | Bioassay Guided Fraction   | <mark>nation</mark>                       | Examples                               |                          |                          |  | Optim                 |            |                      |  |              |                                 |          |                | ibacte<br>roflax | erial ac<br>ricin)  | ction o                | f alkal  | oids    |        |     |
| S-5                              | SLO-1 Plant Extracts vs Purified Compounds Identification |   |  |  |   | Biosynthesis of Alkaloids              |                          |                          | Metabolic Engineering for alkaloid production in Yeast |                       |            |                      |  |              | Neu                             | urostir  | nulato         | ry effe          | ects of             | alkalo                 | oids     |         |        |     |
| 3-3                              | SLO-2   | Quest for Activ   | e Compounds  | Analytical Techniques –M   | Mass Spectrometry                         | Tissue Cultures for producti           | on of                    | metab                    | olites   | Metab<br>produ        |            |                      |  | or terp      | enoid                           |          | Neu            | uropro           | tective             | e effe                 | cts of a | alkaloi | ids    |     |

| Durati | ion (hour) | 9   | 9   | 9   | 9  | 9  |
|--------|------------|---|---|---|--|--|
| S-6    | SLO-1      | Modern Approaches                                 | Standardization   | Examples  |  | Antiinflammatory mechanism of action of flavanoids |
|        | SLO-2      | Screening plants for Drugs                        | Clinical Validation   | Organ Cultures for production of metabolites          | Metabolic Engineering for caffeine production in Yeast               | Antimalarial action of Terpenoids (Quinine)        |
| S-7    | SLO-1      | Plant Families associated with Drug<br>Production | Example from TIM to clinical trials   | Examples  | ICITAEL EXAMPLES   | Antimalarial action of Terpenoids (Artemesin)      |
| -      | SLO-2      | Drug discovery by relatedness                     | Example from TCM to clinical trials   |   | Metabolic Engineering in Plants and Plant<br>Cell Cultures           | Terpenoids against Trypaonosomes                   |
| S-8    | SLO-1      | Phytoconstituents                                 | Central Drugs Control Standard Organization                                     | Manipulation of hairy roots for metabolite production | Metabolic Engineering of Terpenoids in Plants                        | Terpenoids against Leishmanias                     |
|        | SLO-2      | Alkaloids   | Drugs Technical Advisory Board (DTAB)<br>and Drugs Consultative Committee (DCC) | Production of Gingsenolides                           | Metabolic Engineerin <mark>g of Alkalo</mark> ids in Plants          | Ephedra- Use and Misuse                            |
| S-9    | SLO-1      | Flavanoids  | Regulatory Approval   | in vitro production – Role of Endophytes              | Plants   | Ginseng – The Panacea                              |
|        | SLO-2      | Terpenoids  | Pharmacovigilence   | Production of Taxol                                   | High throughput methods to identify genes intermediates and pathways | Traditional vs Western Medicine                    |

| Learning<br>Resources | 1.<br>2. | 0 , | , William Evans, Sixteenth Edition Elsivie<br>o Modern Techniques in Plant Analysis, |             | 3.<br>4. | Text Book of Pharmacognasy and Phytochemistry, First Edition, Biren Shah, Elsevier 2009 Fundementals of Pharmacognosy and Phytotherapy Second Edition Michael Heinrich, Joanne Barnes, Simon Gibbons and Elizabeth M. Williamson, Elsivier 2012 |
|-----------------------|----------|-----|--|-------------|----------|---|
|                       |          |     | 36777  | 12 KEN (48) |          |   |

| Learning | Assessment         |         |  | 1.75 Ta VA |                     | 1111             | THE CHARLES  |         |                  |                   |                    |
|----------|--------------------|---------|--|------------|---------------------|------------------|--------------|---------|------------------|-------------------|--------------------|
|          | Bloom's            |         |  | Continuo   | ous Learning Assess | ment (50% weight | age)         |         |                  | Final Evamination | n (E00/ weightege) |
|          | Level of Thinking  | CLA - 1 | (10%)  | CLA – 2    | 2 (15%)             | CLA -            | 3 (15%)      | CLA – 4 | l (10%)#         | Final Examinatio  | n (50% weightage)  |
|          | Level of Thirtking | Theory  | Practice   | Theory     | Practice            | Theory           | Practice     | Theory  | Practice         | Theory            | Practice           |
| Level 1  | Remember           | 40 %    |  | 30%        |                     | 30%              |              | 30%     |                  | 30%               |                    |
| rever    | Understand         | 40 /0   | Contract of the Contract of th | 3070       |                     | 3070             | -            | 3070    |                  | 3070              | -                  |
| Level 2  | Apply              | 40 %    |  | 40%        |                     | 40%              |              | 40%     |                  | 40%               |                    |
| Level 2  | Analyze            | 40 /0   | 17541  | 40 /0      | - 1/                | 4070             | _            | 4070    |                  | 4070              | -                  |
| Level 3  | Evaluate           | 20 %    |  | 30%        | . 111               | 30%              |              | 30%     |                  | 30%               | _                  |
| LC ACI 2 | Create             |         |  | 3070       |                     | 30 /0            | THE STATE OF | 3070    |                  | 30 /0             | -                  |
|          | Total              | 100     | %  | 100        | ) %                 | 10               | 0 %          | 100     | <mark>) %</mark> | 10                | 0 %                |

<sup>#</sup>CLA – 4 can be from any combination of these: Assignments, Seminars, Tech Talks, Mini-Projects, Case-Studies, Self-Study, MOOCs, Certifications, Conf. Paper etc.,

| Course Designers   |   |                               |
|--|---|-------------------------------|
| Experts from Industry  | Experts from Higher Technical Institutions              | Internal Experts              |
| 1. Dr. G. N. Ramchand, Saksin Life sciences Pvt Ltd, Chennai, ramchand@saksinlife.com  | 1. Prof K Subramaniam, IITM, Chennai, suubu@iitm.ac.in  | 1. Dr. R. Pachaiappan, SRMIST |
| <ol> <li>Dr. Karthik Periyasamy, Scientist I, Aurozymes Unit, Aurobindo Pharma Limited, Hyderabad,<br/>karthikmpk@gmail.com</li> </ol> | 2. Prof. R. B. Narayanan, SVCE, Chennai, rbn@svce.ac.in | 2. Dr. Sarada, DVL, SRMIST    |

|       | urse<br>ode  | 18BTE406T                                 | Course Name                                | FOOD SAFETY AND QUALITY MA  | NAGEMEN              | NT                        |                          |                         | urse<br>egory            | Е                  |                         |                               | F                               | Profess           | sional El                    | lective        |                           |               | -                      | L<br>3      | T<br>0 | P<br>0  | C<br>3        |
|-------|--|---|--|---|----------------------|---------------------------|--------------------------|-------------------------|--------------------------|--------------------|-------------------------|-------------------------------|---------------------------------|-------------------|------------------------------|----------------|---------------------------|---------------|------------------------|-------------|--------|---------|---------------|
|       | Pre-requis   | site Courses                              | Nil C                                      | o-requisite Courses   Nil   |                      |                           |                          | Proc                    | ressive                  | Cours              | es N                    | il                            |                                 |                   |                              |                |                           |               |                        |             |        |         | $\overline{}$ |
|       |  | Department                                | Biotechnology                              | Data Book / Codes/Star  | dards                |                           |                          | Nil                     | 1000110                  | Oddic              | 100                     | "                             |                                 |                   |                              |                |                           |               |                        |             |        |         |               |
|       |  | , = -                                     | <b></b>                                    |   | - 11 11              | 1                         | 7                        |                         |                          |                    |                         |                               |                                 |                   |                              |                |                           |               |                        |             |        |         |               |
| Cours | e Learnin  | g Rationale (CLR)                         | ): The purpose of                          | of learnin <mark>g this course is t</mark> o:                       |                      |                           | Learnin                  | ]                       |                          |                    |                         |                               | Prog                            | gram L            | earning                      | Outco          | mes (                     | PLO)          |                        |             |        |         |               |
| CLR-  |  |   | ts of food additives and ris               | k as <mark>sessment</mark>  |                      | 1                         | 2                        | 3                       | 1                        | 2                  | 3                       | 4                             | 5                               | 6                 | 7                            | 8              | 9                         | 10            | 11                     | 12          | 13     | 14      | 15            |
| CLR-2 | 2: <i>Me</i>   | emorize to prepare                        | e HACCP based SOP                          |   |                      |                           | >                        | Ħ                       | 71                       |                    |                         |                               |                                 |                   |                              |                |                           |               |                        |             |        |         |               |
| CLR-3 |  |   | ogram to any food industry                 | ,   |                      |                           | enc                      | mer                     | - 1                      | S                  |                         | -                             | age                             | υ                 |                              |                | Ε                         |               |                        | ng          |        |         |               |
| CLR-4 |  |   | ng in the food industries                  |   |                      | Ĕ.                        | Jic.                     | ain                     |                          | llysi              | 1                       | sigr                          | Us                              | Itu               | જ ્                          |                | Геа                       | <u>.</u>      | ∞ర                     | arri        |        |         |               |
| CLR-  |  |   | ISO 14000, ISO 2200 <mark>0</mark>         |   |                      | įĘ                        | P.                       | H#                      | ge ag                    | Ana                | ner                     | _ De                          | .00                             | ਠੋ                | ent                          |                | ∞ర                        | cat           | gt.                    | Learning    |        |         |               |
| CLR-6 | i: En  | nploy ISO 22000                           | in food industry                           |   | 100                  | p (-                      | ted                      | ted                     | ed co                    | E                  | n &<br>opn              | sis,<br>arch                  | T.                              | ∞<br>>-           | nat                          |                | la l                      | ٦             | ₩ გ                    | ong         | _      | 7       | - 3           |
|       |  |   |  |   |                      | Level of Thinking (Bloom) | Expected Proficiency (%) | Expected Attainment (%) | Engineering<br>Knowledge | Problem Analysis   | Design &<br>Development | Analysis, Design,<br>Research | Modern Tool Usage               | Society & Culture | Environment & Sustainability | Ethics         | Individual & Team<br>Work | Communication | Project Mgt. & Finance | Life Long I | PSO-   | PSO -   | PSO-          |
|       |  | g Outcomes (CLC                           |  | his course, learners will be able to:                               |                      |                           | ĭ %                      | ĭ %                     | 교 준                      |                    | De<br>De                | A Re                          | ĕ                               |                   | ᄪᇲ                           | 並              | <u>≅</u> ≥                | ပိ            | ᇫᇤ                     | Ë           |        | 8       | 8             |
| CLO-  |  | scribe about the f                        | T  |   | 2                    | 80                        | 70                       |                         | Н                        |                    |                         |                               | Н                               |                   | Н                            | Н              |                           |               |                        | Н           |        | Н       |               |
| CLO-2 |  | entify the issues o                       |  | TO THE  | 2                    | 80                        | 70                       |                         | Н                        | Н                  |                         |                               |                                 | Н                 |                              |                |                           |               |                        | Н           | Н      | Н       |               |
| CLO-  | 0-4: Describe basic concepts of Food Safety and Quality Management                 |   |  |   |                      | 2                         | 80                       | 70                      | M                        | Н                  | Н                       | М                             | Н                               |                   | Н                            |                | H                         |               | H                      |             | Н      | Н       | Н             |
|       |  |   |  |   |                      | 2                         | 80                       | 70                      | Н                        |                    | Н                       |                               | Н                               |                   | M                            |                | H                         |               | Н                      |             | Н      |         | Н             |
|       |  |   |  |   |                      | 3                         | 80                       | 70<br>70                | H                        | Н                  | Н                       | H                             | H                               |                   | M                            |                | Н                         |               | H                      |             | Н      |         | H             |
| CLO-  | o: Pra   | actice quality audi                       | iting method <mark>s in the f</mark> ood i | ndustries   |                      | 2                         | 80                       | 70                      | Н                        | Н                  | Н                       | Н                             | Н                               |                   | IVI                          |                | Н                         |               | П                      | Н           | Н      | Н       | П             |
| Durat | ion (hour)   |   | 9  | 9   | 100                  | -                         | 9                        |                         | -                        |                    |                         | - 1                           | 9                               |                   |                              |                |                           |               | ç                      | <u> </u>    |        |         |               |
| Dulai |  |   |  |   | - 77                 | 90                        |                          |                         |                          |                    |                         |                               | even o                          | d and             | new Q                        | •              | nanai                     | reme          | nt                     |             |        |         |               |
|       | SLO-1  | Definition of Qua                         | ality, Dimen <mark>sions of Q</mark> uali  | Safety limits of Food additives                                     | Sampling             | Sampling Qualit           |                          |                         |                          |                    |                         | ods                           |                                 |                   |                              |                | ols                       | u unc         | now Q                  | uanty i     | παπαξ  | joinoi  | ,,,,          |
| S-1   | 01.0.0   | 0 " 5' '                                  | 0 " (                                      | Risk assessment and risk benefit Indices                            | concept, n           | nethods                   | and imp                  | ortance c               | of                       | Quali              | tv Stand                | dards - r                     | nanda                           | atorv a           | and                          |                |                           |               |                        |             |        |         | _             |
|       | SLO-2  | Quality Planning                          | g, Quality costs                           | of human exposure   | sampling             |                           |                          |                         |                          |                    | nal stan                |                               |                                 | ,                 |                              | St             | atistica                  | al prod       | ess cor                | ntroi       |        |         |               |
|       | SLO-1  | Basic concepts                            | of Food Safety and Qualit                  | acute toxicity  | Statistical          | Dragona                   | and O                    | ality Can               | tral                     | ,<br>              | Cofoty                  | Systems                       |                                 |                   |                              | 14             | 0                         |               | chart, F               | 7 ahar      | . and  | Caba    | 4             |
| S-2   |  | Management                                |  | acute toxicity  | Statistical          | Process                   | anu Qu                   | anty Com                | li Oi                    |                    |                         |                               |                                 |                   |                              | IVI            | ean &                     | ange          | спап, г                | Cilar       | anu    | J CIIA  | πι            |
|       | SLO-2  | Historical Revie                          | w, Principles of <mark>FSQM</mark>         | mutagenicity and carcinogenicity                                    | concept, ii          | nportan                   | ce and t                 | ools                    |                          |                    |                         | O 1400                        |                                 |                   |                              |                | even d                    | eadly         | wastage                | es          |        |         |               |
| S-3   | SLO-1  | Leadership Con                            | ncepts                                     | reproductive and developmental toxicity                             | Control ch           | arts                      |                          |                         |                          | Mech<br>stand      |                         | of develo                     | ping                            | and fi            | xi <mark>ng f</mark> oo      | d<br>PL        | DCA cy                    | <i>cle</i>    |                        |             |        |         |               |
| 3-3   | SLO-2  | Quality Council,                          | Quality Statements                         | teratogenicity, neurotoxicity and behavioral effect, immunotoxicity | importance<br>limits | e, types,                 | design                   | process (               | control                  | Good               | Manuf                   | acturing                      | Pract                           | tice              |                              | Qı             | uality c                  | ircle,        | Quality                | audit,      | Intern | al au   | dit           |
| S     | SLO-1  | Strategic Planni                          | ing Barriers to Food Safet                 |   | 1                    | 7 7 7 7                   | Trans.                   |                         | Times                    |                    | 05 04                   |                               |                                 |                   |                              | Co             | ontinuc                   | us im         | provem                 | ent of      | produ  | ıctivit | v             |
|       | SLO-2  |   |  |   |                      | process                   | control                  | V. E.                   | 1774                     | HAC                | SP Star                 | dards o                       | t wei                           | gnts              |                              |                |                           |               | ting for               |             |        |         |               |
| S-6   | SLO-1 Barriers to Food Safety Implementation LD50, FSSAI regulations and GRAS      |   |  |   | Process C            | apability                 | <i>'</i> .               |                         | 1111                     | HAC                | CP Star                 | d <mark>ards</mark> o         | f <mark>M</mark> ea             | sures             |                              |                | x Sigm                    |               |                        |             | •      |         |               |
| 3-0   | SLO-2 Definition of Quality, Dimensions of Quality Safety limits of Food additives |   |  | Sampling  |                      |                           |                          |                         | Quali                    | ty of Fo           | ods                     |                               |                                 |                   |                              | even oi<br>ols | d and                     | new Q         | uality i               | nana        | geme   | nt      |               |
| 0.7   | SLO-1  | Quality Planning                          | cs concept, methods and important sampling |   |                      |                           | of                       |                         | ty Stand<br>nal stan     | dards - r<br>dards | nanda                   | atory a                       | and                             | St                | atistica                     | al prod        | ess cor                   | ntrol         |                        |             |        |         |               |
| S-7   | SLO-2  | Pools concepts of Food Sofety and Quality |  |   |                      |                           |                          |                         |                          |                    |                         | range                         | ange chart, P chart and C chart |                   |                              |                |                           |               |                        |             |        |         |               |

| Duration (hour) |                | 9                                     | 9   | 9   | 9   | 9   |
|-----------------|----------------|---------------------------------------|---|---|---|---|
| S-8             | SLO-1          | Historical Review, Principles of FSQM | Imiliagenicity and carcinogenicity                                  | concept, importance and tools for quality control | ISO 9000, ISO 14000, ISO 22000                    | Seven deadly wastages                         |
|                 | SLO-2          | · '                                   |   | quality control charts                            | Mechanism of developing and fixing food standards | PDCA cycle                                    |
| S-9             | SLO-1<br>SLO-2 | Quality Council, Quality Statements   | teratogenicity, neurotoxicity and behavioral effect, immunotoxicity | importance, types, design process                 | Good Manufacturing Practice                       | Quality circle, Quality audit, Internal audit |

| Lograina  | 1. | Andres Vasconcellos J. 2 nd edition. Quality Assurance for the Food industry - A practical approach. 2005, | 3. | Sara Mortimore and Carol Wallace. 3rd edition HACCP - A practical approach.2013,                |
|-----------|----|--|----|---|
| Learning  |    | CRC press.   |    | Chapman and Hall, L <mark>ondon.</mark>   |
| Resources | 2. | Inteaz Alli. 1st edition, Food quality assurance - Principles & practices. 2004, CRC Press. New York.      | 4. | Roday, S. 2 <sup>nd</sup> edition Food Hygiene and Sanitation, 201, Tata McGraw-Hill Education. |

| Learning | Assessment             |  |          |        | J. K. G.      | A CONTRACTOR OF THE PARTY OF TH |          |         |          |        |                   |  |  |  |
|----------|------------------------|--|----------|--------|---------------|--|----------|---------|----------|--------|-------------------|--|--|--|
|          | Bloom's                | Continuous Learning Assessment (50% weightage) |          |        |               |  |          |         |          |        |                   |  |  |  |
|          | Level of Thinking      | CLA –  | 1 (10%)  | CLA –  | CLA – 2 (15%) |  | 3 (15%)  | CLA – 4 | 4 (10%)# |        | n (50% weightage) |  |  |  |
|          | Level of Thinking      | Theory   | Practice | Theory | Practice      | Theory   | Practice | Theory  | Practice | Theory | Practice          |  |  |  |
| Level 1  | Remember<br>Understand | 40 <mark>%</mark>                              | 1        | 30%    | Showing.      | 30%  | V . W    | 30%     | -        | 30%    | -                 |  |  |  |
| Level 2  | Apply<br>Analyze       | 40 <mark>%</mark>                              | N. S.    | 40%    | 516           | 40%  | 15 3 10  | 40%     | -        | 40%    | -                 |  |  |  |
| Level 3  | Evaluate<br>Create     | - 20 <mark>%</mark>                            | 3        | 30%    |               | 30%  | The r    | 30%     | -        | 30%    | -                 |  |  |  |
|          | Total                  | 10   | 0 %      | 10     | 0 %           | 100  | 0 %      | 10      | 0 %      | 100 %  |                   |  |  |  |

| Course Designers  |  |                               |
|---|--|-------------------------------|
| Experts from Industry   | Experts from Higher Technical Institutions   | Internal Experts              |
| Dr. S. Sam Gunasekar, Orchid Chemicals and Pharmaceuticals Ltd., sam@orchidpharma.com | Dr. A. Gnanamani, CSIR-Central Leather Research Institute, agmani_2000@yahoomail.com         | 1. Dr. K.A.Athmaselvi, SRMIST |
| 2. Dr. D. Gunaseelan, BIOCON Ltd., guna.sachin@gmail.com                              | 2. Dr. Anbumani Sadasivam, CSIR-Indian Institute of Toxicology Research,anbumani@iitr.res.in | 2. Dr. R.Preetha, SRMIST      |

| 1                            | urse<br>ode                              | 18BTE313T   | Course Name  | ENZ'   | YME ENGINEERING AND                        | rechnolog                         | SY SY                        |                          | _                       | ourse<br>I <mark>tegory</mark> | Е                |                         |                               | F                 | Profes            | sional El                    | lective | Э                         |               |                           | L<br>3            | T<br>0  | P<br>0  | C<br>3 |
|------------------------------|--|---|--|--|--|-----------------------------------|------------------------------|--------------------------|-------------------------|--------------------------------|------------------|-------------------------|-------------------------------|-------------------|-------------------|------------------------------|---------|---------------------------|---------------|---------------------------|-------------------|---------|---------|--------|
|                              | re-requisite<br>se Offering              | Courses Nil Department                                      | Biote  | Co-requisite Courses                         | S Nil Data Book / Codes                    | :/Standards                       |                              |                          | Nil                     | rogressiv                      | e Cou            | ses                     | Nil                           |                   |                   |                              |         |                           |               |                           |                   |         |         |        |
| Cour                         |  | Rationale (CLR)   |  | The purpose of learn                         |  | $\cdots$                          |                              | Learnin                  | g                       |                                |                  |                         |                               | Prog              | gram L            | .earning                     | Outo    | omes (                    |               |                           |                   |         |         |        |
| CLR-                         |  |   |  |  | <mark>fact</mark> ors affecting enzyme ac  | tivity                            | 1                            | 2                        | 3                       | 1                              | 2                | 3                       | 4                             | 5                 | 6                 | 7                            | 8       | 9                         | 10            | 11                        | 12                | 13      | 14      | 15     |
| CLR-<br>CLR-<br>CLR-<br>CLR- | 3 : Exar<br>4: Appl<br>5: Disc<br>6: Dem | mine the sequent<br>y the various met<br>uss the applicatio | ial procedure of th<br>thods of enzyme in<br>ons of enzymes in<br>portance of enzyme | various industries<br>es in engineering rese | process<br>luating their kinetic efficienc |                                   | Level of Thinking<br>(Bloom) | Expected Proficiency (%) | Expected Attainment (%) | Engineering<br>Knowledge       | Problem Analysis | Design &<br>Development | Analysis, Design,<br>Research | Modern Tool Usage | Society & Culture | Environment & Sustainability | Ethics  | Individual & Team<br>Work | Communication | Project Mgt. &<br>Finance | ife Long Learning | PSO - 1 | PSO - 2 | PSO-3  |
| CLO-                         |  |   |  |  | mechanism of working                       | 7, 10 25                          | 1                            | 80                       | 80                      | H                              | М                | L                       | H                             | M                 | 0)                | Н                            | ш       | = ><br>H                  |               | Н                         | _                 | H       | H       | H      |
| CLO-                         |  |   |  | <mark>is and</mark> regulation of e          |  | W. 100                            | 2                            | 85                       | 75                      | Н                              | Н                | Н                       | Н                             | Н                 |                   | Н                            |         | Н                         |               |                           |                   | Н       | Н       | Н      |
| CLO-                         |  |   |  | <mark>rifica</mark> tion and their cha       |  |                                   | 2                            | 75                       | 80                      | М                              | L                | Н                       | Н                             | Н                 |                   | Н                            |         | Н                         |               | Н                         |                   | Н       | Н       | Н      |
| CLO-                         |  |   |  |  | g the effectiveness of immo                | bilization                        | 2                            | 85                       | 80                      | Н                              | Н                | Н                       | Н                             | Н                 |                   | Н                            |         | Н                         |               | Μ                         |                   | Н       | Н       | Н      |
| CLO-                         |  |   |  | <mark>ns-</mark> in various industrie        |  |                                   | 3                            | 85                       | 75                      | Н                              | L                | Н                       | Н                             | М                 |                   | Н                            |         | Н                         |               | Η                         | Н                 | Н       | Н       | Н      |
| CLO-                         | 6 : Inter                                | rpret the mechan  | isms of enz <mark>yme a</mark>   | <mark>cti</mark> on and evaluating t         | heir importance in various a               | applications                      | 2                            | 80                       | 80                      | Н                              | Н                | Н                       | H                             | Н                 |                   | Н                            |         | Н                         |               | Н                         | Н                 | Н       | Н       | Н      |
| _                            |  |   |  |  |  | 10000                             |                              |                          | 2.50                    | 100                            |                  |                         | -                             |                   |                   |                              |         |                           |               |                           |                   |         |         |        |
| Dura                         | tion (hour)                              |   | 9  |  | 9  | D / "                             |                              | 9                        | -                       |                                |                  |                         |                               | 9                 |                   |                              |         |                           |               |                           | 9                 |         |         |        |
| S-1                          | SLO-1                                    | Chemical natur  | e of enzym <mark>es</mark>   | Basics of enzyr                              | ne kinetics                                | Production scale                  |                              |                          |                         | rciai                          | Enzym            | e immo                  | bilizatio                     | on                |                   |                              | Αμ      | oplicatio                 | ons o         | f enzym                   | nes - F           | ood p   | roces   | sing   |
|                              | SLO-2                                    | Characteristics   |  |  | en Kinetic equation                        | Nature of th                      |                              |                          |                         |                                |                  | tages a                 |                               |                   |                   |                              |         |                           |               | crose in                  | ndustri           | es      |         |        |
|                              | SLO-1                                    | Enzymes and to  | heir actions   | Significance of                              | Michaelis-Menten Kinetics                  | Extraction of                     | of soluble                   | enzyme                   | es                      |                                |                  |                         |                               |                   |                   | obilization                  | on Da   | airy ind                  | ustrie        | S                         |                   |         |         |        |
| S-2                          | SLO-2                                    | Mechanism of e  | enzyme action  | Solving problen                              | ns in enzyme kinetics                      | Extraction                        | of <mark>memb</mark> i       | rane-bou                 | ınd enzy                |                                |                  | cal met<br>ilization    |                               | enzyn             | ne                |                              | Ві      | rewing i                  | indus         | tries                     |                   |         |         |        |
| S-3                          | SLO-1                                    | Structural comp   | oonents of enzy <mark>me</mark>  | Evaluation of M<br>parameters                | lichaelis-Menten kinetic                   | Technologi                        | es for en                    | zyme pr                  | oduction                |                                | Carrie           | r-based                 | immol                         | oilizatio         | on                |                              | Ве      | everage                   | e indu        | ıstries                   |                   |         |         |        |
| 3-3                          | SLO-2                                    | The active site   | of an enzyme   | Line weaver Bu<br>and Eadie Hofs             | rk plot, Hanes Woolf plot<br>tee plot      | Recovery and purification enzymes |                              |                          | nethods                 | for                            | Carrie           | r free im               | mobiliz                       | ation             |                   |                              | Le      | eather                    | indus         | tries                     |                   |         |         |        |
|                              | SLO-1                                    | Cofactors and o   | coenzymes  |  | per, Catalytic efficiency                  | Cell disrupt                      | tion                         | -                        |                         |                                | Immob            | ilization               | by us                         | ing po            | rous s            | <mark>up</mark> port         | Τe      | extile in                 | dustr         | ies                       |                   |         |         |        |
| S-4                          | SLO-2                                    | Role of cofactor  | rs and coenzymes   | Enzyme Inhibito                              | ors  | Solid-liquid                      | separati                     | on                       |                         | THE                            |                  | ransfer                 |                               |                   |                   |                              | De      | etergen                   | t indu        | dustries                  |                   |         |         |        |
|                              |  |   |  |  |  |                                   |                              |                          | IIIIIItatiONS           |                                |                  |                         |                               |                   |                   | -                            | -       |                           |               |                           |                   |         |         |        |

lon exchange chromatography

Concentration

Precipitation

Liquid- liquid extraction

Classification of enzymes

Oxidoreductase, Transferase,

Lyase, Isomerase, Ligase

enzymes

Hydrolase

Enzyme commission classification of

SLO-1

SLO-2

SLO-1

SLO-2

S-5

S-6

Types of enzyme inhibition

Competitive inhibition

Uncompetitive inhibition

Noncompetitive inhibition

Immobilization by using non-porous

Mass transfer effects and diffusion

Stabilization of immobilized enzymes in

Stabilization of immobilized enzymes in

support

limitations

aqueous environment

non-aqueous environment

Pulp and paper industries

Analytical applications of enzymes

Diagnostic applications of enzymes

Polymer industries

| Dura | ation (hour) | 9  | 9                                     | 9   | 9  | 9                                 |
|------|--------------|--|---------------------------------------|---|--|-----------------------------------|
| S-7  | SLO-1        | Enzyme-substrate complex formation models                                  | Substrate inhibition                  | Gel filtration, Affinity chromatography                 | Electrostatic and steric effects in immobilized enzyme systems | Role of enzymes - Pharmaceuticals |
| 3-1  | SLO-2        | Lock and Key and Induced fit models  | Feedback inhibition                   | Criteria of purity – Electrophoresis                    | Analyzing the effectiveness factor of immobilized enzymes      | Medicine                          |
| S-8  | SLO-1        | Mechanisms of enzyme catalysis   | Enzyme deactivation model             | Isoelectric focusing, Capillary electrophoresis         | Applications of immobilized enzyme systems                     | Medical research                  |
| 5-6  | SLO-2        | Proximity and orientation effects,<br>Conformational distortion            | Allosteric activation and inhibition  | Monitoring of purification of enzymes                   | Limitations of immobilized enzyme systems                      | ~                                 |
|      | SLO-1        | Factors affecting enzyme activity  | Solving problems in enzyme inhibition | Determination of molecular weight of enzymes- MALDI-TOF | Solving problems in enzyme immobilization and their kinetics   | Environment protection            |
| S-9  | SLO-2        | Effect of substrate, enzyme and inhibitor concentration on enzyme activity | Solving problems in enzyme inhibition | Drying and packing                                      | Solving problems in enzyme immobilization and their kinetics   | Biofuels development              |

| Learning  | 1. | Trevor Palmer and Philip L Bonner. "Enzymes: Biochemistry, Biotechnology, Clinical Chemistry," East-West Press, 2004.      | 3. | Ka <mark>rgi. F., Shu</mark> ler. M.L., "Bioprocess Engineering: Basic |
|-----------|----|--|----|--|
| Resources | 2. | Syed Tanveer Ahmed Inamdar. "Biochemical Engineering: Principles and Concepts "Third Edition, PHI Learning Pvt. Ltd., 2012 |    | Concepts," 3 <sup>rd</sup> Edition. Prentice Hall, 2017.               |

| Learning A | Assessment             |                    |  | THE STATE OF | Total State of | No.    | 100          |         |          |                   |                   |  |  |  |  |
|------------|------------------------|--------------------|--|--------------|----------------|--------|--------------|---------|----------|-------------------|-------------------|--|--|--|--|
|            | Bloom's                |                    | Continuous Learning Assessment (50% weightage) |              |                |        |              |         |          |                   |                   |  |  |  |  |
|            |                        | CLA – 1            | (10%)  | CLA – 2      | CLA – 2 (15%)  |        | 3 (15%)      | CLA – 4 | (10%)#   | Filiai Examinatio | n (50% weightage) |  |  |  |  |
|            | Level of Thinking      | Theory             | Practice                                       | Theory       | Practice       | Theory | Practice     | Theory  | Practice | Theory            | Practice          |  |  |  |  |
| Level 1    | Remember<br>Understand | <mark>40 %</mark>  | (a)  | 30%          |                | 30%    | THE STATE OF | 30%     |          | 30%               | -                 |  |  |  |  |
| Level 2    | Apply<br>Analyze       | <mark>40 %</mark>  | -  | 40%          | 1              | 40%    | Service N    | 40%     |          | 40%               | -                 |  |  |  |  |
| Level 3    | Evaluate<br>Create     | 2 <mark>0 %</mark> | 21   | 30%          |                | 30%    | S. Maria     | 30%     | 111-1    | 30%               | -                 |  |  |  |  |
|            | Total                  | 100                | 1%   | 100          | %              | 100    | 0 %          | 100     | 1%       | 100 %             |                   |  |  |  |  |

<sup>#</sup> CLA – 4 can be from any combination of these: Assignments, Seminars, Tech Talks, Mini-Projects, Case-Studies, Self-Study, MOOCs, Certifications, Conf. Paper etc.,

| Course Designers  |   |   |
|---|---|---|
| Experts from Industry   | Experts from Higher Technical Institutions              | Internal Experts  |
| Dr. G. N. Ramchand, Saksin Life sciences Pvt Ltd, Chennai, ramchand@saksinlife.com  | 1. Prof. K Subramaniam, IITM, Chennai, subbu@iitm.ac.in | 1. Dr. V.Vinothkumar, SRMIST, vinothkumar.v@ktr.srmuniv.ac.in |
| 2. Dr. Karthik Periyasamy, Scientist I, Aurozymes <mark>Unit, Auro</mark> bindo Pharma Limited, Hyderabad, karthikmpk@gmail.com | 2. Prof. R. B. Narayanan, SVCE, Chennai, rbn@svce.ac.in | 2. Ms. P.Radha, SRMIST, radha.p@ktr.srmuniv.ac.in             |

| Course<br>Code                                 | 18BTE314T   | Course N   | lame   |  | MEMBRANE TECHNOLOGY                     |                              |                          | Cou<br>Cate             | ırse<br>gory             | Е                |                         |                               | Pi                | ofess             | ional El                        | ective | e                         |               |                           | L<br>3             | T<br>0  | P<br>0  | C<br>3  |
|--|---|--|--|--|---|------------------------------|--------------------------|-------------------------|--------------------------|------------------|-------------------------|-------------------------------|-------------------|-------------------|---------------------------------|--------|---------------------------|---------------|---------------------------|--------------------|---------|---------|---------|
|  | ite Courses   Nil<br>ring Department  | E  | Co<br>Biotechn                                 | o-requisite Courses<br>ology   | Nil Data Book / Codes/Standards         |                              |                          | Progre<br>Nil           | essive C                 | ourse            | s Nil                   |                               |                   |                   |                                 |        |                           |               |                           |                    |         |         |         |
| Course Lear                                    | ning Rationale (CLR)  | ): The pu  | rpose of                                       | learning this course is t  | 0:                                      |                              | Learnin                  | ]                       |                          |                  |                         |                               | Prog              | ram L             | .earning                        | Outo   | comes (                   | PLO)          |                           |                    |         |         |         |
| CLR-1:   | Acquire knowledge   | on membra  | ne and i                                       | ts types cum application   | 4                                       | 1                            | 2                        | 3                       | 1                        | 2                | 3                       | 4                             | 5                 | 6                 | 7                               | 8      | 9                         | 10            | 11                        | 12                 | 13      | 14      | 15      |
| CLR-2:<br>CLR-3:<br>CLR-4:<br>CLR-5:<br>CLR-6: | Analyse the function Discuss the function Discuss the membra Get acquaint on me | ons of revers<br>ns of dialysi<br>anes as rea<br>embranes fo | se osmos<br>s and ele<br>ctor and<br>r industr | zation of membrane sis, Micro and ultra-filtra ectro dialysis membrane I distillation of alcohol ial application iis course, learners will b |   | Level of Thinking<br>(Bloom) | Expected Proficiency (%) | Expected Attainment (%) | Engineering<br>Knowledge | Problem Analysis | Design &<br>Development | Analysis, Design,<br>Research | Modern Tool Usage | Society & Culture | Environment &<br>Sustainability | Ethics | Individual & Team<br>Work | Communication | Project Mgt. &<br>Finance | Life Long Learning | JSO - 1 | PSO - 2 | PSO – 3 |
| CLO-1 :  | Apply membranes f   |  |  |  | A PERMIT AND A SECOND                   | 2                            | 80                       | 90                      | M                        | М                | Н                       | M                             | M                 | 0,                | шо                              |        |                           |               | Н                         | H                  | H       | H       | H       |
| CLO-2:   | Demonstrate metho   |  |  |  | - 1000000000000000000000000000000000000 | 2                            | 85                       | 90                      | М                        | М                | Н                       | М                             | М                 |                   |                                 |        |                           |               | Н                         | Н                  | Н       | Н       | Н       |
| CLO-3:   |   |  |  | <mark>nicr</mark> o and Macro molecu   | les separation                          | 2                            | 75                       | 80                      | М                        | М                | Н                       | М                             | L                 |                   |                                 |        |                           |               | Н                         | Н                  | Н       | Н       | Н       |
| CLO-4:   | Apply membrane fo   |  |  |  |   | 2                            | 90                       | 85                      | М                        | М                | Н                       | М                             | М                 |                   |                                 |        |                           |               | Н                         | Н                  | Н       | Н       | Н       |
| CLO-5:   | Demonstrate memi  | brane for dis  | st <mark>illa</mark> tion                      | and production   |   | 2                            | 80                       | 80                      | М                        | М                | Н                       | М                             | М                 |                   |                                 |        |                           |               | Н                         | Н                  | Н       | Н       | Н       |
| CLO-6:   | Explain membrane  | in upstream  | and dov  | wnstream process econ  | omically                                | 2                            | 80                       | 80                      | М                        | М                | Н                       | М                             | Н                 |                   |                                 |        |                           |               | Н                         | Н                  | Н       | Н       | Н       |

| Dura | tion (hour) | 9  | 9   | 9  | 9  | 9  |
|------|-------------|--|---|--|--|--|
| S-1  | SLO-1       | Overview of membrane separation process                          | Membrane Types, Materials, Preparation and Characterization | Reverse Osmosis, Nano filtration,<br>Ultra filtration, and Microfiltration | Dialysis, pervaporation and electro dialysis | Membrane distillation, Membrane bioreactors and industrial membranes |
| J-1  | 151 U-7     | Equilibrium and rate controlled separation                       | Types of Synthetic Membranes- Micro porous Membranes        | Concept of osmosis   | Principles of Dialysis                       | Membrane contactors, Principles                                      |
| S-2  | SLO-1       | What is membrane?  | Asymmetric, thin film                                       | Determination of osmotic pressure and thermodynamics of osmosis            | Dialysis membranes                           | Advantages and Disadvantages   |
| 3-2  | 151 U-2     | Basic principles of Membrane<br>Separation                       | Electrically Charged Inorganic Membrane                     | Phenomena of Reverse osmosis   | Mass transfer in dialysis                    | Applications   |
| S-3  | SLO-1       | Historical development of Membranes                              | Membrane Modules-Plate and frame,<br>Tubular.               | Models of Reverse osmosis  | Design of Dialysis membranes                 | Membrane Distillation  |
|      | SLO-2       | Golden age of Membranes  | Spiral wound and Hollow fiber                               | Design and operating parameters  | Applications and its advantages.             | Mechanism  |
| S-4  | SLO-1       | Classification of Membrane<br>Processes                          | Typical Flow pattern  | Design of Reverse Osmosis module   | Principles                                   | Membrane recycle bioreactors   |
| 3-4  | SLO-2       | Pressure driven, Concentration gradient and Electrical Potential | Membrane Material   | Principles , Transport Mechanism   | Operation of Pervaporation                   | Plug flow bioreactors  |
| 0.5  | SLO-1       | Advantages of Membrane Processes                                 | Pore Characterization                                       | Mass transfer and Industrial Application of Nano filtration                | Application of Pervaporation                 | Perstraction   |
| S-5  | SLO-2       | Disadvantages of Membrane<br>Processes                           | General Methods of Membrane<br>Manufacture                  | Process Limitation   | Design of pervaporation modules              | Flux and separation in Perstraction                                  |
| S-6  | SLO-1       | Biotechnology Industry   | Phase Inversion Method,                                     | Basic principles of Ultra filtration Types of Ultra filtration             | Factors affecting pervaporation              | Membrane Chromatography  |

| Durat | tion (hour) | 9   | 9                                 | 9  | 9   | 9                                   |
|-------|-------------|---|-----------------------------------|--|---|-------------------------------------|
|       | SLO-2       | Micro and Macromolecule Separation                  | Track-etching                     | Factors affecting Ultra filtration and membrane flux of ultra filtration | Applications  | Design and application              |
| S-7   | ISLO-1      | Chemical and Pharmaceutical<br>Industry             | Sol-gel Peptisation Method        | Principles of Microfiltration  | Principles of Electro dialysis Ion Exchange Membranes | Membranes in Wastewater Treatment   |
|       | SLO-2       | Recovery of salt, acid and Bases                    | Interfacial Polymerization        | Microfiltration Membranes  | Energy requirements                                   | Design and Application              |
|       | SLO-1       | Food and Dairy Industry                             | Melt pressing                     | Mechanism of Transport   | Current utilization and Efficiency                    | Membrane in Desalination            |
| S-8   |             | Dairy, animal Products , Fruits and Vegetables etc. | Film Stretching                   | Flow characterization  | Application   | Membrane in in Fuel cells           |
| S-9   | SLO-1       | Electrochemical Industry                            | Template Leaching                 | Fouling and applications in Microfiltration                              | Batch electro- dialysis                               | Biomedical application of membranes |
| 3-9   | SLO-2       | Effluent Treatment Plant                            | Ion Exchange Membrane Preparation | Energy Consideration and Application                                     | Continuous electro- dialysis                          | Blood Oxygenator and Drug Delivery  |

| Learning 1. Kaushik Nath," Membrane Separation Processes", PHI, Publication, India, 2012. Resources 2. William.KWang," Membrane Separations in Biotechnology", Marcel Dekker. INC, New York, 2001 | 3. Scott .K, "Hand Book <mark>of Industria</mark> l Membranes "Elsevier Publication, 1995. |
|---|--|
|---|--|

|         | Diamila                |                    |          | Continue | ous Learning Asses | sment (50% weight | age)       |         |          | Final Examination (50% weightage) |                   |  |  |  |
|---------|------------------------|--------------------|----------|----------|--------------------|-------------------|------------|---------|----------|-----------------------------------|-------------------|--|--|--|
|         | Bloom's                | CLA - 1            | (10%)    |          | CLA – 2 (15%)      |                   | 3 (15%)    | CLA – 4 | · (10%)# | Finai Examinatio                  | n (50% weightage) |  |  |  |
|         | Level of Thinking      | Theory             | Practice | Theory   | Practice           | Theory            | Practice   | Theory  | Practice | Theory                            | Practice          |  |  |  |
| Level 1 | Remember<br>Understand | 4 <mark>0 %</mark> |          | 30%      |                    | 30%               | The second | 30%     | -        | 30%                               | -                 |  |  |  |
| Level 2 | Apply<br>Analyze       | 4 <mark>0 %</mark> | Z        | 40%      | 8 75 5             | 40%               |            | 40%     |          | 40%                               | -                 |  |  |  |
| Level 3 | Evaluate<br>Create     | 2 <mark>0 %</mark> |          | 30%      |                    | 30%               |            | 30%     | -        | 30%                               | -                 |  |  |  |
|         | Total                  | tal 100 % 100 %    |          | 0 %      | 10                 | 0 %               | 100        | 0 %     | 100 %    |                                   |                   |  |  |  |

| Course Designers   |   |                                  |
|--|---|----------------------------------|
| Experts from Industry  | Experts from Higher Technical Institutions              | Internal Experts                 |
| 1. Dr. P. BalaKumaran, Proklean Technologies (P) Limited, Chennai, genbalu86@gmail.com | 1. Prof. K Subramaniam, IITM, Chennai, subbu@iitm.ac.in | 1 .Dr.M.Venkatesh Prabhu SRM IST |
| 2. Dr. Karthik Periyasamy, Aurobindo Pharma Limited, Hyderabad, karthikmpk@gmail.com   | 2. Prof. R. B. Narayanan, SVCE, Chennai, rbn@svce.ac.in | 2 .Dr. Y.Ravichandran SRM IST    |

| Course<br>Code   | 18BTE315T                     | 18BTE3151   COURSE NAME   INDITSTRIAL FERMENTATION FECHNOLOGY |   | Cou  | se Ca    | itegory     | Е              |                       |                  | F           | Profes                  | siona      | l Electi | ive                             |        |              |               | L<br>3       | T<br>0   | P<br>0 | <u>C</u> |     |
|--|-------------------------------|---|---|--|----------|-------------|----------------|-----------------------|------------------|-------------|-------------------------|------------|----------|---------------------------------|--------|--------------|---------------|--------------|----------|--------|----------|-----|
| Pre-requi  | isite Courses   Nil           |   | Co-requisite Courses                        | Nil  | Prog     | gressiv     | e Cour         | ses N                 | I                |             |                         |            |          |                                 |        |              |               |              |          |        |          |     |
| Course Off   | fering Department             | Biote   | chnology                                    | Data Book / Codes/Standards                  | Nil      |             |                |                       |                  |             |                         |            |          |                                 |        |              |               |              |          |        |          |     |
| Course Learning Rationale (CLR):  The purpose of learning this course is to: |                               |   |   |  |          | .earnir     | ng             |                       |                  |             |                         | Progi      | ram L    | earnin                          | g Out  | come         | s (PLC        | D)           |          |        |          |     |
| CLR-1:   | Analyze the fundame           | ntal behind the need  | of ase <mark>ptic strain dev</mark> elopm   | ent.   | 1        | 2           | 3              | 1                     | 2                | 3           | 4                       | 5          | 6        | 7                               | 8      | 9            | 10            | 11           | 12       | 13     | 14       | 15  |
| CLR-2:   | Explore the important         | ce of Isolation and So  | reen <mark>ing of Indust</mark> rially Impo | ortant Microorganisms                        | E C      | (%)         | (%)            | Φ                     |                  |             |                         |            |          |                                 |        | ĸ            |               |              |          |        |          |     |
| CLR-3:   | Decipher an understa          | nding on the product  | io <mark>n of various</mark> primary meta   | bolites from microbial fermentation          | (Bloom)  | >           | Attainment (%) | gbe                   |                  | Development |                         | -          |          |                                 |        | Work         |               | Finance      |          |        |          |     |
| CLR-4:   | Comprehend the impo           | ortance and production  | o <mark>n of secon</mark> dary metabolite   | s with commercial significance               |          | enc         | Je             | N N                   | S                | ppu         |                         | age        | Ф        |                                 |        | m \          |               | ina.         | В        |        |          |     |
| CLR-5:   | Apprehend the bioche          | emical transformation   | in the production of recom                  | binant protein with medical importance       | Thinking | Proficiency | i i            | Ş                     | lysi             | ĕ           | Design,                 | Tool Usage | Culture  | ∞ .                             |        | Team         | on            | ∞ ⊏          | Learning |        |          |     |
| CLR-6:   | Instigate knowledge of        | n food fermentati <mark>on,</mark>                            | food flavourants, preserva                  | nts and SCP                                  | 声        | F.          | Aff            | l b                   | √na              | De          | Ğ                       | 8          | Cu       | ital                            | ]      | ∞ ∞          | cati          |              | Fe       |        |          |     |
| ·-   |                               |   |   | A STATE STATE                                | of T     | Expected    | Expected       | Engineering Knowledge | Problem Analysis | ∞ర          | Analysis, I<br>Research | L          | <u>م</u> | Environment 8<br>Sustainability |        | Individual & | Communication | Project Mgt. | Long     | -      | 7        | က   |
| Course Lea   | arning Outcomes               | he and of this course   | , learners will be able to:                 | 一般に対して記れている。                                 | evel     | Sec         | Sec            | gine                  | ple              | Design      | Analysis,<br>Research   | Modern     | Society  | viro<br>stai                    | Ethics | ivid         | шш            | je.          | )<br>C   | 0      | 0        | 0   |
|  | Atti                          | ie end of this course   | , learners will be able to.                 |  | Le l     | Ä           |                | En                    | Pro              | De          | Ang<br>Re               | ₩<br>W     | Soc      | Sus                             | 量      | lnd          | S             | Pro          | Life     | PSO    | PSO      | PSO |
| CLO-1:   | Accomplish knowledge          | ge on improv <mark>ement o</mark>                             | <mark>f s</mark> train development for pr   | mary and secondary metabolites               | 2        | 80          | 70             | Н                     | Н                | Н           | Н                       |            |          | Н                               |        | Н            |               | Н            | Н        | Н      | Н        | Н   |
| CLO-2:   | Explain the upstream          | and Downstream fer  | mentation process of orgai                  | nic acids and aminoacids                     | 2        | 85          | 75             | Н                     | Н                | Н           | H                       |            |          | Н                               |        | Н            |               | Η            | Η        | Н      | Н        | Η   |
| CLO-3:   | Describe the industria        | nl scale meth <mark>odologie</mark>                           | s for Antibiotic and microbi                | al enzyme production                         | 3        | 75          | 80             | Н                     | Н                | Н           | M                       | Н          |          | Н                               |        | Н            |               | Н            | Н        | Н      | Н        | Н   |
| CLO-4:   | Understand enzyme timportance | piotransform <mark>ation bio</mark>                           | stratergies and recombinar                  | t protein production with commercial and med | cal 3    | 85          | 80             | Н                     | Н                | Н           | Н                       | Н          |          | М                               |        | Н            |               | Н            | Н        | Н      | Н        | Н   |
| CLO-5:   | Apprehend the food fe         | ermentation process   | and its preservants used fo                 | r improving the shelf period                 | 3        | 85          | 80             | Н                     | Н                | Н           | Н                       | Н          |          | М                               |        | Н            |               | Н            | Н        | Н      | Н        | Н   |
| CLO-6:   |                               |   | various food colourants, fl                 |  | 2        | 80          | 75             | · H                   | Н                | Н           | Н                       | Н          |          | М                               |        | Н            |               | Н            | Н        | Н      | Н        | Н   |

|     | uration<br>(hour) | 9  | 9                                  | 9  | 9   |                                       |
|-----|-------------------|--|------------------------------------|--|---|---------------------------------------|
|     | SLO-1             | Introduction to industrial fermentations                                   | Production of primary metabolites  | Production of secondary metabolites                                    | Recombinant protein production            | Food fermentations                    |
| S-1 | SLO-2             | Chronological Development of the Fermentation Industry                     | Organic acids fermentation         | Antibiotic production  | Insulin - Upstre <mark>am proces</mark> s | Cheese and Yogurt fermentation        |
| S-2 | SLO-1             | Isolation and Screening of Industrially Important Microorganisms           | Citric acid – Upstream process     | Carbohydrate containing antibiotic: Streptomycin -<br>Upstream process | Insulin - Downstream process              | Sauerkraut and Soy sauce fermentation |
| 3-2 | SLO-2             | Types of fermentation process  | Citric acid – Downstream process   | Streptomycin - Downstream process                                      | Interferon - Upstream process             | Food flavoring agents' fermentations  |
| S-3 |                   | Microbial growth metabolism  | Lactic acid – Upstream process     | Macro cyclic lactones: Erythromycin - Upstream process                 | Interferon - Downstream process           | Mono sodium glutamate fermentation    |
| 3-3 | SLO-2             | Microbial metabolites  | Lactic acid – Downstream process   | Erythromycin - Downstream process                                      | Production of nucleosides and nucleotides | γ-decalactone fermentation            |
|     | SLO-1             | Strain development   | Acetic acid – Upstream process     | Peptide antibiotic: Bacitracin - Upstream process                      | 5' Inosine monophosphate                  | Food preservative fermentation        |
| S-4 | SLO-2             | Improvement of Strains Producing Primary metabolites                       | Acetic acid – Downstream process   | Peptide antibiotic: Bacitracin - Downstream process                    | 5' Guanosine monophosphate                | Nisin fermentation                    |
| C E | SLO-1             | Improvement of Strains Producing Secondary metabolites                     | Amino acids fermentation           | Industrial Enzyme production   | Enzyme biotransformations                 | Food colorants fermentation           |
| S-5 | SLO-2             | Preservation of Industrially Important Cell<br>Cultures and Microorganisms | L-glutamic acid - Upstream process | Protease - Upstream process  | Steroid transformations                   | Monascus pigments fermentation        |

|     | uration<br>(hour) | 9   | 9  | 9                                    | 9                                       |   |
|-----|-------------------|---|--|--------------------------------------|---|---|
| 0.6 | SLO-1<br>SLO-2    | Inoculum Development                            | L-glutamic acid – Downstream process             | Protease - Downstream process        | Antibiotic transformations              | Carotenoid production                       |
| 3-0 | SLO-2             | Aseptic Inoculation of Plant Fermenters         | L-lysine – Upstream process                      | Lipase - Upstream process            | Biopolymers fermentation                | Astaxanthin Production                      |
|     | SLO-1             | Measuring Process Variables                     | L-lysine – Downstream process                    | Lipase - Downstream process          | Xanthan gum                             | Production of single cell protein           |
| S-7 | SLO-2             | Product development:                            | L-tryptophan - Upstream process                  | Vitamins production                  | Polyhydroxyalkanoates                   | Bel – symba – pekilo – pruteen<br>processes |
| C 0 | SLO-1             | Regulation and safety Use of Process flowcharts | L-tryptophan - Downstream process                | Cyanaocobalamin - Upstream process   | Polyhydroxybutyrate Polyhydroxybutyrate | Beverages                                   |
| 3-0 | SLO-2             | Use of Process flowcharts                       | Solvents fermentation                            | Cyanaocobalamin - Downstream process | Agrochemicals production                | Brewing process                             |
| S-9 | SLO-1             | Use of Process block diagrams                   | Acetone - Butanol – Ethanol - Upstream process   | Riboflavin - Upstream process        | Bacillus thuringenesis                  | Wine production                             |
| 3-9 | SLO-2             | Examples  | Acetone - Butanol – Ethanol - Downstream process | Riboflavin - Downstream process      | Artemisinin Artemisinin                 | Cider production                            |

|           | 1. | Cruger W., Cruger A., Aneja K.R., "Biotechnology: A Textbook of Industrial Microbiology", Medtech Publishing, 3rd edition, 2017. | 4. | Saran S., Babu V., Chuabey A., "High Value Fermentation Products:     |
|-----------|----|--|----|---|
| Learning  | 2. | Lee Y.K., "Microbial Biotechnology: Principles and Applications", World Scientific Publishing, 3rd edition, 2013.                |    | Human Health", Scrivener Publishing, 2019                             |
| Resources | 3. | Waites M. J., Morgan N.L., Rockey J.S., Higton G., "Industrial Microbiology: An Introduction", Blackwell Science, 2013.          | 5. | Stanbury. P.F., Whitaker. A., Hall. S.J., "Principles of Fermentation |
|           |    |  |    | Technology", 3 <sup>rd</sup> Edition, Butterworth– Heinemann, 2016.   |

| Learning | Assessment                   |                   |          | 100           | 0.000             | Maria Comme        | A 100 CO. | - 7 -   |                      |                   |                   |
|----------|------------------------------|-------------------|----------|---------------|-------------------|--------------------|-----------|---------|----------------------|-------------------|-------------------|
|          | Dla ama'a                    |                   | -00      | Continuou     | s Learning Assess | ment (50% weightag | ge)       | 200     |                      | Final Evamination | n (FOO) weightege |
|          | Bloom's<br>Level of Thinking | CLA - 1 (1        | 10%)     | CLA – 2 (15%) |                   | CLA – 3            | 3 (15%)   | CLA – 4 | (10% <mark>)#</mark> |                   | n (50% weightage) |
|          | Level of Thinking            | Theory            | Practice | Theory        | Practice          | Theory             | Practice  | Theory  | Practice             | Theory            | Practice          |
| Level 1  | Remember<br>Understand       | 40 <mark>%</mark> | - 1      | 30%           | 100               | 30%                |           | 30%     | -                    | 30%               | -                 |
| Level 2  | Apply<br>Analyze             | 40 <mark>%</mark> | Test V   | 40%           |                   | 40%                | Sec.      | 40%     | -                    | 40%               | -                 |
| Level 3  | Evaluate<br>Create           | 20 <mark>%</mark> | 155 V    | 30%           | - 1               | 30%                | -         | 30%     | <u> </u>             | 30%               | -                 |
|          | Total 100 % 100 %            |                   | 100      | ) %           | 100               | ) <mark>%</mark>   | 100 %     |         |                      |                   |                   |

<sup>#</sup> CLA – 4 can be from any combination of these: Assignments, Seminars, Tech Talks, Mini-Projects, Case-Studies, Self-Study, MOOCs, Certifications, Conf. Paper etc.,

| Course Designers   |   |                                    |
|--|---|------------------------------------|
| Experts from Industry  | Experts from Higher Technical Institutions              | Internal Experts                   |
| 1. Dr. P. BalaKumaran, Proklean Technologies (P) Limited, Chennai, genbalu86@gmail.com | 1. Prof. K Subramaniam, IITM, Chennai, subbu@iitm.ac.in | 1. Dr. V. Vinoth Kumar, SRMIST     |
| 2. Dr. Karthik Periyasamy, Aurobindo Pharma Limited, Hyderabad, karthikmpk@gmail.com   | 2. Prof. R. B. Narayanan, SVCE, Chennai, rbn@svce.ac.in | 2. Dr. M. Venkatesh Prabhu, SRMIST |

|           |   | Course Name                         | BIOREACTOR I  | DESIGN                                |                          |                          | Cours<br>Catego         | I -                     |                  |                      |                               | Profe             | ssional                            | Electiv                                       | 'e         |               | -            | 3          | 0     | P<br>0 | 3<br>3        |
|-----------|---|-------------------------------------|---|---------------------------------------|--------------------------|--------------------------|-------------------------|-------------------------|------------------|----------------------|-------------------------------|-------------------|------------------------------------|---|------------|---------------|--------------|------------|-------|--------|---------------|
| Dro       | requisite Courses   | 18BTC107J                           | Co-requisite Courses  | Nil                                   |                          |                          | Drogra                  | ssive Co                | ourcoc           | N                    | il                            |                   |                                    |   |            |               |              |            |       |        |               |
|           | fering Department   | 100101013                           |   | Data Book / Codes/Standa              | arde                     | Nil                      | riogie                  | 33116 0                 | Juises           | / N                  | "                             |                   |                                    |   |            |               |              |            |       |        | -             |
| Oourse Or | iening Department   |                                     | Diotecrinology  | Data Book / Godes/Gtarida             | arus                     | 1111                     |                         |                         |                  |                      |                               |                   |                                    |   |            |               |              |            |       |        |               |
| Course Le | arning Rationale The  | e purpose of learning               | g this course is to:  | CHEV                                  |                          | _earnin                  | g                       |                         |                  |                      |                               | Progra            | ım Learı                           | ning O  | utcomes    | s (PLO)       | )            |            |       |        |               |
| CLR-1:    | Understand the ba   | asic design and deve                | elopment of Bioreactors and its operation                               |                                       | 1                        | 2                        | 3                       | 1                       | 2                | 3                    | 4                             | 5                 | 6 7                                | 8   | 9          | 10            | 11           | 12         | 13    | 14     | 15            |
| CLR-2:    | Design the air driv   |                                     |   |                                       | Ê                        |                          | -                       | a)                      |                  |                      |                               |                   |                                    |   | ~          |               |              |            |       |        |               |
| CLR-3:    |   |                                     | of Solid state bioreactors and its operation                            |                                       | evel of Thinking (Bloom) | Expected Proficiency (%) | Expected Attainment (%) | Engineering Knowledge   | 7                | Design & Development |                               |                   |                                    |   | Team Work  |               | & Finance    |            |       |        |               |
| CLR-4:    |   |                                     | to <mark>r and biofilm</mark> reactors                                  | and the same of                       | <u>B</u>                 | auc<br>Suc               | nen                     | × ×                     | (0               | pm                   | _                             | age               | a)                                 |   | <u>ہ</u>   |               | nar          | ρ          |       |        |               |
| CLR-5:    |   |                                     | Control and CFD analysis of bioraector                                  |                                       | ing                      | ficie                    | <u>=</u>                | S)                      | ysis             | e<br>e               | .B                            | Use               | in ex                              |   | ear        | L C           | 正            | Learning   |       |        |               |
| CLR-6:    |   |                                     | nd application of reactors  | 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 | Ę                        | 20                       | \<br> <br>              | D X                     | nal              | )ev                  | Sec                           |                   |                                    | <b>≧</b>                                      | ∾          | atic          |              | -ea        |       |        |               |
| 02.110.   | r arrimarized marr  | someopt or design a                 | a approal of reasons  | COLUMN TO SERVICE                     | Ţ                        | pe                       | р<br>В                  | eri                     | Problem Analysis | ∞<br>□               | Analysis, Design,<br>Research | Modern Tool Usage | Society & Culture<br>Environment & | ag ag   | <u>a</u>   | Communication | Project Mgt. | l gc       | _     | 2      | က             |
| Course Le | arning Outcomes   |                                     | A DAYON   | AT ACTIVITIES                         | 0                        | ecte                     | ecte                    | ije.                    | le le            | g                    | lysi                          | ern               | ro ety                             | <u>a</u> ⊟ 83                                 | Individual | 1 1           | ect          | Life Long  | `.    | -,     | ) – 3         |
| (CLO):    | At i  | the end of this c <mark>ours</mark> | <mark>e, lear</mark> ners will be able to:                              | all the Suit Control                  | eve                      | ă.                       | , Š                     | Bu                      | log              | sə(                  | na<br>Ses                     | lod               |                                    | Sustair                                       | j          | νo            | ō            | <u>i</u> e | PSO   | PSO-   | PSO           |
| CLO-1:    | Know the basic d  | esian of reactor                    |   |                                       | 1                        | 85                       | 80                      | Н                       | Н                | Н                    | H                             | M                 | о) ш                               | л ш   | H          | М             | H            | H          | Н     | H      | Н             |
| CLO-1:    |   | e on air driven <mark>react</mark>  | or  | Service was treed                     | 2                        | 90                       | 80                      | Н                       | Н                | Н                    | H                             | M                 |                                    |   | H          | M             | H            | Н          | Н     | Н      | Н             |
|           | CLO-3: Know about reactors for solid state fermentation                   |                                     |   |                                       |                          |                          |                         | H                       | Н                | Н                    | M                             | L                 |                                    |   | H          | M             | H            | Н          | Н     | Н      | Н             |
|           | CLO-4: Have knowledge on biofilm reactor                                  |                                     |   |                                       |                          |                          |                         | H                       | H                | Н                    | Н                             | M                 |                                    |   | H          | M             | H            | Н          | H     | Н      | Н             |
|           | CLO-5: Know about modeling, simulation and control system used in reactor |                                     |   |                                       |                          |                          |                         | Н                       | H                | Н                    | Н                             | M                 |                                    |   | H          | M             | H            | Н          | Н     | Н      | Н             |
| CLO-6:    |   |                                     |   |                                       |                          | 85<br>80                 | 80                      | H                       | H                | Н                    | Н                             | Н                 |                                    |   | H          | M             | - <u>''</u>  | H          | Н     | Н      | Н             |
| CLO-0.    | Acquire the basic   | knowledge on desig                  | ill or Sivir and SSF and its control                                    |                                       | 2                        | 00                       | 00                      | - 11                    | 111              | - / /                | ,,                            | -//               |                                    |   | 11         | IVI           | - 11         | 11         | 11    | 11     | -11           |
| Duration  | <u> </u>  |                                     |   |                                       |                          | -                        | _                       | 4                       | -                | -                    | _                             |                   |                                    |   |            |               |              |            |       |        | $\overline{}$ |
| (hour)    | '   | 9                                   | 9   | 9                                     |                          | - 1                      |                         |                         |                  |                      | 9                             |                   |                                    |   |            |               | 9            |            |       |        |               |
| (Hour)    |   |                                     |   |                                       | -                        |                          |                         | Sogu                    | ontial E         | Patch                | Biofilm                       | and Tri           | oklo                               | Pioros  | ctor Mo    | dolina        | cimula       | tion .     | ontro | Jano   | ,             |
| SLO-      | 1 Understanding of  | Bioreactor De <mark>sign</mark>     | Air Driven Reactors   | Solid State Fermentation              | Biorea                   | actors                   |                         |                         | ential L         |                      | ווווווטום,                    | anu m             |                                    |   | analysis   |               | Silliuic     | ilion , i  | JOHU  | ı anu  |               |
| S-1       |   |                                     | General features of bubble column and airlift                           | Solid-State Bioreactor Fu             | ndəm                     | ontole.                  |                         |                         |                  |                      | -                             |                   |                                    |   |            |               |              |            |       |        |               |
| SLO-      | 2 Basics and import   | tance of bioreactors                | reactor   | Selection and design of S             |                          |                          |                         | Sequ                    | ential E         | Batch i              | reactors                      |                   |                                    | Model   | ing and    | Simula        | tion         |            |       |        |               |
|           |   |                                     | Factors influencing mass transfer in bubble                             | Selection and design of S             | 101 10                   | aciors                   |                         |                         | -                |                      |                               |                   |                                    |   |            |               |              |            |       |        | -             |
| SLO-      | 1 Guidelines for bio  | reactor design                      | column  | Heat transfer in SSF reac             | tors                     |                          |                         | Biore                   | actors           | contai               | ining mi                      | crobial           | films                              | Types   | of Mod     | elling        |              |            |       |        |               |
| S-2       | General requirem  | ent for Mechanical                  | Flow patterns , liquid mixing and gas                                   |                                       |                          | 1                        |                         |                         |                  | 7                    |                               |                   |                                    |   |            |               |              |            |       |        |               |
| SLO-      | 2 construction of Bio   |                                     | dispersion in bubble column, Mass and Heat<br>transfer in bubble column | Mass transfer in SSF read             | ctors                    |                          |                         | Com                     | oletely          | nixed                | microb                        | ial reac          | tor                                | Types   | of simu    | lation        |              |            |       |        |               |
|           | Design of thin wal  | lled internal                       |   | Laboratory and pilot scale            | o of s                   | olid star                | to                      |                         |                  | -                    |                               |                   |                                    |   |            |               |              |            |       |        |               |
| S-3       | 1 pressure, stirred t   | ank reactor                         | Airlift bioreactors   | bioreactor                            | 0 0/ 3                   | ona Stat                 |                         | Micro                   | bial film        | n Bior               | eactor                        |                   |                                    | Steps   | involve    | d in Mo       | deling       |            |       |        |               |
| SLO-      | 2 Solving Problems  |                                     | Design and construction of the airlift loop reactor                     | Industrial scale of solid st          | ate bi                   | oreacto                  | r                       | Desig                   | gn and           | Const                | ruction                       |                   |                                    | Steps   |            |               |              |            |       |        |               |
| SLO-      | 1 Development of b  | ioreactors                          | Modeling in Air Lift Reactor  | Classification of SSF Bior            | eacto                    | r                        |                         | Trick                   | e flow           | eacto                | r                             |                   |                                    | Methods and strategies for bioreactor control |            |               |              |            |       |        |               |
| C 4       | In a turium a inta ti a in a i  |                                     | ž   |                                       |                          |                          |                         |                         |                  |                      |                               |                   |                                    | ·   |            |               |              |            |       |        |               |
| SLO-      | bioreactor  |                                     | Mass and Energy B <mark>alance</mark>                                   | Mode of Operation                     |                          |                          |                         | Design and Construction |                  |                      |                               |                   |                                    | Control loop                                  |            |               |              |            |       |        |               |
| SLO-      | 1 Sensors   |                                     | Hydrodynamics in ALR  | Un aerated and Unmixed                | Biore                    | actor                    |                         | Theo                    | ry of Tr         | ickle t              | low rea                       | ctor              |                                    | Analo   | que and    | digital       | contro       | I          |       |        |               |
| S-5 SLO-  |   | tor                                 | Three phase flow in ALR   | Design and Construction               |                          |                          |                         |                         | ical mo          |                      |                               |                   |                                    |   | ol algorit |               |              |            |       |        |               |

| [   | Ouration<br>(hour) | 9  | 9   | 9   | 9  | 9                                  |
|-----|--------------------|--|---|---|--|------------------------------------|
| S-6 | SLO-1              | Common operations of bioreactor                | Mixing  | Forcefully – Aerated bioreactors without mixing | Mathematical model of Trickle flow reactor                   | Physical control of Bioreactor     |
|     |                    | Types of Reactor                               | Oxygen transfer in ALR  | Design and Construction                         | Solving Problems   | Methods                            |
| S-T |                    | Performance of Batch Reactor                   | Design of fluidized bed bioreactor                                      | Rotating –Drum and Stirred –Drum bioreactors    | Performance analysis of Trickle flow reactor                 | Computers in control of Bioreactor |
| 3-  |                    | Solving Problems                               | Operation of fluidized bed bioreactor                                   |   | High substrate concentration and low substrate concentration | Solving Problems                   |
| S-8 |                    | Performance of Continuous reactor              | Desig <mark>n and operati</mark> on of inverse fluidized bed bioreactor | Mixed ,Forcefully – Aerated Bioreactors         | Calculation of parameter estimation                          | Control Strategy for Bioreactor    |
| 3-0 | SLO-2              | Performance of Continuous reactor with recycle | Models in Fluidized bed bioreactor                                      | Design and Construction                         | Problems   | Solving Problems                   |
|     | SLO-1              | Fed Batch Reactor                              | Hydrodynamics of fluidized bed rector                                   | Intermittently Mixed bioreactors                | Design method  | CFD analysis in Bioreactor design. |
| S-9 | SLO-2              | Solving Problems                               | Solving Problems  | I I I I I I I I I I I I I I I I I I I           | Calculation procedure and Evaluation of parameter estimation | Solving Problems                   |

| Learning  | 1. | Scragg. H., "Bioreactors in Biotechnology", Ellis Horwood series, 1991.  B.Atkinson., "Biochemical Reactors", Pion limited, London, 1974 | 3.  | Panda. T., "Bioreactors: Analysis and Design", McGraw H <mark>ill Educati</mark> on (India) Private Limited, 2011 |
|-----------|----|--|-----|---|
| Resources | 2. |  | 4.  | Riet. K. V., Tramper. J., "Basic Bioreactor Design", 2nd ed. <mark>, Marcel D</mark> ekker, Inc., New York, 1991. |
|           |    |  | 200 |   |

| Learning . | Assessment        |  |             |        |               |        |          |         |                        |                                   |          |  |
|------------|-------------------|--|-------------|--------|---------------|--------|----------|---------|------------------------|-----------------------------------|----------|--|
|            | Dloom'o           | Bloom's Continuous Learning Assessment (50% weightage) |             |        |               |        |          |         |                        |                                   |          |  |
|            |                   | CLA – 1 (10%)  |             | CLA –  | CLA – 2 (15%) |        | 3 (15%)  | CLA – 4 | 1 (10 <mark>%)#</mark> | Final Examination (50% weightage) |          |  |
|            | Level of Thinking | Theory   | Practice    | Theory | Practice      | Theory | Practice | Theory  | Practice               | Theory                            | Practice |  |
| Laural 4   | Remember          | 40.0/  |             | 200/   |               | 200/   |          | 2007    |                        | 2007                              |          |  |
| Level 1    | Understand        | 40 <mark>%</mark>                                      |             | 30%    | 11.00         | 30%    | 47.10    | 30%     |                        | 30%                               | -        |  |
| Level 2    | Apply             | 40 %   |             | 40%    |               | 40%    | -3-24    | 40%     |                        | 40%                               |          |  |
| Level 2    | Analyze           | 40 %   | Contract to | 40%    |               | 40%    | -        | 40%     |                        | 40%                               | -        |  |
| ا امیدا ۱  | Evaluate          | 20.0/  |             | 30%    |               | 30%    |          | 200/    |                        | 200/                              |          |  |
| Level 3    | Create            | 20 %   | 175A15      | 30%    | - 11/1        | 30%    | -        | 30%     |                        | 30%                               | -        |  |
|            | Total             | 100  | %           | 10     | 0 %           | 10     | 00 %     | 10      | 0 %                    | 100                               | ) %      |  |

<sup>#</sup> CLA – 4 can be from any combination of these: Assignments, Seminars, Tech Talks, Mini-Projects, Case-Studies, Self-Study, MOOCs, Certifications, Conf. Paper etc.,

| Course Designers  |  |                                |
|---|--|--------------------------------|
| Experts from Industry   | Experts from Higher Technical Institutions           | Internal Experts               |
| Dr. P. BalaKumaran, Proklean Technologies (P) Limited, Chennai, genbalu86@gmail.com | Prof. K Subramaniam, IITM, Chennai, subbu@iitm.ac.in | Dr.M.Venkatesh Prabhu, SRM IST |
| Dr. Karthik Periyasamy, Aurobindo Pharma Limited, Hyderabad, karthikmpk@gmail.com   | Prof. R. B. Narayanan, SVCE, Chennai, rbn@svce.ac.in | Dr. Y.Ravichandran SRM IST     |

|              | ourse<br>Code    | 18BTE407T                      | Course Name                            | BIOP                              | ROCESS MODELLING AN         | ND SIMULATION  |                           | Cou<br>Cate   |                         | Е                     |                  |                      |                               | Profes            | ssiona            | l Electiv  | 'e                                    |            |               | _l                     | _ T                | · F    | ) 3                |
|--------------|------------------|--------------------------------|--|-----------------------------------|-----------------------------|--|---------------------------|---|-------------------------|-----------------------|------------------|----------------------|-------------------------------|-------------------|-------------------|--|---------------------------------------|------------|---------------|------------------------|--------------------|--------|--------------------|
|              | Pre-regu         | isite Courses /                | Vil                                    | Co-requisite                      | Courses Nil                 |  |                           | F   | rogres                  | ssive C               | ourse            | ς                    | Nil                           |                   |                   |  |                                       |            |               |                        |                    |        |                    |
|              |                  | ng Department                  | ***                                    | Biotechnology                     |                             | / Codes/Standards  | N                         |   | rogroc                  | 00110 0               | 00100            |                      | 1 111                         |                   |                   |  |                                       |            |               |                        |                    |        |                    |
|              |                  |                                |  | ,                                 |                             | 2-11/2/2017  |                           |   |                         |                       |                  |                      |                               |                   |                   |  |                                       |            |               |                        |                    |        |                    |
| Cour<br>(CLF |                  | ning Rationale Th              | he purpose of learning                 | g this course <mark>is to:</mark> | 40 6                        | CHINE  | 1                         | earnir  | ng                      |                       |                  |                      |                               | Prog              | ram L             | earning  | Outco                                 | mes (      | PLO)          |                        |                    |        |                    |
| CLR          |                  |                                | ge on various mathem                   |                                   |                             |  | 1                         | 2   | 3                       | 1                     | 2                | 3                    | 4                             | 5                 | 6                 | 7  | 8                                     | 9          | 10            | 11                     | 12                 | 13     | 14 15              |
| CLR          |                  |                                | of bioprocess with a                   |                                   |                             |  | (ma                       | (%  | (%                      | Φ                     |                  | t                    |                               |                   |                   |  |                                       | ķ          |               | -                      |                    |        |                    |
| CLR          |                  |                                |  |                                   | tion of bioprocess systems  |  | Level of Thinking (Bloom) | Expected Proficiency (%)  | Expected Attainment (%) | Engineering Knowledge |                  | Design & Development |                               | a)                |                   |  |                                       | Team Work  |               | Project Mgt. & Finance |                    |        | ,                  |
| CLR          |                  |                                |  |                                   | ess system for the product  | ion of bioproducts.  | g (E                      | ei.   | me                      | NO.                   | .s               | udc                  | <u>۔</u>                      | age               | بو                |  |                                       | E          |               | ina                    | ing                |        |                    |
| CLR          |                  |                                | of various mathema <mark>ti</mark>     |                                   |                             |  | ř                         | )jjc  | ain                     | 조                     | ılys             | velc                 | sigi                          | N                 | 草                 | ∞ _  |                                       | Lea        | ioi           | ∞ ∞                    | arı                |        |                    |
| CLR          | -6: <i>Fa</i>    | miliarize the studen           | nts with the variou <mark>s bio</mark> | <mark>proces</mark> s models an   | d softwares.                | 100-6  | Ę                         | P.  | A#                      | В                     | Ana              | De                   | Ö                             | 00                | ਠ                 | ent  |                                       | ∞ర         | cat           | g:                     | Ĕ                  |        |                    |
|              |                  |                                |  |                                   | <u> </u>                    | NAME OF STATES   | J L                       | ted   | ted                     | eri                   | Ē                | م<br>م               | ırch<br>İrch                  |                   | ⊗<br>>-           | nm   |                                       | <u>ra</u>  | ī             | Σ                      | buc                | -      | -2<br>-3           |
|              |                  | ning Outcomes                  | t the end of this <mark>cours</mark>   | a learners will he a              | hle to:                     |  | <del> </del> e            | bec   | bec                     | gi                    | Problem Analysis | sign                 | Analysis, Design,<br>Research | Modern Tool Usage | Society & Culture | Environment & Sustainability   | Ethics                                | Individual | Communication | )ec                    | Life Long Learning | 0      | PSO - 2<br>PSO - 3 |
| (CLC         |                  |                                |  |                                   |                             | State of the state |                           | Image: Control of the control of the | Ä                       | Ш                     |                  |                      | A B                           | §<br>S            | So                | En<br>Su   | 亩                                     | <u> </u>   | ပိ            |                        |                    | PSO    | PSO.               |
| CLO          |                  |                                | ental laws and <mark>concep</mark>     |                                   |                             | 1.00   | 2                         | 80  | 70                      | Н                     | Н                | Н                    | Н                             |                   |                   | Н  |                                       | Н          |               | Н                      | Η                  |        | H H                |
| CLO          |                  |                                |  |                                   | engineering systems         | Aller and Marie and  | 2                         | 85  | 75                      | Н                     | Н                | Н                    | Н                             |                   |                   | Н  |                                       | Η          |               | Н                      | Η                  |        | H H                |
| CLO          |                  |                                |  |                                   | erial and energy balance o  | f biochemical reaction   | 3                         | 75  | 80                      | Н                     | Н                | Н                    | М                             | Н                 |                   | Н  |                                       | Н          |               | Η                      | Н                  |        | H H                |
| CLO          |                  |                                | cepts of MAT <mark>LAB, dat</mark>     |                                   |                             |  | 3                         | 85  | 80                      | Н                     | Н                | Н                    | H                             | Н                 |                   | M  |                                       | Н          |               | Η                      | Н                  |        | H H                |
| CLO          |                  |                                | cepts of SIM <mark>ULINK, d</mark>     |                                   |                             | WEDIGE   | 3                         | 85  | 80                      | H                     | Н                | Н                    | Н                             | Н                 |                   | M  |                                       | Н          |               | Н                      | Н                  |        | H H                |
| CLO          | -6: Ac           | complish knowledge             | e about the f <mark>undamer</mark>     | itals of modeling an              | d simulations of bioprocess | S  | 2                         | 80  | 75                      | Н                     | Н                | Н                    | Н                             | Н                 |                   | M  |                                       | Н          |               | Н                      | Н                  | Н      | H H                |
|              |                  | T                              |  |                                   | Mark to the last            |  |                           |   |                         |                       |                  |                      |                               |                   |                   | The state of the s |                                       |            |               |                        |                    |        |                    |
|              | ıration<br>hour) |                                | 9                                      |                                   | 9                           | 9  |                           |   |                         | M                     |                  |                      | 9                             |                   |                   |  |                                       |            |               | 9                      |                    |        |                    |
| S-1          | SLO-1            | Models - Introducti            | ion                                    | Basic Mathematic                  | al Models                   | Introduction to Superpro   |                           |   | ٨                       | NATLA                 | B - Int          | roduc                | tion                          |                   |                   | b  | asics                                 | J          |               |                        |                    | g MA   | NTLAB –            |
|              | SLO-2            | Basic modeling pri             |  | Setting up a mode                 |                             | Developing a Process Mode  | 1                         |   | ٨                       | <i>MATLA</i>          | B - ba           | sics                 |                               |                   |                   | В  | atch C                                | ulture     | – pro         | gramı                  | пе                 |        |                    |
|              | SLO-1            | Introduction of mat            | thematical mod <mark>eling</mark>      | Continuous flow to                | anks - enclosed vessel      | Process design   |                           |   | ٨                       | <i>MATLA</i>          | B - Da           | ata ana              | alysis                        |                   |                   | В  | atch C                                | ulture     | – ехр         | pected                 | Ι outpι            | ıts    |                    |
| S-2          | SLO-2            | Uses of mathemat               | tical modeling                         | Continuous flow ta                | anks - mixing vessel        | Process Modeling and Simu  | lation                    |   | C                       | Curve fi              | tting -          | Introd               | luction                       |                   |                   |  | lodelin<br>IATLA                      |            |               | tch C                  | ulture             | Using  | 7                  |
|              | SLO-1            | Classification of m            | odeling techniques                     | Steam jacketed ve                 | essel                       | Process flow diagrams  |                           |   | (                       | Curve fi              | ttina u          | isina I              | ИATLA                         | 3 - The           | eorv              |  | ed-bat                                |            |               | – proa                 | ramm               | е      |                    |
| S-3          | SLO-2            |                                | ls into opposite pairs                 |                                   |                             | Process flow diagram to pro<br>insulin   | duce i                    | numan   |                         |                       |                  |                      | <i>NATLAE</i>                 |                   |                   |  | ed-bat                                |            |               |                        |                    |        | ts                 |
| C 4          | SLO-1            | Classification base complexity | ed on Mathematical                     | Batch distillation –              |                             |  | S                         | Ŀ   | ٨                       | Numerio               | cal Int          | egratio              | on                            |                   |                   |  | lodelin<br>IATLA                      |            |               | uous (                 | Culture            | e Usir | ıg                 |
| S-4          | SLO-2            | Classification of moscale      | _                                      | Batch distillation n              | nodel                       | The Industrial Wastewater 1 Process  | reatm                     | ent   | ^                       | Numerio               | cal Int          | egratio              | on Tech                       | niques            | s                 |  | ontinu                                |            |               | – pro                  | gramı              | ne     |                    |
| S-5          | SLO-1            | Fundamental laws examples      | - Expression and                       | Bioprocess model                  | ing                         | Procedures & Operations  |                           |   | 7                       | Trapezo               | oidal F          | Rule                 |                               |                   |                   | С  | Continuous Culture – expected outputs |            |               |                        |                    |        |                    |
| 3-3          | SLO-2            | Energy equations               |  | Modelling approac                 | ches for biomanufacturing   | Resources  |                           |   | 7                       | Trapezo               | oidal F          | Rule - I             | Problem                       | าร                |                   | P  | rocess                                | Simu       | ılation       | )                      |                    |        |                    |

Simpson's Rule

Simulink - Introduction

Scheduling

Energy equations - expression and examples

Types of bioprocess model

S-6 SLO-1

|    | Ouration<br>(hour) | 9  | 9  | 9                               | 9  | 9  |
|----|--------------------|--|--|---------------------------------|--|--|
|    | SLO-2              | Continuity equations                           | Mathematical models of microbial process                                   | Process Properties & Simulation | Simpson's Rule - Problems                | Simulink - basics  |
| S- | SLU-1              | Continuity equations – expression and examples | Applying mechanistic models in bioprocess development                      | Economics                       | Euler's Method                           | Simulation of gravity flow tank  |
| 3- | SLO-2              | Transport equations                            | Model formulation for aerobic cultivation of budding yeast                 | Reports                         | Euler's Method - Problems                | Simulation of three isothermal CSTR                                      |
| S- | SLO-1              | Transport equations expression and examples    | Parameter identifiable analysis  | Material-Balance Calculations   | Runge-Kutta 4 <sup>th</sup> Order Method | Simulation by Simulink in Batch Culture                                  |
|    | SLO-2              | Equations of motion                            | Uncertainty analysis   | Material-Balance Problems       | Runge-Kutta 4th Order Method - Problems  | Simulation by Simulink in fed-batch Culture                              |
| S- |                    | Chemical kinetics                              | Metabolic flux modelling (MFM)   | Energy-Balance Calculations     | Programming with MATLAB                  | Simulation by Simulink in continuous<br>Culture                          |
| 3- | -                  | Examples                                       | MFM as a tool to analyze the behavior of genetically modified yeast strain | Energy-Balance Problems         | Program design and development           | Expected outputs of Batch, Continuous and Fed-batch fermentation process |

|           | 1. | Mandenius C., Titchener-Hooker N. J., "Measurement, Monitoring, Modelling and Control of Bioprocesses", Springer | 5.  | Biquette. W.B., "Process Dynamics- Modeling analysis with simulation", Prentice Hall; |  |  |  |  |
|-----------|----|--|-----|---|--|--|--|--|
| Lograina  |    | Publishers, 2013.  |     | 1 edition, 1998.  |  |  |  |  |
| Learning  | 2. | Burstein L., "Matlab® in Bioscience and Biotechnology, Woodhead Publishing, 2011.                                | 6.  | Beers. K.J., "Numerical Methods for Chemical Engineering Applications in              |  |  |  |  |
| Resources | 3. | Luben. W.L., "Proces <mark>s Modellin</mark> g Simulation and Control for Chemical Engineers", McGrawHill, 1990. |     | MATLAB®", Massachusetts Institute of Technology, Cambridge University press.          |  |  |  |  |
|           | 4. | Franks. R.G.E., "Mathematical Modeling in Chemical Engineering", John Wiley and Sons, Inc., 2004.                | 100 | 2007. www.intelligen.com/ SuperPro Designer user guide.                               |  |  |  |  |
|           |    |  |     |   |  |  |  |  |

| Learning | Learning Assessment             |                   |                                   |               |          |        |          |         |                    |                  |                   |
|----------|---------------------------------|-------------------|-----------------------------------|---------------|----------|--------|----------|---------|--------------------|------------------|-------------------|
|          | Bloom's                         |                   | Final Examination (50% weightage) |               |          |        |          |         |                    |                  |                   |
|          | Level of Thinking CLA – 1 (10%) |                   | 0%)                               | CLA – 2 (15%) |          | CLA –  | 3 (15%)  | CLA – 4 | (10%) <del>#</del> | Finai Examinatio | n (50% weightage) |
|          | Level of Thinking               | Theory            | Practice                          | Theory        | Practice | Theory | Practice | Theory  | Practice           | Theory           | Practice          |
| Level 1  | Remember<br>Understand          | 40 <mark>%</mark> |                                   | 30%           |          | 30%    | 340      | 30%     |                    | 30%              | -                 |
| Level 2  | Apply<br>Analyze                | 40 <mark>%</mark> | 155 V                             | 40%           |          | 40%    | -        | 40%     |                    | 40%              | -                 |
| Level 3  | Evaluate<br>Create              | 20 %              | 254                               | 30%           | - 4/     | 30%    | - 10     | 30%     |                    | 30%              | -                 |
|          | Total                           | 100 %             |                                   | 100           | %        | 100    | 0 %      | 100     | 0 %                | 10               | 0 %               |

<sup>#</sup> CLA – 4 can be from any combination of these: Assignments, Seminars, Tech Talks, Mini-Projects, Case-Studies, Self-Study, MOOCs, Certifications, Conf. Paper etc.,

| Course Designers  | Address of the same of the                           | 2                               |
|---|--|---------------------------------|
| Experts from Industry   | Experts from Higher Technical Institutions           | Internal Experts                |
| Dr. P. BalaKumaran, Proklean Technologies (P) Limited, Chennai, genbalu86@gmail.com | Prof K Subramaniam, IITM, Chennai, subbu@iitm.ac.in  | Dr. V. Vinoth Kumar, SRMIST     |
| Dr. Karthik Periyasamy, Aurobindo Pharma Limited, Hyderabad, karthikmpk@gmail.com   | Prof. R. B. Narayanan, SVCE, Chennai, rbn@svce.ac.in | Dr. M. Venkatesh Prabhu, SRMIST |

|              | ourse<br>ode  | 18BTE408T              | Course Name   |  | BIOPROCESS PLANT [                           | DESIGN                               |                           |                            | Course<br>ategor        |                                  | Е                |                      |                               | Prof              | essio             | nal Elect                    | tive                             |                        |                 |                          | L 3                  | T F            | ) ;     | C<br>3  |
|--------------|---|------------------------|---|--|--|--------------------------------------|---------------------------|----------------------------|-------------------------|----------------------------------|------------------|----------------------|-------------------------------|-------------------|-------------------|------------------------------|----------------------------------|------------------------|-----------------|--------------------------|----------------------|----------------|---------|---------|
|              |   | Courses   Nil          | Co-requisite Cou<br>Biotechnology   |  | ta Book / Codes/Standards                    |                                      |                           | Pı<br>Nil                  | rogress                 | sive Co                          | urses            | Nil                  |                               |                   |                   |                              |                                  |                        |                 |                          |                      |                |         |         |
| Cour<br>(CLF |   | ing Rationale Th       | ne purpose of learning thi  | s course is to:  | -0 G   |                                      |                           | .earnir                    | ng                      |                                  |                  |                      |                               | Prog              | ram L             | earning                      | Outco                            | mes (                  | (PLO)           |                          |                      |                |         |         |
| CLR          |   | uip the students wit   | th designing aspects for i  | ndu <mark>strial scale</mark>                                    | fermenter                                    |                                      | 1                         | 2                          | 3                       | 1                                | 2                | 3                    | 4                             | 5                 | 6                 | 7                            | 8                                | 9                      | 10              | 11                       | 12                   | 13             | 14 1    | 15      |
| CLR          | 2: Infe   | er various scale up    | and scale down paramet  | e <mark>rs for good</mark> o                                     | ptimization process                          |                                      | (E                        | (%)                        | (%                      | Φ                                |                  |                      |                               |                   |                   |                              |                                  | ¥                      |                 |                          |                      |                |         |         |
| CLR          |   |                        |   |  | udies for controlling process pa             | arameters                            | Level of Thinking (Bloom) | 5                          | nt (                    | edg                              | 1                | neu                  |                               | (I)               |                   |                              |                                  | Wor                    |                 | nce                      |                      | l              |         |         |
| CLR          |   |                        | es for plant operatio <mark>n and</mark>  |  |  | and as higher                        | g e                       | ien                        | me                      | NO N                             | .s               | obu                  | c                             | sage              | உ                 |                              |                                  | me                     |                 | -ina                     | ing                  | l              |         |         |
| CLR          |   |                        | nomics involved in i <mark>ndus</mark> t  |  |  |                                      |                           |                            | tai                     | 조                                | alys             | s e                  | ssig                          | Š                 | 井                 | t &<br>.y                    |                                  | Teg                    | tion            | ∞                        | l al                 | 1              |         |         |
| CLR          | 6:   <i>Ins</i>   | tigate the productio   | on strategies in pr <mark>otein a</mark> i  | <mark>nd</mark> other metal                                      | other metabolites with commercial importance |                                      |                           |                            | A                       | ing                              | An               | ۵                    | ا ۾ ر                         | <u>8</u>          | Ö                 | Delit<br>Delit               |                                  | ∞ =                    | ica             | ∕lgt.                    | J Le                 | i I            |         |         |
| (CLC         | )):   |                        | the end of this course, le  |  |  |                                      |                           | S Expected Proficiency (%) | Expected Attainment (%) | Engineering Knowledge            | Problem Analysis | Design & Development | Analysis, Design,<br>Research | Modern Tool Usage | Society & Culture | Environment & Sustainability | Ethics                           | Individual & Team Work | Communication   | ⊤ Project Mgt. & Finance | ⊤ Life Long Learning | PSO -          | PSO - ; | PS0 - 3 |
| CLO          |   |                        |   |  | alance for product conversion.               |                                      |                           |                            |                         | Н                                | Н                | Н                    | Н                             |                   |                   | Н                            |                                  | Н                      |                 |                          |                      |                |         | Н       |
|              | O-2 : learn about the mass and energy balance of bioprocess           |                        |   |  |  | Total State of                       | 2                         | 85                         | 75                      | Н                                | Н                | Н                    | Н                             |                   |                   | Н                            |                                  | Н                      |                 | Н                        | Н                    |                |         | Н       |
|              | CLO-3: develop and optimize the process parameters for the industries |                        |   |  |  | 3                                    | 75                        |                            | Н                       | Н                                | -Н               | М                    | Н                             |                   | Н                 |                              | Н                                |                        | Н               | Н                        |                      |                | Н       |         |
| CLO          |   |                        | or scale up i <mark>n the indu</mark> stry  |  | Annual Property and                          |                                      | 3                         | 85                         | 80                      | Н                                | Н                | Н                    | Н                             | Н                 |                   | M                            |                                  | Н                      |                 | Н                        | Н                    |                |         | Н       |
| CLO<br>CLO   |   |                        | plant design <mark>for regul</mark> ator<br>for processin <mark>g of biol</mark> ogic |  |  | 7                                    | 3                         | 85                         | 80<br>75                | H                                | H                | H                    | H                             | H                 |                   | M<br>M                       |                                  | H                      |                 | H                        | H                    |                | H .     | Н       |
| CLO          | o. jue:   | siyii a piani iayoul i | or processing or biologica  | ai illateriais   |  |                                      |                           | 00                         | 75                      | П                                | П                | П                    | П                             | П                 |                   | IVI                          |                                  | П                      |                 | п                        | П                    | п              | п       | П       |
|              | uration<br>hour)  |                        | 9   |  | 9  |                                      |                           |                            |                         |                                  | X                | 7                    | 9                             | 9                 |                   |                              |                                  |                        |                 | 9                        |                      |                |         |         |
| S-1          | SLO-1   | Design-Project Pro     | rocedure  | Heat and Ma  | ass Transfer studies                         | Selection of bioproces upstream      |                           |                            |                         | Pla                              | ant loca         | ation a              | nd site s                     | electic           | n                 |                              | Cash                             | Flow                   | for Inc         | dustria                  | l Opera              | ations         |         |         |
| 3-1          | SLO-2   | Types of Designs       |   | Effect of sca  | le on oxygenation                            | Selection of bioproces downstream    | ss equ                    | ipmen                      | t -                     | Pla                              | ant Lay          | out                  | w                             | i                 |                   |                              |                                  |                        | e Cash          |                          |                      |                |         |         |
| S-2          | SLO-1   | Feasibility Survey     |   | mixing and s   |  | Specifications of biopi              | ocess                     | equip                      | ment                    | Pla                              | ant ope          | eration              | and con                       | trol              |                   |                              |                                  |                        | ecting<br>costs | invest                   | tment a              | ınd            |         |         |
| 0-2          |   | Flow Diagrams          |   | Inoculum development and nutrient availability  Mechanical desig |  |                                      |                           | rs                         |                         | Te                               | chniqu           | es Use               | ed in Site                    | and I             | Plant I           | ayout                        | ,                                |                        | estme           |                          |                      |                |         |         |
|              | SLO-1   | Process Flow she       | eting   | Bioreactor s   |  | Heat transfer equipme                | ent                       |                            |                         | Uti                              | lity sup         | ply as               | pects                         |                   |                   |                              | Estin                            | nation                 | of Cap          | oital In                 | vestme               | ent            |         |         |
| S-3          | SLO-2   | Equipment Desigr       | า   | volume   | onstant power consumption pe                 | Heat exchangers and                  | Evapo                     | orators                    |                         | En                               | vironn           | ental (              | Consider                      | ations            |                   |                              | Cost                             | Index                  | es              |                          |                      |                |         |         |
| S-4          |   | Equipment Selecti      |   | Scale-up - m   |  | Mass transfer equipm                 |                           |                            |                         |                                  |                  |                      | ning asp                      | ects              |                   |                              | Cost                             | Facto                  | rs in C         | Capital                  | Invest               | ment           |         |         |
| 3-4          |   |                        | fferent Design-Projects   |  | npeller tip speed (shear)                    | Finite-Stage Contacto                |                           |                            |                         |                                  |                  | ell ban              |                               |                   |                   |                              |                                  |                        |                 |                          | Costs b              |                | aling   |         |
| S-5          |   | Material balance       |   |  | nass transfer coefficients                   | Continuous contactors                | s - Pad                   | ked to                     | wers                    | cG                               | MP gu            | ideline              | S                             |                   |                   |                              |                                  |                        |                 |                          | Installa             |                |         |         |
|              | SLO-2   | Material balance of    | calculations  | Problems   |  | Pressure Drop Factors Influencing Pl |                           |                            |                         | Glo                              | bal R            | egulato              | ory Envir                     | onmer             | nt _              |                              | Meth                             | ods fo                 | r estin         | nating                   | capita               | <u>I inves</u> | stmen   | t       |
| S-6          | SLO-1   | Examples               |   | Scale up of  |  |                                      |                           | d Colu                     | ımn                     | De                               | sign a           | nd Eng               | itical Reg<br>ineering        |                   |                   | lated to                     | Estimation of Total Product Cost |                        |                 |                          |                      |                |         |         |
|              | SLO-2   | Problems               |   | Adsorption   |  |                                      | ation                     |                            |                         | Implications for Performance and |                  |                      | Fixed Charges                 |                   |                   |                              |                                  |                        |                 |                          |                      |                |         |         |

Compliance

Piping and instrumentation

Fixed Charges

SLO-2 Problems

Adsorption

|     | uration<br>(hour) | 9  | 9  | 9  | 9                         | 9                                    |
|-----|-------------------|--|--|--|---------------------------|--------------------------------------|
|     | SLO-1             | Energy balance                           | Adsorption (LUB method)                        | HAZOPS Study   | Risk Assessments          | Case study – Commodity chemicals     |
| S-7 | SLO-2             | Energy balance calculations              | Chromatography                                 | Safety checklist for identifying process hazards                       | Validation                | Cost analysis of enzyme production   |
| S-8 | SLO-1             | Examples                                 | It informatiography (constant resolution etc.) | Materials of construction for bioprocess plants                        | Project Plans             | Bioethanol from Corn Stover          |
| 3-0 | SLO-2             | Problems                                 |  | Classification of stainless steels by alloy content and microstructure | Detailed Design Phase     | Furfural and lignin from Corn Stover |
| 0.0 | SLO-1             | Scale-Up in Design                       | Centrifugation (equivalent times etc.)         | Low- and high-temperature Materials                                    | Process Safety Management | Insulin production                   |
| 3-9 | SLO-2             | Factors in equipment scale-up and design | Scale-down related aspects                     | Economics in Selection of Materials                                    | Safety Indices            | Monoclonal Antibody Production       |

|           | 1. | Jacobs T., Signore A. A., "Good Design Practices for GMP Pharmaceutical Facilities", 2nd edition, |
|-----------|----|---|
| Learning  |    | Taylor and Francis, 201 <mark>7.</mark>   |
| Resources | 2. | Peters M. S., Timmerhaus. K. D., "Plant Design and Economics for Chemical Engineers", 5th         |
|           |    | Edition McGrawHill Book Co. 2003  |

- Perry R. H., Green D. W., "Perry's Chemical Engineers' Handbook", 9th Edition, McGraw Hill Book Co., 2018.
- 4. Towler G., Sinnott R., "Chemical Engineering Design Principles, Practice and Economics of Plant and Process Design, Elsevier, 2007.

| Learning . | Learning Assessment |               |          |               |                   |                    |                 |         |          |                   |                    |  |
|------------|---------------------|---------------|----------|---------------|-------------------|--------------------|-----------------|---------|----------|-------------------|--------------------|--|
|            | Dlaamia             |               |          | Conti         | nuous Learning As | sessment (50% weig | htage)          |         |          | Final Examination | n (EOO) waishtasa) |  |
|            | Bloom's             | CLA – 1 (10%) |          | CLA – 2 (15%) |                   | CLA -              | 3 (15%)         | CLA – 4 | (10%)#   |                   | n (50% weightage)  |  |
|            | Level of Thinking   | Theory        | Practice | Theory        | Practice          | Theory             | Practice        | Theory  | Practice | Theory            | Practice           |  |
| Level 1    | Remember            | 40 %          |          | 30%           | a steple          | 30%                | 100 C           | 30%     |          | 30%               |                    |  |
| Level      | Understand          | 40 %          |          | 30%           |                   | 30%                | THE PLANT       | 30%     |          | 30%               | -                  |  |
| Level 2    | Apply               | 40 %          |          | 40%           |                   | 40%                | THE STATE OF    | 40%     |          | 40%               |                    |  |
| Level 2    | Analyze             | 40 %          | _        | 40%           |                   | 40%                | Service Control | 40%     |          | 40%               | -                  |  |
| Level 3    | Evaluate            | 20 %          |          | 30%           |                   | 30%                | 1               | 30%     |          | 30%               |                    |  |
| Level 3    | Create              | 20 /0         |          | 3070          |                   | 30%                | - 1200          | 3070    | -        | 3070              | -                  |  |
|            | Total               | 10            | 0 %      | 100           | ) %               | 10                 | 0 %             | 100     | ) %      | 10                | 00 %               |  |

<sup>#</sup> CLA – 4 can be from any combination of these: Assignments, Seminars, Tech Talks, Mini-Projects, Case-Studies, Self-Study, MOOCs, Certifications, Conf. Paper etc.,

| Course Designers  | 111  | A TO SECULIAR SECULIA |
|---|--|--|
| Experts from Industry   | Experts from Higher Technical Institutions           | Internal Experts   |
| Dr. P. BalaKumaran, Proklean Technologies (P) Limited, Chennai, genbalu86@gmail.com | Prof. K Subramaniam, IITM, Chennai, subbu@iitm.ac.in | Dr. V. Vinoth Kumar, SRMIST  |
| Dr. Karthik Periyasamy, Aurobindo Pharma Limited, Hyderabad, karthikmpk@gmail.com   | Prof. R. B. Narayanan, SVCE, Chennai, rbn@svce.ac.in | Dr. M. Venkatesh Prabhu, SRMIST  |

| Cours            |           | 18BTE317T                         | Course Name                                 | ENVIRONMENTAL  | BIOTECHNOLOGY   | Course (                  | Catego                     | ry E   |  |                    |                                  | Profe   | ssiona            | ıl Electi                    | ve      |                          |   |                | L<br>3             | T<br>0              | P C 0 3        |
|------------------|-----------|-----------------------------------|---|--|---|---------------------------|----------------------------|--|--|--------------------|----------------------------------|---|-------------------|------------------------------|---------|--------------------------|---|----------------|--------------------|---------------------|----------------|
|                  |           | Courses /                         | Nil Bio                                     | Co-requisite Courses Nil otechnology Date                                    | a Book / Codes/Standards  | Pro                       | gressiv                    | ve Cou   | ırses  | Nil                |                                  |   |                   |                              |         |                          |   |                |                    |                     |                |
| Course<br>(CLR): | Learning  | Rationale The                     | e purpose of learning th                    |  | CHAC  |                           | earnin                     | g  |  |                    |                                  | Pro   | gram              | Learnir                      | ıg Out  | tcome                    | s (PL0  | <b>O</b> )     |                    |                     |                |
| CLR-1:           | 0         | reate awarenes                    | s on environmental noli                     | lution and the need for advanced tech  | nologies for their mitigation   | 1                         | 2                          | 3  | 1  | 2 3                | 3 4                              | 5   | 6                 | 7                            | 8       | 9                        | 10  | 11             | 12                 | 13                  | 14 15          |
| CLR-2:           |           |                                   |   | fo <mark>r the conversi</mark> on of various environn                        |   | = =                       |                            |  |  |                    |                                  | 3   | -                 | '                            | 0       |                          | 10  | 11             | 12                 | 10                  | 17 10          |
| CLR-3:           |           |                                   |   | l <mark>ogy in the e</mark> nvironmental managemer                           |   | 9                         | / (%                       | t (%   | dge  | ţ                  | <u></u>                          |   |                   |                              |         | /ork                     |   | 8              |                    |                     |                |
| CLR-4:           |           |                                   |   | tributions to the industries to reduce t                                     |   |                           | Suc                        | ner  | Ne.  | , 2                |                                  | ge  |                   |                              |         | N N                      |   | & Finance      | g                  |                     |                |
| CLR-5:           | Ē         | ducate the relev                  | /ant information about r                    | ecovery of bioproducts from industrial                                       | wastes  |                           | ficie                      | inn  | Su o   | ysis               | ig in                            | Jsa   | ture              | ంగ                           |         | ear                      | 드   | 這              | Ē                  |                     |                |
| CLR-6:           |           |                                   |   | ronmental pollution abatement  |   |                           | 20                         | Atta   | D X  | nal                | )es                              | 0   | Cul               | i ≟                          |         | _×<br>⊥×                 | atic  | - <u>-</u> -   | -ea                |                     |                |
| 0 2. 1 01        |           | ,                                 |   |  |   | <b>-</b>   <u></u>        | l pe                       | pe /   | erir   | ۲ م                | 8 'S' C                          | Ę   | ∞                 | ıme                          |         | la                       | iğ  | S <sub>0</sub> | β                  | <b>—</b>            | 2 8            |
| Course (CLO):    | Learning  | Outcomes At to                    | he end of this course, le                   | earners will be able to:   |   | Level of Thinking (Bloom) | S Expected Proficiency (%) | S Expected Attainment (%)  | Engineering Knowledge  | T Problem Analysis | Analysis, Design,                | Modern Tool Usage                                     | Society & Culture | Environment & Sustainability | Ethics  | エ Individual & Team Work | Communication     Com | ☐ Project Mgt. | Life Long Learning |                     | PSO            |
| CLO-1 :          | U         | nderstand the b                   | oiotechnologic <mark>al solution</mark>     | s for the treatment of industrial liquid                                     | and solid wastes  | 1                         | 80                         | 80   | H  | H F                | H                                | M   | M                 | L                            | Н       | H                        | Н   | H              | H                  |                     | H H            |
| CLO-2:           |           |                                   |   | obic biological treatment technologies                                       |   | 2                         | 85                         | 75   |  | H                  |                                  | Н   |                   | М                            | Н       | Н                        | Н   |                | Н                  | Н                   | Н Н            |
| CLO-3:           |           |                                   |   | logy in the environmental pollution ma                                       |   | 2                         | 75                         | 80   |  | ΗΛ                 |                                  | М   | М                 | М                            | М       | Н                        | Н   | Н              | Н                  | Н                   | Н Н            |
| CLO-4:           |           |                                   |   | for the degradation of various xenobic                                       |   | 2                         | 85                         | 80   | Н  | H F                | H                                | Н   | M                 | Н                            | L       | Н                        | Н   | Н              | Н                  | Н                   | H H            |
| CLO-5:           |           |                                   |   | value-added bioproducts from industr   |   | 3                         | 85                         | 75   |  | H F                |                                  | М   |                   | Н                            | Н       | Н                        | L   |                |                    |                     | Н Н            |
| CLO-6:           |           |                                   |   | waste into economic goods  |   | 2                         | 80                         | 80   |  | H I                |                                  | L   | М                 | М                            | М       | Н                        | Н   | Н              |                    |                     | Н Н            |
|                  | •         |                                   |   |  |   |                           |                            |  |  |                    |                                  |   |                   |                              |         |                          |   |                |                    | •                   |                |
| Duratio          | on (hour) |                                   | 9   | 9  | 9   |                           |                            | - 11   |  |                    | 9                                |   |                   |                              |         |                          |   | 9              |                    |                     |                |
|                  | SLO-1     | Introduction to pollution-water   | Environmen <mark>tal</mark><br>r, air, soil | Recent trends in Biological wastewater treatment                             | Xenobiotics and recalcitrants   | 5.0                       | was                        | stes   | cent trends in Biodegradation of in <mark>dustria</mark><br>stes |                    |                                  |   | Wa Wa             | ste to                       | Wea     | th                       |   |                |                    |                     |                |
| S-1              | SLO-2     | Perspectives o wastes             | of liquid and so <mark>lid</mark>           | Aerobic biological treatment technologies                                    | Environmental effects of Xenobiotic recalcitrants   | cs and                    | env<br>app                 | Contributions of Biotechnology for the<br>nvironmental managements and industrial<br>pplications |  |                    |                                  | <i>,</i>  | ue-ao<br>stes     | lded b                       | ioproc  | lucts                    | from I  | ndusti         | rial               |                     |                |
| S-2              | SLO-1     | Overview of state                 | ages of wastewat <mark>er</mark>            | Anaerobic digestion process  | Biodegradation of xenobiotics  Microbial enzymes for environmental applications  Slaughte |                           |                            |  |  | rhous              | e indu                           | ıstry v   | vastes            | 8                            |         |                          |   |                |                    |                     |                |
| 5-2              | SLO-2     | primary, secon<br>treatment       | ndary and tertiary                          | Stages of anaerobic digestion process  | Mechanisms of Biodegradation of x Reductive/Oxidative/Hydrolytic                          | enobiotics                |                            |  | e <mark>s</mark> of ir<br>cells ai                               |                    | le cells <mark>o</mark><br>symes | r enzy  | mes               | ind                          | ustry i | waste                    | for in  | dustri         | al app             | licatio             |                |
| S-3              | SLO-1     | Physicochemic<br>liquid waste dis |   | Anaerobic Biological treatment technologies                                  | Aliphatic and Hydrocarbons  | 1. [                      | Rol                        | le of B  | iocataly   | sts in             | pollutant                        | remo  | val               | sla                          |         | rhous                    |   |                |                    | lites fr<br>for ind | om<br>Iustrial |
| 5-3              | SLO-2     | Coagulation, F<br>Sedimentation   | Flocculation,                               | Advantages of anaerobic digestion processes over aerobic digestion processes | Biotransformation of Aliphatic and Hydrocarbons   |                           |                            | noval  |  |                    | i <mark>zed ce</mark> lls        |   |                   | s Lea                        | ather i | ndust                    | ry was  |                |                    |                     |                |
| 6.4              | SLO-1     | Chemical preci                    | ipitation                                   | Microbiology of anaerobic digester   | ster Aromatic Hydrocarbons  |                           |                            | Role of Biocatalysts in pollutant removal –<br>Immobilized Enzymes                               |  |                    |                                  | Types of solid wastes generated from leather industry |                   |                              |         |                          |   |                |                    |                     |                |

Biotransformation of Aromatic Hydrocarbons

Application of Immobilized enzymes in pollutants removal

Recovery of enzymes from leather industry wastes for industrial applications

Factors affecting anaerobic digestion

process

Pros and Cons of chemical precipitation

S-4

SLO-2

| Duratio | on (hour) | 9  | 9  | 9  | 9   | 9  |
|---------|-----------|--|--|--|---|--|
| S-5     | SLO-1     | Filtration processes-mechanisms  | Attached growth system-Biofilm                             | Polyaromatic nydrocarbons                                | Classification of dyes and their effects on the environment                                       | Recovery of secondary metabolites from<br>leather industry wastes for industrial<br>applications |
|         | SLO-2     | , , ,  | bioliliti development process                              |  | Microbial dye decolourization   | Plastic wastes   |
| S-7     | SLO-1     | Adsorption processes-Activated carbon technology-applications            | Biofilm Technologies in environmental pollution management | Polycyclic aromatic Hydrocarbons                         | Enzyme based dye decolourization  | Environmental impacts  |
| 3-1     | SLO-2     |  | Advantages of attached growth system over suspended system | Biotransformation of Polycyclic aromatic<br>Hydrocarbons | Biodegradation of textile dyes  | Recycling of plastic wastes  |
| S-8     |           | Solid waste disposal-Effects   | Nutrients removal-Eutrophication                           | I Halogenated hydrocarbons                               | Laccases and their role in Bioremediation of Industrial wastes                                    | Bioplastics  |
| 3-0     | SLO-2     | Secured Landfill, Bacterial and Vermi composting, incineration/pyrolysis | Recent advances in Nitrogen removal                        | Biotransformation of halogenated hydrocarbons            | Heavy metal toxicity to the environment   | Renewable resources for energy generation  |
|         |           | Advanced oxidation processes for recalcitrants treatment                 | Biological Phosphorous Removal                             | Oil pollution and its effect on the environment          | Microbial heavy metal removal-mechanisms  | Alternate technologies for Energy recovery   |
| S-9     | SLO-2     | Electrolysis-Cu removal  | EBPR process-mechanisms                                    | Microbial treatment of oil pollution                     | Role of biosurfactants, Extracellular polysaccharides and siderophores in the heavy metal removal | Biomass residue as a fertilizer  |

|                       | 1. | Bruce E.Rittmann and Perry L.McCarty, Environmental Biotechnology: Principles and Applications,    |
|-----------------------|----|--|
| Loorning              |    | McGraw Hill.2001.  |
| Learning<br>Resources | 2. | Bimal C Bhattacharyy <mark>a, Enviro</mark> nmental Biotechnology, Oxford University press, 2007.  |
| Resources             | 3. | Milton Wainwright, an Introduction to Environmental Biotechnology, Springer, 1999.                 |
|                       | 4  | P. Rajendran, P. Guna <mark>sekaran, Microbial Rioremediation, M.IP Publishers, India, 2006</mark> |

- Ram Chandra, Advances in biodegradation and bioremediation of industrial wastes, CRC Press, Taylor&Francis, 2015.
- Hanes Joachim Joardening, Environmental Biotechnology, Concepts and Applications, 2017. Chatterjee A.K, Introduction to Environmental Biotechnology, Prentice Hall of India, 2011.

## SLO – Session Learning Outcome

| Learning . | Assessment        |                       |                   | Establish State  |             | and the said | . 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. |        |                        |                                   |          |  |
|------------|-------------------|-----------------------|-------------------|------------------|-------------|--------------|--|--------|------------------------|-----------------------------------|----------|--|
|            | Bloom's           |                       | Final Evamination | (E00/ woightage) |             |              |  |        |                        |                                   |          |  |
|            |                   | $(1 \Delta = 1/10\%)$ |                   | CLA – 2 (15%)    |             | CLA –        | 3 (15%)                                  | CLA -  | 4 ( <mark>10%)#</mark> | Final Examination (50% weightage) |          |  |
|            | Level of Thinking | Theory                | Practice          | Theory           | Practice    | Theory       | Practice                                 | Theory | Practice               | Theory                            | Practice |  |
| Level 1    | Remember          | 40 %                  |                   | 30%              |             | 30%          |  | 30%    |                        | 30%                               |          |  |
| Level I    | Understand        | 40 /0                 |                   | 30 /8            |             | 30 /0        | Transfer                                 | 3070   |                        | 3070                              | -        |  |
| Level 2    | Apply             | 40 %                  |                   | 40%              |             | 40%          |  | 40%    | T 11                   | 40%                               | _        |  |
| Level 2    | Analyze           | 40 /0                 |                   | 4070             |             | 4070         |  | 4070   |                        | 4070                              | -        |  |
| Level 3    | Evaluate          | 20 %                  |                   | 30%              | Water To    | 30%          | 771107-1-7                               | 30%    |                        | 30%                               |          |  |
| Level 3    | Create            | 20 %                  |                   | 30%              | AIRLA TOTAL | 30%          |  | 30%    |                        | 30%                               | -        |  |
|            | Total             | 100 %                 |                   | 100 %            |             | 10           | 0 %                                      | 10     | 0 %                    | 100 %                             |          |  |

| Course Designers   |  |   |
|--|--|---|
| Experts from Industry  | Experts from Higher Technical Institutions                     | Internal Experts  |
| 1 Dr. C. Som Cunacokar, Orabid Chamicala and Pharmacouticals Ltd., com@arabidpharma.com  | 1. Dr. A. Gnanamani, CSIR-Central Leather Research Institute,  | 1 Dr. K.Ramani SRM Inst. of Science & Technology,       |
| 1. Dr. S. Sam Gunasekar, Orchid Chemicals and Pharmaceuticals Ltd., sam@orchidpharma.com | agmani_2000@yahoomail.com                                      | ramani.k@ktr.srmuniv.ac.in                              |
| 2 Dr. D. Cumassalan DIOCON I tal. guma sashin@gmail.com                                  | 2. Dr. Anbumani Sadasivam, CSIR-Indian Institute of Toxicology | 2 Dr. B.Samuel Jacob SRM Inst. of Science & Technology, |
| 2. Dr. D. Gunaseelan, BIOCON Ltd., guna.sachin@gmail.com                                 | Research, anbumani@iitr.res.in                                 | Samueljacob.b@, ktr.srmuniv.ac.in                       |

| Course<br>Code | 18BTE318T     | Course Name | INDUSTRIA            | L WASTE MANAGEMENT          | Cours |             |                      | Professional Elective | L3 | T 0 | P<br>0 | <u>C</u> |
|----------------|---------------|-------------|----------------------|-----------------------------|-------|-------------|----------------------|-----------------------|----|-----|--------|----------|
|                |               |             |                      |                             |       |             |                      |                       |    |     |        |          |
| Pre-requ       | isite Courses | Nil         | Co-requisite Courses | Nil                         | Pr    | ogressive C | <mark>o</mark> urses | Nil                   |    |     |        |          |
| Course Offeri  | ng Department | Bi          | otechnology          | Data Book / Codes/Standards | Nil   |             |                      |                       |    |     |        |          |

|                      |  |  |          | -               |                |             |          |             |                 |        |         |                               |        |            |               |              |         |             |      |      |
|----------------------|--|--|----------|-----------------|----------------|-------------|----------|-------------|-----------------|--------|---------|-------------------------------|--------|------------|---------------|--------------|---------|-------------|------|------|
| (CLR):               | arning Rationale   | The purpose of learning this course is to:   | 1        | .earnin         | g              |             |          |             |                 | Pro    | gram l  | _earning                      | g Out  | comes      | (PLO)         | )            |         |             |      |      |
| CLR-1:               | Identify the rele  | vant information about industrial solid waste reduction and hazardous waste management                     | 1        | 2               | 3              | 1           | 2        | 3           | 4               | 5      | 6       | 7                             | 8      | 9          | 10            | 11           | 12      | 13          | 14   | 15   |
| CLR-2:               | Identify the app   | (Bloom)  | (%       | (%              | ω              |             |          |             |                 |        |         |                               | ¥      |            |               |              |         |             |      |      |
| CLR-3:               | Demonstrate th   | e state of the art in technolog <mark>y, organiz</mark> ational and legislative developments and practices | 8        | > ×             | )<br>=         | bo          | 1        | ien         |                 | -      |         |                               |        | Work       |               | Se l         |         |             |      |      |
| CLR-4:               | Create insights  | to the waste characterization aspects  |          | Proficiency (%) | Attainment (%) | Knowledge   | S        | Development | e e             | Usage  | Ф       |                               |        | am V       |               | inance       | В       |             |      |      |
| CLR-5:               | Analyze the ma   | ss balance and carbon f <mark>oot print fo</mark> r a given industrial process                             | Š        | ofici           | aj.            | X           | lysi     | velc        | sign            | Ns     | ulture  | જ ્                           |        | Геа        | lon           | ∞<br>⊏       | ï.      |             |      |      |
| CLR-6:               | Utilize the conc   | epts environmental re <mark>gulation an</mark> d inculcate in newly developed treatment technologies       | Thinking | Pr              | H H            |             | Analysis | De          | De              | Tool   | 0       | ment<br>ability               |        | ∞          | cat           |              | ĕ       |             |      |      |
|                      |  |  | of T     | ted             | ted            | eri         | E        | ∞ ~         | sis,<br>arch    |        | ∞ >     | na Fi                         |        | ual        | Ĭ.            | ₹            | ong     | <del></del> | 7    | က    |
| Course Lea<br>(CLO): | arning Outcomes  | At the end of this <mark>course, lea</mark> rners will be able to:   | Level    | Expected        | Expected       | Engineering | Problem, | Design      | Analys<br>Resea | Modern | Society | Environment<br>Sustainability | Ethics | Individual | Communication | Project Mgt. | Life Lo | PSO-        | PSO- | PSO- |
| CLO-1 :              | Formulate an in pollutants                                       | sight into the pollution from major industries including the sources and characteristics of                | 1        | 80              | 70             | Н           | Н        | М           | М               | М      | Н       | Н                             | Н      | М          | Н             | М            | Н       | М           | Н    | Н    |
| CLO-2:               | Analyze the mo   | de of treatment b <mark>ased on w</mark> aste characteristics  | 2        | 85              | 75             | Н           | M        | М           | М               | М      | Н       | Н                             | Н      | Μ          | L             | Н            | Н       | Μ           | Н    | Н    |
| CLO-3:               | Design of waste  | ewater treatment <mark>plants to</mark> attain standard limits   | 2        | 75              | 70             | Н           | Н        | М           | М               | М      | Н       | Н                             | Н      | Н          | М             | Н            | Н       | Н           | М    | Н    |
| CLO-4:               | Assess the imp   | act of industrial wastes on the environmental compartments (land, water and air)                           | 2        | 85              | 80             | Н           | Н        | М           | М               | М      | Н       | Н                             | Н      | Н          | М             | Н            | Н       | Н           | Н    | Н    |
| CLO-5:               |  |  |          | 85              | 75             | Н           | Н        | М           | М               | М      | Н       | Н                             | Н      | М          | Н             | М            | Н       | Н           | Н    | Н    |
| CLO-6:               | Develop knowledge on environmental regulations and legal aspects |  |          |                 | 70             | Н           | M        | М           | М               | М      | Н       | Н                             | Н      | М          | Н             | Μ            | Н       | Н           | М    | Н    |

| Durat | ion (hour) | 9   | 9   | 9  | 9  | 9  |
|-------|------------|---|---|--|--|--|
| S-1   | SLO-1      | Introduction to industrial wastes and their impacts-Industrial wastes - Sources | Standards for waste disposal & methods of waste reduction –                               | Treatment and disposal of industrial effluents                                 | Blodegradation/ Recycling Of Industrial                            | Environmental Concerns,<br>Legislations And Environmental<br>Impact Assessment   |
| 3-1   | SLO-2      | Classification of industrial wastes   | different industries  | Stages of effluent treatment- primary, secondary and tertiary                  | for the effluent treatment   | Environmental Assessment and<br>Management Systems                               |
|       | SLO-1      | Industrial waste generation scenario in India                                   | Characteristics of industrial wastewater-<br>COD, BOD and TOC                             | Physicochemical treatment-Coagulation, flocculation and their mechanisms       |  | Applicable federal and provincial environmental regulations                      |
| S-2   | SLO-2      | Industrial waste generation scenario in Global context                          |   | Precipitation –heavy metal removal-<br>Merits and Demerits                     |  | Environmental impact assessment<br>(EIA) legislation and regulatory<br>framework |
| S-3   | SLO-1      | Environmental impacts   | Characteristics of industrial wastewater-,<br>TKN, Ammonia, Chloride, Sulfide and Sulfate | Secondary Biological treatment: Aerobicactivated sludge process,               | Algal based technologies for nutrient and pollutant removal        | EIA applied to solid and liquid waste management                                 |
| 3-3   | SLO-2      | Threat to biodiversity  | Metal analysis using AAS and ICP-MS   | Sequential batch process. fluidized bed reactor                                | 0 0  | Environmental toxicology assessment and regulations                              |
| S-4   | SLO-1      | Toxicity of industrial effluents  | chemical process  | Secondary Biological treatment:<br>Anaerobic-UASB, MBR –Merits and<br>Demerits | Bioelectricity production through MFC with leachate and wastewater | Management of toxic chemicals  |

| Durat | tion (hour) | 9  | 9  | 9  | 9  | 9  |
|-------|-------------|--|--|--|--|--|
|       | SLO-2       | gas leak, Chernobyl etc.)  | Biological process for heavy metal removal   | High rate bioreactors                                  | Water splitting technologies   | Nuclear waste management   |
|       | SLO-1       | Functions of Regulatory bodies-State and<br>Central Pollution Control Board      | Individual and Common Effluent Treatment Plants  | Reprocessing of bio-sludge for value addition          |  | Effluent control, air pollution control and urban development          |
| S-5   | SLO-2       | and tannery industry wastewater treatment  | Case study of Indian industries waste<br>treatment through common effluent treatment<br>process                              | Energy recovery from sludge                            |  | Pollution abatement in national river bodies: Case studies             |
| S-6   | SLO-1       | Selection of candidate technologies for waste treatment based on characteristics | Volume and strength reduction  | Removal of refractory organics-strategies              | Plastics degrading bacteria  | Environmental auditing   |
| S-0   | SLO-2       | Rationale for biological treatment over convetional methods                      | Material and process modifications   | Advanced oxidation processes                           | Phytoremediation for removal of heavy metals   | ISO 14001:2015 And its implication in environmental assessment         |
| S-7   | SLO-1       | The solid waste landfill   | 4R principles– Recycle, reuse and by-<br>product recovery  | Photo-oxidation process                                | Bioremediation of hydrocarbon<br>contaminated wastewater of refinery plants<br>through super bugs (GM Pseudomonas<br>putida) | Carbon foot print for an industry                                      |
|       | SLO-2       | Leachate management  | Waste treatment flow sheets for selected industries such as Textiles, Tanneries, Pharmaceuticals, Electroplating industries, | Volatile organic compound (VOC) removal by Evaporation | Ocean cleaning for oil spill using super bugs  | Carbon credit  |
| S-8   | SLO-1       | The process of compostin <mark>g Industri</mark> al wastes                       | Dairy, Sugar, Paper, distilleries, Steel plants,<br>Refineries, fertilizer, thermal power plants                             | Air and steam stripping                                | Iniogeoragation of Various notificants   | Occupational Safety and Health<br>Assessment                           |
| 5-0   | SLO-2       | Vermi-composting and its advantages  | Hazardous waste management– Physico chemical treatment   | Adsorption processes (Activated carbon)                | Itechnologies for solids reduction in  | Waste Hazard identification and problem formulation                    |
| S-9   | SLO-1       | , ,  | Solidification and incineration – Zero discharge   | Colour removal from wastewater from textile industries |  | Life cycle assessment of industrial wastes                             |
| S-8   | SLO-2       |  | Secure land fills  | Role of microorganisms and enzymes for dye removal     |  | Implications of biological agents on environment for pollutant removal |

| Lametra   | 1. | Eckenfelder, W.W., (1999) "Industrial Water Pollution Control", Mc-Graw Hill.                    |    |  |  |
|-----------|----|--|----|--|--|
| Learning  | 2. | Clair N. Sawyer, Perry L. McCarty, "Chemistry for Environmental Engineering and Science" McGraw- | 3. | Metcalf & Eddy Inc. Wastewater Engineering: Treatment and reuse 2016 |  |
| Resources |    | Hill, 1978   |    |  |  |

| Learning | Assessment        |        |          | 77 . 15 . 1 | 10 No. 1           |                   |          |         |          |                                    |          |  |  |
|----------|-------------------|--------|----------|-------------|--------------------|-------------------|----------|---------|----------|------------------------------------|----------|--|--|
|          | Bloom's           |        |          | Conti       | nuous Learning Ass | essment (50% weig | htage)   |         |          | Final Examination (50% weightage   |          |  |  |
|          | Level of Thinking | CLA –  | 1 (10%)  | CLA –       | 2 (15%)            | CLA –             | 3 (15%)  | CLA – 4 | l (10%)# | Tillal Examination (30% weightage) |          |  |  |
|          | Level of Thirking | Theory | Practice | Theory      | Practice           | Theory            | Practice | Theory  | Practice | Theory                             | Practice |  |  |
| Level 1  | Remember          | 40 %   |          | 30%         | _                  | 30%               | -        | 30%     | _        | 30%                                | _        |  |  |
|          | Understand        | 10 /0  |          | 307,0       |                    | 00,0              |          |         |          | 0070                               |          |  |  |
| Level 2  | Apply             | 40 %   | _        | 40%         | _                  | 40%               |          | 40%     | _        | 40%                                | _        |  |  |
| LOVOIZ   | Analyze           | 10 70  |          | 1070        |                    | 1070              |          | 1070    |          | 1070                               |          |  |  |
| Level 3  | Evaluate          | 20 %   | _        | 30%         |                    | 30%               |          | 30%     | _        | 30%                                | _        |  |  |
| Level 3  | Create            | 20 70  | _        | 3070        |                    | 3070              |          | 3070    | _        | 3070                               | _        |  |  |
|          | Total             | 10     | 0 %      | 100         | ) %                | 10                | 0 %      | 100     | 0 %      | 100                                | 0 %      |  |  |

# CLA – 4 can be from any combination of these: Assignments, Seminars, Tech Talks, Mini-Projects, Case-Studies, Self-Study, MOOCs, Certifications, Conf. Paper etc.,

| Course Designers  |  |   |
|---|--|---|
| Experts from Industry   | Experts from Higher Technical Institutions                     | Internal Experts                                      |
| 1. Dr. S. Sam Gunasekar, Orchid Chemicals and Pharmaceuticals Ltd., | 1. Dr. A. Gnanamani, CSIR-Central Leather Research Institute,  | Dr. K.Ramani SRM Inst. of Science & Technology,       |
| sam@orchidpharma.com  | agmani_2000@yahoomail.com                                      | ramani.k@ktr.srmuniv.ac.in                            |
| 2 Dr. D. Cunacaclan PIOCON I td. guna cachin@gmail.com              | 2. Dr. Anbumani Sadasivam, CSIR-Indian Institute of Toxicology | Dr. B.Samuel Jacob SRM Inst. of Science & Technology, |
| 2.Dr. D. Gunaseelan, BIOCON Ltd., guna.sachin@gmail.com             | Research,anbumani@iitr.res.in                                  | ssamueljacob.b@ ktr.srmuniv.ac.in                     |



| Course<br>Code                        | 18BTE319T   | Course<br>Name  | BIOENEF  | BIOENERGY  |      |                     | Е                        |                         |                       |        | Profe         | ession                     | al Elec          | ctive  |        |                 |                   | L<br>3  | T<br>0        | P (  |
|---------------------------------------|---|---|--|--|------|---------------------|--------------------------|-------------------------|-----------------------|--------|---------------|----------------------------|------------------|--------|--------|-----------------|-------------------|---------|---------------|------|
|                                       | -requisite Courses<br>ring Department               | Nil<br>Biotechnology  | Co-requisite Courses   | Nil Data Book / Codes/Standards  | Nil  | Progi               | ressive                  | Cours                   | es                    |        | Nil           |                            |                  |        |        |                 |                   |         |               |      |
| Course Lea<br>(CLR):                  | rning Rationale The                                 | ourpose of learning to                                      | his course is to:  | CH YC  | 1    | Le                  | arning                   | T                       |                       |        |               | Pro                        | gram             | Learn  | ing Οι | utcome          | es (PL            | O)      |               |      |
| CLR-1 :<br>CLR-2 :                    | Identify the potent bid<br>Identify the application |   |  |  |      | 1                   | 2                        | 3                       | 1                     | 2      | 3             | 4 5                        | 5 6              | 7      | 8      | 9 ′             | 10 1 <sup>-</sup> | 1 12    | 13            | 14   |
| CLR-3 :<br>CLR-4:<br>CLR-5:<br>CLR-6: | Create insights to the<br>Analyze the important     | e concepts of sustain<br>It wastes to energy <mark>c</mark> | ental benefits of bioenergy<br>able and green technologies<br>onversion<br>r biomass based energy production |  |      | of Thinking (Bloom) | Expected Proficiency (%) | Expected Attainment (%) | Engineering Knowledge | _      | & Development | Analysis, Design, Research | & Culture        | ∈      |        | ual & Team Work | Communication     | ਂ ਲੋ    | _             | 2    |
| Course Lea<br>(CLO):                  | rning Outcomes At th                                | e end of this <mark>course,</mark>                          | learners will be able to:  | - Florence   | WHY. | Level               | Expec                    | Expec                   | Engine                | Proble | Design        | Analysis,                  | Society          | Enviro | Ethics | Individual &    | Comm              | Life Lo | PSO-          | PSO- |
| CLO-1:                                | Formulate the approp                                | oriate biofue <mark>l product</mark>                        | ion based on available feedstocks  | The state of the s |      | 1                   | 80 7                     | 70                      | Н                     | Н      |               | MΛ                         |                  |        | Н      | М               | H N               | 1 H     | М             | Н    |
| CLO-2 :                               | Analyze cell wall con                               |   | 7.00   |  |      | 2                   | 85 7                     | <b>7</b> 5              | Н                     | М      | M             | MΛ                         | Л <mark>Н</mark> | Н      | Н      | М               | L H               | Н       | М             | Н    |
| CLO-3 :                               | Apply thermo-chemic                                 | al conversi <mark>on proce</mark> s                         | ss for biomass conversion to produce b   | piofuel  | 100  | 2                   |                          | 70                      | Н                     | Н      | M             | MΛ                         | Л <mark>Н</mark> | _      | Н      |                 | M H               | Н Н     | Н             | М    |
| CLO-4 :                               |   |   | ass t fuel and value added chemicals   | WITE WILLIAM A   | 100  | 2                   |                          | 30                      | Н                     | Н      | M             | MΛ                         | 1 H              | Н      | Н      | H .             | M H               | H H     | Н             | Н    |
| CLO-5 :                               | Employ synthetic rou                                |   |  | 1786-139-17-1  |      | 2                   |                          | 75                      | Н                     | Н      |               | M A                        | 1 H              |        | Н      | М               | H N               | 1 H     | Н             | Н    |
| CLO-6 :                               | Describe the Nationa                                | I policy tow <mark>ards bio</mark> fu                       | iel production and Energy security   |  |      | 1                   | 80 7                     | 0                       | Н                     | M      | M             | ΜI                         | 1 H              | H      | Н      | M               | $H \mid N$        | 1   H   | $\mid H \mid$ | M    |

| Dura | ition (hour) | Introduction to Sou <mark>rces of en</mark> ergy                  | First Generation Bioenergy   | Second & Third Generation Bioenergy                                     | Fourth generation bioenergy and next generation bio-molecules      | Policies and future R&D of biofuels & Bioenergy                                  |
|------|--------------|---|--|---|--|--|
|      |              | 9   | 9  | 9   | 9  | 9  |
| S-1  | SLO-1        | Non-renewable Resources (Fossil fuel)                             | I Sugar and Starch hased hineherdy   | 2 <sup>nd</sup> generation (Non-edible lignocellulosics)                | CO <sub>2</sub> biosequestration and biofuel production strategies | Policies and Future R&D of Biofuels & Bioenergy                                  |
| 3-1  | 151 U-7      | Alternate and renewable resources (Solar, wind and biomass based) | Corn, sugarcane, sugar beets, soybeans, canola oil, fryer grease, and coconut oil                              | Wood bioenergy  | Use of plants and microalgae for CO <sub>2</sub> sequestration     | National biofuel policy framework  |
| 6.3  | SLU-1        | Bioenergy – Classification (Liquid and gaseous biofuel)           | Fuel from food crops   | Pretreatment strategies for biofuel production                          | Synthetic (bio)fuels   | Evaluation of current and future R&D needs                                       |
| 3-2  | S-2<br>SLO-2 | An overview of bioenergy in Global and national context           | Consequences for food crops as fuel source   | Green chemicals for biomass pretreatment                                | Sustainability aspects of synthetic biofuels                       | Focus area such as Mission Innovations<br>India and Horizon 2020                 |
| S-3  | 151 O-1      | Rationale of biomass power sustainable environment                | Role of cell wall components (Lignin, cellulose and hemicelluloses) in different plants for ethanol production | Rationale for biological pretreatment over physical and chemical modes. | Pyrolysis bio-oil/bio-char   | Legal framework to support sustainable development and increased use of biofuels |
|      | SLO-2        | Treatment technologies for biomass to useful energy               | TBOMERECKS IN DIOMASS CONVERSION TO THEIS  | Bioethanol plant design and its components                              | Hydrogenated biodiesels  | Need for International cooperation and intervention in biofuel sectior in India  |
| S-3  | SLO-1        | Circular & Biobased Economy                                       | Recalcitrant lignin and its biochemistry   | Bio refinery demonstration projects of Bioethanol                       |  | Government policies and programs with regard to biofuels                         |
| 3-3  | SLO-2        | Environment impact over biofuel usage                             | Importance of cellulose and hemicelluloses   |   | Comparative analysis of different grades of diesel based on ASTM   | R and D focus area for biofuel in India  |

| Dura | tion (hour) | Introduction to Sources of energy   | First Generation Bioenergy   | Second & Third Generation Bioenergy                                       | Fourth generation bioenergy and next generation bio-molecules     | Policies and future R&D of biofuels & Bioenergy   |
|------|-------------|---|--|---|---|---|
|      | , ,         | 9   | 9  | 9   | 9   | 9   |
| S-4  | SLO-1       | Feedstocks – Food Vs Feed Vs Fuel   | Conversions Process: Physico-chemical  | Biomethanation process  | Dimethyl ether (DME)  | Investment opportunities on biofuels worldwide  |
|      | SLO-2       | Characteristics for feedstock for bioenergy                                   | Constraints of conventional processing technologies  | Microbiology of anaerobic digestion                                       | Bio-synthetic natural gas (SNG)                                   | Industrial opportunities of biofuels in India  – at a glance                            |
|      | SLO-1       | Waste resources – Industrial (solid and liquid) and MSW                       | Biological route and Enzymatic Conversion  | Biological Processes for Hydrogen<br>Production                           | Comparative analysis of CNG/SNG/bio-gas based on ASTM             | Economic, Social and Ecological Impacts of Bioenergy                                    |
| S-5  | SLO-2       | Agro waste resources – Crop residues and by-<br>products                      | Enzymology for conversion of biomass to biofuels – Ligninolytic enzymes (MnP, LiP and laccase) | Dark fermentation and algal based technologies                            |   | Comparative analysis of National and<br>Global Levels                                   |
| S-6  | SLO-1       | Energy crops – Terrestrial  | Mechanism of depolymerization of lignin by enzymes and whole cells                             | 3 <sup>rd</sup> generation biofuel  | and Ethanol)  | Current and Emerging Challenges to<br>Bioenergy Development                             |
|      | SLO-2       | Energy crops – Aquatic  | Hexose sugar conversion to ethanol   | Need for 3rd generation biofuels  | Bottlenecks in ABE fermentation;<br>Types of feedstocks preferred | Impact of solar and wind energy over biomass energy                                     |
| S-7  | SLO 1       | Potential Benefits of Replacing Fossil Fuels with Biofuel, Biomass and Biogas | Pentose sugar conversion to ethanol  | Genetically modified organisms for improved fuel production               | Metabolic pathway engineering for ABE biosynthesis                | Community Participation in Renewable<br>Energy Development                              |
|      | SLO 2       | Cradle to grave approach of waste raw materials for bioenergy development     | By-products of ethanol production and its  | Case study of insect ruminant biology for biofuel production              | Case study of GM microbes on ABE fermentation                     | Techno-economic feasibility for biofuel production                                      |
|      | SLO 1       | Political Drivers for Biofuel Development                                     | Inhibitory products of bioethanol production   | GM plants for enhanced biomass for ethanol production                     | Bio-alkanes and alkenes from waste biomass                        | Combined industrial waste treatment for energy recovery                                 |
| S-8  | SLO 2       | Consequences of Burning Fossil Fuel   | Plausible contaminants from bioethanol production and its re-utilization                       | GM based oil crops for biodiesel production                               | Economic advantage of chemicals production from biomass           | Zero-discharge concept for wastewater<br>from industries and energy recovery<br>process |
| S-9  | SLO 1       | Mitigation of Global Warming  | Biodiesel from vegetable oils  | Hybrid energy system through biomass                                      | New energy research Projects in Global context                    | Urban and rural integration system for sustainable waste utilization                    |
|      | SLO 2       | Carbon dioxide sequestration Approaches                                       | Transesterification process  | Algal based technologies for biofuel and value added chemical preparation | New energy research Projects in Indian context                    | Life-cycle Analysis of Biofuels   |

| Loorning  | 1. | David M. Mousdale, "Biofuels: Biotechnology, Chemistry, and Sustainable Development, "CRC Press, 2008. | 3. | A.H.Scragg, "Biofuels, Production, Application and Development", CAB Internaional, 2009 |
|-----------|----|--|----|---|
| Learning  | 2. | Roland A. Jansen, "Second Generation Biofuels and Biomass", Wiley – VCH Verlag GmbH Co., 2013.         | 4. | Robert C. Brown and Tristan R.Brown, "Biorenewable Resources: Engineering New Products  |
| Resources |    |  |    | from Agriculture," Wiley-Blackwell Publishing, 2 <sup>nd</sup> Edition, 2014.           |

| Learning Asse | essment                |        |               | 37 (1 142.3 | A 11 1 1           | 100000            |          |         |          |                                  |                   |  |
|---------------|------------------------|--------|---------------|-------------|--------------------|-------------------|----------|---------|----------|----------------------------------|-------------------|--|
|               | Bloom's                |        |               | Conti       | nuous Learning Ass | essment (50% weig | htage)   |         |          | Final Examination (50% weightage |                   |  |
|               | Level of Thinking      | CLA –  | CLA – 1 (10%) |             | CLA – 2 (15%)      |                   | 3 (15%)  | CLA – 4 | 4 (10%)# | Final Examinatio                 | n (50% weightage) |  |
|               | Remember               | Theory | Practice      | Theory      | Practice           | Theory            | Practice | Theory  | Practice | Theory                           | Practice          |  |
| Level 1       | Remember<br>Understand | 40 %   | -             | 30%         | -                  | 30%               | -        | 30%     | -        | 30%                              | -                 |  |
| Level 2       | Apply<br>Analyze       | 40 %   |               | 40%         | -                  | 40%               |          | 40%     | -        | 40%                              | -                 |  |
| Level 3       | Evaluate<br>Create     | 20 %   | -             | 30%         | -                  | 30%               |          | 30%     | -        | 30%                              | -                 |  |
|               | Total                  | 10     | 0 %           | 100 %       |                    | 100 %             |          | 10      | 0 %      | 100 %                            |                   |  |

# CLA – 4 can be from any combination of these: Assignments, Seminars, Tech Talks, Mini-Projects, Case-Studies, Self-Study, MOOCs, Certifications, Conf. Paper etc.,

| Course Designers  |  |   |
|---|--|---|
| Experts from Industry                                   | Experts from Higher Technical Institutions                 | Internal Experts  |
| Dr. D. Gunaseelan Biocon Limited, guna.sachin@gmail.com | Dr. Rintu Banerjee IIT Kharagpur, rb@agfe.iitkgp.ernet.in  | Dr. Samuel Jacob Department of Biotechnology SRM Inst. of Science & Technology, samueljacob.b@ktr.srmuniv.ac.in |
| Dr. S. Sam Gunasekar Orchid Pharma Ltd., Chennai        | Dr. Subhabrata Ray IIT Kharagpur, sray@che.iitkgp.ernet.in | Dr. K.Ramani Department of Biotechnology SRM Inst. of Science & Technology, ramani.k@ktr.srmuniv.ac.in          |



| _              |   |  |  |   |                |  |             |                    | ,   |                       |                  |                     |            |            |                   |                              |                |                       | ,                  |             |        |           |
|----------------|---|--|--|---|----------------|--|-------------|--------------------|---|-----------------------|------------------|---------------------|------------|------------|-------------------|------------------------------|----------------|-----------------------|--------------------|-------------|--------|-----------|
|                | urse  | 18BTE320T  | Course                                       | ENVIRONMENTAL MICROBIOLOG   | SY AND META    | AGENOMICS Cou  |             | E                  |   |                       | F                | rofes               | sional     | Elect      | tive C            | ourse                        | 9              |                       |                    | L           | •      | P C       |
| Co             | ode   |  | Name   |   |                | Cate   | gory        |                    |   |                       |                  |                     |            |            |                   |                              |                |                       |                    | 3           | 0      | 0 3       |
|                | Pro-ro  | quisite Courses  | Nil  | Co-requisite Courses Ni   | lil            |  | Pr          | oarae              | sive Co   | IIreae                |                  | 1                   | Vil        |            |                   |                              |                |                       |                    |             |        |           |
| Cours          |   | g Department   | Biotechnology                                |   | ata Book / Co  | des/Standards Nil  | - 11        | ogres              | SIVE CO   | urses                 |                  |                     | VII        |            |                   |                              |                |                       |                    |             |        | -         |
| Oourc          | C Oncini  | g Department   | Dioteonnology                                |   | ata Book / Co  | JUST Ottaliaaras   |             |                    |   |                       |                  |                     |            |            |                   |                              |                |                       |                    |             |        |           |
| Cours<br>(CLR) |   | ng Rationale The   | purpose of learning this c                   | ourse is to:  | 501            | Tant I   | L           | _earnir            | ng  |                       |                  |                     | F          | Progra     | am Le             | earnin                       | g Out          | come                  | s (PLC             | ))          |        |           |
| CLR-           |   | rovide the awarene   | ess on the microbial applic                  | c <mark>ations in the en</mark> vironmental pollution   | n abatement    |  | 1           | 2                  | 3   | 1                     | 2                | 3                   | 4          | 5          | 6                 | 7                            | 8              | 9 1                   | 0 11               | 12          | 13     | 14 15     |
|                | CLR-2: Give an overview of indigenous microbes on environmental bioremediation    |  |  |   |                |  |             |                    |   |                       |                  |                     | _          |            |                   | £                            |                |                       |                    |             |        |           |
|                | CLR-3 : Educate the molecular insights on conservation of biodiversity            |  |  |   |                |  |             |                    |   | 43                    |                  |                     | Research   |            |                   | iig                          |                |                       |                    |             |        |           |
|                | CLR-4: Understand the environmental metagenomics for novel species identification |  |  |   |                |  |             |                    |   | age                   | )                | ent                 | seg        |            |                   | ig                           |                | Š                     | 8                  |             |        | .         |
| CLR-           | 5: A <sub>l</sub>   |  | eomic concepts for environ                   |   | 11.75          |  | (Bloom)     | enc                | Jen   | ₩<br>We               | "                | bu                  | , Re       | ge         |                   | nst                          | -              | S                     | Finance            | р           |        | .         |
| CLR-6          | CLR-6: Educate the soil microbiome and biofilm organisms in the environment       |  |  |   |                |  |             |                    |   | Ŝ                     | ysis             | ole                 | ign        | OSS        | t tre             | ഗ<br>&                       |                | , eg                  | <sub>₹</sub> │iĒ   | Ē           |        |           |
|                | ·   |  |  | 5/ 8  | 4000           | the same of  | of Thinking | ed Proficiency (%) | ed Atta   | ering k               | n Anal           | & Development       | s, Design, | Tool Usage | & Cul             | ment                         | F              |                       | Mgt. &             | ng Learning | 1      | 2 8.      |
| Cours<br>(CLO  |   | ng Outcomes At the   | he end of this <mark>course, le</mark> arr   | ners will be able to:   | T-INTE         | AL SALA  | Levelo      | Expected           | Expected Attainment (%)                         | Engineering Knowledge | Problem Analysis | Design &            | Analysis,  | Modern     | Society & Culture | Environment & Sustainability | Ethics         | maiyidual & Team Work | Project Mgt.       | Life Long   |        | PSO -     |
| CLO-           | 1 : A   | oply the concepts  | of microbial d <mark>iversity an</mark> d it | s taxonomic make up.  | E 177.00       | The street of  | 1           |                    | 80  | Н                     |                  | H                   | Ĥ          | M          | M                 |                              | Н              | 7 F                   | H H                |             | H      | H H       |
| CLO-           |   |  | emophiles a <mark>nd its use</mark> s in l   |   |                |  | 2           | 85                 | 75  | Н                     | Н                | Н                   | Н          | М          | Н                 | М                            | Н              | H                     | н н                | Н           | Н      | H H       |
| CLO-           | 3. A  |  |  | nic make-up and ecological processe   | es of microbia | communities from a range of  | 2           | 75                 | 80  | М                     | Н                | М                   | Н          | М          | М                 | Н                            | М              | H F                   | Н                  | Н           | Н      | н н       |
| CLO-           | 1: As   | ssemble and anno   | tate genom <mark>es by iden</mark> tifyin    | g genes   | 200            | The state of the s | 2           | 85                 | 80  | Н                     | Н                | Н                   | Н          | Н          | Н                 |                              | L              | H F                   | н н                | Н           | Н      | Н Н       |
| CLO-           | 5: A  |  | on sequenci <mark>ng techno</mark> logy.     |   |                |  | 3           | 85                 | 75  | Н                     | Н                | Н                   | Н          | Н          | М                 | Н                            | Н              | H = L                 | . H                | Н           | Н      | H H       |
| CLO-           | 6 : <i>Ui</i>   | nderstand the soil   | microbiome and biofilm or                    | ganisms in the environmental cleanu   | ир             |  | 2           | 80                 | 80  | Н                     | Н                | Н                   | Н          | М          | М                 | М                            | М              | 1 F                   | Н                  | Н           | Н      | H H       |
|                |   |  |  |   |                |  | 1           |                    |   | Ш                     |                  |                     |            |            |                   |                              |                |                       |                    |             |        |           |
| Dura           | tion (hour  |  | 9  | 9   |                | 9  |             |                    |   |                       | 9                |                     |            |            |                   |                              |                |                       | 9                  |             |        |           |
|                | SLO-1   | Microbial divers   | sity   | Extremophiles   |                | vironmental Metagenomics   |             |                    | vironme   |                       |                  |                     |            |            |                   |                              |                |                       | and bi             |             | :      |           |
| S-1            | SLO-2   | Microbial existe   | ence in the env <mark>ironment</mark>        | Extremophiles-various types   | ecc            | ortance of metagenomics in mid<br>logy   | crobia      |                    | oortanc<br>ology                                | e of me               | etapro           | oteom               | ics in     | micro      |                   |                              |                |                       | me —<br>meta       |             | mics   |           |
|                | SLO-1   | Biodiversity and<br>Environment  | d its relationship <mark>with</mark>         | Extremophiles in the environmental management   | tal<br>Me      | tagenomics-types, steps  |             | Ge                 | l-based   | proted                | omics            | : 2 <mark>-D</mark> | E          |            |                   |                              |                |                       | structu<br>henor   |             | d con  | nectivity |
| S-2            | SLO-2   | Classification o   | f microorganisms                             | Role of Acidophilic microorganism their biomolecules in Environment remediation   | ntal Mo.       | ecular Diversity and Metagenor   | nics        | Ge                 | l-baseo   | l proted              | omics            | : DIG               | E          |            |                   |                              | nce o<br>phenc |                       | siologio           | cal sta     | itus o | n the soi |
| S-3            | SLO-1   | Role of microor sustainability of  | f biosphere                                  | ns in the Role of alkalophilic microorganisms and their hiemplocules in Environmental Concept of a DNA (opvironmental Concept |                |  |             |                    |   | l proted              |                  |                     |            | <b>=</b>   |                   | intera                       | actions        | on tl                 | obial c<br>ne soil | metaj       | ohenc  |           |
|                | SLO-2   | ecology princip  |  | Role of psychrophilic microorganis<br>Environmental remediation   | env            |  |             | pro                | rits a <mark>nd</mark><br>I <mark>teomic</mark> | techni                | ques             | •                   |            |            |                   | healti                       | h unde         | er cha                | nging              | climat      | te .   | ring soil |
|                |   | ecology principles Environmental remediation environments  Classification of micrographics Relation environments |  |   |                |  |             |                    |   |                       |                  |                     | -          |            |                   |                              |                |                       |                    |             |        |           |

Conventional methods to study diversity;

Cultured and Uncultured Methods

16S-rDNA sequencing of microbial

communities

Affinity Tag (ICAT)

Quantitation (iTRAQ)

Gel-free proteomics: Isotope-Coded

Isobaric Tagging for Relative and Absolute

Biofilm mediated decontamination of

pollutants from the environment

Role of Biofilms in Bioremediation

Environmental remediation

Environmental remediation

Role of mesophilic microorganisms and in

Role of thermophilic microorganisms in

Classification of microorganisms-Bacteria,

Yeasts, Moulds, Viruses, Protozoans

Lichens and their role in the biosphere.

SLO-1

SLO-2

S-4

| Dura | ation (hour)   | 9   | 9   | 9   | 9   | 9   |
|------|--|---|---|---|---|---|
| S-5  | SLO-1  | Mycorrhiza-types  | Role of barophilic microorganisms in<br>Environmental remediation                 | Partial community analysis methods -<br>Genetic fingerprinting techniques - T-RFLP              | Multidimensional Protein Identification Technology -MudPIT)                   | Strategies for Use of Biofilms in Remediation   |
| 3-0  | SLO-2  | Mycorrhiza-Environmental applications                         | Role of osmophili <mark>c microorganisms in</mark><br>Environmental remediation   | Partial community analysis methods -<br>Genetic fingerprinting techniques - DGGE                | Merits and demerits of gel-free proteomic techniques                          | Biofilm Survival Strategies in Polluted<br>Environments   |
|      | SLO-1  | Photosynthetic organisms and their environmental applications | Halophil <mark>es- types</mark>   | Partial community analysis methods -<br>Genetic fingerprinting techniques RISA                  | Application of gel-free techniques in biological systems                      | Molecular Methods for the Assessment of Microbial Biofilms in Bioremediation                            |
| S-6  | SLO-2  |   | Halophiles- their biomolecules in<br>Environmental remediation                    | Partial community analysis methods -<br>Genetic fingerprinting techniques LH-PCR<br>microarrays | Protein microarrays   | Detoxification of Hexavalent Chromium<br>from Industrial Wastewater using a<br>Bacterial Biofilm System |
|      | SLO-1  | General characteristics of purple and green sulphur bacteria. | Molecular aspects of extremophiles-<br>Genes, Protein s and Enzymes.              | Partial community analysis methods -<br>Genetic fingerprinting techniques RAPD                  | Isotope-Coded Protein Label (ICPL)  | Biofilm-mediated Degradation of PAHs and Pesticides   |
| S-7  | SLO-2  | II IVVAENIC NNOTOSVNTNETIC MICRONES                           | Perspectives of Archaebacteria in<br>Environment- distinguishing features         |   | Combined FRActional Dlagonal Chromatography (COFRADIC)                        | Metagenome Analyses of Multispecies<br>Microbial Biofilms   |
|      | SLO-1  | General characteristics of Cyanobacteria and Prochlorales     | Phylogenetic groups of Archaebacteria,<br>Ecology and habitats of Archaebacteria, | Whole community analysis methods: DNA-DNA reassociation,  | Application of gel-free techniques in biological systems                      | Metagenomic approach for the biofilm community analysis   |
| S-8  | SLO-2  | Methanogens   | Physiology of Archaebacteria-their role in environmental sustainability           | Whole community analysis methods: G+C fractionation   | Mass Spectrometry; Matrix Assisted Laser<br>Desorption and Ionization (MALDI) | Metagenomic Approaches for<br>Understanding New Concepts in Microbial<br>Science                        |
|      | SLO-1  | Methanogenic-General characteristics and properties           | Role of Archaebacteria in the environmental pollution management                  | Whole genome sequencing; DNA<br>Microarray Technology   | Electronspray Ionization (ESI)  | Accessing the Soil Metagenome for<br>Studies of Microbial Diversity                                     |
| S-9  | SLO-1   envi<br>  SLO-2   Ano<br>  SLO-1   Gen<br>  gree<br>  SLO-2   Oxy<br>  SLO-1   Gen<br>  and<br>  SLO-2   Met | Methanogens –Environmental applications                       | Magneto tactic bacteria.  | LINEYT I-eneration Lechnology   | Mass spectrometry data analysis – computational tools.                        | Recent Advances and Perspectives in<br>Metagenomic Studies of Soil Microbial<br>Communities             |

| Learning  | 1. | Joanne M Willey, Joanne Willey, "Prescott's Microbiology," McGraw-Hill Education; 9th edition, 2013. |
|-----------|----|--|
|           | 2. | Stephen P. Hunt and Frederick J. Livesey, "Functional Genomics" Oxford University Press, 2000.       |
| Resources | 3. | R. M. Twyman. "Principles of Proteomics". Taylor & Francis. 2 <sup>nd</sup> edition. 2008.           |

- Diana Marco Universidad Nacional de Cord<mark>oba, Arge</mark>ntina "Metagenomics: Current Innovations and Future Trends", Caister Academic Press, 2011.
- Maier, R.M. Pepper, I.L and Gerba, "Environmental Microbiology," C.P. Academic press, 2000.

  Gavin Lear, "Biofilms in Bioremediation: Current Research and Emerging Technologies", Caister Academic Press, 2016.

| Learning Asse | essment                                 |        |          |        |                    |                  |           | - 7    |          |                   |                    |  |
|---------------|---|--------|----------|--------|--------------------|------------------|-----------|--------|----------|-------------------|--------------------|--|
|               | Bloom's                                 |        |          | Conti  | nuous Learning Ass | essment (50% wei | ghtage)   |        |          | Final Evamination | n /EOO/ waightaga) |  |
|               |   | CLA –  | 1 (10%)  | CLA –  | 2 (15%)            | CLA -            | - 3 (15%) | CLA -  | 4 (10%)# |                   | n (50% weightage)  |  |
|               | Level of Thinking  Remember  Understand | Theory | Practice | Theory | Practice           | Theory           | Practice  | Theory | Practice | Theory            | Practice           |  |
| Level 1       |   | 40 %   | T //     | 30%    | -                  | 30%              | CHERRY    | 30%    | -        | 30%               | -                  |  |
| Level 2       | Apply<br>Analyze                        | 40 %   |          | 40%    | -                  | 40%              | -         | 40%    | -        | 40%               | -                  |  |
| Level 3       | Evaluate<br>Create                      | 20 %   |          | 30%    | -                  | 30%              | •         | 30%    | -        | 30%               | -                  |  |
|               | Total                                   | 10     | 0 %      | 100 %  |                    | 10               | 00 %      | 10     | 0 %      | 100 %             |                    |  |

<sup>#</sup> CLA – 4 can be from any combination of these: Assignments, Seminars, Tech Talks, Mini-Projects, Case-Studies, Self-Study, MOOCs, Certifications, Conf. Paper etc.,

| Course Designers  |  |                         |
|---|--|-------------------------|
| Experts from Industry   | Experts from Higher Technical Institutions   | Internal Experts        |
| Dr. S. Sam Gunasekar, Orchid Chemicals and Pharmaceuticals Ltd., sam@orchidpharma.com | Dr. A. Gnanamani, CSIR-Central Leather Research Institute, agmani_2000@yahoomail.com       | Dr. Ramani, SRMIST      |
| Dr. D. Gunaseelan, BIOCON Ltd., guna.sachin@gmail.com                                 | Dr. Anbumani Sadasivam, CSIR-Indian Institute of Toxicology Research, anbumani@jitr.res.in | Dr.W.Richard Thilagaraj |



SRM Institute of Science & Technology – Academic Curricula (2018 Regulations) - Control copy

| Course<br>Code             | 18BTE409T        | Course<br>Name | BIOREMEDIATION T     | BIOREMEDIATION TECHNOLOGY   |     | e E        | Professional E | ective | L<br>3 | T<br>0 | P<br>0 | C<br>3 |
|----------------------------|------------------|----------------|----------------------|-----------------------------|-----|------------|----------------|--------|--------|--------|--------|--------|
|                            |                  |                |                      |                             |     |            |                |        | '      |        |        |        |
| Pre-re                     | equisite Courses | Nil            | Co-requisite Courses | Nil                         | F   | rogressive | Courses Nil    |        |        |        |        |        |
| Course Offering Department |                  | Biotechnoi     | logy                 | Data Book / Codes/Standards | Nil |            |                |        |        |        |        |        |

| Course Lo           | earning Rationale             | The purpose of learning this course is to:   | L        | earnir          | ng         |
|---------------------|-------------------------------|--|----------|-----------------|------------|
| CLR-1:              | Create the awarer             | ness on the microbial applications in the environmental pollution abatement  | 1        | 2               | 3          |
| CLR-2:              | Give an overview              | of indigenous microbes on environmental bioremediation   | m)       | (%              | (%)        |
| CLR-3:              | Educate the mole              | cular insights on conservati <mark>on of biodiv</mark> ersity  | (Bloom)  | Proficiency (%) | ) t        |
| CLR-4:              | Apply the metager             | nomic approach for the environmental microbial analysis  | ) (B     | enc             | Attainment |
| CLR-5:              | Apply the metapro             | teomic approach for th <mark>e environm</mark> ental applications  | Thinking | fici            | aji        |
| CLR-6:              | Demonstrate the a             | application of biofilm communities in environmental applications and their metagenomic approach                            | i=       | P               | Att        |
|                     | •                             |  | ofT      | eg              | cted       |
| Course Lo<br>(CLO): | earning Outcomes              | At the end of this <mark>course, le</mark> arners will be able to:   | Level    | Expected        | Expect     |
| CLO-1:              | Apply the concept             | s of biodiversity <mark>and their i</mark> mportance.  | 1        | 80              | 80         |
| CLO-2:              | Understand the ex             | tremophiles and its applications in environmental remediation.   | 2        | 85              | 75         |
| CLO-3:              | Use metagenomic environments. | is data to describ <mark>e the tax</mark> onomic make-up and ecological processes of microbial communities from a range of | 2        | 75              | 80         |
| CLO-4:              | Assemble and ani              | notate genomes by identifying genes.   | 2        | 85              | 80         |
| CLO-5:              | Apply next genera             | tion sequencin <mark>g technol</mark> ogy.   | 3        | 85              | 75         |
| CLO-6:              | Analyze the biofile           | n communities in the soil microbiome and their metagenomic strategies.   | 2        | 80              | 80         |

|                       |                  |                      |                   | Prog              | ram L             | _earn         | ing C  | utco                   | mes (         | (PLO                   | )                  |         |       |       |
|-----------------------|------------------|----------------------|-------------------|-------------------|-------------------|---------------|--------|------------------------|---------------|------------------------|--------------------|---------|-------|-------|
| 1                     | 2                | 3                    | 4                 | 5                 | 6                 | 7             | 8      | 9                      | 10            | 11                     | 12                 | 13      | 14    | 15    |
| Engineering Knowledge | Problem Analysis | Design & Development | Analysis, Design, | Modern Tool Usage | Society & Culture | Environment & | Ethics | Individual & Team Work | Communication | Project Mgt. & Finance | Life Long Learning | PSO - 1 | PSO-2 | PSO-3 |
| Н                     | Н                | Н                    | Н                 |                   | М                 | L             | Н      | Н                      | Н             | Н                      | Н                  | Н       | Н     | Н     |
| Н                     | Н                | Н                    | Н                 |                   |                   | М             | Н      | Н                      | Н             | Н                      | Н                  | Н       | Н     | Н     |
| М                     | Н                | М                    | Н                 | М                 | М                 |               | М      | Н                      | Н             | Н                      | Н                  | Н       | Н     | Н     |
| Н                     | Н                | Н                    | Н                 |                   |                   | Н             | L      | Н                      | Н             | Н                      | Н                  | Н       | Н     | Н     |
| Н                     | Н                | Н                    | Н                 |                   | М                 | Н             | Н      | Н                      | L             | Н                      | Н                  | Н       | Н     | Н     |
| Н                     | Н                | Н                    | Н                 | L                 | М                 | М             | М      | Н                      | Н             | Н                      | Н                  | Н       | Н     | Н     |

|    | N            |   |  |   |   |   |
|----|--------------|---|--|---|---|---|
| ,  | Ouration (h) | 9   | 9  | 9   | 9   | 9   |
|    | (hour)       |   |  |   |   |   |
|    | SLO-1        | Principles of bioremediation                            | Bioremediation technologies  | Bioremediation project management                             | Microbial oxidation of heavy metals                       | Nuclear waste bioremediation  |
| S- | SLO-2        | Introduction to Bioremediation: Types of Bioremediation | augmentation Deliring the project and goals                                |   | Bioleaching   | Microbes in pollution Remediation                                       |
| S- | SLO-1        | Bioremediation Mechanisms                               | In situ and ex situ remediation technologies : (Bio) venting               | Site characterization   | Biomining   | Heavy metal toxicity in the environment                                 |
| 3- | SLO-2        | Microbes for Bioremediation                             | In situ and ex situ remediation technologies : (Bio)sparging               | Screening and selecting remediation alternatives              | Microbial sources for the oxidation of minerals from ores | Heavy metal bioremediation  |
| S- | SLO-1        | Metabolic process involved in bioremediation            | In situ and ex situ remediation technologies : (Bio)stripping              | Process design  | Bio-oxidation mechanisms                                  | Various reactors for heavy metal removal                                |
| 3- | SLO-2        | Factors affecting bioremediation                        | In situ and ex situ remediation technologies : (Bio)sorption barriers      | Remediation field activities- Aerobic Bioremediation          | Enzymes for heavy metal detoxification                    | Actinides pollutant removal strategeis                                  |
| S- | SLO-1        | Metabolic process involved in bioremediation            | In situ <mark>and ex situ re</mark> mediation technologies :<br>Biofilters | Bioremediation of Surface Soils                               | Bacterial oxidation of pyrite                             | Nuclear waste disposal methods  |
| 3- | SLO-2        | Limitations of Bioremediations                          | In situ and ex <mark>situ remediation</mark> technologies :<br>Bioreactors | Fate and transport of contaminants in the Vadose zone         | Siderophores  | Case studies of nuclear accidents and its further remediation stratgies |
| S- | 5 SLO-1      | Mycoremediation, Use of bioreactors for bioremediation  |  | Anoxic/Anaerobic Bioremediation: Anoxic/Anaerobic Environment | Bacterial oxidation of chalcopyrite                       | Types of nuclear wastcs and environmental effects                       |

|          | ration<br>our)  | 9                                     | 9  | 9  | 9   | 9  |
|----------|---|---------------------------------------|--|--|---|--|
| S        | SLO-2   | Phytoremediation technologies.        | Molecular techniques in bioremediation   | Potential anaerobic Bioremediation               | Metallothinenis and Biosurfactants<br>from microbial sources and their role in<br>heavy metal removal | Natural nuclear wastes                               |
|          | SLO-1 Xenobiotics and recalcitrant Man-made pollution |                                       | Application, specific advantages and disadvantages of bioremediation technologies, | Anoxic/Anaerobic Processes –<br>Fermentation     | Bacterial oxidation Sphalerite  | Man-made nuclear wastes                              |
| S-6<br>S | SLO-2   | Dyes and Detergents                   | Use of pioreactors for pioremediation  | Bioremediation in fresh water and marine systems | Heavy metal bioremediation by filamentous fungi   | In situ disposal strategies                          |
| S-7      | SLO-1   | PAH and Aliphatic hydrocarbons        | Soil bioreactors: Dry and slurry bioreactors                                       | Bioremediation in marine systems                 | Microbial Desulfurization of coal   | Bioremediation of oil/hydrocarbon contaminated sites |
|          | SLO-2   | Ocean oil spills and its consequences | Anaerobic and aerobic bioreactors for ex situ remediation                          | Natural Attenuation process                      | Biosorption by live and dead cells  | Pathways for hydrocarbon degradation                 |
|          | SLO-1   | Heavy metals leach in ground water    | Composting of recalcitrant wastes  | Ground water bioremediation                      | Extraction of metals from ores and metal recovery   | Nuclear waste management by microbial intervention   |
| S-8<br>S | SLO-2   | Antibiotics in wastewater             | Land farm bioremediation for in situ wastes  | Water desalination                               | Nano-sponges  | e-waste management by microbial intervention         |
|          | SLO-1   | Volatile organic compounds (VOCs)     | I Fundai pioremediation  | Reverse osmosis for toxic pollutant removal      | Microbial enhanced oil recovery (MEOR)  | Case studies of e-waste industries                   |
| S-9<br>S | SLO-2   | Radioactive compounds                 | Trunchonamy of unioal enzymes  | Membrane technology for pollutant removal        | Nano material for metal recovery and treatment  | Emerging contaminants                                |

| Learning  | 1.<br>2. | Principles and Applications" McGraw-Hill, 2001.<br>Agarwal S. K., "Environmental Biotechnology", APH Publishing, 2000 |
|-----------|----------|---|
| Resources | 3.       | Martin Alexander, "Biodegradation & Bioremediation", Academic press, 1999.  |

| Learning Ass | essment                |                   |          | Established St. |                     | 450               | 1.5.00.0 |        |                        |                   |                    |
|--------------|------------------------|-------------------|----------|-----------------|---------------------|-------------------|----------|--------|------------------------|-------------------|--------------------|
| •            | Dloom's                |                   | 1        | Cont            | inuous Learning Ass | essment (50% weig | htage)   |        |                        | Final Evamination | n /E00/ woightaga) |
|              | Bloom's                | CLA -             | 1 (10%)  | CLA – 2 (15%)   |                     | CLA –             | 3 (15%)  | CLA –  | 4 (1 <mark>0%)#</mark> |                   | n (50% weightage)  |
|              | Level of Thinking      | Theory            | Practice | Theory          | Practice            | Theory            | Practice | Theory | Practice               | Theory            | Practice           |
| Level 1      | Remember<br>Understand | 40 <mark>%</mark> | - 6      | 30%             | - 1                 | 30%               | - 7      | 30%    | -                      | 30%               | -                  |
| Level 2      | Apply<br>Analyze       | 40 %              | 5        | 40%             |                     | 40%               |          | 40%    | -                      | 40%               | -                  |
| Level 3      | Evaluate<br>Create     | 20 %              | -        | 30%             | WEND                | 30%               | EFFREN   | 30%    | -                      | 30%               | -                  |
|              | Total                  | 10                | 0 %      | 10              | 00 %                | 10                | 0 %      | 10     | 0 %                    | 10                | 00 %               |

<sup>#</sup> CLA – 4 can be from any combination of these: Assignments, Seminars, Tech Talks, Mini-Projects, Case-Studies, Self-Study, MOOCs, Certifications, Conf. Paper etc.,

| Course Designers   |  |                                       |
|--|--|---------------------------------------|
| Experts from Industry  | Experts from Higher Technical Institutions   | Internal Experts                      |
| 1. Dr. S. Sam Gunasekar, Orchid Chemicals and Pharmaceuticals Ltd., sam@orchidpharma.com | 1. Dr. A. Gnanamani, CSIR-Central Leather Research Institute, agmani_2000@yahoomail.com      | 1.Dr. K.Ramani, SRMIST                |
| 2.Dr. D. Gunaseelan, BIOCON Ltd., guna.sachin@gmail.com                                  | 2. Dr. Anbumani Sadasivam, CSIR-Indian Institute of Toxicology Research,anbumani@iitr.res.in | 2. Dr.W.Richard Thilagaraj,<br>SRMIST |

|                | ırse<br>de     | 18BTE410T             | Course<br>Name                  | ENVIRONMENTAL E  | COSENSORS  | Course E E  |                       |                  | Pi                   | ofessi                     | onal E            | Elective                                       | <b>!</b> |                       |               | ;              | L 1                | Γ F | ) (    |        |
|----------------|----------------|-----------------------|---------------------------------|--|--|---|-----------------------|------------------|----------------------|----------------------------|-------------------|--|----------|-----------------------|---------------|----------------|--------------------|-----|--------|--------|
| Pre-re         | auisite C      | ourses Nil            |                                 | Co-requisite Courses N                                     | il   | Progressive Course  | es                    | Nil              |                      |                            |                   |  |          |                       |               |                |                    |     |        | $\neg$ |
|                |                | g Department          | Biotechn                        |  | ata Book / Codes/Standards Nil   |   |                       |                  |                      |                            |                   |  |          |                       |               |                |                    |     |        |        |
|                |                |                       |                                 |  | THE RESERVE  |   |                       |                  |                      |                            |                   |  |          |                       |               |                |                    |     |        |        |
| Cours<br>(CLR) |                | g Rationale The p     | ourpose of lear                 | ning this course is to:                                    | COM MAN  | Learning  |                       |                  |                      | P                          | rogra             | m Lear   | ning     | Outco                 | mes (         | (PLO)          |                    |     |        |        |
| CLR-           | : Unc          | derstand the fundam   |                                 |  |  | 1 2 3   | 1                     | 2                | 3                    | 4                          | 5                 | 6 7  | 8        | 9                     | 10            | 11             | 12                 | 13  | 14   1 | 5      |
| CLR-2          |                | icate the various typ |                                 |  |  |   |                       |                  |                      |                            |                   | .≥   | ·        |                       |               |                |                    |     |        |        |
| CLR-3          | : Ider         | ntify and choose the  | biosensor for                   | the environmental monitoring                               |  | <u>E</u> © ©  | 0                     |                  |                      | arc                        |                   | je   | 5        | ~                     |               |                |                    |     |        |        |
| CLR-4          |                |                       |                                 | the environmental applications                             |  | 15 (%)   10   10   10   10   10   10   10   1   | dae                   | ?                | ent                  | ese                        |                   | je.  |          | Vor                   |               | Finance        |                    |     |        |        |
| CLR-5          | i: Des         | sign the biosensor b  | ased on the po                  | ollut <mark>ant parame</mark> ters                         |  | anc lenc  | M W                   | (0)              | md                   | Δ,                         | age               |  | 5        | \<br>\<br>\           |               | nar            | б                  |     |        |        |
| CLR-6          | i: App         | ly the biomolecules   | in the dev <mark>el</mark> op   | o <mark>ment of bios</mark> ensors                         |  | din ficie   | 9                     | VSis             | , lee                | ig                         | Use               | ture S   | 5        | ear                   | LC.           | iΞ             | Ē                  |     |        |        |
|                |                |                       |                                 |  | The state of the state of  | Level of Thinking (Bloom)  © Expected Proficiency (%)  © Expected Attainment (%)            | Engineering Knowledge | Problem Analysis | Design & Development | Analysis, Design, Research | Modern Tool Usage | Society & Culture Environment & Sustainability |          | ndividual & Team Work | Communication | Project Mgt. & | Life Long Learning | _   | 2      | 2      |
| Cours<br>(CLO) | e Learnin<br>: | g Outcomes At the     | e end of this <mark>co</mark>   | ourse, learners will be able to:                           | Carried and the  | Expect  | Ingine                | Proble           | Design               | Analys                     | Modern            | Society  | Ethics   | ndividı               | Comm          | Project        | ife Lo             |     | PSO-   | 3      |
| CLO-           | : Des          | cribe the fundamen    | ital principle <mark>s c</mark> | of biosensors  | Control of the state of the sta | 1 80 80   | Н                     |                  |                      | Ĥ                          |                   | H H  |          | H                     | Н             | H              |                    |     | HI     | ī      |
| CLO-2          |                | plain the biosensor o |                                 |  |  | 2 85 75   | H                     | Н                | Н                    | Н                          | Н                 | Н М  | l H      | Н                     | Н             | Н              | Н                  | Н   | НІ     | 1      |
| CLO-3          |                |                       |                                 | on of emerging contaminants                                |  | 2 75 80   | M                     |                  | М                    | Н                          |                   | М  |          | Н                     | Н             | Н              | Н                  | Н   |        | 1      |
| CLO-4          | : Apj          | ply the specific biom | nolecules f <mark>or th</mark>  | ne sensor development for the pollutants moni              | toring   | 2 85 80   | Н                     | Н                | Н                    | Н                          | М                 | H H  | ' H      | Н                     | Н             | Н              | Н                  | Н   | ΗΙ     | Η      |
| CLO-           | 5 : Ap         | oly the nanomateria   | I for the de <mark>vel</mark> d | opment of environmental biosensors                         | THE PLANT BY A BREET   | 3 85 75   | Н                     | Н                |                      | Н                          | Н                 | M H  | H        | Н                     | М             | Н              | Н                  | Н   | ΗΙ     | Ī      |
| CLO-6          | S: Unc         | derstand the importa  | ance of nov <mark>el b</mark>   | <mark>iose</mark> nsor development for the environmental a | applications   | 2 80 80   | Н                     | Н                | Н                    | Н                          | Н                 | M M  | M        | Н                     | Н             | Н              | Н                  | Н   | ΗI     | ł      |
|                |                |                       |                                 | (4) (1) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4             | Alberta College  | 200   |                       |                  |                      |                            |                   |  |          |                       |               |                |                    |     |        |        |
| Durat          | ion (hour)     | ) 9                   |                                 | 9  | 9  | The second  | 9                     | -                |                      |                            |                   |  |          |                       |               | 9              |                    |     |        |        |
| S-1            | SLO-1          | Short Biosensor F     | History                         | Biotransducers   | Application of biosensors for<br>Environmental Monitoring- Detection of<br>Organic Compounds   | DNA, Biological R<br>Sensors  |                       | •                |                      |                            |                   | Nanoi  | techn    | ology-                | based         | d Bios         | sensoi             | •   |        |        |
|                | SLO-2          | Fundamentals of I     | Biosensors                      | Classification of Biosensors                               | Polychlorinated biphenyls (PCB)  | A Fiber Optic DNA of Environmental  | E.coli                |                  |                      |                            |                   | Multi-   | analy    | te det                | ermin         | ation          |                    |     |        |        |
|                | SLO-1          | Components of Bi      | iosensor                        | Electrochemical Biosensors                                 | Endocrine-disrupting chemicals   | Application of elector to Environmental   |                       |                  | DNA-                 | Biosen                     | sor               | Minia  | turisa   | tion                  |               |                |                    |     |        |        |
| S-2            | SLO-2          | Types of Biosenso     | ors                             | Electrochemical Immunosensors                              | Antibiotics  | Application of nucleic acid based optical bioprobe for environmental and pharmaceu analysis |                       |                  |                      |                            |                   | Mass   | Produ    | uction                |               |                |                    |     |        |        |
| S-3            | SLO-1          | Characteristics of    | <sup>†</sup> Biosensor          | Optical Biosensors   | Pesticides   | screening of environmental pollutants in the field.   |                       |                  |                      |                            |                   | Netwo  | ork Sy   | /stem:                | S             |                |                    |     |        |        |
|                | SLO-2          | Biosensor Techno      | ologies                         | Electronic Biosensors                                      | Hormones   | Immunochemical assays for pesticides and PCBs Validation                                    |                       |                  |                      |                            |                   |  |          | _                     |               |                |                    |     |        |        |

| Dura | tion (hour) | 9   | 9                                       | 9   | 9   | 9  |
|------|-------------|---|---|---|---|--|
| S-4  | SLO-1       | Types of Bioreceptors   | FET- based Electronic Biosensors        | Application of Biosensors for<br>Environmental Monitoring- Detection of<br>Inorganic Compounds  | Direct piezoelectric immunosensor for pesticides  | Bioengineering (GMO)   |
|      | SLO-2       | Sensing Techniques of Biosensors                                    | Piezoelectric Biosensors                | Heavy Metals  | Enzyme sensors for detection of pesticides families                                       | Biosensors for environmental monitoring- An EPA perspective                                    |
|      | SLO-1       | Biosensors Development for<br>Environmental Monitoring              | Gravimetric Biosensors                  | Inorganic phosphate and nitrate   | Biosensors for water quality and exposure assessment issues                               | Microsystem Technology in Biosensors   |
| S-5  | SLO-2       | Architectural Design  | Pyroelectric Biosensors                 | Application of Biosensors for<br>Environmental Monitoring- Detection of<br>Biological Compounds | Nanomaterials- based biosensor for detection of environmental pollutants                  | Recent biosensors for the detection of pathogens   |
| S-6  | SLO-1       | Bio element and Sensor Element<br>Coupling                          | Impedimetric Biosensors                 | Biosides  | Recent progress in biosensors for environmental monitoring                                | Recent biosensors for the detection of potentially toxic elements                              |
| 5-0  | SLO-2       | Various Coupling Mechanisms   | Amperometric Biosensors                 | Whole cell bacteria detection   | Application of nucleic acid hybridization for the detection of organisms                  | Recent biosensors for the detection of Toxins  |
| S-7  | SLO-1       | Covalent Fabrication  | Ion Channel Switch                      | Estimation of Biological Oxygen Demand (BOD)  | Enzyme-based electrochemical biosensors to detect pharmaceuticals residues in waste water | Recent biosensors for the detection of<br>Endocrine disrupting chemicals                       |
| 5-1  | SLO-2       | Matrix Immobilization   | Optical Biosensors                      | Microbial Detection   | Biosensor for the detection of antibiotics residues in milk                               | Recent biosensors for the detection and monitoring of air pollutants                           |
|      | SLO-1       | Membrane Encapsulation  | Microarrays                             | Antibiotic resistant organisms  | Lipid membranes based biosensor for the rapid detection of toxins                         | Recent biosensors for the detection and monitoring of water pollutants                         |
| S-8  | SLO-2       | Physical Adsorption Fabrication                                     | Surface Plasmon Resonance               | Application of Biosensors for<br>Environmental Monitoring- Detection of<br>Air Pollutants       | Nucleic acid based biosensors for environmental pollution monitoring                      | Future sensing system based on conjugation of biosensor and drones for monitoring remote areas |
| 0.0  | SLO-1       | Nano Biosensors   | Reagentless Fluorescent (RF) Biosensors | Biosensors for direct monitoring and indoor air quality and exposure assessment issues          | Reporter genes based biosensors for chemical contamination sensing                        | Recent biosensors for the detection of pollutants in effluents                                 |
| S-9  | SLO-2       | Advantages of nanotechnological approaches to biosensor development | Glucose Biosensors                      | Application in Biodefense Biosensing  | Biosensor for the detection of antibiotics in Poultry effluent                            | Recent biosensor for the detection of contaminants in effluent treatment plant                 |


Learning
1. Biosensors for Direct Monitoring of Environmental Pollutants in Field edited by D.P. Nikolelis, Ulrich J. Krull, Joseph Wang, Marco Mascini..

Resources
2. Chemical Sensors and Biosensors: Fundamentals and Applications edited by F.G. Bănică, Wiley, 2012 W. Strickberger, "Genetics," 3 rd edition – Phi Learning, 2008

| Learning Ass | sessment               |        |          | THE WORLD     | THE STREET        | 7.1                 |          | 1383   |          |                   |                    |  |  |
|--------------|------------------------|--------|----------|---------------|-------------------|---------------------|----------|--------|----------|-------------------|--------------------|--|--|
|              | Bloom's                |        |          | Contin        | uous Learning Ass | sessment (50% weigl | htage)   |        |          | Final Evamination | n (50% weightage)  |  |  |
|              |                        | CLA –  | 1 (10%)  | CLA – 2 (15%) |                   | CLA – :             | 3 (15%)  | CLA -  | 4 (10%)# |                   | ii (50% weightage) |  |  |
|              | Level of Thinking      | Theory | Practice | Theory        | Practice          | Theory              | Practice | Theory | Practice | Theory            | Practice           |  |  |
| Level 1      | Remember<br>Understand | 40 %   | -        | 30%           | -                 | 30%                 | -        | 30%    | -        | 30%               | -                  |  |  |
| Level 2      | Apply<br>Analyze       | 40 %   |          | 40%           | -                 | 40%                 |          | 40%    | -        | 40%               | -                  |  |  |
| Level 3      | Evaluate<br>Create     | 20 %   | -        | 30%           |                   | 30%                 |          | 30%    | -        | 30%               | -                  |  |  |
|              | Total                  | 10     | 0 %      | 100           | %                 | 100                 | ) %      | 10     | 00 %     | 100 %             |                    |  |  |

# CLA – 4 can be from any combination of these: Assignments, Seminars, Tech Talks, Mini-Projects, Case-Studies, Self-Study, MOOCs, Certifications, Conf. Paper etc.,

| Course Designers   |  |                                    |
|--|--|------------------------------------|
| Experts from Industry  | Experts from Higher Technical Institutions   | Internal Experts                   |
| 1. Dr. S. Sam Gunasekar, Orchid Chemicals and Pharmaceuticals Ltd., sam@orchidpharma.com | 1. Dr. A. Gnanamani, CSIR-Central Leather Research Institute, agmani_2000@yahoomail.com      | 1. Dr.K.Ramani, SRMIST             |
| 2 .Dr. D. Gunaseelan, BIOCON Ltd., guna.sachin@gmail.com                                 | 2. Dr. Anbumani Sadasivam, CSIR-Indian Institute of Toxicology Research, anbumani@itr.res.in | 2. Dr.W.Richard Thilagaraj, SRMIST |



|               | urse<br>ode     | 18BTE411T Course Name  | MOLECULAR  | CELL BIOLOGY Cours Catego  |  | Е       |                        |        |                  |                        | Profe                      | essiona           | l Elect                      | ive             |                        |               |   | L<br>3   | T<br>0    | P<br>0    | <u>C</u> |
|---------------|-----------------|--|--|--|--|---------|------------------------|--------|------------------|------------------------|----------------------------|-------------------|------------------------------|-----------------|------------------------|---------------|---|----------|-----------|-----------|----------|
| Cour          |                 | e-requisite Courses Nil<br>ng Department Biotech   | Co-requisite Courses nology  | Nil Data Book / Codes/Standards  | Pro  | gress   | ive Cou                | ırses  |                  | Ni                     | I                          |                   |                              |                 |                        |               |   |          |           |           |          |
| Cours<br>(CLR |                 | ing Rationale The purpose of learnin   | g this course is to:   | CHACL  |  | Lear    | ning                   |        |                  |                        |                            | Pr                | ogram                        | Learr           | ing O                  | utcon         | nes (F                                  | LO)      |           |           |          |
| CLR-          | 1 : <i>Pr</i>   | ovide basic knowledge of stem cell sp  | ecific ge <mark>ne expression</mark> in lineage ba                     | ased tissues from the perspective of engineers.  |  | 1 2     | 2 3                    |        | 1                | 2                      | 3                          | 4 !               | 5 6                          | 7               |                        | 9             | 10                                      | 11 12    | 13        | 14        | 15       |
| CLR-          |                 | entify the role of epigenetic regulation   |  |  |  | 1/3     |                        |        |                  |                        | 등                          |                   | iii y                        |                 |                        |               |   |          |           |           |          |
| CLR-          | o dit           | reliver the knowledge on signaling molecules and molecular mechanisms that regulate the stem cell proliferation and ifferentiation.  Inalyze transcriptomics and its applications in tissue engineering in the strategies for novel gene editing techniques for tissue engineering  Ining Outcomes  At the end of this course, learners will be able to: |  |  |  |         |                        |        |                  |                        |                            |                   | 10                           | tainab          |                        | Nork          |   | Finance  |           |           |          |
| CLR-          |                 | nalyze transcriptomics and its applicat  |  |  | owk owk n, R age   |         |                        |        |                  |                        |                            | e g               | Sus                          |                 | m.                     |               | i la                                    | 2        |           |           |          |
| CLR-          |                 | reate insights on genome reprogramm  |  | 10 G   | Akin offic offic allys seign seign offic o |         |                        |        |                  |                        |                            |                   | ∞ +                          |                 | Tea                    | tion          | %   %                                   |          |           |           |          |
| CLR-          | 6: Ut           | tilize the strategies for novel gene ed <mark>it</mark>  | ing techniques for tissue engineeri                                    | ing  | Thin Thin Ans  |         |                        |        |                  |                        |                            | 3 0               | nen                          |                 | ∞<br>—                 | ig            | .jg                                     |          |           |           |          |
| Cours<br>(CLO | ):              | ing Outcomes At the end of this course entify gene regulation in stem cells.   |  | 9000   | Exper  |         | k                      |        | Problem Analysis | S Design & Development | Analysis, Design, Research | Society & Culture | Environment & Sustainability | H Ethics        | Individual & Team Work | Communication | Project Mgt. & Fina  Tife Long Learning |          | H PSO - 2 | H PSO - 3 |          |
| CLO-          |                 | nalyze gene expression in stem cells a   | nd artificial generation of pluripoter                                 | icy.   |  | 2 80    |                        |        | М                | -                      | М                          | Н                 |                              | -               | М                      | -             | -                                       | - M      |           | Н         | Н        |
| CLO-          |                 | entify the applications of growth factor   |  |  |  | 2 80    | 0 75                   |        | М                | -                      | М                          | Н                 | -                            | -               | Н                      | -             | -                                       | - H      | Н         | Н         | Н        |
| CLO-          |                 | nalyze the regulation of molecul <mark>es invo</mark>  | Ived in self-renewal of stem cells.                                    | Walter Steplet Palace  |  |         | 5 80                   |        | М                | -                      | М                          | Н                 | -     -                      | -               | Н                      | -             | -                                       | - M      |           | Н         | Н        |
| CLO-          |                 | scuss stem cell death mechanis <mark>ms.</mark>  | F-15-02  |  |  |         | 5 80                   |        | Н                | -                      | М                          | Н                 | -   -                        | -               | М                      | -             | -                                       | - H      |           | Н         | Н        |
| CLO-          | 6:   <i>E</i> > | kplain nerve cell regeneration, c <mark>ell surv</mark>  | r <mark>iv</mark> al and cell death.                                   |  | - 2  | 2 80    | 0 75                   |        | Н                | -                      | М                          | Н                 | -   -                        | -               | Н                      | -             | -                                       | - M      | Н         | Н         | Н        |
| Du            | ration          |  | 2000   | and the same of th |  |         |                        |        |                  | -                      | -                          |                   |                              |                 |                        |               |   |          |           |           |          |
|               | our)            | 9  | 9  | 9  | 9  |         |                        |        |                  |                        | 9                          |                   |                              |                 |                        |               |   |          |           |           |          |
| S-1           | SLO-1           | Introduction to nucleic acids - genetic material,  | Overview of Central dogma.   | Principles of membrane organization membrane proteins  | Differ   | entiat  | tion in E              | arly   | Deve             | lopme                  | ent                        |                   |                              | Newb            | orn so                 | reeni         | ng: Ne                                  | eonatal  | PKU       |           |          |
| 5-1           | SLO-2           | Structure and physicochemical properties of elements.  | Characteristics promoter and enhancer sequences.                       | cytoskeletal proteins Extra cellular matrix  | Poter  | гсу, С  | Commitn                | nent,  | 7                |                        |                            |                   |                              | Cysti           | c fibro                | sis ar        | nd swe                                  | eat test | S.        |           |          |
| S-2           | SLO-1           | Primary and secondary structure of DNA   | Transcriptional bubble - prokaryotic and eukaryotic RNA polymerase     | Cell-cell junctions, various types of transport across cell membrane.  | Polar<br>divisi  | •       | d the <mark>s</mark> p | pecifi | catior           | n of a                 | symn                       | netric            |                              | Prena           | tal dia                | agnos         | is of a                                 | isease.  | s, amr    | niotic    | fluid    |
| 3-2           | SLO-2           | Watson & Crick model   | RNA synthesis- Fidelity of RNA synthesis. Inhibitors of transcription. | Protein sorting and trafficking, cargo proteins.   | Cellular differentiation of the Nervous system   |         |                        |        |                  |                        | Fetal i                    | blood             | exam                         | inatio          | n.                     |               |   |          |           |           |          |
| C 2           | SLO-1           | Hogsteen base pairing, Triple helix,<br>Quadruple helix.   | Differences in prokaryotic and eukaryotic transcription.               | Growth factor signaling, cell-cell communication   | Neuro  | onal a  | nd Glia                | l Pro  | genito           | ors in                 | Adul                       | t Brain,          |                              | Karyo<br>cytoge |                        |               | omos                                    | omal al  | norm      | alities   | by       |
| S-3           | SLO-2           | DNA super-coiling  | Regulatory elements  | Mechanism of action of different class of hormones.  | Epithelial Stem Cells; Adult Progenitor Cells,   |         |                        |        | Restr<br>(RFLF   |                        | fragn                      | nent le           | ngth p                       | olymoi          | rphisr                 | n             |   |          |           |           |          |
| C 4           | SLO-1           | Linking number- satellite  | Mechanism of transcription regulation.                                 | Cell cycle –Molecules controlling cell cycle   | Mesenchymal Stem Cells, Plasticity   |         |                        |        | Polym            | erase                  | chail                      | n reac            | tion (P                      | CR)             |                        |               |   |          |           |           |          |
| S-4           | SLO-2           | DNA replication  | Transcription termination.   | Cancer, role of Ras and Raf Oncogenesis and apoptosis.   | De-di  | ifferen | ntiation a             | and r  | rediffe          | rentia                 | ation                      |                   |                              | Nucle           | ar inje                | ection        |   |          |           |           |          |

|     | ration<br>nour) | 9   | 9  | 9  | 9  | 9   |
|-----|-----------------|---|--|--|--|---|
| S-5 | SLO-1           | Meselson & Stahl experiment bi-<br>directional DNA replication  | Splicing - nuclear export of mRNA - mRNA stability.                        | Cell culture and immortalization of cells and its applications.  | Cancer cells and cancer stem Cells.  | stem cell transplantations for sickle-cell anemia, hemophilia,    |
| 3-3 | SLO-2           |   | Role of gene expression in microRNA  | Molecular Basis of Pluripotency  | Hematopoietic Stem Cells.  | Stem cell transplantation for cancer (leukemia and myeloma).      |
| S-6 | SLO-1           | replication   | okaryotic and eukaryotic DNA LncRNA, snoRNA, piRNA Induced plurip          |  | Stem Cells and tissue engineerings.  | Muscular dystrophy and stem cell therapy                          |
|     | SLO-2           | Role of telomerase in aging and cancer  | srRN <mark>A, siRNA</mark> and shRNA.                                      | IA, siRNA and shRNA.  Cell cycle regulators in Stem Cells  Embryonic Stem Cells in Tissue Engineering. |  | Stem cell therapy   |
| S-7 | SLO-1           | Mutagens, DNA mutations and their mechanism   | Genetic code: Elucidation of genetic code                                  | Stem Cell Niches,  | Organ culture  | Neurodegenerative disease   |
| 3-1 | SLO-2           | Telomere replication in eukaryotes DNA Repair.  | Codon degeneracy, Wobble hypothesis and its importance                     | Change of Phenotype and Differentiation,   | Characterization and maintenance of murine and human embryonic stem cells, | Stem cell transplantation   |
|     | SLO-1           | DNA mismatch, Base-excision   | Prokaryotic and eukaryotic ribosomes.                                      | Aging and stem cell renewal, Quiescent Stem Cells.   | Differentiation of embryonic Stem Cells                                    | Dementia  |
| S-8 | SLO-2           | Nucleotide-excision and direct repair DNA recombination   | Prokaryotic and eukaryotic translation and post-translational modification | Lineage tracing experiments in stem cells  | Embryonic stem cell cloning  | Neurodegenerative disease   |
| S-9 | SLO-1           | Homologous, site-specific and DNA transposition  Regulation of gene expression with reference to λ phage life cycle.  Techniques used to study cells: flow cytometry and Confocal Microscopy. |  | Therapeutic cloning of stem cells  | CRIPSR/Cas9 system-gene editing  |   |
|     | SLO-2           | Operon concept - Lac and Trp operon   | Eukaryotic gene regulation   | Antibody labeling and Immunohistochemistry   | Genomic Reprogramming  | Applications of CRISPR/CAS-9 techniques in regenerative medicine. |

|           | <ol> <li>Fundamentals of Biochemistry. Life at the molecular level by Donald Voet, Judith G. Voet and</li> </ol> |
|-----------|--|
| Laamainaa | Charlotte W. Pratt. Willey 2016.   |
| Learning  | 2. Tietz Fundamentals of Clinical Chemistry and Molecular Diagnostics, Carl A. Burtis, David E. Bruns. 7th       |
| Resources | ed. Elsevier, 2014.  |
|           | 3 Practical Clinical Biochemistry, Harold Varley, Interscience Publishers Inc. 2005                              |

- 4. Lecture Notes Clinical Biochemistry (8th Edition). Simon Walker, S., Ashby, P., Rae, P., and Beckett,
- G., Blackwell, 2010.


  5. Textbook of Biochemistry With Clinical Correlations. Devlin, D.M., (Ed). Wiley-Liss, 2010.

SLO - Session Learning Outcome

| Learning Ass | essment                |        |                   | The second       |          |        |          | The same of the sa |          |                                   |          |  |  |
|--------------|------------------------|--------|-------------------|------------------|----------|--------|----------|--|----------|-----------------------------------|----------|--|--|
|              | Bloom's                |        | Final Evamination | (E00/ woightogo) |          |        |          |  |          |                                   |          |  |  |
|              | Level of Thinking      | CLA –  | 1 (10%)           | CLA – 2 (15%)    |          | CLA –  | 3 (15%)  | CLA -  | 4 (10%)# | Final Examination (50% weightage) |          |  |  |
|              | Level of Thinking      | Theory | Practice          | Theory           | Practice | Theory | Practice | Theory   | Practice | Theory                            | Practice |  |  |
| Level 1      | Remember<br>Understand | 40 %   | -                 | 30%              | -        | 30%    |          | 30%  | -        | 30%                               | -        |  |  |
| Level 2      | Apply<br>Analyze       | 40 %   | - 1               | 40%              | -        | 40%    |          | 40%  | -        | 40%                               | -        |  |  |
| Level 3      | Evaluate<br>Create     | 20 %   | -                 | 30%              | -        | 30%    |          | 30%  | -        | 30%                               | -        |  |  |
|              | Total                  | 10     | 0 %               | 100              | ) %      | 10     | 0 %      | 10   | 00 %     | 10                                | 0 %      |  |  |

<sup>#</sup> CLA – 4 can be from any combination of these: Assignments, Seminars, Tech Talks, Mini-Projects, Case-Studies, Self-Study, MOOCs, Certifications, Conf. Paper etc.,

| Course Designers   |  |   |
|--|--|---|
| Experts from Industry  | Experts from Higher Technical Institutions   | Internal Experts                                      |
| Dr. Sudarshan Reddy Oncosimis Biotech Pvt. Ltd. email: info@oncosimis.com          | Dr. C. Parthasarathy, University of Oklahoma Parathasarathy-<br>chandrakesan@ouhsc.edu | 1. Dr. P. Kanagaraj, SRMIST kanagarajp@srmist.edu.in  |
| 2. Mr.J.B. Vijayakumar BioArtis Life Sciences Pvt. Ltd. email: contact@bioartis.in | 2. Dr. R. Ilangovan , University of Madras Ilnagovan2000@yahoo.com                     | 2. Dr. N. Selvamurugan, SRMIST selvamur@srmist.edu.in |



| Cours<br>Code      |  | 18BTE412T                   | Course<br>Name                              | CELL COMMUNICATION AND SIGNAL                                 | IN(-i  | ırse<br>gory | E                   |                           |       |                       | Р       | ofessi                 | onal E | Electiv     | /e             |                     |               |                | L<br>3        | T<br>0 | P C 0 3    |
|--------------------|--|-----------------------------|---|---|--|--------------|---------------------|---------------------------|-------|-----------------------|---------|------------------------|--------|-------------|----------------|---------------------|---------------|----------------|---------------|--------|------------|
|                    |  | isite Courses<br>Department | Nil<br>Biotechnology                        | Co-requisite Courses Nil                                      | / Codes/Standards  | Progres      | sive (              | Course                    | es    | Nil                   |         |                        |        |             |                |                     |               |                |               |        |            |
| Oourse .           | Jileting L   | Department                  | Diotechnology                               | Data Book   | ouces/otandards  |              |                     |                           |       |                       |         |                        |        |             |                |                     |               |                |               |        |            |
| Course I<br>(CLR): | earning  | Rationale The               | purpose of learning this co                 | urse is to:   | TINC!  |              | Learn               | ing                       |       |                       |         |                        | Prog   | ram L       | earnir.        | ng Outo             | comes         | (PLO           | )             |        |            |
| CLR-1:             | Provid   | de basic concep             | ts of gene expression patte                 | rns from the perspective of engineers                         |  | 1            | 2                   | 3                         |       | 1                     | 2 :     | 4                      | 5      | 6           | 7              | 8 9                 | 10            | 11             | 12            | 13     | 14 15      |
| CLR-2:             | Identii  | fy the role of ep           | igenetic regulation in adult                | stem cells  |  |              |                     |                           |       |                       |         | ے                      |        |             | ity            |                     |               |                |               |        |            |
| CLR-3:             | Identii  | fy the external a           | nd internal signaling mol <mark>ec</mark> i | <mark>ules that</mark> regulate the stem cell proliferation a | nd differentiation   | (E           | ्र                  | (9)                       |       | 4)                    |         | Research               |        |             | Sustainability |                     | _             |                |               |        |            |
| CLR-4:             |  |                             | val and cell death me <mark>chani</mark>    |   | ORDER DE LA COMPANSION DE LA COMPANSION DE LA COMPANSION DE LA COMPANSION DE LA COMPANSION DE LA COMPANSION DE   | (Bloom)      | 9)                  | t (9                      | 1     | g                     | 1       | ese                    |        |             | aj.            | Vio.                | 5             | 92             |               |        |            |
| CLR-5:             | Encou  | ırage engineerir            | g students to think <mark>solving</mark>    | neural degenerative diseases with stem cells                  |  | 9            | - I S               | Jen                       |       | We                    | (0      | Z Z                    | ge     | 0           | nst            | 5                   | -             | Finance        | б             |        |            |
| CLR-6:             | Analy.   | ze the molecula             | r mechanism of st <mark>emness-</mark>      | signaling pathways and transcription factors                  |  | ding         |                     | ainn                      | -     | S)                    | ysis    | ig                     | Use    | ture        |                |                     | tion          | ⊗<br>E         | Ē             |        |            |
|                    |  |                             |   | E HALL  |  | Thinking     | ted Proficiency (%) | S Expected Attainment (%) |       | Engineering Knowledge | - 0     |                        |        | y & Culture | Environment &  | <u> </u>            | Communication | Project Mgt. 8 | Long Learning | _      | 2 %        |
| (CLO):             |  |                             | ne end of this <mark>course, le</mark> arne |   |  | امرم         | ]                   | Expec                     |       | Engin                 | Problem | Analysis,              | Modern | Society     | Enviro         | Ethics              | Comm          | Projec         | Life Lo       | PSO-   | PSO-       |
| CLO-1:             | Apply  | the basic unde              | rstanding of g <mark>ene regu</mark> lation | n in stem cells   | A DESCRIPTION OF THE PARTY OF T | 2            | 85                  | 80                        |       | Н                     | Н       | · H                    | -      | -           | -              | М -                 | Н             | -              | Н             | Н      | $H \mid H$ |
| CLO-2:             | Manip  | ulate the gene e            | expression i <mark>n stem cell</mark> s and | d artificial generation of pluripotency                       |  | 2            |                     |                           |       | М                     | М       | M                      | -      | -           | -              | М -                 | Н             | -              | Н             |        | $H \mid H$ |
| CLO-3:             |  |                             |   | g and th <mark>eir r</mark> eceptor molecules                 |  | 2            |                     |                           |       | Н                     | М       | M                      | -      | -           | -              | М -                 | Н             | -              | Н             |        | H H        |
| CLO-4:             |  |                             | f molecules <mark>involved</mark> in self   | renewal of stem cells   | William of Charles   | 2            |                     |                           |       | Н                     | Н       | M                      | -      | -           | -              | М -                 | Н             | -              | Н             | Н      | H          |
| CLO-5:             |  |                             | death mech <mark>anisms</mark>              |   | THE RESERVE OF THE PARTY.  | 2            | 80                  |                           |       | М                     | M       | Н                      | -      | -           | -              | М -                 | Н             | -              | Н             |        | H H        |
| CLO-6:             | Analy.   | ze nerve cell reg           | generation, <mark>cell surviv</mark> al and | l cell death.   | and the second second  | 2            | 80                  | 80                        |       | Н                     | M       | H                      | -      | -           | -              | М -                 | Н             | -              | Н             | Н      | H H        |
|                    |  |                             |   | The second second   |  | -            |                     | 435                       |       |                       |         |                        |        |             |                |                     |               |                |               |        |            |
| Duratio            | n (hour)   |                             | 9   | 9   | 9  |              |                     |                           |       |                       | 9       |                        |        |             |                |                     |               | 9              |               |        |            |
| S-1                | transduction   |                             |   |   | cell surface receptor mediated signal<br>ransduction Stem cell aging and apoptosis   |              |                     | leural                    | stem  | cells                 |         |                        |        |             |                | enerati<br>Iution c |               |                |               |        |            |
| 3-1                | SLO-2 Embryonic fate cell decision Growth factor and receptors Regulation and significance apostem cells |                             |   | e apoptosis in Neural progenitors                             |  |              |                     |                           | Sma   | ads - Po              | olycom  | nb ger                 | ies    |             |                |                     |               |                |               |        |            |
|                    | SI O-1   | Interaction bet             | veen stem cells <mark>and their</mark>      | tyrosine kinases Mediated signaling (Ras-                     | Stem cell necrosis   |              | 7                   | he he                     | terog | eneity                | of adu  | ılt <mark>neu</mark> r | al ste | m           | Colli          | ular sic            | nalina        | of AV          | +/DK¤         | - R-0  | atonin     |

| Duration | n (hour) | 9  | 9  | 9  | 9   | 9  |
|----------|----------|--|--|--|---|--|
|          | SLO-1    | Alternative splicing in embryonic stem cells         | FGF signaling pathways   | Heat shock proteins  | cholinergic-dopaminergic signals                | Leukemia, lymphoma and Myeloma                         |
| S-6      | 3LU-2    |  |  | Apoptosis intracellular kinases  | Nerve cell growth factor                        | Bone marrow transplantation                            |
| S-7      | SLO-1    | Homeostasis and Feed-back regulation in niche        | Progenitor cell differentiation factors                                      | Apoptosis adaptor proteins   | Induced regeneration of neuronal cells          | Cytokine and chemokine therapies                       |
|          | OLU-Z    | Cytokines and growth factors maintenance of stemness | Colo <mark>ny stimulatin</mark> g factor and its receptor signaling pathways | Small molecules-induced apoptosis  | Neurosphere culture                             | Cancer stem cell - cell survival and tumor maintenance |
| S-8      | SLO-1    | INDOGETIO TO STERLICETT ASSUMPLET                    | Platelet-derived growth factor signaling pathways                            | Inhibitors of apoptosis in cancer stem cells                             | Astrocyte, oligodendrocyte differentiation      | Mechanism of cancer stem cell resistance               |
| 3-0      | SLO-2    | Pluripotency genes, expression and regulation        | Role of oncogenes in embryonic stem cells                                    | Cellular senescence pathways   | Glial cell differentiation                      | Targeting cancer stem cells                            |
| S-9      | SLO-1    | Epigenetic changes in DNA                            |  | Telomerase in adult and pluripotent stem cells and Telomerase shortening | Pathophysiology of neuronal stem cell signaling | Selective killing of cancer stem cells                 |
|          | SLO-2    | #Enigenetic changes in histories                     | Effects of melatonin and seratonin in stem cells                             | I ATHORMUNE RESTRICTION OF STEM CEILS                                    | Multiple sclerosis, Parkinson's and Alzhimer's  | Nanocarrier mediated drug delivery                     |

|                  | 1.      | The science of stem cells - Jonathan M.W Slack - Wiley Blackwell - 2018.   |
|------------------|---------|--|
| Learning         | 2.      | Transcriptional and Translational regulation of stem cells - (Advances in experimental medicine and biology - Gary Hime and Helen Abud, 2013 |
| Resources        | 3.      | Stem cell regulators (Vitamins and Hormones Book 87) - Gerald Litwack - Academic Press – 2011  |
|                  | 4.      | Control and regulation of stem cells- Bruce Stillman, David Stewart, Terri Grodzicker - Cold Spring Harbor Laboratory -2008                  |
| SLO - Session Lo | earning | Outcome  |
|                  | _       |  |

## SLO – Session Learning Outcome

| Learning Ass | sessment   |                   |          | THE STATE |          |        |          |         |                        |                                   |                    |  |  |
|--------------|--|-------------------|----------|-----------|----------|--------|----------|---------|------------------------|-----------------------------------|--------------------|--|--|
|              | Bloom's Continuous Learning Assessment (50% weightage) |                   |          |           |          |        |          |         |                        |                                   | n (EOO/ waightaga) |  |  |
|              | Level of Thinking                                      | CLA -             | 1 (10%)  | CLA –     | 2 (15%)  | CLA -  | 3 (15%)  | CLA – 4 | 1 (10 <mark>%)#</mark> | Final Examination (50% weightage) |                    |  |  |
|              | Level of Thirtking                                     | Theory            | Practice | Theory    | Practice | Theory | Practice | Theory  | Practice               | Theory                            | Practice           |  |  |
| Level 1      | Remember<br>Understand                                 | 40 %              | 5        | 30%       | - 11     | 30%    | -        | 30%     | 1 -                    | 30%                               | -                  |  |  |
| Level 2      | Apply<br>Analyze                                       | 40 <mark>%</mark> | 7        | 40%       | - 1//    | 40%    | - 7      | 40%     | -                      | 40%                               | -                  |  |  |
| Level 3      | Evaluate<br>Create                                     | 20 %              | 11/2     | 30%       |          | 30%    |          | 30%     | -                      | 30%                               | -                  |  |  |
|              | Total  | 10                | 0 %      | 10        | 0 %      | 100    | 0 %      | 10      | 0 %                    | 10                                | 0 %                |  |  |

<sup>#</sup> CLA – 4 can be from any combination of these: Assignments, Seminars, Tech Talks, Mini-Projects, Case-Studies, Self-Study, MOOCs, Certifications, Conf. Paper etc.,

| Course Designers   | THE STATE OF THE S |  |
|--|--|--|
| Experts from Industry  | Experts from Higher Technical Institutions   | Internal Experts                                     |
| 1. Dr. Sudarshan Reddy Oncosimis Biotech Pvt. Ltd. email: info@oncosimis.com       | 1. Dr. C. Parthasarathy, University of Oklahoma Parathasarathy-chandrakesan@ouhsc.edu  | 1. Dr. P. Kanagaraj, SRMIST kanagarajp@srmist.edu.in |
| 2. Mr.J.B. Vijayakumar BioArtis Life Sciences Pvt. Ltd. email: contact@bioartis.in | 2. Dr. R. Ilangovan University of Madras Ilnagovan2000@yahoo.com   | 2. Dr. R. Satish, SRMIST satisr@srmist.edu.in        |

| Course<br>Code | 18BTE413T        | Course<br>Name           | STEM CELL TECHNOLOGY        | Course Category   | Е       | Professional Elective       |    | T 0 | P 0 | C<br>3 |
|----------------|------------------|--------------------------|-----------------------------|-------------------|---------|-----------------------------|----|-----|-----|--------|
|                |                  |                          |                             |                   |         |                             |    |     |     |        |
| Pre-re         | equisite Courses | Nil                      | Co-requisite Courses   Nil  | Progressive Cours | ses Nil |                             |    |     |     |        |
| Course Offeri  | ng Department    | Biotechnology            | Data Book / Codes/Standards | Nil               |         |                             |    |     |     |        |
|                |                  |                          |                             |                   |         |                             |    |     |     |        |
| Course Learn   | ing Rationale    | a numaca of laaming this | agurag in for               | la                | ownin a | Dragram Lagraina Outcomes ( | חח |     |     |        |

| Course Le (CLR): | earning Rationale             | The purpose of learning this course is to:  | Learning Outcomes (PLO) |              |                   |    |               |          |              |                   |             |              |                |    |      |         |          |      |        |            |     |
|------------------|-------------------------------|---|-------------------------|--------------|-------------------|----|---------------|----------|--------------|-------------------|-------------|--------------|----------------|----|------|---------|----------|------|--------|------------|-----|
| CLR-1:           | Provide basic kno             | wledge on embryogenesis from the perspective of engineers.  | 1                       | 2            | 3                 | Ī  | 1             | 2        | 3            | 4                 | 5           | 6            | 7              | 8  | 9 '  | 10      | 11       | 12   | 13   1 | 14         | 15  |
| CLR-2:           | Create an interest            | to know about the different types of stem cells, its isolation, differentiation and transdifferentiation.                   |                         |              |                   |    |               |          |              | ے                 |             |              | iť             |    |      |         |          |      |        |            |     |
| CLR-3:           | Develop awarenes              | ss about cancer stem cells, iPSCs and importance of stem cell niches.   | E                       | (%           | (%)               |    | 4)            |          |              | earch             |             |              | Sustainability |    | ~    |         |          |      |        |            |     |
| CLR-4:           | Initiate interest on          | signaling pathways, epi <mark>genetics and</mark> latest techniques on gene editing.  | 0                       | -            |                   | /  | Knowledge     |          | Development  | ese               |             |              | aj.            |    | Work |         | 9        |      |        |            |     |
| CLR-5:           | Generate interest             | on applications and us <mark>es of stem c</mark> ells and create awareness on ethics and regulations of stem cell research. | (Blo                    | roficiency   | neu               |    | We            | <i>γ</i> | md           | Δ,                | Usage       | a)           | nst            |    |      |         | inar     | б    |        |            |     |
| CLR-6:           | Encourage engine              | ering students to de <mark>velop the st</mark> rategies for ex vivo for tissue development and disease                      | ing                     | ficie        | i.                | +  | 9             | ysis     | e<br>e       | igi               | USS         | ulture       | ∞<br>∞         |    | eam  |         | ĕ<br>Z   | rii  |        |            |     |
| Course Le        | earning Outcomes              | At the end of this course, learners will be able to:  | evel of Thinki          | Expected Pro | pected Attainment |    | Engineering l | 7        | Design & Dev | Analysis, Design, | Modern Tool | Society & Cu | Environment    |    | ੁ    | municat | ect Mgt. | 힉    |        | 0-2        | 0-3 |
| (CLO):           |                               | At the cita of this course, learners will be able to.   | Le l                    | Ш            | Exp               |    | ᇤ             | F.       | <u>a</u>     | A                 | M           | တ္တ          | ᇤ              | 亩. | 2 ,  | Com     | 풉        | Life | PSO    | <u>2  </u> | 8   |
| CLO-1:           | Apply knowledge               | about embryoge <mark>nesis, stem</mark> cells <mark>and its characteristics.</mark>   | 2                       | 80           | 70                | 77 | -             | -        | Н            | М                 | -           | -            | Μ              | Н  | -    | Н       | -        | Н    | Н      | Н          | Η   |
| CLO-2:           | Gain knowledge o              | n different types <mark>of stem c</mark> ells isolation of ESCs, its specialized functions and transdifferentiation.        | 3                       | 85           | 70                |    | -             | -        | Н            | М                 | -           | -            | Μ              | Η  | -    | Н       | -        | Н    | H .    | Н          | Н   |
| CLO-3:           | Discuss about car             | icer stem cells, i <mark>PSCs an</mark> d stem cell niches.   | 2                       | 80           | 75                | 3  | -             |          | Н            | М                 | -           | -            | М              | Н  | -    | Н       | -        | Н    | Н      | Н          | Н   |
| CLO-4:           | Identify the role of          | signaling pathw <mark>ays, epig</mark> enetics and genome editing in engineering of stem cells.                             | 2                       | 80           | 70                |    | -             | -        | Н            | М                 | -           | -            | М              | Н  | -    | Н       | -        | Н    | Н      | Н          | Н   |
| CLO-5 :          | Utilize application research. | of stem cells in <mark>tissue en</mark> gineering, treatment of different diseases & ethics and regulations of stem cell    | 3                       | 80           | 70                |    | -             | -        | Н            | М                 | -           | -            | М              | Н  | -    | Н       | -        | Н    | Н      | Н          | Н   |
| CLO-6:           | Apply knowledge               | on CRISPR/Cas <mark>9 gene e</mark> diting system.  | 3                       | 80           | 70                |    | -             | -        | Н            | М                 | -           | -            | М              | Н  | -    | Н       | -        | Н    | Н      | Н          | Н   |

| Duration | on (hour)                               | 9                                    | 9  | 9   | 9  | 9  |
|----------|---|--------------------------------------|--|---|--|--|
| S-1      |   | Overview of Stem cells               | ESCs –IVF, Primate and Mouse<br>ES cells, Markerss                   |   | ESC pluripotency and signaling- JAK-<br>STAT pathway         | Stem Cells in Tissue Engineering                                       |
| 3-1      | SLO-2                                   | Early development of embryos         | Nuclear transfer technology in ES cells                              | Sources of ASCs and its properties and its role as specialised cells in differentiation         | Activin/Nodal/TGFβ Signaling Pathway                         | Therapeutic Applications   |
|          | SLO-1                                   | Stem Cells in research               | Human ESCs   | Transdifferentiation-Definition   | FGF Signaling Pathway  | Parkinson's disease  |
| S-2      | SLO-2                                   | Totipotent, multipotent, oligopotent | Isolation and culturing of hESC's                                    | Fusion experiments  | Wnt signaling and Insulin-like growth factors                | Factors for a Successful Cell Therapy in PD- Problems                  |
|          | SLO-1 "Stemness": Definitions, Criteria |                                      | Differentiation of stem cells  | Experiments on transdifferentiation   | HSC signaling pathways- Notch                                | Autograft, allograft and xenograft-stem cells                          |
| S-3      | SLO-2                                   | Criteria and Standard of stemness    | Stem Cell Niche in Regenerative Medicine-Stem cells and their niches | Intestine-oseophagus cell transition, lens<br>regeneration, liver to pancreas and vice<br>versa | Wnt signaling  | Bone defects-biomaterials- stem cells-<br>osteoprogenitors-osteoblasts |
| S-4      | SLO-1                                   | Formation of stem cells              | Stem Cells derived from early mouse embryos-ES cells                 | Induced pluripotent stem cells (iPSCs)-<br>Methodology  | TGF signaling  | Stem Cells for Spinal Cord Injury-<br>Introduction                     |
|          |   | Embryonic and adult stem cells       | EC cells   | Induced pluripotent stem cells (iPSCs)-<br>Applications   | SMAD signalling  | Common strategies toward regeneration of the damaged spinal cord.      |
| S-5      | SLO-1                                   | Potency of Stem Cells                | EG cells   | I SU IVII   | Epigenetic control of stem cells-<br>experimental background | Stem Cell treatment for diabetes-Types of diabetes                     |

| Duration (hour) |       | 9  | 9   | 9                                      | 9  | 9   |  |
|-----------------|-------|--|---|--|--|---|--|
|                 | SLO-2 | Types and classification of stem cells based on potency        | TS cells  | Cell fusion, treatment                 | Effects of global histone modifications                                  | Development of cell-based therapies for diabetes                                  |  |
| S-6             | SLO-1 | Types of stem cells –Embryonic stem cells (ESCs)               | Systems/models for ES differentiation                             | Cancer stem cells- Isolation           | DNA methylation in differentiated versus undifferentiated cells          | Cardiac tissue engineering using stem cells-Methodology                           |  |
|                 | SLO-2 | Types of stem cells-Adult stem cells (ASCs)                    | 3D bioprinting using stem cells                                   | Cancer stem cells -Characterization    | Effect of TSA on stem cell differentiation                               | Cardiac tissue engineering using stem cells - Applications                        |  |
| S-7             | SLO-1 | Differences between ESCs and ASCs                              | Formation of early extraembryonic lineages                        | Cancer Stem Cells - properties, origin | Transcriptional factors network  | Stem cell treatment for burns   |  |
|                 | SLO-2 | Similarities between ESCs and ASCs                             | Pluripotent cell development                                      | Cancer Stem Cells - Theories           | Effects of histone demethylases  | Transplantable matrices   |  |
| S-8             | SLO-1 | Identification and characterization of ESCs at cellular level  | Formation of somatic lineages—<br>Haematopoietic Lineages         | CSCs and Metastasis: The Primary TME   | Epigenetics in somatic cells   | Ethics of Stem Cell Research- The Ethics of Destroying Human Embryos for Research |  |
|                 | SLO-2 |  | Formation of somatic lineages—<br>Neuronal Lineages               | CSCs and Metastasis: Metastatic Niche  | Epigenetics in iPSCs   | The Ethics of Using Human Embryonic Stem Cells in Research                        |  |
| S-9             | SLO-1 | Identification and characterization of ASCs at cellular level  | Therapeutic cloning using ESCs-<br>Disease cell model development | Breast cancer metastasis               | Genome Editing in Stem Cells- ZFN,<br>TALENS                             | Regulations governing Stem Cell research-ICMR, Drugs and Cosmetic Act             |  |
|                 | SLO-2 | Identification and characterization of ASCs at molecular level | Reproductive cloning using ESCs                                   | Tumor suppressor and Proto-oncogenes   | CRISPR/CAs9 strategies, Design of DNA donor templates for gene knock-ins | Stem Cell as the investigational new drug   |  |

Learning
1. Robert Lanza, Edited by: Robert Lanza and Anthony Atala, "Essentials of Stem Cell Biology"3rd Edition, Academic Press, Copyright © 2014 Elsevier Inc. 4.

Resources
2. Huang G, Ye S, Zhou X, Liu D, Ying QL. Molecular basis of embryonic stem cell self-renewal: from signaling pathways to pluripotency network. Cell Mol Life Sci. 2015, May; 72 (9):1741-57.

| Learning Ass | essment                      |  |          | N 14 15 15 15 15 |          |               |          |                |                                     |                                   |          |
|--------------|------------------------------|--|----------|------------------|----------|---------------|----------|----------------|-------------------------------------|-----------------------------------|----------|
|              | Dlaam'a                      | Continuous Learning Assessment (50% weightage) |          |                  |          |               |          |                | Final Eventination (E00/ veriables) |                                   |          |
|              | Bloom's<br>Level of Thinking | CLA – 1 (10%)                                  |          | CLA – 2 (15%)    |          | CLA – 3 (15%) |          | CLA – 4 (10%)# |                                     | Final Examination (50% weightage) |          |
|              |                              | Theory   | Practice | Theory           | Practice | Theory        | Practice | Theory         | Practice                            | Theory                            | Practice |
| Level 1      | Remember<br>Understand       | 40 %   | 157 V    | 30%              | - 1      | 30%           | -        | 30%            | <u>-</u>                            | 30%                               | -        |
| Level 2      | Apply<br>Analyze             | 40 <mark>%</mark>                              | 34       | 40%              | - 11     | 40%           | - 7      | 40%            |                                     | 40%                               | -        |
| Level 3      | Evaluate<br>Create           | 20 %   | J.       | 30%              |          | 30%           |          | 30%            | F -                                 | 30%                               | -        |
|              | Total                        | 10   | 0 %      | 10               | 0 %      | 10            | 0 %      | 10             | 0 %                                 | 10                                | 00 %     |

| Course Designers  |   |  |
|---|---|--|
| Experts from Industry   | Experts from Higher Technical Institutions  | Internal Experts                                     |
| Dr. B.R.Desikachari, Medical Directior, Westminster Health Care, Chennai, brdesikachari@hotmail.com | 1. Prof .Halagowder D,Univ. of Madras, hdrajum@yahoo.com                                  | 1. Dr. Devi.A, SRMIST devia@srmist.edu.in            |
| 2. Dr. A. Premkumar, Ph.D., GVK Biosciences, Hyderabad aprem70@yahoo.com                            | Dr.Sudha Warrier, Associate Professor, Manipal University,     sudha.warrier@mannipal.edu | 2. Dr. N.Selvamurugan, SRMIST selvamun@srmist.edu.in |

| Course<br>Code  |                 | 18BTE414T                   | Course<br>Name                             | BIOMATERIALS IN TISSUE ENG                            | SINEER                   | ING  | Course<br>Category | E Professional Elective –   |                          |                                |                       |                        |                      |                        |                   |                              | L<br>3  | T<br>0                | P<br>0        | C<br>3                                      |        |       |      |
|---|-----------------|-----------------------------|--|---|--------------------------|--|--------------------|---|--------------------------|--------------------------------|-----------------------|------------------------|----------------------|------------------------|-------------------|------------------------------|---------|-----------------------|---------------|---|--------|-------|------|
|   |                 | site Courses<br>Department  | Nil<br>Biotechonolgy                       | Co-requisite Courses Nil Data                         | Book /                   | Codes/Standards  | Prog               | gress   | ive Cou                  | rses                           | Nil                   |                        |                      |                        |                   |                              |         |                       |               |   |        |       |      |
| Course L<br>(CLR):  | earning F       | Rationale The               | purpose of learning this co                | urse i <mark>s to:</mark>                             |                          | Thursday.  | 1:                 | L   | .earning                 |                                |                       |                        |                      | Prog                   | gram l            | _earnin                      | g Out   | come                  | s (PL         | O)  |        |       |      |
|   | Demons          | strate the hasic l          | knowledge on biomaterials                  | from the perspective of engineers.                    | -                        |  |                    | 1   | 2                        | 3                              | 1                     | 2                      | 3 4                  | 5                      | 6                 | 7                            | 8       | 9 1                   | 0 1           | 1 12  | 13     | 14    | 15   |
| CLR-2:  |                 |                             | e engineering problems wi                  |   |                          |  |                    |   |                          |                                |                       |                        |                      |                        |                   | ,                            |         |                       |               |   |        |       |      |
|   | Demons          | strate basic cond           | cepts regarding design <mark>and</mark>    | <mark>l mecha</mark> nical properties of selected bio | materia                  | ıls.   |                    | (mc   | (%)                      | <u></u>                        | e Je                  |                        | 11                   | 5                      |                   |                              |         | 논                     |               | 1)  |        |       |      |
| CLR-4:  | Analyze         | the design and              | mechanical properties of                   | selected biomaterials for specific medic              | cal appli                | ications.  |                    | evel of Thinking (Bloom)  | Expected Proficiency (%) | Expected Attainment (%)        | Engineering Knowledge |                        | Design & Development | e e                    |                   |                              |         | ndividual & Team Work |               | roject mgt. & rinance<br>life Long Learning |        |       |      |
|   |                 |                             | nufacturing of biom <mark>aterials</mark>  |   |                          | No. of Street, or other party of the street, or other party of the |                    | ) gu  | cier                     | Ĕ                              | NO V                  | Sis                    | dol                  | Sag                    |                   |                              |         | g g                   | _   i         | ii lie                                      |        |       |      |
| CLR-6:  | Analyz          | e the strategies            | for global marke <mark>ting of bio</mark>  | omaterials  |                          |  |                    | Ξ   | rofi                     | Ital                           | 조                     | Problem Analysis       | eve<br>Porice        | Modern Tool Usage      | Society & Culture | Environment & Sustainability |         | <u>e</u>              | Communication | roject Mgt. & Fina<br>ife Long Learning     |        |       |      |
|   |                 |                             |  |   |                          | ASS. STATE   |                    | ΪĒ  | g                        | D P                            | erin (                | ٦Ar                    | ے اح<br>س            | i o                    | 8                 | mer                          |         | <u></u>   <u>∞</u>    |               | ig L  |        | 2     | က    |
| Course I  | earning (       | Outcomes A446               |  | 100   | 77.75                    |  |                    | <del> </del>  | ecte                     | ecte                           | inee                  | Jen .                  | ıgı 🥳                | ern                    | ety               | iron                         | છ       | ᅙ                     |               |   | -1     |       |      |
| (CLO):  |                 | At the                      | e end of this <mark>course, le</mark> arn  | ers will be able to:                                  |                          |  |                    | ě   | ă l                      | X                              | ing                   | orof                   | Jes<br>Ana           | 90                     | 300               | Env<br>Sus                   | 語       | <u>ģ</u>   <u>ģ</u>   | 5 .           | []<br>[]                                    | PSO    | PSO   | PSO. |
| CLO-1 :   | Explain biomate |                             | iques to man <mark>ufacture</mark> scaff   | olds from raw biomaterials and explain                | the diff                 | ferent prerequisites for t   | he                 | 2   |                          | 70                             |                       |                        | M N                  |                        |                   |                              | Н       |                       | 7             | Н   | Н      | Н     | Н    |
| CLO-2:  | Illustrate      | e the types of bid          | omaterials f <mark>or biomed</mark> ical a | applications.   | 177                      | THE STATE OF   | F 10.51            | 2   | 75 8                     | 30                             |                       |                        | M N                  | 1                      |                   |                              | Н       | 1                     | Ή             | Н   | Н      | Н     | Н    |
|   |                 |                             |  | ing that require engineering expertise to             | to solve                 | them.  |                    | 2   | 80                       | 70                             |                       |                        | M N                  | 1                      |                   |                              | Н       |                       | 4             | Н   | Н      |       | Н    |
|   |                 |                             | of biomate <mark>rials for v</mark> arious |   |                          | 137 (36) 71 7  |                    | 2   |                          | 75                             |                       |                        | M N                  | 1                      |                   |                              | Н       |                       | Ή             | Н   | Н      | Н     | Н    |
|   |                 |                             | ıring of bio <mark>materials</mark> relate |   |                          |  |                    | 3   | 80                       | 70                             |                       |                        | M N                  |                        |                   |                              | Н       |                       | Ή             | Н   | Н      | Н     | Н    |
| CLO-6:  | Illustrate      | e global marketi            | ing of biom <mark>aterials fo</mark> r com | mercialization  |                          | 1000   | 200                | 2   | 85                       | 75                             |                       |                        | $M \mid N$           | 1                      |                   |                              | Н       | 1                     | Ή             | Н   | Н      | Н     | Н    |
| Duration  | (hour)          |                             | 9  | 9   |                          | 9  | 100                |   | -                        |                                |                       | 9                      |                      |                        |                   | 1                            |         |                       |               | 9   |        |       |      |
| Duration  |                 |                             |  |   |                          |  |                    |   |                          |                                |                       |                        |                      |                        |                   | Riom                         | ateria  | ıls anı               |               | r applic                                    | ations | s in  |      |
| S-1   |                 | Introduction to t           |  | Introduction to tissue engineering                    |                          | Bioactive molecules  |                    |   | Арр                      | lication                       | s of b                | oiomate                | rials                |                        |                   | medi                         |         | io un                 | 1 11101       | гаррис                                      | ation  | 3 111 |      |
| 0-1   | SLO-2           | Properties and biomaterials | salient feature <mark>s of</mark>          | Basic concepts in tissue engineering                  | ~ I                      | Classification and role molecules in tissue eng  |                    |   | Hea                      | lthcare                        |                       |                        |                      |                        |                   | Biom                         | edica   | l appl                | icatic        | ns  |        |       |      |
| S-2   |                 | Elements of Bio             |  | Fundamentals of tissue engineering                    |                          | Stimuli responsive in bi   | iomaterials        |   |                          |                                |                       | iomedio                | al <mark>ap</mark> p | li <mark>cati</mark> c | ons               | _                            |         |                       |               | ions of                                     |        |       | als  |
| 3-2   |                 | Metals, implants            |  | Complexity of tissue engineering                      |                          | Stimuli responsive in po   | olymers            |   |                          | u <mark>e</mark> engi          |                       |                        |                      |                        |                   |                              |         |                       |               | bioma                                       |        |       |      |
|   | SLO-1           | Biomaterials pre            | eparation                                  | <u>Tissues</u>  |                          | Biomimetics  |                    |   |                          |                                |                       | sutur <mark>e l</mark> |                      |                        |                   |                              |         |                       |               | for bic                                     |        |       |      |
| S-3   | SLO-2           | Biomaterials ch             | aracterization                             | Organization of tissues in vertebrate                 | body                     | Dental and bone  | 0.1                | M   |                          | ular im <sub>l</sub><br>erials | olants                | s and b                | o-insp               | ired                   |                   | Moni<br>biom                 |         |                       | gulati        | ory stra                                    | tegies | for   |      |
| S-4   |                 |                             | different bioceramic and                   | Cell sources  |                          | Drug deliveries  |                    | Ш   | _                        | nimetic                        | _                     |                        |                      |                        |                   | _                            |         |                       |               | with bi                                     |        |       |      |
|   |                 | Properties of big           |  | Stem cells  |                          | Nanoparticles in drug  |                    |   | Orga                     | an trans                       | plant                 |                        |                      |                        |                   | Enap                         | oint s  | trateg                | iles t        | or biom                                     | ateria | IS    |      |
| S-5   | SLU-1           | materials                   | different polymeric                        | Cell lineages   |                          | Designing of nanopartion delivery  | cies for arug      |   |                          | sue Cor                        |                       |                        |                      |                        |                   |                              |         |                       |               | f bioma                                     |        |       |      |
|   |                 |                             |  |   | Targeted delivery        |  |                    | Bioartificial tissues   |                          |                                |                       |                        |                      |                        |                   |                              | f bioma |                       | 3             |   |        |       |      |
| S-6   |                 | biocomposites i             |  | Cell-material interactions                            |                          | Peptides in drug delive  |                    | Connective tissues Supply chain of bi                             |                          |                                |                       |                        | naterial             | S                      |                   |                              |         |                       |               |   |        |       |      |
| SLO-2   Polymers-ceramics   Celi-material response   Proteins in drug   |                 |                             |  |   | Proteins in drug deliver | ery Regeneration of connective tissues Biomaterials control  |                    |   |                          |                                |                       |                        |                      |                        |                   |                              |         |                       |               |   |        |       |      |
| S-7 SLO-1 Physical properties of biomaterials  Assessment of biocompatibility of biomaterials  DNAs in drug of biomaterials |                 |                             |  |   |                          | DNAs in drug delivery  |                    | Targeting ligands in drug delivery Strategies of global marketing |                          |                                |                       |                        | ng                   |                        |                   |                              |         |                       |               |   |        |       |      |

| Duratio | on (hour) | 9                                     | 9   | 9   | 9   | 9  |
|---------|-----------|---------------------------------------|---|---|---|--|
|         | SLO-2     | Chemical properties of biomaterials   | MTT and cytotoxicity assays               | RNAs, oligos in drug delivery                               | Targeting ligands in cancer treatment     | Regulatory controls in global marketing              |
| S-8     | SLO-1     | Mechanical properties of biomaterials | Cell viability assays                     | Surface modifications                                       | Tissue regeneration and growth and repair | Global authorization of biomaterials                 |
| 3-0     | SLO-2     | Thermal properties off biomaterials   | Antibacterial assessment of biomaterials- | Applications in drug delivery                               | Cell growth and repair                    | Global marketing of biomaterials                     |
| S-9     | SLO-1     | Evaluation of biomaterials            | In vitro evaluation of biomaterials-      | Advantages and limitations of biomaterials in drug delivery | Drug discovery                            | Post-market surveillance approaches for biomaterials |
| 3-9     | SLO-2     | Biological response                   | In vivo evaluation of biomaterials        | Limitations of biomaterials in drug delivery                | Impact of drug discovery and development  | Good manufacturing practice for biomaterials         |

|           | 1. | Hench L. Larry, and Jones J., (Editors), Biomaterials, Artificial organs and Tissue Engineering, Woodhead Publishing Limited, 2005   |  |
|-----------|----|--|--|
| Loorning  | 2. | Nanocomposite science an <mark>d technolo</mark> gy, Pulickel M. Ajayan, Linda S. Schadler and Paul V. Braun, Wiley-VCH, 2005  |  |
| Learning  | 3. | Ulrich Meyer, Thomas M <mark>eyer, Jörg H</mark> andschel, Hans Peter Wiesmann (2009): Fundamentals of Tissue Engineering and Regenerative Medicin <mark>e, Springe</mark> r |  |
| Resources | 4. | Regenerative Medicine and Tissue Engineering, Edited by Jose A. Andrades, ISBN 978-953-51-1108-5, Publisher: InTech,2013   |  |
|           | 5. | S. Amato and B. Ezz <mark>ell, (Editor</mark> s), Regulatory Affairs for Biomaterials and Medical Devices, Woodhead Publisher, 2015  |  |

| Learning Ass | essment                      |        |           | 10 1-714 | A 12 15 12 15 15  | 130                |          |         |                       |                   |                    |
|--------------|------------------------------|--------|-----------|----------|-------------------|--------------------|----------|---------|-----------------------|-------------------|--------------------|
|              | Dla am'a                     |        | 2.71      | Contin   | uous Learning Ass | essment (50% weigh | ntage)   |         |                       | Final Evamination | o (E00/ woightage) |
|              | Bloom's<br>Level of Thinking | CLA -  | - 1 (10%) | CLA – 2  | 2 (15%)           | CLA – 3            | 3 (15%)  | CLA – 4 | (10 <mark>%)</mark> # |                   | n (50% weightage)  |
|              | Level of Thirtking           | Theory | Practice  | Theory   | Practice          | Theory             | Practice | Theory  | Practice              | Theory            | Practice           |
| Level 1      | Remember<br>Understand       | 40 %   |           | 30%      | 100               | 30%                |          | 30%     | -                     | 30%               | -                  |
| Level 2      | Apply<br>Analyze             | 40 %   | Z         | 40%      |                   | 40%                |          | 40%     |                       | 40%               | -                  |
| Level 3      | Evaluate<br>Create           | 20 %   |           | 30% —    |                   | 30%                | N. E. N  | 30%     |                       | 30%               | -                  |
|              | Total                        | 10     | 00 %      | 100      | 1%                | 100                | ) %      | 100     | 0 %                   | 10                | 0 %                |

<sup>#</sup> CLA – 4 can be from any combination of these: Assignments, Seminars, Tech Talks, Mini-Projects, Case-Studies, Self-Study, MOOCs, Certifications, Conf. Paper etc.,

| Course Designers   |   |  |
|--|---|--|
| Experts from Industry  | Experts from Higher Technical Institutions  | Internal Expert  |
| 1.Dr. Giridharan, Life Cell, giridharan.a@lifecell.in  | 1. R. Jayakumar, Ph. D, Amrita Medical Center, Kochi jayakumar77@yahool.com       | 1 .Dr. N. Selvamururgan, SRMIST selvamun@srmist.edu.in |
| 2. Dr. Gokuladhas Krishnan , Director, Laboratory, World Stem Cell Clinic, Chennai, care@worldstemcellclinic.com | 2. N. Srinivasan, Ph. D., Chettinad Health City, Chennai srinivasanibms@gmail.com | 2. Dr. M. Pandima Devi, SRMIST pandimam@srmist.edu.in  |

| Cours<br>Code      | 1 12   | BBTE415T Course<br>Name  | NANOTECHNOLOGY IN REGENERATIVE MI                                 | EDICINE   | Course<br>Category | E        |                 |                         |   |                        | Profe                | ssion                      | nal Ele           | ective  |                              |                   |                    | L               | L 1                | Γ (   | P<br>0 | C<br>3 |
|--------------------|--|--|---|---|--------------------|----------|-----------------|-------------------------|---|------------------------|----------------------|----------------------------|-------------------|---------|------------------------------|-------------------|--------------------|-----------------|--------------------|-------|--------|--------|
|                    | Pre-requisi  | ite Courses Nil epartment Biotechonolgy                          | Co-requisite Courses Nil Data Rook / J                            | Codes/Standards   | Prog               | gressi   | ve Cou          | urses                   | Nil   |                        |                      |                            |                   |         |                              |                   |                    | *               |                    | •     |        | _      |
| Course             | Jiletilig De   | spartment biotechonolgy  | Data Book /   | Codes/Standards   |                    |          |                 |                         |   |                        |                      |                            |                   |         |                              |                   |                    |                 |                    |       |        |        |
| Course L<br>(CLR): | earning R  | ationale The purpose of learning this                            | course is to:   | 11.76   | 115                | Le       | earnin          | g                       |   |                        |                      | F                          | Progra            | am Lea  | arning                       | Outco             | omes (             | PLO)            | 1                  |       |        |        |
| CLR-1:             |  | le an overview of the distinctive featur<br>ective of engineers. | es o <mark>f nanotechnol</mark> ogy and their application to bio- | medical problems fro  | rom the            | 1        | 2               | 3                       | 1   | 2                      | 3                    | 4                          | 5                 | 6       | 7 8                          | 9                 | 10                 | 11              | 12                 | 13    | 14     | 1      |
| CLR-2 :            | applic   | ations.  | d <mark>icine techn</mark> ologies for sensing and imaging, drug  | delivery, and other t   | therapeutic        | (Bloom)  | (%              | (%                      | Φ   |                        |                      | arch                       |                   |         | Environment & Sustainability | بح                |                    | _               |                    |       |        |        |
| CLR-3:             |  | op the strategies for drug delivery.                             |   |   |                    | 300      | 5               | ot (                    | gbe   |                        | Jen                  | ese                        | a                 |         | ţajı                         | Nor               |                    | nce             | ı                  |       |        | i      |
| CLR-4:             |  | e interest for utilizing nanotechn <mark>ology</mark>            |   | 110   |                    | g (E     | ien             | mel                     | owle  | <u>.s</u>              | opu                  | , R                        | age               | و ب     | Sus                          | Ē                 |                    | Finance         | ing                |       |        | i      |
| CLR-5:             |  | rate interest on applications rel <mark>ated to</mark>           |   | Control of the Control  |                    | Thinking | Proficiency (%) | tain                    | 호   | alys                   | ve                   | sigi                       | S)                | Culture | ∞                            | Les               | ţi                 | ∞<br>T          | au                 |       |        | i      |
| CLR-6:             | Епсои  | ırage engineering students to <mark>develop</mark>               | nanomaterials in intellectual property perspective                |   | ALC: UNIT          |          | 교               | A                       | ing   | Ans                    | De                   | a                          | 8                 | න<br>ට  | Je l                         | ∞                 | <u>ica</u>         | gt.             | _ <u>_</u> _       |       |        |        |
|                    |  |  |   | 10 Table 10 | 1000               | _ ᠸ      | Sec             | ) Sec                   | eer   | E E                    | ∞ _                  | Sis,                       | Ε                 | ty &    | <u>ا</u> يا                  | dua               | l E                | ≥               | oug                | -     | - 2    | ۲      |
| (CLO):             | earning O  | At the end of this course, lea                                   |   | As me   |                    | Level    | Expected        | Expected Attainment (%) | Engineering Knowledge                                       | Problem Analysis       | Design & Development | Analysis, Design, Research | Modern Tool Usage | Society | Envirol<br>Ethics            |                   |                    | Project Mgt. &  | Life Long Learning | PSO   | PSO    | 000    |
| CLO-1:             |  | in the basics of nanobiotec <mark>hnology i</mark> n l           |   |   |                    | 1        |                 | 70                      |   | 1                      |                      | М                          | М                 |         |                              | М                 |                    |                 | Н                  | Н     | Η      | ŀ      |
| CLO-2:             |  | about the role of nanomat <mark>erials as v</mark> e             |   | A 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1   | 100                | 3        |                 | 70                      |   |                        | Н                    |                            | М                 |         |                              | М                 |                    |                 | Н                  | Н     |        | ŀ      |
| CLO-3:             |  | n the knowledge on nanom <mark>edical de</mark> vi               |   |   | A STATE OF         | 2        |                 | 70                      |   |                        |                      |                            | М                 |         |                              | М                 |                    |                 |                    | Н     | Н      |        |
| CLO-4:             |  | about various types of nanobiosensor                             |   |   | 31/17 11           | 2        |                 | 75                      | -   |                        | Н                    |                            | М                 |         |                              | M                 |                    |                 |                    | Н     | Н      |        |
| CLO-5:             |  | ss about toxicity of nanom <mark>aterials a</mark> nd            |   |   |                    | 2        |                 | 70                      |   |                        | Н                    | М                          | M                 |         |                              | M                 |                    |                 |                    | Н     | Н      |        |
| CLO-6:             | Gain i   | knowledge on nanomateria <mark>ls in ther</mark> ap              | eutic applications.   |   |                    | 2        | 80              | 70                      | 1   |                        | Н                    | М                          | М                 |         |                              | М                 | Н                  |                 | Н                  | Η     | Н      | Н      |
| Duratio            | on (hour)  | 9  | 9   |   | 9                  |          |                 |                         |   |                        | 9                    |                            |                   |         |                              |                   |                    | 9               | )                  |       |        | _      |
| S-1                | SLO-1  | Basics of nanobiotechnology in relation to nanomedicine          | Nanomaterials as vehicles for drug delivery                       | nanorobots in me  | edicine            |          |                 | Introd                  | uction-   | - nanc                 | biose                | ensor                      | s                 |         | Na                           | anoma             | terials            | exhik           | biting             | toxic | ity    |        |
| 3-1                | SLO-2  | Scientific principles of nanomedicine                            | Types of Nanomaterials  | nanorobots in na  | anosurgery         |          |                 | Biosei                  | nsing   | Techn                  | ique <mark>s</mark>  | 3                          |                   |         | de                           | pende             | -chemi<br>ent toxi | city            |                    |       | ics    |        |
|                    | SLO-1  | Nanotools – types  | criteria and selection of Nanomaterials                           | nanocameras   |                    |          |                 | unique                  | prop  | erties                 | of na                | nobio                      | osens             | ors     | To                           | xicity            | – carb             | on na           | ınotuk             | es,   |        |        |
| S-2                | SLO-2  | Nanotools – various techniques of detection                      | Sources of Nanomaterials  | Application of na   | anocameras         |          |                 | nanob                   | iosens  | sors                   |                      |                            |                   |         | qu                           | antan             | n dots t           | oxicit          | ty                 |       |        |        |
| S-3                | S-3 SLO-1 Scanning Tunneling microscope Drug loading and release nanochips |  |   | VP. E   | D. FIN             |          |                 |                         | Preparation of nanobiosensors-<br>immobilsation stratergies |                        |                      |                            | Toxicity – Gold   |         |                              | ld nanomaterials, |                    |                 |                    |       |        |        |
|                    | SLO-2  | Atomic Force Microscope  | biodegradation biodegradation                                     | nanoimplants  |                    |          |                 | covale                  | ent <mark>co</mark> r                                       | njug <mark>at</mark> i | ion te               | chnic                      | que               |         | sil                          | ver na            | nopart             | ticles toxicity |                    |       |        |        |
|                    | SLO-1  | Functional biological nanomaterials                              | Nanomaterial clearance  | nanomaterials fo  | or bone and carti  | ilage    |                 | Prepa                   | ration  |                        |                      |                            |                   |         | На                           | andling           | g, stora           | ige ai          | nd dis             | posa  | of of  |        |

applications

skin disorders

Nanogenetics

nanomaterials for vascular applications and

assembled monolayer nanomaterial

detection

Nano biosensors for protein and DNA

Detection methods – optical detection

nanomaterials

of nanoparticles

spills

Remediation in case of nanomaterials

In vitro and in vivo toxicity assessment

nanopolymers

Types of nanomaterials for clearance

SLO-2

SLO-1

S-4

S-5

nanoengines

nanoengines

Functional biological nanomaterials

Nanomaterials and their Production

| Duratio | on (hour) | 9  | 9   | 9   | 9  | 9  |
|---------|-----------|--|---|---|--|--|
|         | SLO-2     | Nanomaterials and their Production                             | Classification of biopolymers                       | nanoparticle-based therapy for genetic diseases           | Detection methods- electronic detection          | Embryonic Toxicity of Nanoparticles                |
| S-6     | SLO-1     | Nanodevices-Quantum Computing                                  | magnetic nanoparticles – preparation and properties | Cell Delivery of Therapeutic Nanoparticles                | In vivo Biosensors                               | quantitative nanostructure-toxicity relationship   |
| 3-0     | SLO-2     | Spintronics, Photonic and fluidic devices                      | magnetic nanoparticles - applications               | nanomaterials for delivery in cells- nerve cell repair    | Nanowire Biosensors                              | Modelling the Toxicity of Nanoparticles            |
| S-7     | SLO-1     | Impact of nanotechnology - Scientific and technical Impacts    | nanotubes, dendrimers                               | Applications of Nanofibers in Tissue Engineering          | Cantilever Biosensors                            | Green Synthesis of Nanoparticles –<br>mechanism    |
| 3-1     | SLO-2     | Environmental Impacts  | Nano immunotherapy                                  | Applications of Nanofibers in Tissue Engineering          | Applications – DNA nanobiosensor                 | Green Synthesis of Nanoparticles –<br>Applications |
| S-8     | SLO-1     | Grand challenges of nanomedicine                               | Nanomaterials for vaccine delivery                  | nanomaterials for stem cells growth                       | Applications – Protein biosensor                 | Nanoparticles: Environmental<br>Problems           |
|         | SLO-2     | Ethical issues   | Types of nanomaterials as vaccine adjuvants         | Stem Cell Tracking with Nanoparticles                     | whole cell biosenso <mark>r applicatio</mark> ns | nanotoxicity regulations                           |
| S-9     | SI ( )-1  | Government Promotion of Advancements in Nanomedicine           |   |   | Nanobiosensor in diagnostics                     | nanomaterials intellectual property perspective    |
| S-8     | SLO-2     | Government Evaluation, Policy and Regulation of Nanotechnology | Nanomaterials as contrast agents in clinical use    | Nanotechnology in the regulation of stem cell<br>behavior | Biosensors in forensic sciences                  | nanomaterials intellectual property perspective    |

| Learning<br>Resources | <ol> <li>Zoraida P. Aguilar. Nanomaterials for Medical Applications (2012), Elsevier Publications</li> <li>Harry F. Tibbals, Medical Nanotechnology and Nanomedicine Perspectives in Nanotechnology (2017), CRC Press</li> </ol> |  |
|-----------------------|--|--|
|                       |  |  |

| Learning Asse | essment                      |                   |          |         |                     |                    |          |         |                        |                    |                    |
|---------------|------------------------------|-------------------|----------|---------|---------------------|--------------------|----------|---------|------------------------|--------------------|--------------------|
|               | Dia a mai'a                  |                   |          | Conti   | nuous Learning Asse | essment (50% weigh | ntage)   |         |                        | Final Evansination | n /EOO/ waishtasa) |
|               | Bloom's<br>Level of Thinking | CLA -             | 1 (10%)  | CLA – : | 2 (15%)             | CLA – 3            | 3 (15%)  | CLA – 4 | 4 (10 <mark>%)#</mark> | Final Examinatio   | n (50% weightage)  |
|               | Level of Thirtking           | Theory            | Practice | Theory  | Practice            | Theory             | Practice | Theory  | Practice               | Theory             | Practice           |
| Level 1       | Remember<br>Understand       | <mark>40 %</mark> | 15 V     | 30%     | ==.                 | 30%                | -        | 30%     | <u> </u>               | 30%                | -                  |
| Level 2       | Apply<br>Analyze             | 40 %              | 1254     | 40%     | - 1//               | 40%                | -        | 40%     |                        | 40%                | -                  |
| Level 3       | Evaluate<br>Create           | 20 %              | .):      | 30%     |                     | 30%                | -197     | 30%     | <b>117</b> -           | 30%                | -                  |
|               | Total                        | 10                | 0 %      | 100     | 0 %                 | 100                | ) %      | 10      | 0 %                    | 10                 | 0 %                |

<sup>#</sup> CLA – 4 can be from any combination of these: Assignments, Seminars, Tech Talks, Mini-Projects, Case-Studies, Self-Study, MOOCs, Certifications, Conf. Paper etc.,

| Course Designers   |   |   |
|--|---|---|
| Experts from Industry  | Experts from Higher Technical Institutions                                      | Internal Experts  |
| 1. Dr. S Natarajan Advisor / Sr. Vice President - R & D; Sami Labs Limited | 1. Prof. Sundara Ramaprabhu, Department of Physics IIT-Madras. ramp@iitm.ac.in; | 1 Dr. Ramkumar K M, SRMIST ramkumar.km@res.srmuniv.ac.in.             |
| Bangalore. mail@samilabs.com   | ramp@physics.iitm.ac.in   | T Dr. Kariikuriai K W, SKWiST Tariikuriar.kiri@res.siriiuriiv.ac.iii. |
| 2. Dr. Gokuladhas Krishnan, Director, Laboratory, World Stem Cell Clinic,  | 2. Prof. Ashok M. Raichur, Department of Materials Engineering IISc, Bangalore. | 2. Dr. N. Selvamururgan, SRMIST selvamun@srmist.edu.in                |
| Chennai, care@worldstemcellclinic.com                                      | amr@materials.iisc.ernet.in   | 2. Dr. N. Selvamururgan, Skiviis i selvamun@simisi.edu.in             |

| Course Code 18BTE416T Course Name TISSUE  | ENGINEERING FOR REGENERATIVE MEDICINE   | Course<br>Category | Е           |                      |                     |                       | P                | rofes         | sional      | Electiv      | /e             |        |              |         | L 3                                     | Γ P  | )     | 3    |
|---|---|--------------------|-------------|----------------------|---------------------|-----------------------|------------------|---------------|-------------|--------------|----------------|--------|--------------|---------|---|------|-------|------|
| Pre-requisite Courses   Nil   Course Offering Department   Biotechonolgy  | Co-requisite Courses Nil Data Book / Codes/Standards                          | Progre<br>Nil      | ssive       | Cours                | es N                | il                    |                  |               |             |              |                |        |              |         |   |      |       |      |
| Course Offering Department Biotechonolgy  | Data Book / Codes/Standards   | IVII               |             |                      |                     |                       |                  |               |             |              |                |        |              |         |   |      |       |      |
| Course Learning Rationale (CLR):  The purpose of learning this course   | is to:  | W/S                | Le          | earnin               | g                   |                       |                  |               | Pr          | ogram        | Learn          | ing Ou | utcome       | es (PL  | .0)                                     |      |       |      |
| CLR-1: Describe the fundamentals of tissue engineering an   |   |                    | 1           | 2                    | 3                   | 1                     | 2                | 3             | 4           | 5 6          | 7              | 8      | 9            | 10 1    | 1 12                                    | 13   | 14    | 15   |
| CLR-2: Express knowledge on clinical applications of tissue   |   |                    |             | 1                    |                     |                       |                  |               | ج           |              | <u> </u>       |        |              |         |   |      |       |      |
| CLR-3: Identify the basic concept behind tissue engineering   |   |                    | (Bloom)     | (%)                  | (%)                 | Φ                     |                  |               | Research    |              | Sustainability |        | بح           |         |   |      |       |      |
|   | <mark>lly generated tissue</mark> s for their tissue engineering applications | 3                  | 300         |                      | ) t                 | gbe                   |                  | jen           | ese         |              | tain           |        | Team Work    |         | ning                                    |      |       |      |
| CLR-5: Discuss the knowledge on 3D-bioprinting  |   |                    | g (E        | enc                  | me                  | - We                  | S                | pdc           | Α,          | _ age        | Sns            |        | E            |         | <u> </u>                                | ,    |       |      |
| CLR-6: Explain the strategies for innovative bioactive resea  | rch on tissue engineering   |                    | kin         | offici               | aju                 | Y P                   | lysi             | Ne Ne         | sign        |              |                |        | ea           | <u></u> | ۳   E                                   |      |       |      |
|   | S PROPERTY.   | 200                | of Thinking | Expected Proficiency | Expected Attainment | Engineering Knowledge | Problem Analysis | & Development | is, Design, | n Tool Usage | غ ا خ          |        | ual & J      |         | roject mgt. & rind<br>ife Long Learning | ,    | 2     | د    |
| Course Learning Outcomes (CLO):  At the end of this course, learners were course, learners were course, learners were course, learners were course. | rill be able to:  | * XIII             | Level       | Expec                |                     | Engine                | Proble           | Design        | Analysis,   | Modern       | Enviro         | Ethics | Individual & | Comm    | riojec<br>Life Lo                       | PSO- | PSO - | PS0- |
| CLO-1: Apply the components of the tissue architecture  |   | 311 11             | 1           | 80                   | 70                  | Н                     | Н                | Н             | М           | N            | 1 M            | Н      | Н            | H I     | H                                       | Н    | Н     | Н    |
| CLO-2: Illustrate the characteristics of stem cells and their r   | elevance in medicine  |                    | 3           | 85                   | 75                  | Н                     | Н                | Н             | М           |              | M              | Н      | Н            | ΗI      | H H                                     | Н    | Н     | Η    |
| CLO-3: Employ an awareness about the properties and bro   | ad applications of biomaterials   | STATE OF STATE     | 2           | 80                   | 70                  | М                     | Н                | Н             | М           | M N          | 1 M            | Н      | Н            | ΗI      | H                                       | Н    | Н     | Н    |
| CLO-4: Demonstrate the role of tissue engineering and ster  |   | A Control of       | 2           |                      | 70                  | Н                     | Н                | Н             | М           |              | М              | Н      | Н            |         | H H                                     | Н    | Н     | Н    |
|   | ials for the construction of functional tissue and organ substi               | itute\s            | 2           | 75                   | 80                  | Н                     | Н                | Н             | М           | N            | 1 M            | Н      | Н            | H I     | H                                       | Н    | Н     | Н    |
| CLO-6: Analyze the testing of biomaterials in vitro and in viv  | 0   |                    | 2           | 80                   | 70                  | Н                     | Н                | Н             | М           | M N          | 1 M            | Н      | Н            | ΗI      | H H                                     | Н    | Н     | Н    |

| Duratio | n (hour) | 9   | 9                                   | 9   | 9   | 9  |
|---------|----------|---|-------------------------------------|---|---|--|
| S-1     | SLO-1    | Cellular Basis of Regeneration  | Tissue types                        | Fundamentals of biomaterials science  | Introduction to Stem Cells                          | Discussion on Stem cell therapy                      |
| 3-1     | SLO-2    | Molecular Basis of Regeneration                                       | Tissue components                   | Concept of biocompatibility   | Different types of Stem cells                       | Discussion on Molecular therapy                      |
| S-2     | SLO-1    | Introduction to tissue engineering                                    | Tissue repair                       | Classes of biomaterials   | Hematopoietic differentiation pathway of stem cells | Therapies for spinal cord injury, muscular dystrophy |
|         | SLO-2    | Basic definitions used tissue engineering                             | Engineering wound healing           | Basic properties of Biomaterials  | Potency of stem cells                               | Orthopedic applications                              |
| S-3     | SLO-1    | Current scope of development in tissue engineering                    | Sequence of events of wound healing | Disinfection and sterilization of biomaterials  | Plasticity of stem cells                            | Stem cells and Gene therapy                          |
| 5-3     | SLO-2    | Use of tissue engineering in therapeutics                             | Three-Dimensional Cell Culture      | Physico-chemical properties of biomaterials:  | Sources of embryonic stem cells                     | Tissue engineering of bones                          |
| S-4     | SLO-1    | Components used in tissue engineering                                 | Organ Culture                       | Mechanical (elasticity, yield stress,<br>ductility, toughness, strength, fatigue,<br>hardness, wear resistance) | Sources of hematopoietic and mesenchymal stem cells | Tissue engineering of cartilages                     |
|         | SLO-2    | Primary cells, cell lines and immortalization of cells                | Organotypic Culture                 | Tribological (friction, wear, lubricity)  | Stem Cell markers, FACS analysis                    | Neural tissue engineering                            |
| S-5     | SLO-1    | Measurement of tissue characteristics, appearance, cellular component | Introduction to Basic wound healing | Morphological and texture, Physical (electrical, optical, magnetic, thermical)                                  | Differentiation of Stem cell systems- Liver         | Skin tissue engineering                              |
| 3-0     | SLO-2    | Cellular fate processes, Cell<br>differentiation, Cell migration      | Applications of growth factors:     | Chemical and biological properties  | Differentiation of neuronal stem cells              | Cardiovascular tissue Engineering                    |

| Duratio | n (hour) | 9  | 9  | 9                                       | 9  | 9   |
|---------|----------|--|--|---|--|---|
| S-6     | SLO-1    | Direct Cell-Cell contact – Cell junctions in tissues                               | Role of VEGF/angiogenesis                                | proteins cells tissues                  | Types & sources of stem cell with characteristics: | Therapeutic applications  |
|         | SLO-2    | Malfunctions in direct cell-cell contact signaling. Response to mechanical stimuli | Different approaches for angiogenesis and its importance | Role of Scaffolds in tissue engineering | Embryonic stem cells and Adult stem cells          | Introduction to the basic principles for Biofabrication and 3D printing |
| S-7     | SLO-1    | Extracellular matrix (ECM) component and their regulation of cell behavior         | Basic properties of the growth factors                   | Biodolymers                             | Comparison between embryonic and adult stem cells  | Methods and materials, for Biofabrication and 3D printing               |
| 3-1     | SLO-2    | Mechanical measurements of the ECM component                                       | Cell-Matrix Interactions                                 | Modifications of Biomaterials           | I Rone marrow primordial derm cells                | Applications of Biofabrication and 3D printing:                         |
| S-8     | SLO-1    | Physical properties of the ECM component   | Cell-Cell Interactions                                   | In vitro testing of biomaterials        | Cancer stem cells                                  | Lab-on-chip, Organ-on-chip  |
| 5-8     | SLO-2    | Cell-ECM interactions – Binding to the ECM   | Telomeres and Self-renewal                               | In vivo testing of biomaterials         | Induced pleuripotent ste <mark>m cells</mark>      | Prosthetics and Implants  |
|         | SLO-1    | Modifying the ECM  | Cell migration   | Role of Nanotechnology                  | Culture of stem cells                              | Innovative bioactive research   |
| S-9     | SLO-2    | IMAITUNCTIONS IN ECM SIGNAUNG  | Control of cell migration in tissue engineering          | ADDITICATIONS OF BIOMATERIALS           | Immunomodulation of mesenchymal stem cell          | Regenerative medicine   |

|           | 1. | Clemens Van Blitterswijk, Jan De Boer, "Tissue Engineering", 2 <sup>nd</sup> Edition - Academic Press, 2014   |
|-----------|----|---|
| Lograina  | 2. | Robert Lanza, Robert Langer, Joseph Vacanti,"Principles of Tissue Engineering", 4th Edition - Academic Press, 2013  |
| Learning  | 3. | John P. Fisher <mark>, Antonio</mark> s G. Mikos, Joseph D. Bronzino, Donald R. Peterson, "Tissue Engineering: Principles and Practices", 1st Edition - CRC Press, 2017                               |
| Resources | 4. | Buddy D. Rate <mark>ner, Allan</mark> S. Hoffman, Frederick J. Schoen, Jack E. Lemons, "Biomaterial Science: An Introduction to Material in Medicine", 3 <sup>rd</sup> edition – Academic Press, 2013 |
|           | 5. | Lijie Grace Zhang, John Fisher, Kam Leong, "3D Bioprinting and Nanotechnology in Tissue Engineering and Regenerative Medicine", 1st Edition - Academic Press, 2015                                    |

| Learning Ass | sessment               |                    |          | A STATE OF    |                    | 1 Tr. 17 200      |          |         |                        |                                   |                    |  |
|--------------|------------------------|--------------------|----------|---------------|--------------------|-------------------|----------|---------|------------------------|-----------------------------------|--------------------|--|
|              | Bloom's                |                    |          | Conti         | nuous Learning Ass | essment (50% weig | htage)   |         |                        | Final Examination                 | n /EOO/ woightogo) |  |
|              | Level of Thinking      | CLA –              | 1 (10%)  | CLA – 2 (15%) |                    | CLA – 3 (15%)     |          | CLA – 4 | 1 (10 <mark>%)#</mark> | Final Examination (50% weightage) |                    |  |
|              | Level of Thinking      | Theory             | Practice | Theory        | Practice           | Theory            | Practice | Theory  | Practice               | Theory                            | Practice           |  |
| Level 1      | Remember<br>Understand | 4 <mark>0 %</mark> | Par 1    | 30%           | - 1/               | 30%               | -        | 30%     | -                      | 30%                               | -                  |  |
| Level 2      | Apply<br>Analyze       | 40 <mark>%</mark>  | - 10     | 40%           | - 1/2              | 40%               | - 7      | 40%     |                        | 40%                               | -                  |  |
| Level 3      | Evaluate<br>Create     | 20 %               | - 5      | 30%           |                    | 30%               |          | 30%     | - 1                    | 30%                               | -                  |  |
|              | Total                  | 10                 | 0 %      | 100           | 0 %                | 10                | 0 %      | 10      | 0 %                    | 10                                | 00 %               |  |

<sup>#</sup> CLA – 4 can be from any combination of these: Assignments, Seminars, Tech Talks, Mini-Projects, Case-Studies, Self-Study, MOOCs, Certifications, Conf. Paper etc.,

| Course Designers   |  |  |
|--|--|--|
| Experts from Industry  | Experts from Higher Technical Institutions       | Internal Experts                         |
| 1. Dr. Harikrishna Varma, SCTIMST, Thiruvananthapuram, India | 1.Dr. Sourabh Ghosh, IIT Delhi, India            | 1.Dr. Koutsav Sarkar, SRMIST             |
| e-mail: head-bmtw@sctimst.ac.in                              | e-mail: sghosh08@textile.iitd.ac.in              | e-mail: koustavm@srmist.edu.in           |
| 2. Dr. Dipak Datta, CDRI, Lucknow, India                     | 2.Dr. Rathindranath Baral, CNCI, Kolkata., India | 2. Dr. N. Selvamururgan, SRMIST          |
| e-mail: dipak.datta@cdri.res.in                              | e-mail: baralrathin@hotmail.com                  | e-mail: selvamurugan.n@ktr.srmuniv.ac.in |

| Course             | 1 188164171                     | Course   |                              | BIOREACTORS IN TISSUE ENGINEER   | RING  | Course             | Е                        |  |         |                       | Pr               | ofess                | ional E           | lectiv            | /e                           |                |                        |                   |                       | T                     | Р       | C<br>3 |
|--------------------|---------------------------------|--|------------------------------|--|---|--------------------|--------------------------|--|---------|-----------------------|------------------|----------------------|-------------------|-------------------|------------------------------|----------------|------------------------|-------------------|-----------------------|-----------------------|---------|--------|
| Code               |                                 | Name   |                              |  |   | Category           |                          |  |         |                       |                  |                      |                   |                   |                              |                |                        |                   | 3                     | 0                     | 0       |        |
| F                  | Pre-requisite Course            | s Nil  |                              | Co-requisite Courses Nil   |   | Progres            | sive C                   | ourses /   | Vil     |                       |                  |                      |                   |                   |                              |                |                        |                   |                       |                       |         |        |
|                    | Offering Department             | Biotechono   | olav                         |  | / Codes/Standards   |                    |                          |  |         |                       |                  |                      |                   |                   |                              |                |                        |                   |                       |                       |         |        |
|                    |                                 |  | - 37                         |  | - 11 11 11 11 11  | P                  |                          |  |         |                       |                  |                      |                   |                   |                              |                |                        |                   |                       |                       |         |        |
| Course L<br>(CLR): | earning Rationale               | The purpose of learni  | ing this cours               | se is to:  | AL.N.   | 4/30               | Le                       | arning   |         |                       |                  |                      | Prog              | ram l             | Learnii                      | ng O           | utcom                  | es (Pl            | _O)                   |                       |         |        |
| CLR-1:             | Provide the basi                | c concepts of tissue e   | engineering a                | <mark>and bioreact</mark> ors from the perspective of en   | gineers.  |                    | 1                        | 2 3  |         | 1                     | 2                | 3 4                  | 1 5               | 6                 | 7                            | 8              | 9                      | 10 1              | 11 1                  | 2 1                   | 3 14    | 15     |
| CLR-2:             | Identify the 3D-                | culture of stem cells  | and orga <mark>nog</mark>    | enesis   |   |                    |                          |  |         |                       |                  | ي ا                  |                   |                   | ity                          |                |                        |                   |                       |                       |         |        |
| CLR-3:             |                                 |  |                              | s of different disease conditions.   | THE STATE OF  |                    | Ê                        | 9 9  |         | a)                    |                  | 3                    | 2                 |                   | abil                         |                | ~                      |                   |                       |                       |         |        |
| CLR-4:             |                                 | ty and efficacy of biol  |                              |  | and an Administra   |                    | 8                        | 3 (9)  | 1       | gg                    |                  |                      | מא                |                   | aji                          |                | Vor                    |                   | වූ                    |                       |         |        |
| CLR-5:             |                                 | tegies for designing c   |                              |  | N. O. Philip  |                    | 9                        | ner  |         | Ne Ne                 | S                |                      | age ,             | a                 | nst                          |                | ٦<br>ا                 |                   | nar<br>S              | 20                    |         |        |
| CLR-6:             | Identify the usa                | ges of bioreactors and   | d <mark>their adv</mark> an  | tages in tissue engineering  | 11.0  | ( - +              | king                     | ainr   |         | Ş                     | İ                | i e                  | Us                | Ē                 | ∞ ∞                          |                | ea                     | ا S               | χ .                   |                       |         |        |
|                    |                                 |  |                              |  | San Park  | ded in             | of Thin                  | ed Pro   | ıĭ      | ering I               | n Ana            | & De                 | Tool r            | / & Cu            | nment                        |                | Jal & J                | unicati           | Mgt.                  |                       | -2      | - 3    |
| Course L<br>(CLO): | earning Outcomes                | At the end of this <mark>cou</mark>  | rse, learners                | will be able to:   |   | -X+1               | evel of Thinking (Bloom) | Expected Proficiency (%) Expected Attainment (%) |         | Engineering Knowledge | Problem Analysis | Design & Development | Modern Tool Usage | Society & Culture | Environment & Sustainability | Ethics         | Individual & Team Work | Communication     | roject Mgt. & Finance | LIIE LUIIG LEAIIIIIIG | PSO -   | PSO-   |
| CLO-1 :            | Apply the basic                 | understanding of larg  | g <mark>e sc</mark> ale prod | uction stem cells in bioreactors   | The state of  |                    | 1                        | 85 85  |         | Н                     |                  | - F                  | 1 -               | -                 | -                            | Н              | -                      |                   |                       | 1 F                   | I H     | H      |
| CLO-2:             |                                 | culture systems and  |                              |  |   |                    | 2                        | 80 80  |         | М                     | -                |                      | 1 -               | -                 | -                            | М              | -                      | -                 |                       | 1 F                   |         | Н      |
| CLO-3:             |                                 | eactor based str <mark>ategie</mark>   |                              |  | 25-27 5-15  | The state of       | 2                        | 85 80  |         | Н                     |                  | - 1                  |                   | -                 | -                            | М              | -                      | -                 |                       | 1 F                   |         | Н      |
| CLO-4:             |                                 |  |                              | nent of drug development and therapy   | W. J. W. J. C.  | Same British       |                          | 80 85  |         | М                     | -                | - 1                  | 1 -               | -                 | -                            | М              | -                      | -                 | - F                   | 1 F                   |         |        |
| CLO-5:             |                                 | scale production of  |                              |  |   | AND STREET         |                          | 80 80  |         | Н                     | -                | - I                  | 1 -               | -                 | -                            | М              | -                      | -                 |                       | 1 F                   |         | Н      |
| CLO-6:             | Apply the clinica               | l applications of <mark>biore</mark>   | actors                       | - U MAN ROTATION   |   |                    | 3                        | 85 85  |         | Н                     | -                | -   <i>F</i>         | 1 -               | -                 | -                            | М              | -                      | -                 | - <i>F</i>            | 1 F                   | Н       | Н      |
| Donation           | . (1                            |  |                              |  |   | ^                  | -                        |  | -       |                       | _                |                      |                   |                   |                              |                |                        |                   | ^                     |                       |         |        |
| Duration           |                                 | 9  |                              | 9  |   | 9                  | 3                        | D/   |         |                       | 9                | - f D!-              |                   | -1-               |                              |                |                        |                   | 9                     |                       |         |        |
| S-1                |                                 | n to tissue engin <mark>eerin</mark><br>evelopment; Cell as t <mark>l</mark> |                              | Bioreactors in Tissue Engineering;<br>Tissue formation in Bioreactor systems -<br>Generation of functional tissues     | Bioreacto <mark>rs- Link</mark> be vivo studie <mark>s</mark>   | etween in vitro ar | nd in                    | Biomat<br>,Surfac<br>proper                      | e, bu   |                       |                  |                      |                   |                   |                              |                | pplica<br>r thera      |                   | - Sten                | n cell                | therap  | у,     |
|                    | SLO-1 cell number               | rs and growth rates  |                              | Principles of functional tissue  |   |                    |                          |  |         |                       |                  |                      |                   |                   |                              |                |                        |                   |                       |                       |         |        |
| S-2                | measurem                        | ent of cell characteris<br>y, cell viability, motility                       |                              | engineering – Functional tissue<br>engineering and role of Biomechanics in<br>a 3D environment                         | Novel approaches ir for stem cell seeding bioscaffolds          |                    |                          | Scaffol<br>Biomat<br>materia                     | terials |                       |                  |                      |                   |                   |                              | tro oi<br>ases |                        | genes             | is, Ne                | urode                 | egenrai | ive    |
|                    | CI O 1                          | al Danies for Nestriti-  | and Cray th                  | Ex vivo engineering of living tissues –  | Bioreactor-based str  | rategies with      |                          |  | 100     | 4                     |                  |                      |                   |                   |                              |                |                        |                   |                       |                       |         |        |
| S-3                | of living Ce                    | al Basics for Nutrition<br>Ils - Measurement of<br>tics, appearance, tiss    | tissue                       | generation of mammalian tissue<br>equivalents in vitro – Bioreactors role in<br>tissue engineering of Cartilage        | reconstructive applic<br>(Vascularized compallotransplantation) | cations of osite   | HV.                      | Biopoly<br>biomat                                |         |                       |                  |                      | Biomate           | erials            |                              |                |                        | ıry, he<br>ulcers |                       | sease                 | , diabe | tes,   |
|                    |                                 | amics and Cell migra   |                              | Cardiovascular tissue (Cardiomyocytes,   | Stem cell cultivation   | in scaffold-biore  | eactor                   | Role of  | f Nand  | techn                 | oloav            | Sens                 | ing an            | d                 | mus                          | cular          | dvstr                  | ophy,             | ortho                 | pedic                 |         |        |
| S-4                |                                 | t, ECM component, ments and physical pro                                     |                              | valves), Vascular tissue,<br>musculoskeletal tissue and Skin –Bone   | systems; Physiologic  |                    | 2 30.01                  | Autom  |         |                       |                  |                      |                   | •                 |                              | icatio         |                        | -,,,,             | 5, 11, 10             |                       |         |        |
|                    | SLO-1                           |  |                              | microfluidic devices and   |   |                    |                          |  |         |                       |                  |                      |                   |                   |                              |                |                        |                   |                       |                       |         |        |
| S-5                | Complexity<br>SLO-2 system; Bid | and organization of toreactors; History of E                                 | the Organ<br>Bioreactors     | microbioreactors for stem cell micro<br>environment – Perfusion bioreactors for<br>granulocyte progenitor cell growth; | Understanding Meclorgans and function                           |                    | n                        | Biorea<br>testing                                |         |                       |                  |                      | and im            | olant             | Ster                         | n cel          | ls and                 | Gene              | thera                 | ару                   |         |        |

environment – Perfusion bioreactors for granulocyte progenitor cell growth; Bioreactor stimulation

| Duration (hour)       | 9   | 9  | 9                                       | 9  | 9  |
|-----------------------|---|--|---|--|--|
| SLO-1<br>S-6<br>SLO-2 | Types of Bioreactors – Perfusion Bioreactors<br>for 3D cultures, Spinner Flask Bioreactor | of Bioreactors – Temperature, pH,  | ISCATIONS AND CONSTRUCTS FOR BIOREACTOR |  | Physiological models, tissue engineering therapies, product characterization     |
| S-7 SLO-1             | Rotating Wall Bioreactor, Compression<br>Bioreactor, Strain Bioreactor                    | Nutrient Transport, Waste Removal; Predicting Mechanical Functionality of Engineered Tissues |   | Large-scale bioreactor cultivation of pluripotent stem cells | Components, safety, efficacy. Preservation – freezing and drying                 |
| S-8 SLO-2             | static culture, stem cell cultivation in scaffold<br>Bioreactor systems                   | Inioreactors- Livingen tension   |   | Engineering of functional bone tissue from human stem cells  | Patent protection and regulation of of tissue-engineered products,ethical issues |
| S-9 SLO-2             | Hydrostatic pressure Bioreactor, Flow<br>Perfusion Bioreactor, Combined Bioreactor        | forces Floatrical stimulation Flow sheer   | properties, Cell-Matrix& Cell-Cell      |  | Emerging trends in clinically relevant<br>bioreactor design and future direction |

|               | 1.         | Molecular and cellular tissue engineering (The biomedical hand book, 4th edition), Joseph D. Bronzino and Donald R. Peterson, 2015       |  |
|---------------|------------|--|--|
| Learning      | 2.         | Biomaterials sci <mark>ence and T</mark> issue engineering: Principles and methods (Cambridge IISc series) - Bikramjit Basu, 2017        |  |
| Resources     | 3.         | 3D Cell culture: Fundamental and applications in tissue engineering and regenerative medicine, Ranjana C. Dutta and Aroop K Dutta, 2018. |  |
|               | 4.         | Raphael Gorod <mark>etsky, Richard Schäfer. Cambridge: RSC publishing, c2011.Stem cell based tissue repair.</mark>                       |  |
| SLO – Session | n Learning | Outcome[[  |  |
|               |            |  |  |

## SLO – Session Learning Outcome[[

| Learning Ass | essment                |  |               |        |               |        |               |        |                                   |                                   |          |  |
|--------------|------------------------|--|---------------|--------|---------------|--------|---------------|--------|-----------------------------------|-----------------------------------|----------|--|
|              | Bloom's                | Continuous Learning Assessment (50% weightage) |               |        |               |        |               |        | Final Examination (50% weightage) |                                   |          |  |
|              |                        | CLA –  | CLA – 1 (10%) |        | CLA – 2 (15%) |        | CLA – 3 (15%) |        | 1 (10%) <mark>#</mark>            | Final Examination (50% weightage) |          |  |
|              | Level of Thinking      | Theory   | Practice      | Theory | Practice      | Theory | Practice      | Theory | Practice                          | Theory                            | Practice |  |
| Level 1      | Remember<br>Understand | 4 <mark>0 %</mark>                             | 551           | 30%    |               | 30%    | _             | 30%    |                                   | 30%                               | -        |  |
| Level 2      | Apply<br>Analyze       | 40 <mark>%</mark>                              | 1200          | 40%    | - 4/          | 40%    | - 1           | 40%    |                                   | 40%                               | -        |  |
| Level 3      | Evaluate<br>Create     | 20 %   | 1             | 30%    |               | 30%    | - 11/2        | 30%    |                                   | 30%                               | -        |  |
|              | Total                  | 10   | 0 %           | 100 %  |               | 100 %  |               | 10     | 0 %                               | 100 %                             |          |  |

# CLA – 4 can be from any combination of these: Assignments, Seminars, Tech Talks, Mini-Projects, Case-Studies, Self-Study, MOOCs, Certifications, Conf. Paper etc.,

| Course Designers   | District Control of the Control of t |   |
|--|--|---|
| Experts from Industry  | Experts from Higher Technical Institutions   | Internal Experts                                    |
| 1. Mr.J.B. Vijayakumar BioArtis Life Sciences Pvt. Ltd. email: contact@bioartis.in | 1. Dr. C. Parthasarathy, University of Oklahoma Parathasarathy-<br>chandrakesan@ouhsc.edu  | 1. Dr. P. Kanagaraj, SRMIST kanagaraj@srmist.edu.in |
| 2. Dr. Sudarshan Reddy Oncosimis Biotech Pvt. Ltd. email: info@oncosimis.com       | 2. Dr. R. llangovan , University of Madras Ilnagovan2000@yahoo.com   | 2. Dr. R. Satish, SRMIST satishr@srmisst.edu.in     |

| Cours<br>Code      |            | 18BTE418T Course<br>Name  | DEVELOPMENTAL BIOLOGY IN TISSI                | UE ENGINEERING   | Course<br>Category | E  | Professional Elective  | L T P C 3 0 0 3   |  |  |
|--------------------|------------|---|---|--|--------------------|--|--|---|--|--|
|                    |            | site Courses Nil Department Biotechonolgy   | Co-requisite Courses Nil Data                 | a Book / Codes/Standards   | Progre             | essive Courses Nil   |  |   |  |  |
| Course L<br>(CLR): | _earning l | Rationale The purpose of learning th  | is course is to:                              |  | 100                | Learning   | Program Lea  | arning Outcomes (PLO)   |  |  |
| CLR-1:             | Desc       | cribe the biology of animal embryogenes   | sis and development                           |  |                    | 1 2 3  | 1 2 3 4 5 6  | 7   8   9   10   11   12   13   14   15   |  |  |
| CLR-2:             |            | ognize cell-cell interactions from the con  |   |  |                    |  |  |   |  |  |
| CLR-3:             |            |   | niches in organogenesis and tissue rege       | neration.  |                    | Ê 0 0  |  |   |  |  |
| CLR-4:             |            | uss the biology of organogenesis.   | y y   |  |                    | 000 / (%)  | gs land  |   |  |  |
| CLR-5:             | Sum        | marize the concepts of tissue an <mark>d orgar</mark>                             | n regeneration.                               |  |                    | (B)  | Me Ne Ne Ne Ne Ne Ne Ne Ne Ne Ne Ne Ne Ne  | ust:  |  |  |
| CLR-6:             | Appr       | aise the biology of ageing.   |   |  |                    | ing<br>ficie   | ysisysisysisysisysisysisysisysisysisysi  | S     Ba   D   Ba   Ba   Ba   Ba   Ba   B   |  |  |
|                    | 1 11       | <i>y</i>  |   |  |                    | Level of Thinking (Bloom)  Expected Proficiency (%)  Expected Attainment (%) | Engineering Knowledge Problem Analysis  Design & Development  Analysis, Design, Research Modern Tool Usage Society & Culture | Ethics Individual & Team Work Communication Project Mgt. & Finance Life Long Learning PSO - 1 PSO - 2 PSO - 3 |  |  |
| Course L<br>(CLO): | _earning ( | Outcomes At the end of this course, le  | earners will be able to:                      | 30 A 20 12   |                    | Expec  | Engine<br>Proble<br>Design<br>Analys<br>Moder<br>Societ  | Ethics Individu Commu Project Life Lor PSO PSO  |  |  |
| CLO-1:             |            | pret the basics of embryolog <mark>y and ce</mark> ll s                           |   |  |                    | 1 80 70  | M H  | M   |  |  |
| CLO-2:             |            | cribe the types of cell specif <mark>ication an</mark> d c                        |   |  | 100                | 2 80 75  | M H  | M M H H H H   |  |  |
| CLO-3:             |            | aise the role of stem cells i <mark>n organ d</mark> eve                          | elopment.                                     | TO STEEL STEEL STEEL   | A 15/31            | 2 80 70  | M H  | M M H H H H   |  |  |
| CLO-4:             |            | y the genetics behind organ <mark>ogenesis</mark> .                               | F-1 F-1 GU-10                                 | Reference a  |                    | 2 80 75  | M H  | M M H H H H   |  |  |
| CLO-5:             |            | tify the developmental biolo <mark>gy conce</mark> pts                            | behind tissue regeneration.                   |  |                    | 2 80 70  | M H  | M M H H H H   |  |  |
| CLO-6:             | Anal       | yze the genetics of ageing.   |   | Marie Control  |                    | 2 80 75  | M H  | M M H H H H   |  |  |
|                    |            |   |   |  |                    |  |  |   |  |  |
| Dura<br>(ho        |            | 9   | 9   | 9  |                    |  | 9  | 9   |  |  |
| S-1                |            | Differential cell affinity  | Cell commitment                               | Introduction to germ layers                                      |                    | Overview of kidn   |  | Ageing  |  |  |
|                    |            | Cadherins and cell adhesion   | Levels of cell commitment                     | Ectoderm - Derivatives   |                    | Development of   |  | Genes and ageing  |  |  |
| S-2                |            | Adhesion dynamics   | Cell specification                            | Endoderm - Derivatives   |                    |  | orocal interactions  | DNA repair enzymes in ageing  |  |  |
|                    |            | Cell migration  | Autonomous specification                      | Mesoderm - Derivatives   |                    |  | eciprocal ind <mark>uction</mark>  | Insulin signaling pathway in ageing   |  |  |
| S-3                |            | Induction and competence  | Conditional specification                     | Neurulation  |                    | Lateral plate me   |  | Stem cells and ageing   |  |  |
|                    |            | Cell-cell interactions  | Morphogen gradients                           | Formation of the neural tube                                     |                    |  | ateral plat <mark>e mesoderm</mark>  | Senescence  |  |  |
| S-4                |            | Paracrine factors   | Syncytial specification                       | Patterning of neural tube – A                                    |                    | Vasculogenesis   | A h land was a la  | Epimorphic regeneration in Salamander   |  |  |
|                    | SLO-2      | Signal transduction cascades The RTK pathway, the Jak-STAT pathway in development | Cell fate determination The stem cell concept | Patterning of neural tube – D  Neural crest cells - Introduction |                    | Initial formation of Angiogenesis  | or blood vessels   | Blastema formation  Morphallactic regeneration in Hydra   |  |  |
| S-5                | SLO-2      | The Wnt pathway and TGF-β pathway in development                                  | Embryonic stem cells in developmet            | Regionalization of neural crea                                   | st cells           | Sprouting of bloc  | od vessels   | Activation gradients  |  |  |
|                    |            | Juxtacrine signaling in development   | Adult stem cells in developmet                | Paraxial mesoderm  |                    | Hematopoiesis  |  | Regeneration in mammalian liver   |  |  |
| S-6                |            | The Notch pathway in development  | Stem cell potency                             | Specification of paraxial mes                                    | oderm              | Sites of hematop   | oiesis   | Compensatory regeneration   |  |  |
| 6.7                |            | Cell patterning   | Pluripotent stem cells in development         | Cell types of somites  |                    | Hematopoietic si   |  | Axonal regeneration   |  |  |
| S-7                |            | Maintenance of differentiated state   | Multipotent stem cells in development         | Hox genes and cell fate spec                                     | ificity            | HSC niche  | 1 /  | Regeneration of neural tissues  |  |  |
| S-8                |            | Developmental signals from ECM  | Stem cell niches                              | Somitogenesis  | 7                  | The Digestive tu   | be – Overview  | Regeneration of zebrafish fin tissue  |  |  |

|     | ation<br>our) | 9                                      | 9                                     | 9                                      | 9                               | 9  |
|-----|---------------|--|---------------------------------------|--|---------------------------------|--|
|     | SLO-2         | Integrin signaling in development      | Regulatory microenvironments          | Clock and wave front model             | Specification of gut tissue     | Molecular control of fin regeneration        |
| 6.0 | 1 SLO-1       | Cell-Cell communication in development | Mesenchymal stem cells in development | Intermediate mesoderm                  | The Respiratory tube – Overview | Heart regeneration in zebrafish              |
| S-9 | SLO-2         | Epithelial-mesenchymal transition      | Organogenesis – An introduction       | Specification of intermediate mesoderm | ronnanon or resoliatory inde    | Cardiomyocyte plasticity during regeneration |

| Learning<br>Resources | 1.<br>2.<br>3. | Developmental Biology (2016): <mark>Scott F. Gilbe</mark> rt and Michael J.F. Barresi, Eleventh Edition, Oxford University Press, Inc.<br>Essential Developmental Bio <mark>logy (2012):</mark> J.M.W. Slack, Third Edition, Wiley-Blackwell Publishers<br>Principles of Development ( <mark>2015): Lew</mark> is Wolpert, Cheryll Tickle and Alfonso Arias, Fifth Edition, Oxford Publishers, Inc. |  |
|-----------------------|----------------|---|--|
|                       |                |   |  |

| Learning Ass | essment                   |                    |          | 100     | 18.19             |                     |          |         |          |                                  |                  |  |  |  |
|--------------|---------------------------|--------------------|----------|---------|-------------------|---------------------|----------|---------|----------|----------------------------------|------------------|--|--|--|
|              | Dloom's                   |                    |          | Contin  | uous Learning Ass | sessment (50% weigh | ntage)   | F 11    |          | Final Evamination                | (E00/ woightage) |  |  |  |
|              | Bloom's Level of Thinking | CLA –              | 1 (10%)  | CLA – 2 | (15%)             | CLA – C             | 3 (15%)  | CLA – 4 | 4 (10%)# | Final Examination (50% weightage |                  |  |  |  |
|              | Level of Thinking         | Theory             | Practice | Theory  | Practice          | Theory              | Practice | Theory  | Practice | Theory                           | Practice         |  |  |  |
| Level 1      | Remember<br>Understand    | 4 <mark>0 %</mark> | 1        | 30%     | how high          | 30%                 |          | 30%     | -        | 30%                              | -                |  |  |  |
| Level 2      | Apply<br>Analyze          | 40 %               |          | 40%     | 160               | 40%                 | E 3700   | 40%     |          | 40%                              | -                |  |  |  |
| Level 3      | Evaluate<br>Create        | 20 %               | 3:10     | 30%     |                   | 30%                 | No.      | 30%     | -        | 30%                              | -                |  |  |  |
|              | Total                     | 10                 | 0 %      | 100     | %                 | 100                 | ) %      | 10      | 0 %      | 10                               | 0 %              |  |  |  |

<sup>#</sup> CLA – 4 can be from any combination of these: Assignments, Seminars, Tech Talks, Mini-Projects, Case-Studies, Self-Study, MOOCs, Certifications, Conf. Paper etc.,

| Course Designers   |   |  |
|--|---|--|
| Experts from Industry                                    | Experts from Higher Technical Institutions        | Internal Experts                                   |
| 1. Dr. A. Premkumar, Ph.D., GVK Biosciences, Hyderabad   | 1. Dr. K. Subramaniam, Ph.D., IIT Madras, Chennai | 1. Dr. S. Kira <mark>nkumar, P</mark> h.D., SRMIST |
| aprem70@yahoo.com  | subbu@iitm.ac.in                                  | kirankus <mark>@srmist.ed</mark> u.in              |
| 2. Dr. M.C. Raja, Ph.D., Genotypic Technology, Bangalore | 2. Dr. Naren Ramanan, Ph.D., IISc, Bangalore      | 2. Dr. R. S <mark>atish, Ph.D</mark> ., SRMIST     |
| genotypic@hotmail.com                                    | naren@cns.iisc.ernet.in                           | satishr <mark>@srmist.e</mark> du.in               |

| Cours   |                       | 18BTE419T Course Name ADVANCE  | ED IMMUNOLOGY AND VASCULAR TISS  | UE ENGINEERING Course Category                                   | Е                        |  |   | Profess              | ional El          | ective            | )                                      |                                    |            | T<br>0                        | P C 0 3            |
|---|-----------------------|--|--|--|--------------------------|--|---|----------------------|-------------------|-------------------|--|------------------------------------|------------|-------------------------------|--------------------|
|   |                       | isite Courses Nil Department Biotechonolgy   | Co-requisite Courses Nil Data Book   | / Codes/Standards  | essive                   | Courses N  | Nil                                       |                      |                   |                   |  |                                    |            |                               |                    |
| Course (CLR):                                     | Learning I            | Rationale The purpose of learning this cou   | ırse is to:  | TINC!  | Lea                      | arning   |   |                      | Progr             | am Le             | earning Ou                             | tcomes                             | (PLO)      |                               |                    |
| CLR-1 :<br>CLR-2 :<br>CLR-3 :<br>CLR-4:<br>CLR-5: | Enric<br>Reco<br>Lear | ride the most recent advancement in the fiel<br>ch with knowledge on immunobiology and in<br>ognizing the issue of shortage of organ donc<br>ming of various treating methods for injury a<br>erstanding the potentials of immunotherapy | nmune responses related to regeneration a<br>ors as major limitations in the transplantation<br>ord the significance of vascular engineering | nd transplants   |                          | sincy (%) 2                                      | 1 2 espelv                                | Sment Specials       | ממוכוו            | 6                 | 7 8 8                                  | Team Work © Ition                  | Finance 11 |                               | 14 15              |
| CLR-6:  | Train                 | Outcomes At the end of this course, learne   | explore strategies for stem cell therapy   |  | evel of Thinking (Bloom) | Expected Proficiency (%) Expected Attainment (%) | Engineering Knowledge<br>Problem Analysis | Design & Development | Modern Tool Usage | Society & Culture | Environment & Sustainability<br>Ethics | Individual & Tear<br>Communication | Jt. &      | Life Long Learning<br>PSO - 1 | PSO - 2<br>PSO - 3 |
| (CLO):<br>CLO-1 :<br>CLO-2 :<br>CLO-3 :           | Gain                  | uire knowledge on the latest tools for diagno<br>knowledge in molecular an <mark>d immuno</mark> logica<br>to appreciate the relevance of clinical immu  | l basis of diagnosis   |  | 2 2                      | 80 75<br>85 80<br>80 75                          | Ш <u>а.</u><br>Н -<br>Н -                 | M L M L              | · · ·             | -<br>-<br>-       | <br>- M                                | <u>- H</u><br>- H                  | -          | <u>М</u> Н<br>Н Н<br>Н Н      | H   H  <br>  H   H |
| CLO-4 :<br>CLO-5 :<br>CLO-6 :                     | Acqu<br>Acqu          | uire knowledge on vascular <mark>biology a</mark> nd vasc<br>uire knowledge on host vs G <mark>raft rejec</mark> tion an<br>lerstand the challenges beh <mark>ind succe</mark> ssful tr  | cular tissue engineering<br>d the significance of immune system in this  |  | 2 2                      | 80 75<br>85 80<br>80 75                          | M -<br>H -<br>H -                         | M L M L              |                   | -                 | <br><br>- H                            | - H<br>- H                         | -          | М Н<br>М Н<br>М Н             | H H<br>H H         |
| Duratio   | n (hour)              | 9  | 9  | 9  |                          | 45   | 9   |                      |                   |                   |  |                                    | 9          |                               |                    |
| 0.4   | SLO-1                 | Organs and Cells of the Imm <mark>une Sys</mark> tem –<br>Primary and Secondary Lymphoid Organs  | The Complement Cascades  | Immunobiology of Transplantation                                 |                          | Stem cells -                                     | – <mark>types and</mark>                  | l source             | s                 |                   | Vascular                               | system                             |            |                               |                    |
| S-1   | SLO-2                 | Mucosal and Cutaneous associated lymphoid tissue. (MALT & CALT)  | The role of Major Histocompatibility<br>Complex in Immune Response   | Cells and Factors involved in Transp<br>Acceptance vs. Rejection | plant                    | Stem cells i                                     |   |                      |                   |                   | Mechanis                               | ms of blo                          | ood ves    | sel fori                      | mation             |
| S-2   | SLO-1                 | Mucosal Immunity   | Autoimmune disease   | Importance of Adaptive immunity ful<br>in Graft Recognition      |                          | Stem cell T<br>Neurodeger<br>injury              |   |                      |                   |                   | Hemangio                               | genesis                            | ;          |                               |                    |
|   | SLO-2                 | Antigens – immunogens, haptens   | erpersonal compatibility Importance of Innate immunity functi<br>Graft Recognition   |  |                          | Stem cell Therapy for Olcers,                    |   |                      |                   |                   | Lymphangiogenesis                      |                                    |            |                               |                    |
| S-3   | SLO-1                 | Antibody Structure   | T lymphocyte recognition restrictions  | Molecular Aspects of Acute and Chi<br>Rejection                  |                          | Stem cell Ti<br>diseases, S                      |   | <mark>injur</mark> y |                   |                   | Angiogen                               | ic factors                         | s and th   | eir rece                      | eptors             |
| 1 0-0   | 1                     | II   |  | TI 1:1 : 11 : CO (1)/  |                          | 1  |   |                      | 1.0               |                   |  |                                    |            |                               |                    |

Embryonic stem cells

Disease

The biological basis of Graft Verses Host

Expression of histocompatibility antigens

Immunological considerations and the potential barriers for Stem cell therapy

Killer Immunoglobulin like receptors in

Immunosuppressive therapy

transplantation

Clinical transplantation, Immune tolerance,

Inflammation

Angiogenesis

Tissue injury response

S-4

SLO-2 Antibody Function

SLO-2 B cell maturation

SLO-1 Generation of antibody diversity

Evolutionary diversity

Autoimmune disorders

Kinetics of immune response,

Hypersensitivity and their types

Basis of self - non-self discrimination and

| Duration | n (hour) | 9  | 9   | 9   | 9   | 9  |
|----------|----------|--|---|---|---|--|
| S-5      | SLO-1    | B cell activation and differentiation            | HLA typing  | T-cell response against u/dhESCs measured by functional assays    | Significance of acellular grafts in regeneration                  | Importance of Vascularization in Tissue<br>Engineering                   |
| 3-0      | SLO-2    | T-cell maturation activation and differentiation | Immunological considerations for Tissue Engineering | Interaction of natural killer cells with hESCs                    | Mast cells in allograft rejection                                 | Angiogenesis and Vascular Remodeling                                     |
| S-6      | SLO-1    | T-cell receptors                                 | Stem cell Banking                                   | Generation of patient-specific isogenic hESC lines                | Graft-versus-host disease   | Organization and Patterning of Endothelia<br>Cells in Engineered Tissues |
| 5-0      | SLO-2    | Functional T Cell Subsets                        | Cell-cell co-operation                              | Immunological Aspects of Allogeneic mesenchymal stem cell therapy | Mouse models of graft-versus-host disease                         | Models for studying angiogenesis   |
| S-7      | SLO-1    | Cell-mediated immune responses                   | Hapten-carrier system                               | Autologous Mesenchymal Stem Cell<br>Therapies                     | Cytokines in Graft-versus-Host Disease                            | Blood Capillary analogues  |
| 3-1      | SLO-2    | ADCC   | Types of Tissue injury                              | CML of Haematopoietic stem cells                                  | Potential barriers to engraftment of human pluripotent stem cells | Role of Vascular endothelial growth factors on Angiogenesis              |
|          | SLO-1    | Cytokines-properties, and receptors              | Tissue injury and immune responses                  | allogenic transplantation of HSC                                  | Cancer Stem Cells in Solid Tumors                                 | Signaling pathways of Angiogenesis                                       |
| S-8      | SLO-2    | Cytokines and therapeutic uses                   | Immunoprophylaxis                                   | Graft verses Leukemia   | Immunologic targeting of cancer stem cell population              | Micropatterning approaches to microvessel creation                       |
|          | SLO-1    | Antigen processing                               | Immunotherapy                                       | Targeting Malignant progenitors                                   | Opportunities in Engineered tissue grafts                         | Stem cells for vascular regeneration                                     |
| S-9      | SLO-2    | Antigen presenting cells                         | Current status of Immunotherapy                     | Recent Advances in transplantation                                | Opportunities in Engineered tissue grafts                         | Stem cells and scaffolds for vascular regeneration                       |

|           | 1   |   |  |
|-----------|-----|---|--|
|           | 1.  | The Immunolog <mark>ical Barri</mark> ers to Regenerative Medicine. Editors-Paul J. Fairchild, Humana Press 2013                      |  |
| Learning  | 2.  | Stem Cell Tran <mark>splantatio</mark> n, edited by Carlos López-Larrea, Antonio López Vázquez, Beatriz Suárez Álvarez. Springer 2016 |  |
|           | T 7 |   |  |
| Resources | 3.  | Vascularization: Regenerative Medicine and Tissue Engineering, edited by Eric M. Brey, CRC Press 2017                                 |  |
|           | 4.  | Kuby Immunolo <mark>gy. Thom</mark> as J. Kindt, Richard A. Goldsby, W.H.Freeman, 2007.   |  |
| L         |     |   |  |
|           |     |   |  |

| Learning Ass | essment                |        |          |        |                    |                     |          |        |                        |                   |                    |
|--------------|------------------------|--------|----------|--------|--------------------|---------------------|----------|--------|------------------------|-------------------|--------------------|
|              | Bloom's                |        |          | Conti  | nuous Learning Ass | sessment (50% weigh | ghtage)  |        |                        | Final Evamination | n (50% weightage)  |
| İ            | Level of Thinking      | CLA –  | 1 (10%)  | CLA –  | 2 (15%)            | CLA -               | 3 (15%)  | CLA -  | 4 (10% <mark>)#</mark> |                   | in (50% weightage) |
|              | Level of Thirtking     | Theory | Practice | Theory | Practice           | Theory              | Practice | Theory | Practice               | Theory            | Practice           |
| Level 1      | Remember<br>Understand | 40 %   | 1254     | 30%    | - 4/               | 30%                 | - 10     | 30%    |                        | 30%               | -                  |
| Level 2      | Apply<br>Analyze       | 40 %   | - 1      | 40%    |                    | 40%                 | - 17     | 40%    | 211-                   | 40%               | -                  |
| Level 3      | Evaluate<br>Create     | 20 %   | . 3      | 30%    | OD V               | 30%                 |          | 30%    | 777-                   | 30%               | -                  |
|              | Total                  | 10     | 0 %      | 10     | 0 %                | 10                  | 00 %     | 10     | 0 %                    | 10                | 00 %               |

<sup>#</sup> CLA – 4 can be from any combination of these: Assignments, Seminars, Tech Talks, Mini-Projects, Case-Studies, Self-Study, MOOCs, Certifications, Conf. Paper etc.,

| Course Designers  |   |                                 |
|---|---|---------------------------------|
| Experts from Industry   | Experts from Higher Technical Institutions  | Internal Experts                |
| 1. Dr. Vani, Jeevan Stem Cell Foundation, Chennai, stemcell@jeevan.org    | 1. Prof N. Srinivasan, Tissue Engineering and Regenerative Medicine, Dept. of Allied Health | 1 .Dr. N. Selvamururgan, SRMIST |
| 1. Dr. vani, Jeevan Stein Geil Foundation, Ghennai, SteinGeil@jeevan.org  | Sciences, Chettinad Academy of Research and Education, srinivasanibms@gmail.com             | selvamun@srmist.edu.in          |
| 2. Dr. Gokuladhas Krishnan, Director, Laboratory, World Stem Cell Clinic, | 2. Dr. S. Sittadjody, Research Fellow, Institute for Regenerative Medicine, Winston-Salem,  | 2. Dr. R. Satish, SRMIST        |
| Chennai, care@worldstemcellclinic.com                                     | USA. ssdjody@gmail.com  | satishr@srmist.edu.in           |

| Cou     |  | 18BTE420T Course Name                                   | HUMAN GENETIC                                  | CS   | Cou                                     |                             | Е  |                       |                  | Pro                  | ofessi  | onal E            | Elective                                |         |                        |               |                | L .                | Γ F  | 0   | C<br>3    |
|---------|--|---|--|--|---|-----------------------------|--|-----------------------|------------------|----------------------|---|-------------------|---|---------|------------------------|---------------|----------------|--------------------|------|-----|-----------|
|         | Pre-regi   | uisite Courses 18BTC104T                                | Co-requisite Courses                           |  | Pro                                     | gressive                    | Course   | s I                   | lil              |                      |   |                   |   |         |                        |               |                |                    |      |     |           |
| Course  |  | Department Biotechnology                                |  | Book / Codes/Standards /   | Nil                                     | grooore                     | Course   | o p                   | •••              |                      |   |                   |   |         |                        |               |                |                    |      | -   |           |
| 000,00  | o nonnig   | Doparation: Diotocimiciogy                              | Data   | Dock, Codes, Ctandards   | • |                             |  |                       |                  |                      |   |                   |   |         |                        |               |                |                    |      |     |           |
| Course  | Learning   | Rationale   |  |  |   |                             |  |                       |                  |                      | _   |                   |   |         |                        | /-            | N 0\           |                    |      |     |           |
| (CLR):  | J  | The purpose of learning the                             | his course is to:                              |  |   | Lea                         | rning  |                       |                  |                      | Pr  | ogran             | n Learn                                 | ing Oi  | utcon                  | nes (F        | LO)            |                    |      |     |           |
| CLR-1   | : Cate   | gorize the pattern of inheritance in hun                | nans   |  |   | 1                           | 2 3  | 1                     | 2                | 3 4                  | 1 5   | 6                 | 7                                       | 8       | 9                      | 10            | 11             | 12                 | 13   | 14  | 15        |
| CLR-2   |  | yze human genome structure and orga                     |  |  |   |                             | 1  |                       |                  | 4                    | 5   |                   |   |         |                        |               |                |                    |      |     |           |
| CLR-3   |  | karyotype to analyze human chromoso                     |  | TO THE STATE OF TH |   | evel of Thinking (Bloom)    | Expected Proficiency (%) Expected Attainment (%) | e                     |                  | <u>+</u>             | Modern Tool Head                                    |                   |   |         | 돈                      |               | a)             |                    |      |     |           |
| CLR-4:  |  | y different methods for mapping of ge <mark>n</mark>    |  | POSTURA STEE   | ===                                     | 8                           | in cy  | edc                   |                  | ner                  | S a   | D                 |   |         | 8                      |               | Finance        |                    |      |     |           |
| CLR-5:  |  | pare genetic variations in human pop <mark>u</mark>     |  |  | ) <u>6</u> .                            | Jime                        | MO   | .s                    | lopi             | - 1                  | e g   |                   |   | 릚       | _                      | -ine          | ing            |                    |      |     |           |
| CLR-6:  | Illustr  | rate genetic principles in human bi <mark>olog</mark>   | <mark>ıy studi</mark> es                       | 10-6-5   |   | 볼   :                       | tair   | 조                     | alys             | e e                  |   | 걸                 | ± 5.                                    |         | ĕ                      | ţi            | ∞              | arr                |      |     |           |
|         |  |   |  | The second second  |   | 본   :                       | AA   | Engineering Knowledge | Problem Analysis | Design & Development | Modern Tool Head                                    | Society & Culture | Environment &<br>Sustainability         |         | Individual & Team Work | Communication | Project Mgt. & | Life Long Learning |      |     |           |
| 0       | Lander   | Outroma   |  |  | _                                       | _   <u>o</u>   .            | 를   를  | ee                    | em               | 3n S                 | 5   | <u>\$</u>         | onr                                     | S       | gr                     | l li          | ct             | ùo-                |      | 11  | - 3       |
| (CLO):  | Learning   | Outcomes At the end of this course,                     | learners will be able to:                      |  |   | e e                         | x be   | ng:                   | lop              | esic                 |   | oci e             | nvir                                    | Ethics  | ĕ                      | l li          | roje           | fe L               | PSO  | PSO | PSO       |
| (CLO):  | Door   | ribe the human inheritance concepts a                   | and associated complications                   |  |   |                             | й й<br>30 70                                     | H                     | Н                | H H                  |   | ∑ M               | <u>ш</u> <u>ю</u>                       | H       | <u>⊆</u><br>H          | Н             | <u>_</u>       | H                  |      | H   | H         |
| CLO-1   |  | ain the regulation of human g <mark>ene expre</mark>    |  | A Company of the Comp |   |                             | 80 75  | H                     |                  |                      |   | IVI               | M                                       | H       | Н                      |               |                | Н                  |      |     | H         |
| CLO-3   |  | ognize the nature of human c <mark>hromoson</mark>      |  | THE RESIDENCE OF THE PARTY OF T | -                                       |                             | 30 70  | M                     |                  | M H                  |   | М                 | IVI                                     | H       | Н                      |               |                | Н                  |      |     | H         |
| CLO-3   |  | tify the different methods of h <mark>uman dis</mark> e |  |  |   |                             | 30 75  | H                     | Н                |                      | 1   | IVI               | Н                                       | H       | Н                      | Н             |                | Н                  | • •  |     | H         |
| CLO-5   |  | uss the importance of popula <mark>tion scree</mark>    |  | The state of the s |   |                             | 35 70  | H                     | Н                | H                    |   | М                 | H                                       | H       | Н                      | 1             |                | Н                  |      |     | H         |
| CLO-6   |  | aise the basic concepts of hu <mark>man gen</mark> e    |  |  | -                                       |                             | 30 75  | H                     |                  |                      |   | H                 | H                                       | H       | Н                      | Н             |                | Н                  |      |     | H         |
| 020 0   | . ,,,,,,,,   | aled the sacie concepts of marian gene                  | 0.000  | The state of the s |   | 1-1                         | 70   70  |                       | 11               |                      |   |                   |   | 1       |                        |               |                |                    |      | ••• | <u>··</u> |
| Duratio | n (hour)   | 9   | 9  | 9  |   | 1                           |  |                       | 9                |                      |   |                   |   |         |                        |               | 9              |                    |      |     |           |
| 0.4     | SLO-1  | Human Genetics – Introduction                           | Human chromosome structure                     | Karyotyping  |   | Gene                        | tic mapı   | ing                   |                  |                      |   |                   | Genet                                   | ic test | ing                    |               |                |                    |      |     |           |
| S-1     | SLO-2  | Modern Human Genetics                                   | Human chromosome organization                  | Chromosome banding   |   | Reco                        | mbinatio   | n fracti              | on               | 4                    |   |                   | Gene .                                  |         |                        |               |                |                    |      |     |           |
|         | SLO-1  | Monogenic inheritance                                   | Mitochondrial genome organization              | FISH technique   |   | Gene                        | tic mark   | ers                   |                  |                      |   |                   | Analys                                  |         |                        | ed se         | quen           | ce cha             | nges | ;   |           |
| S-2     | SLO-2  | Incomplete dominance and                                | Limited autonomy of mitochondrial              |  |   | T                           | !4   |                       | ٠,,,,            |                      |   |                   |   |         |                        |               |                |                    |      |     |           |
|         | SLU-2  | Codominance   | genome   | Chromosome painting  |   | I wo p                      | oint ma  | oping                 | 20               |                      |   |                   | MLPA                                    | iesi    |                        |               |                |                    |      |     | _         |
| S-3     |  | Uniparental disomy                                      | Protein coding genes                           | Numerical chromosome abnormal  | lities                                  | Multip                      | oint <mark>ma</mark>                             | oping                 |                  |                      |   |                   | DNA p                                   |         |                        |               |                |                    |      |     |           |
| 3-3     | SLO-2  | Penetrance, nonpenetrance                               | RNA genes                                      | Aneuploidy   |   | Fine i                      | napping  | analys                | is               |                      |   |                   | Applic                                  |         |                        |               |                | g                  |      |     |           |
| S-4     |  | Expressivity  | microRNAs ==================================== | Structural chromosome abnormali  | ities                                   |                             | gation a   |                       |                  |                      |   |                   | Persoi                                  |         |                        |               |                |                    |      |     |           |
| 3-4     |  | Mitochondrial inheritance                               | Regulatory RNAs                                | Mosaicism  |   |                             | ge analy   |                       |                  |                      |   |                   | Drugs                                   |         |                        |               | otype.         | s                  |      |     |           |
| S-5     |  | Late onset diseases                                     | Overlapping genes                              | Autosomal abnormalities  |   |                             | ciation s  |                       |                  |                      |   |                   | Prena                                   |         |                        |               |                |                    |      |     |           |
| 3-3     |  | Disease anticipation, imprinting                        | G <mark>enes-within-</mark> genes              | Sex chromosome abnormalities   |   |                             | ge dised   |                       | n                |                      |   |                   | Cast s                                  |         |                        |               | drome          | 9                  |      |     |           |
| S-6     |  | Heterogeneity, consanguinity                            | Noncoding DNA                                  | Human reproductive disorders   |   |                             | onal clo   |                       |                  |                      |   |                   | Popula                                  |         |                        |               |                |                    |      |     |           |
| 0-0     |  | Pleiotropy, mosaicism                                   | Satellit <mark>e DNA</mark>                    | Congenital abnormalities   |   |                             | idate ge   |                       |                  |                      |   |                   | Ethica                                  |         |                        |               |                |                    |      |     |           |
| S-7     |  | Mendelian pedigree patterns                             | Mini- and microsatellite DNA                   | Polyploidy   |   |                             | on inde <sub>l</sub>                             | enden                 | strate           | egies                |   |                   | Pedigree construction                   |         |                        |               |                |                    |      |     |           |
| 0,      |  | Pedigree analysis                                       | Transposon derived repeats                     | Mixoploidy   |   |                             | Case studies                                     |                       |                  |                      |   |                   | Proband analysis                        |         |                        |               |                |                    |      |     |           |
| S-8     |  | Multifactorial inheritance                              | Alternative transcription                      | X-inactivation   |   | Duchenne muscular dystrophy |  |                       |                  |                      |   |                   | Pharmacogenetics                        |         |                        |               |                |                    |      |     |           |
|         |  | Quantitative traits                                     | Long range control of gene expression          | Mosaicism due to X-inactivation  |   | Cystic fibrosis             |  |                       |                  |                      |   |                   | Genetic differences and drug metabolism |         |                        |               |                |                    |      |     |           |
| S-9     |  | Polygenic theory  | DNA methylation                                | Locus heterogeneity  | Branchio-oto-renal syndrome             |                             |  |                       |                  |                      | Genetic counseling Importance of genetic counseling |                   |   |         |                        |               |                |                    |      |     |           |
|         | SLO-2 Gene and genotype frequencies Epigenetics Clinical heterogeneity |   |  |  |   | Crohi                       | n diseas   | 9                     |                  |                      |   |                   | Import                                  | ance    | of ge                  | netic         | coun           | seling             |      |     |           |

| Learning  | 1. | Strachan, T., Read, A.P., "Human Molecular Genetics", 4th edition - Garland Science, 2012.                                |
|-----------|----|---|
| Resources | 2. | Jack J. Pasternak, "An introduction to Human Molecular <mark>Genetics," 2<sup>nd</sup> edition – Wiley Liss, 2005.</mark> |

| Learning Ass | essment                      |        |          |        |                      |                   |          |         |          |                    |                    |
|--------------|------------------------------|--------|----------|--------|----------------------|-------------------|----------|---------|----------|--------------------|--------------------|
|              | Dloom's                      |        |          | Cont   | inuous Learning Asse | essment (50% weig | htage)   |         |          | Final Evamination  | n /EO0/ woightage) |
|              | Bloom's<br>Level of Thinking | CLA –  | 1 (10%)  | CLA -  | 2 (15%)              | CLA –             | 3 (15%)  | CLA – 4 | 4 (10%)# | Filiai Examination | n (50% weightage)  |
|              | Level of Thinking            | Theory | Practice | Theory | Practice             | Theory            | Practice | Theory  | Practice | Theory             | Practice           |
| Level 1      | Remember<br>Understand       | 40 %   |          | 30%    |                      | 30%               | 11/1/20  | 30%     | -        | 30%                | -                  |
| Level 2      | Apply<br>Analyze             | 40 %   | 7        | 40%    |                      | 40%               | 7.3      | 40%     | <b>3</b> | 40%                | -                  |
| Level 3      | Evaluate<br>Create           | 20 %   |          | 30%    |                      | 30%               | - 1      | 30%     |          | 30%                | -                  |
|              | Total                        | 10     | 0 %      | 10     | 00 %                 | 10                | 0 %      | 10      | 0 %      | 10                 | 0 %                |

# CLA – 4 can be from any combination of these: Assignments, Seminars, Tech Talks, Mini-Projects, Case-Studies, Self-Study, MOOCs, Certifications, Conf. Paper etc.,

| Course Designers  |      |  |                            |
|---|------|--|----------------------------|
| Experts from Industry   |      | Experts from Higher Technical Institutions   | Internal Experts           |
| Dr. A. Premkumar, PhD, GVK Biosciences, Hyderabad aprem70@yahoo.com         |      | Dr. Bibhas Kar, Madras Medical Mission, Chennai, Tamilnadu drbibhaskar65@gmail.com | Dr. S. Kirankumar, SRMIST  |
| Dr. M.C. Raja, PhD, Genotypic Technologies, Bangalore genotypic@hotmail.com | 1.00 | Dr. Partha P. Majumder, NIBG, Kalyani, West Bengal ppm1@nibmg.ac.in                | Dr. M. Jeevankumar, SRMIST |



| Course  | e Code   | 18BTE421T Course Name  | OGIES IN ADVANCED BIOLOGY                  |  | С        | Course  | Cate  | gory                    | ,        | E                |   | Profe             | ssional   | Elec                         | tive   |                        | L<br>3        | T<br>0         | P<br>0             | C<br>3 |                   |
|---------|--|--|--|--|----------|---|---|-------------------------|----------|------------------|---|-------------------|---|------------------------------|--------|------------------------|---------------|----------------|--------------------|--------|-------------------|
|         | Pre-red  | uisite Courses NIL   | Co-requisite Courses                       | NIL  |          |   |   | Pro                     | gres     | ssive            | Cour  | ses               | Nil   |                              |        |                        |               |                |                    |        |                   |
| Course  | Offering De  | epartment Biotechnology  |  | Data Book / Codes/Standards  |          |   |   | NIL                     |          |                  |   |                   |   |                              |        |                        |               |                |                    |        |                   |
| Course  | Learning R   | ationale   | -  | 11-14-7-1  |          |   |   |                         |          |                  |   |                   |   |                              |        |                        |               |                |                    |        |                   |
| (CLR):  | Loaming it   | The purpose of learning this cour  | rse is to:                                 | CHARLES AND A  |          | Learn   | ing   |                         |          |                  |   | Pr                | ogram   | Learnii                      | ng Oι  | ıtcom                  | es (P         | LO)            |                    |        |                   |
| CLR-1:  |  | rious high throughput techniques in biolog <mark>y</mark>  | and 2. applying these techniques in their  | r own research   | 1        | 2   | 3   | 1                       |          | 2                | 3 4   | 5                 | 6   | 7                            | 8      | 9                      | 10            | 11             | 12                 | 13     | 14 15             |
| CLR-2 : |  | ne the basics of genomics and its uses be qualitatively and quantitative the exp <mark>ressi</mark> c                      | on of protoin                              |  | (E       | \ @   | (0)   |                         | ,        |                  | T Design & Development T Analysis Design Research |                   |   |                              |        | _                      |               |                |                    |        |                   |
| CLR-3:  |  | re the differential expression of prot <mark>eins and</mark>   |  |  | 00       | 6)  | 11 (%)  | 900                     | 200      |                  | ese   |                   |   |                              |        | Vor                    |               | ЭС             |                    |        |                   |
| CLR-5:  |  |  |  |  |          |   |   | J.W.O                   | 8        | S                | n a   | sade              | <u>9</u>  |                              |        | m.                     |               | Finance        | ing.               |        |                   |
|         |  | C-13 100 G   | nkin                                       | ofic   | ttain    | K   | Ē   | alys                    | evel     |                  | 릠   | ± ≥               | ,   | Teg                          | ıtion  | 8.                     | au            |                |                    |        |                   |
|         |  | SAR PRACTICAL  | of Thinking (Bloom)                        | D D  | A b      | in  | <u> </u>  | ٦                       | ă č      | Lo               | 8   | mer               | 2   | <u>a</u>                     | nice   | Mgt                    | g Le          |                | 2 8                |        |                   |
| Course  | Learning O   | utcomes  | and the second second                      | CHAIN TO THE PARTY OF THE PARTY | <u> </u> | Expected Proficiency (%)  | © Expected Attainment (%)                               | T Engineering Knowledge | 5        | Problem Analysis | Design & Development<br>Analysis Design Reses     | Modern Tool Usage | Society & Culture                                     | Environment & Sustainability | S      | Individual & Team Work | Communication | Project Mgt. & | Life Long Learning | -1     | 1.1               |
| (CLO):  |  | At the end of this course, learners  |  | 2007010  | PVel     | EX  | - K   | Ц                       | <u> </u> | P<br>D           | Ans Ans   | Mo                |   | Sis                          | Ethics | Indi                   |               |                |                    |        | H PSO .           |
| CLO-1:  |  | e the terminology, technolo <mark>gy charac</mark> teristic  |  |  | 1        |   |   |                         |          |                  |   |                   |   | L                            | Н      |                        | Н             | Н              |                    |        | H H               |
| CLO-2 : |  | rate genomic data, interpre <mark>t the data</mark> in the r<br>re the expression of genes <mark>, develop</mark> necess   |  |  | 2        |   |   | I A                     |          |                  | H H   |                   |   | M                            | H      | H                      | H             | Н              | H                  |        | Н Н<br>Н Н        |
| CLO-3   |  | e trie expression of genes, develop fiecess<br>y proteins qualitatively an <mark>d quantita</mark> tively an               |  |  | 2        |   |   | F                       |          |                  | H H   |                   |   | H                            | M      | Н                      | Н             | H              | Н                  |        | <u>п п</u><br>Н Н |
| CLO-5   |  | y proteine qualitatively an <mark>d qualititati</mark> vely an<br>uish Metabolomics, Epige <mark>nomics an</mark> d lipdon |  |  | 3        |   | 75  | ŀ                       | 1        |                  | H H   |                   |   | H                            | Н      | L                      | L             | Н              | Н                  |        | H H               |
| CLO-6:  |  | e high throughput data usi <mark>ng softwa</mark> re   |  |  | 3        |   |   | F                       |          | Н                | L H   |                   |   | L                            | Н      | М                      | М             | Н              |                    |        | Н Н               |
|         |  |  |  |  | й        |   | -   |                         |          | _                |   |                   |   |                              |        |                        |               |                |                    |        |                   |
| Durat   | ion (hour)   | History of technology advancement in   | 9  | Browser and databases for  | H        |   |   | -4                      |          | 9                |   | -                 |   |                              |        |                        |               | 9              |                    |        |                   |
| S-1     | SLO-1  | biology  | Introduction to Genome                     | transcriptomics  |          |   | ductio  |                         |          |                  |   |                   |   | Introdu                      |        |                        |               |                |                    |        |                   |
|         | SLO-2  | What is high throughput biology  | Ultrafine structure of gene                | Tools for transcriptomics  |          | Anal  | ytical  | Techr                   | nique    | es in            | prote   | omics             |   | Second                       | dary n | netab                  | olites        | and            | their r            | ole in | biology           |
| S-2     | SLO-1  | High content screening and their uses  | Regulatory Landscapes of Mammalian Genomes | Search for transcription factor binding sites  |          | Prote   | ein info  | ormat                   | ion d    | datal            | ases  | ď                 |   | Metabo                       | olome  | of pl                  | ants, a       | anima          | als an             | d mic  | robes             |
| 0-2     | SLO-2  | High throughput screening in biology   | Epigenetic Landscapes of Mammalian Genomes | miRNA targets and regulatory motifs  |          | Swis  | sPRO  | T an                    | d UI     | NIPR             | ОТ  |                   |   | Metabo                       | olites | and n                  | netabo        | olomi          | ics                |        |                   |
| S-3     | SLO-1  | Technology characteristics of high throughput screening  | Genome sequencing                          | Overview of Non-Coding RNAs  |          | Mas   | s spec  | trome                   | etry     |                  |   |                   |   | Target                       | analy  | sis oi                 | meta          | bolite         | es                 |        |                   |
| 5-3     | SLO-2  | Recent theories on High throughput screening   | Genome assembly and annotation             | iCLIP  |          | ESI   | MS-MS   | S                       |          |                  |   |                   |   | Metabo                       | olomic | finge                  | er prin       | ting           |                    |        |                   |
| 0.4     | SLO-1 How high throughput technologies empower the stake holders  Application of population genetics in genomics  Expressed Sequence Tag(ES'   |  |  |  | s        | Mas   | s spec  | trome                   | etry I   | ESI I            | MALD  | -TOF              |   | Epigen                       | ome a  | and II                 | nprint        | ing,           |                    |        |                   |
| S-4     | SLO-2  |  |  |  |          |   | Peptide mass finger printing database Does epigenetic r |                         |          |                  |   |                   | etic regulation is an antithesis to orv of evolution? |                              |        | esis to                |               |                |                    |        |                   |
| Q E     | SLO-1  | Scalability of High through put screening  | Comparative genomics of prokaryotes        | Ribosome Profiling for ribosome-<br>protected mRNA fragments   |          | Targ  | eted N  | lass s                  | spec     | trom             | etry -  | Princi            | ples  | Histone                      | э тоа  | lificati               | on as         | say            |                    |        |                   |
| 3-3     | S-5 SLO-2 Evolvabilty of High through put screening Comparative genomics of eukaryotes What are RNA motifs and their in the second seco |  |  |  |          | nce Targeted Mass spectrometry - Applications DNA Methylation assay |   |                         |          |                  |   |                   |   |                              |        |                        |               |                |                    |        |                   |

| Durat | ion (hour) | 9   | 9   | 9   | 9  | 9   |
|-------|------------|---|---|---|--|---|
| S-6   |            | Exploring and replicating published research work | Functional genomics of prokaryotes                  | Experimental techniques 1- Micro array            | Functional mass spectrometry principles                          | Genome wide assays and their relevance                    |
| 3-0   | SLO-2      | Reviews and their uses                            |   | 2. RT-PCR as a validating tool                    | Functional mass spectrometry applications                        | Bisulphate sequencing and Direct detection of methylation |
| S-7   | SLO-1      | Need of open source research                      | Ecological genomics (Metagenomics) of microbes      | Importance of reference gene                      | Overview of protein quantitation methods                         | Experimental methods for lipid extraction                 |
| 3-1   | SLO-2      | Power of open source research                     | Ecological genomics (Metagenomics) higher organisms | Analysis of differential gene expression          | Quantitation of proteins using MS                                | Lipid assays  |
| S-8   | SLO-1      | Comparison of available data quality              | Pharmacokinetics basics                             | Generation of transcriptional regulatory networks | Post translational modification of proteins                      | Lipid detection techniques                                |
| 3-0   | SLU-Z      | Comparison of methods for published data          | 1Pnarmacogenomics                                   | Analysis of transcriptional regulatory networks   | Analysis of post translational modification of proteins using MS | Lipid based imaging techniques                            |
| S-9   | SLO-1      | 'OMICS' technologies                              | Application of genomics in public health            |   | Protein – Protein interactions                                   | Lipid based disorders                                     |
| 3-9   | SLO-2      | Current status of OMICS technologies              | Application of genomics in industry                 | Understanding signaling pathways                  | Interactomics  | Lipidomic profiling                                       |

|           | 1    | High-Throughp <mark>ut Next G</mark> eneration Sequencing Methods and Applications, Kwon, Young Min, Ricke, Steven C. (Eds.), Humana press, 2011, UK  |
|-----------|------|---|
| I to -    | 1,.  |   |
| Learning  | Z.   | Proteomics: from protein sequence to function, Pennington, Stephen R.; Dunn, Michael J. 1st Edition, 2000, Oxford Publications, UK  |
| Resources | 3.   | Text /Video: Genomics and Proteomics: Principles, Technologies, and Applications, Devarajan Thangadurai (Editor), Jeyabalan Sangeetha(Editor), 1st edition, 2015, Apple academic press, New York, |
|           | USA. |   |

| Learning Ass | essment                          |        | 1        | - 10 L 10 L 10 L 10 L 10 L 10 L 10 L 10 |                    |                   | MARKET AND |         |          |                                   |                   |  |  |
|--------------|----------------------------------|--------|----------|---|--------------------|-------------------|------------|---------|----------|-----------------------------------|-------------------|--|--|
|              | Dlaamia                          |        |          | Conti                                   | nuous Learning Ass | essment (50% weig | htage)     |         |          | Final Evaminatio                  | n (FOO) weightens |  |  |
|              | Bloom's -<br>Level of Thinking - | CLA –  | 1 (10%)  | CLA – 2 (15%)                           |                    | CLA -             | 3 (15%)    | CLA – 4 | (10%)#   | Final Examination (50% weightage) |                   |  |  |
|              | Level of Thinking                | Theory | Practice | Theory                                  | Practice           | Theory            | Practice   | Theory  | Practice | Theory                            | Practice          |  |  |
| Level 1      | Remember<br>Understand           | 40 %   |          | 30%                                     |                    | 30%               | Sales      | 30%     |          | 30%                               | -                 |  |  |
| Level 2      | Apply<br>Analyze                 | 40 %   | 1551     | 40%                                     |                    | 40%               | -          | 40%     | 100      | 40%                               | -                 |  |  |
| Level 3      | Evaluate<br>Create               | 20 %   | 7        | 30%                                     | - 11               | 30%               | - 7/       | 30%     |          | 30%                               | -                 |  |  |
|              | Total                            | 10     | 00 %     | 10                                      | 0 %                | 10                | 0 %        | 100     | ) %      | 10                                | 0 %               |  |  |

<sup>#</sup> CLA – 4 can be from any combination of these: Assignments, Seminars, Tech Talks, Mini-Projects, Case-Studies, Self-Study, MOOCs, Certifications, Conf. Paper etc.,

| Course Designers                                  | VII. VII. VEEL VALLE VAL |   |
|---|--|---|
| Experts from Industry                             | Experts from Higher Technical Institutions   | Internal Experts                                    |
| Arun D, Loreal India Pvt Ltd, Bangaluru, India    | Dr. G. Mathan, Asst. Professor, Department of Biomedical science, Bharathidasan University, Trichy   | Dr. N. C. Daia, CDMICT Empilyraian 2@ armint adu in |
| Email: arun.duraisamy@gmail.com                   | Email: mathan_cell@yahoo.com   | Dr. N S Kaja, SKMIST Email.rajans@smist.edu.in      |
| Shalini M, , Scientist I, ITC Lifescienes PVT LTD | Dr. Nishad Fathima Principal scientist, CSIR-Central Leather Research Institute, Chennai   | Dr. P. Rathinasabapathi, SRMIST                     |
| Email: shalubioc@gmail.com                        | Email: nishad.clri@gmail.com   | Email: rathinap1@srmist.edu.in                      |

| Cour<br>Coc      |          | 18BTE422T         | Course<br>Name   | METABOLIC ENGINEERING OF MICRO  | DBES Course Category   |        | E                          |  |       |                       | 1                | Profe                | ssiona                     | al Ele            | ective            | )                            |        |                       |               | L<br>3         | T<br>0 | P 0  | <u>C</u> |
|------------------|----------|-------------------|--|---|--|--------|----------------------------|--|-------|-----------------------|------------------|----------------------|----------------------------|-------------------|-------------------|------------------------------|--------|-----------------------|---------------|----------------|--------|------|----------|
|                  | Pre-rea  | uisite Courses    | 18BTC103J  | Co-requisite Courses Nil  | Pi   | roare  | essive                     | e Course   | es    | Nil                   | 1                |                      |                            |                   |                   |                              |        |                       |               |                |        |      |          |
| Course           |          | Department        | Biotechnology  |   | Codes/Standards  |        |                            |  |       | 1                     |                  |                      |                            |                   |                   |                              |        |                       |               |                |        |      |          |
|                  |          |                   |  |   | 11.  |        |                            |  |       |                       |                  |                      |                            |                   |                   |                              |        |                       |               |                |        |      |          |
| Course<br>(CLR): | Learning | g Rationale The   | purpose of learning this co                              | urse is to:   | Manual   |        | Lear                       | ning   |       |                       |                  |                      | Pr                         | ogra              | am Le             | earnir                       | ng Oı  | utcom                 | es (Pl        | _O)            |        |      |          |
| CLR-1            |          |                   | engineered organisms and                                 |   |  | 1      | 1 2                        | 2 3  |       | 1                     | 2                | 3                    | 4                          | 5                 | 6                 | 7                            | 8      | 9                     | 10 1          | 11 1:          | 2 13   | 3 14 | 15       |
| CLR-2            |          | tools and method  | ls used for metabolic <mark>e</mark> ngi <mark>ne</mark> | <mark>eering of m</mark> icrobes  |  |        | т.                         |  |       |                       |                  |                      | Ę.                         |                   |                   | ity                          |        |                       |               |                |        |      |          |
| CLR-3            |          |                   | echanisms in metabolic <mark>pati</mark>                 |   |  | Ē      | E S                        | ( ( (  |       | d)                    |                  |                      | arc                        |                   |                   | abil                         |        | ۷                     |               |                |        |      |          |
| CLR-4:           |          |                   | lesign of a metabolic <mark>engine</mark>                | eering in practice  | CAST TO STATE OF   | 2      | 00 3                       | 1 (3)  | Α,    | ğ                     |                  | ent                  | ese                        | _                 |                   | aj.                          |        | Vor                   |               | වු             |        |      |          |
| CLR-5:           |          |                   | x in biochemical pat <mark>hways</mark>                  |   |  | ]   @  | E 2                        | ner ler  | - 14  | Me                    | S                | mdo                  | α,                         | age               | a                 | sns                          |        | E                     |               | Finance        | 20     |      |          |
| CLR-6:           | Stuc     | dy about thermody | mamic principles <mark>of cellular</mark>                | processes   |  | غ ا    | ) K                        | ai.  | •     | ŝ                     | lysi             | )el                  | sign                       | NS.               | 重                 | ∞<br>∞                       |        | eal                   | E i           | χ   . <u>.</u> | בפמ    |      |          |
|                  |          |                   |  |   |  | f Thin | Level of 1 ninking (Bloom) | Expected Proliciency (%) Expected Attainment (%) | Ĭ     | Engineering Knowledge | Problem Analysis | Design & Development | Analysis, Design, Research | Modern Tool Usage | Society & Culture | Environment & Sustainability |        | ndividual & Team Work | Communication | roject Mgt. &  | - 1    | 5    | က        |
| Course<br>(CLO): |          |                   | ne end of this <mark>course, le</mark> arne              | ers will be able to:  | 241  | _      |                            | Expec  |       | Engine                | Proble           | Design               | Analys                     | Moder             | Societ            | Enviro                       | Ethics | Individ               | Comm          | Project Mg     | - USG  |      | H PSO -  |
| CLO-1            |          |                   | metabolic pa <mark>thways</mark>                         | 2 The Control of the | AL AND STREET  |        | 4 8                        | 80 80  | ٧.    | М                     |                  |                      | Н                          |                   |                   |                              | Μ      |                       |               |                | H      |      | Н        |
| CLO-2            |          |                   | ethods used <mark>for meta</mark> bolic e                |   |  | ŀ      |                            | RO 75  | a     | М                     | Н                | Н                    | Н                          |                   |                   |                              | Η      | Н                     |               |                | H      |      |          |
| CLO-3            |          |                   | thods for me <mark>tabolic en</mark> ginee               |   | SECTION OF SHAPE AND ADDRESS.  | ŀ      |                            | 75 75  | -91   | М                     | Н                | Н                    |                            | Н                 |                   |                              | Н      | Н                     |               |                | Н      |      |          |
| CLO-4            |          |                   | ools and tec <mark>hniques u</mark> sed fo               |   | NEW YORK OF THE PARTY OF THE PA |        |                            | 75 75  |       | М                     | Н                | Н                    |                            |                   | Н                 | Н                            | Н      | Н                     |               |                | Н      |      | Н        |
| CLO-5            |          |                   |  | olically engineered microbes  | CANADA DINE  |        | 4 8                        |  |       | М                     | Н                | Н                    |                            | М                 | М                 | Н                            | Η      | Н                     |               |                | Н      | l H  | Н        |
| CLO-6            | Des      | ign pathway engin | neering tech <mark>niques fo</mark> r diver              | ting metabolic flux into product formation  | and the second second  | F      | 4 8                        | 80 80  |       | М                     | Н                | Н                    | Н                          | Н                 | Н                 | Н                            | М      | Н                     |               |                | h      | l H  | Н        |
|                  |          |                   |  | The Management of the Park  |  |        |                            |  |       |                       |                  | 4                    |                            |                   |                   |                              |        |                       |               |                |        |      |          |
| Duratio          | n (hour) |                   | 10   | 10  | 10   | 2      |                            |  |       |                       | 10               |                      |                            |                   |                   |                              |        |                       |               | 10             |        |      |          |
| S-1              |          | · ·               | of metabolic <mark>engineerin</mark> g                   | Overview of metabolic pathways in microbes  | Metabolic engineering for enhancing product formation  | ng     |                            | Tools fo   |       |                       |                  |                      | Ť                          |                   |                   | engi                         | neeri  | ing .                 |               | metal          |        |      |          |
|                  |          |                   | etabolic engin <mark>eering</mark>                       | Regulation of metabolic pathways  | Acetone production   |        | (                          | Classica   | al mu | tager                 | nesis            | techn                | iq <mark>ue</mark> s       |                   |                   | Meta                         | abolio | path:                 | way a         | nalysi         | S      |      |          |
| S-2              |          | Overview of cellu |  | Enzyme mediated pathway regulation  | Amino acid production  |        |                            | Methods  |       |                       |                  |                      | nts                        |                   |                   |                              |        |                       | analys        |                |        |      |          |
| 3-2              |          |                   | on pathways in <mark>microbes</mark>                     | Mechanisms of enzyme action   | Engineering pentose metabolism   |        |                            | Gene sh  |       |                       |                  |                      |                            |                   |                   |                              |        |                       | contro        |                |        |      |          |
| S-3              |          | Anaplerotic reac  |  | Transcriptional control of enzyme activity  | Starch and lignin degradation  |        |                            | Gene kr  | nocko | out us                | sing C           | RISE                 | PR                         |                   |                   | Me                           | thod   | s to ca               | alculat       | e met          | abolio | flux |          |
| 0-0              | SLO-2    | Rate constants a  | and reaction equillib <mark>rium</mark>                  | Enzyme turnover   | Vitamin production   |        |                            | Cloning  | and   | expre                 | essior           | of g                 | e <mark>ne c</mark> l      | ustei             | rs                | Meta                         | abolio | com,                  | onen          | t anal         | ysis   |      |          |
| S-4              | SLO-1    | Fuelling reaction | s – glycolysis   | Enzyme activity by translational control  | Polyketide biosynthesis  |        | N                          | Antisens   | se RI | VA ba                 | ased i           | metho                | ods                        |                   |                   | Line                         | ar pa  | thway                 | analy         | /sis           |        |      |          |
|                  | SLO-2    | Fermentation pa   | thways   | Reversible inhibition   | Biopolymer production  |        |                            | Directed function                                |       | lution                | for in           | <mark>npr</mark> ov  | ving pı                    | oteir             | 1                 | Bran                         | nched  | l path                | way a         | nalysi         | S      |      |          |
| S-5              |          |                   | ts and amino acids                                       | Irreversible inhibition   | Production of novel compounds us metabolic engineering   | sing   | ,                          | Artificial                                       | chro  | mosc                  | omes             |                      |                            |                   |                   | Stru                         | cture  | of a r                | netab         | olic ne        | etwork | ζ    |          |
|                  | SLO-2    | Biosynthetic of p | olymers  | Global regulation of metabolic pathways   | Antibiotics and vitamins   |        |                            | Chromo   | soma  | al eng                | gineel           | ring s               | trateg                     | ies               |                   | Flux                         | distr  | ibutio                | 1             | -              |        |      |          |
| S-6              | SLO-1    | Nucleic acid bios | synthesis  | Allosteric enzymes involved in metabolic regulation   | Production of pigments   |        |                            | RNA er   | ngine | ering                 | techi            | nolog                | ies                        |                   |                   | Flux                         | anal   | ysis o                | f meta        | abolic         | netwo  | orks |          |

| Duratio | n (hour) | 10                              | 10   | 10  | 10   | 10   |
|---------|----------|---------------------------------|--|---|--|--|
|         | SLO-2    | Amino acid biosynthesis         | Regulation of enzyme activity using feedback mechanism | Biopolymer production                         | Improving translational efficiency                         | Determination of Group Control Coefficient   |
| S-7     | SLO-1    | Active transport                | Sigmoidal kinetics                                     | Pesticide degradation                         | Stimulation of product formation using precursor molecules | Thermodynamics of cellular processes         |
|         | SLO-2    | Facilitated diffusion           | Allosteric regulation of enzyme activity               | Xenobiotic degradation                        | Multifunctional enzyme systems                             | Thermodynamic feasibility                    |
| S-8     | SLO-1    | Cellular energetics,            | Co-operativity of allosteric enzymes                   | tivietadolic erigineering of manimalian cells | Engineering of secretory processing pathway                | Metabolic models for growth                  |
| 3-0     | SLO-2    | yield coefficients              | Examples of enzyme cooperativity                       | Cell cycle engineering                        | Phenotype microarrays                                      | Models for product formation                 |
| S-9     | SLO-1    | Primary metabolite production   | Branch point classification                            | Apoptosis control                             | HighThrougput Mutagenesis                                  | Genome scale modeling of cellular metabolism |
| 3-9     | SLO-2    | Secondary metabolite production | Coupled reactions                                      | Inhibition of cell proliferation              | High Throughput screening                                  | Cell free systems for metabolic engineering  |

| Learning<br>Resources | 1.<br>2.<br>3. | Gregory N. Stephanopolous, Aristous A. Aristoudou, Jens Neilsen, Metabolic engineering – Principles and methodologies, Academic press, (1998) Quiong Chen – Microbial Metabolic Engineering – Methods and protocols – first edition – Humana Press (2011) Christina Smoke – Metabolic Engineering Pathway Handbook – 2 <sup>nd</sup> edition, CRC press (2017) |  |
|-----------------------|----------------|--|--|
| SLO – Session Learnin | g Outcome      |  |  |

## SLO – Session Learning Outcome

| Learning Asse | essment           |        |          |        |                    | V1350 1            |                   | 70 Atra |                        |                                   |                  |  |  |
|---------------|-------------------|--------|----------|--------|--------------------|--------------------|-------------------|---------|------------------------|-----------------------------------|------------------|--|--|
|               | Bloom's           |        | - 3      | Conti  | nuous Learning Ass | essment (50% weigl | htage)            | (40)    |                        | Final Evamination                 | (E00/ woightogo) |  |  |
|               | Level of Thinking | CLA -  | 1 (10%)  | CLA –  | 2 (15%)            | CLA – 3            | 3 (15%)           | CLA – 4 | 1 (10% <mark>)#</mark> | Final Examination (50% weightage) |                  |  |  |
|               | Level of Thinking | Theory | Practice | Theory | Practice           | Theory             | Practice          | Theory  | Practice               | Theory                            | Practice         |  |  |
| Level 1       | Remember          | 40 %   |          | 30%    |                    | 30%                | The second second | 30%     |                        | 30%                               |                  |  |  |
| Level I       | Understand        | 40 %   |          | 30%    | 17.10              | 30%                |                   | 30%     |                        | 30%                               | -                |  |  |
| Level 2       | Apply             | 40 %   |          | 40%    |                    | 40%                |                   | 40%     |                        | 40%                               |                  |  |  |
| Level 2       | Analyze           | 40 /0  |          | 4070   |                    | 4070               | _                 | 4070    |                        | 40 /0                             | -                |  |  |
| Level 3       | Evaluate          | 20 %   |          | 30%    |                    | 30%                |                   | 30%     |                        | 30%                               |                  |  |  |
| rever 2       | Create            | 20 70  | P.LA.    | 3070   | - 1                | 30%                | -                 | 3076    |                        | 30%                               | -                |  |  |
|               | Total             | 10     | 0 %      | 100 %  |                    | 100                | 0 %               | 10      | 0 %                    | 100 %                             |                  |  |  |

<sup>#</sup> CLA – 4 can be from any combination of these: Assignments, Seminars, Tech Talks, Mini-Projects, Case-Studies, Self-Study, MOOCs, Certifications, Conf. Paper etc.,

| Course Designers   |   |   |
|--|---|---|
| Experts from Industry  | Experts from Higher Technical Institutions                        | Internal Experts                                      |
| 1 Dr. Rajeev Kumar Sukumaran, NIIST, Trivandrum rajeevs@niist.res.in | 1 Dr. Guhan Jayaraman IIT, Madras, guhanj@iitm.ac.in              | 1 Dr. K. N. Rajnish SRM Inst. of Science & Technology |
| 2. Dr. N. Ayyadurai, CLRI, Adyar, ayyadurai@clri.res.in              | 2 Dr. S. Ramalingam, Anna University, Chennai rama@bioprocess.edu | 2 Dr. M.RamyaSRM Inst. of Science & Technology        |

| Cour<br>Cod      |  | 18BTE423T Course<br>Name                             | GENETICS OF CROP IMPROVE                            | Cours Catego   |   | Е                        |                         |                       |                  | Pro                              | ofessi                    | ional             | Elect     | tive                         |                  |              |                                  | L<br>3    | T<br>0  | P<br>0 | C<br>3  |
|------------------|--|--|---|--|---|--------------------------|-------------------------|-----------------------|------------------|----------------------------------|---------------------------|-------------------|-----------|------------------------------|------------------|--------------|----------------------------------|-----------|---------|--------|---------|
| Course           |  | site Courses 18BTC105J Department Genetic Engin      | Co-requisite Courses Nil                            | Progress  / Codes/Standards Nil  | sive (  | Cours                    | es Nil                  |                       |                  |                                  |                           |                   |           |                              |                  |              |                                  |           |         |        |         |
| Course           | Offering L   | Department Genetic Engli                             | meening Data Book                                   | 7 Codes/Standards   7011   |   |                          |                         |                       |                  |                                  |                           |                   |           |                              |                  |              |                                  |           |         |        |         |
| Course<br>(CLR): | Learning I   | Rationale The purpose of learning                    | this course is to:                                  | THACK  | L   | earnir                   | ng                      |                       |                  |                                  | F                         | Progr             | am L      | _earni                       | ng Ou            | tcome        | s (PL                            | O)        |         |        |         |
| CLR-1:           |  | tify the important attributes that dem               | onstrat <mark>e high yield po</mark> tential        |  | 1   | 2                        | 3                       | 1                     | 2                | 3                                | 4                         | 5                 | 6         | 7                            | 8                | 9 1          | 0 1                              | 1 12      | 2   13  | 14     | 15      |
| CLR-2:           |  | erstanding the factors that control cr               | op pro <mark>ductivity.</mark>                      |  |   |                          |                         |                       |                  |                                  | Ч                         |                   |           | ity                          |                  |              |                                  |           |         |        |         |
| CLR-3:           | Anal   | yze Biotic and abiotic stress-plant in               | itera <mark>ctions</mark>                           |  | Ê   | (%)                      | (0)                     | 4)                    |                  |                                  | arc                       |                   |           | abil                         |                  | <u>_</u>     |                                  |           |         |        |         |
| CLR-4:           |  | ore plant-microbe beneficial interact                |   | CONTRACTOR AND ADDRESS OF THE PARTY OF THE P | (Bloom)   | 5)                       | t (%                    | g                     |                  | ent                              | ese                       |                   |           | aj                           |                  | Team Work    | Finance                          | 3         |         |        |         |
| CLR-5:           |  | yze metabolic pathways for crop va <mark>l</mark>    |   |  | 9   | enc                      | ner                     | We                    | S                | E E                              | , R                       | age .             | d)        | nst                          |                  | <u>ا ج</u>   | j                                |           |         |        |         |
| CLR-6:           | com  | pare, contrast and distinguish th <mark>e rig</mark> | ght molecular strategies for crop improvement       |  | ιŝ  | fici                     | ä                       | ŝ                     | JSi              | le le                            | ign                       | Us                | ₫         | ∞ ∞                          |                  | -ea          | ᄓ                                | earning   |         |        |         |
|                  |  |  |   |  | of Thinking                                     | ed Pro                   | ed Att                  | ering I               | n Ana            | & Development                    | s, Design, Research       | Tool              | & Culture | ment                         |                  | S   E   .    | Mot                              | 70   es   |         | 5      | 3       |
| Course<br>(CLO): | Learning   | Outcomes At the end of this course                   | e, learners will be able to:                        | Total Control  | Level o   | Expected Proficiency (%) | Expected Attainment (%) | Engineering Knowledge | Problem Analysis | Design                           | Analys <mark>is,</mark> I | Modern Tool Usage | Society & | Environment & Sustainability | Ethics           | Individual & | Communication<br>Project Mat & E | life Long | PSO - 1 |        | H PSO - |
| CLO-1            | : Expl   | ain the genetic basis of crop produc                 | tivity  | A STATE OF THE STA | 1   | 85                       | 75                      |                       | Н                | М                                | L                         | М                 | M         | M                            |                  |              | 4                                | Н         |         | Н      | Н       |
| CLO-2            | : Anal   | yze the tools for crop improvement                   |   |  | 2   | 90                       | 80                      |                       | Н                | М                                | L                         | М                 | М         |                              |                  |              | 4                                | Н         | Ή       |        | Н       |
| CLO-3            | Deve   | elop tolerance against abioti <mark>c stress</mark>  | The second of the second                            | CAROLINA STATE   | 2   | 75                       | 65                      |                       | М                | L                                | L                         | L                 | М         |                              |                  |              | 4                                | Н         | H       |        | Н       |
| CLO-4            | Deve   | elop tolerance against biotic stress                 |   | Section 1981   | 2   | 75                       | 65                      |                       | М                | L                                | L                         | L                 | M         | Μ                            |                  | M            | 4                                | Н         |         |        | Н       |
| CLO-5            |  | yze pathways to engineer v <mark>alue ado</mark>     | <mark>lit</mark> ion                                | THE PARTY OF THE P | 3   | 70                       | 60                      |                       | М                | L                                | L                         | L                 | М         | М                            |                  | M            | 4                                | Н         |         |        | Н       |
| CLO-6            | Deve   | elop elite cultivars                                 |   |  | 3   | 70                       | 60                      |                       | М                | L                                | L                         | Н                 | Н         | Н                            |                  | M            | 4                                | Н         | H       | Н      | Н       |
|                  |  |  | Charles and the second                              |  |   | - 11                     |                         |                       |                  |                                  |                           |                   |           |                              |                  |              |                                  |           |         |        |         |
| Duration         | on (hour)  | 9  | 9   | 9  |   |                          |                         |                       | 9                |                                  |                           |                   |           | <u> </u>                     |                  |              |                                  |           |         |        |         |
| S-1              |  | Traditional breeding                                 | Pest tolerance and agriculture sustainability       | Abiotic stress and agriculture sustain   | abili   | ty Ph                    | otosyn                  | thetic et             | ficien           | ісу                              |                           |                   |           | and                          | nt Meta<br>produ | cts          |                                  | vays      |         |        |         |
|                  |  | Methods of breeding                                  | Pathogens and insect pests                          | Major abiotic stresses   |   |                          |                         | n of pho              |                  | nthes                            | is                        |                   |           |                              | nals ca          |              |                                  |           |         |        |         |
| S-2              |  | Marker assisted breeding                             | Genetics of host-pathogen interactions              | Biochemical basis of abiotic stresses  | 3   |                          |                         | nd CAN                |                  |                                  |                           |                   |           |                              | abolic           |              |                                  |           |         |        | n       |
|                  | SLO-2  | Methods to generate markers                          | signal transduction                                 | signal transduction  |   | Мс                       | leculai                 | r control             | of pr            | notos                            | ynthe                     | sis               |           | Met                          | hods t           | o mod        | lify me                          | etabol    | ic pat  | hway   |         |
| S-3              | SLO-1  | Mutation breeding                                    | Virulence- Avirulence in host–pathogens interaction | drought, salinity  |   |                          |                         | l Nitroge             |                  |                                  |                           |                   |           | Sug                          | ar me            | tabolis      | sm                               |           |         |        |         |
|                  |  | Steps in mutation breeding                           | Molecular mechanism of virulence                    | Regulation of drought response   |   |                          |                         |                       | 1                | Amino acid pathway               |                           |                   |           |                              |                  |              |                                  |           |         |        |         |
| S-4              | SLO-1 transgenic technology Molecular strategies of pathogen tolerance |  |   | Temperature  |   |                          |                         |                       |                  | Vitamin A and carotenoid pathway |                           |                   |           |                              |                  |              |                                  |           |         |        |         |
| 0-7              | SLO-2  | Over expression and knock outs                       | Approaches against fungal pathogens                 | Regulation of temperature respose  |   |                          |                         | involve               |                  |                                  |                           |                   |           | vitamin A fortified rice     |                  |              |                                  |           |         |        |         |
|                  | SLO-1  | Loss of /Gain of function mutants                    | Approaches against bacterial pathogens              | Stress signal transduction   | Hormonal in plant growth and Fortified edible o |                          |                         |                       | oil              |                                  |                           |                   |           |                              |                  |              |                                  |           |         |        |         |

Stress signal transduction

Reactive oxygen species

Regulation of ROS

abiotic stress

response

Key transcriptional factors in stress

Molecular strategies for tolerance against

development

bacteria

Plant Growth Promoting bacteria

Phosphorus Solubilizing/Mobilizing

Molecular basis of P mobilization

Sucrose as a signaling molecule

Omega fatty acids

Secondary metabolites

antinutritional compounds

Industrially and medicinal metabolites

metabolic engineering to remove

SLO-1 Loss of /Gain of function mutants

SLO-2 Genetic screens

SLO-2 Genome editing

SLO-1 Zinc finger

SLO-1 RNAi

S-5

S-6

Approaches against bacterial pathogens

Molecular strategies of insect pest tolerance

Biological control of insect pests

Insect pest resistance

multi-gene pyramiding

| Duratio | on (hour) | 9                            | 9   | 9  | 9  | 9  |
|---------|-----------|------------------------------|---|--|--|--|
|         | SLO-2     | TALEN                        | Pathogenesis related proteins                         | calcium, nitric oxide and salicylic acid in plant defence      | Vesicular Arbuscular Mycorrhiza  | Phytates   |
|         | SLO-1     | CRISPR/Cas                   | Virus resistance                                      | synthesis and functions of proline                             | Microbes that mimics stress response                                   | Engineering to improve food digestibility                      |
| S-8     | SLO-2     | CRISPR/Cas mechanism         | Strategies of virus resistance                        | synthesis and functions of glycine betaine in stress tolerance | Nutrient translocation   | Engineering for aesthetic value                                |
| S-9     | SLO-1     | GMO                          | Molecular methods to generate virus resistance        | TROID OF DOLLDONE IN STASS TESTODISE                           | Applications of plant – beneficial microbe association                 | Applications of metabolic engineering in crop improvement      |
| 3-9     | SLO-2     | Regulation and Monitoring GM | Applications of genetic engineering in pest tolerance |  | Genetic engineering approaches to enhance plant growth and development | Applications of metabolic engineering in agricultural industry |

| Learning  | 1. | S. Mohan Jain and D.S. B <mark>rar Molecul</mark> ar Techniques in Crop Improvement 2 <sup>nd</sup> edition. 2010 Springer. ISBN 978-90-481-2966-9 e-ISBN 978-90- <mark>481-2967-</mark> 6 |
|-----------|----|--|
| Resources | 2. | Khalid Rehman Hakeem and Parvaiz Ahmad Munir Ozturk. 2013. Springer. Crop Improvement New Approaches and Modern Techniques. ISBN 978-1-4614-7027-4 ISBN 978-1-4614-7028-1                  |

| Learning Ass | essment                      |        |          |         | 157 / E 1                   | 777                |          |                         |                                  |                                   |          |  |
|--------------|------------------------------|--------|----------|---------|-----------------------------|--------------------|----------|-------------------------|----------------------------------|-----------------------------------|----------|--|
| _            | Dloom's                      |        |          | Contin  | uous Learning Ass           | essment (50% weigl | htage)   |                         |                                  | Final Examination (50% weightage) |          |  |
|              | Bloom's<br>Level of Thinking |        |          | CLA - 2 | CLA – 2 (15%) CLA – 3 (15%) |                    | CLA – 4  | · (1 <mark>0%</mark> )# | Final Examination (50% weightage |                                   |          |  |
|              | Level of Thinking            | Theory | Practice | Theory  | Practice                    | Theory             | Practice | Theory                  | Practice                         | Theory                            | Practice |  |
| Level 1      | Remember<br>Understand       | 40 %   | N-EN     | 30%     | 1165                        | 30%                | 15 3.00  | 30%                     |                                  | 30%                               | -        |  |
| Level 2      | Apply<br>Analyze             | 40 %   | - IN     | 40%     |                             | 40%                | The 'es  | 40%                     | -                                | 40%                               | -        |  |
| Level 3      | Evaluate<br>Create           | 20 %   |          | 30%     |                             | 30%                | - Figure | 30%                     |                                  | 30%                               | -        |  |
|              | Total                        | 100 %  |          | 100 %   |                             | 100 %              |          | 100                     | ) %                              | 100 %                             |          |  |

# CLA – 4 can be from any combination of these: Assignments, Seminars, Tech Talks, Mini-Projects, Case-Studies, Self-Study, MOOCs, Certifications, Conf. Paper etc.,

| Course Designers  |  |  |
|---|--|--|
| Experts from Industry   | Experts from Higher Technical Institutions                     | Internal Experts                                 |
| Dr. Florida Tilton, Biozone Research Technologies Pvt, Ltd, Chennai (floridatilton@gmail.com) | Dr. Ravindran, TNAU, Coimbatore, TN – (sivakasiravi@yahoo.com) | Dr. D. Rex Arunraj, SRM IST                      |
| 2. Dr. N. Ayyadurai, CLRI, Adyar, ayyadurai@clri.res.in                                       | Dr. Gopalakrishnan, IARI New Delhi – (krish.icar@gmail.com)    | 2 Dr. M.Ramya, SRM Inst. of Science & Technology |

| Course (   | Code  | 18BTE424T C   | Course Name   | MOLECULAR BIOLOGY OF   | INFECTIOUS DISEASES  |                            | Cours  | se Ca                         | tegory                | E                |           | F                          | rofess                    | sional           | Electi   | ve                    | <br>             | L 3                         | T<br>0        | P<br>0           | C<br>3            |
|--|---|---|---|--|--|----------------------------|--|-------------------------------|-----------------------|------------------|-----------|----------------------------|---------------------------|------------------|----------|-----------------------|------------------|-----------------------------|---------------|------------------|-------------------|
| Course C   |   | equisite Courses Department   | 18BTC10   |  | Nil Data Book / Codes/Standards  |                            |  | Pro<br>Nil                    | ogress                | sive Co          | ourses    | s Nil                      |                           |                  |          |                       |                  |                             |               |                  |                   |
| Course L<br>(CLR):<br>CLR-1:   | State t   | the basics of infectious  |   | - 1/1-1.   | MENCE  | Le<br>1                    | earning 2 3  |                               | 1                     | 2                | 3         |                            | ogram                     | _                | ing O    |                       | `                | PLO)                        | 2   13        | 14               | 15                |
| CLR-2 :<br>CLR-3 :<br>CLR-4:<br>CLR-5:<br>CLR-6:                     | Discus<br>Explaid<br>Illustra<br>Recog          | ss molecular pathogenes<br>ss molecular pathogenes<br>n molecular pathogenes<br>te the molecular pathog<br>nize defense mechanism | sis of viral dise<br>is of parasit <mark>ic</mark><br>enesis of f <mark>ung</mark>                      | a <mark>ses<br/>and fung</mark> al diseases<br><mark>al path</mark> ogens                                  |  | of Thinking (Bloom)        | Expected Proficiency (%) Expected Attainment (%)   | į                             | Engineering Knowledge | Problem Analysis | & Develop | Analysis, Design, Research | Society & Culture         | ⊆                |          | ndividual & Team Work | Communication    | Project Mgt. & Finance      | ang Leaning   | 2                | -3                |
| Course L<br>(CLO):<br>CLO-1:<br>CLO-2:<br>CLO-3:<br>CLO-4:<br>CLO-5: | Descri<br>Investi<br>Investi<br>Exami<br>Explai |   | lar pathology ogenesis of ba<br>ogenesis of vir<br>ogenesis of vir<br>renesis of para<br>nesis of funga | ral pathogens<br>sitic diseases<br>I infections  |  | 1<br>2<br>2<br>2<br>2<br>3 | 80 75<br>80 75<br>80 75<br>80 70<br>85 75<br>90 80 |                               | M<br>M<br>M<br>M      | M<br>M<br>M<br>M | M M M M M | M H M H M H M H M H        | H H H Society             | H<br>H<br>H<br>H | M HEHICS | M M M M M             | L<br>L<br>L<br>L | L H L H M H M H             | H H H H H H H | H<br>H<br>H<br>H | - OSA H H M H H H |
| CLO-0.   | Necai   | Title detelise mechanisi  | ns of imedious  | Similitiones   |  | 3                          | 90   00  |                               | IVI                   | IVI              | IVI       | IVI I                      | 1   11                    | 11               | IVI      | IVI                   |                  | IVI I                       | 1   11        | 111              |                   |
| Duration   | (hour)  | 9   |   | 9  | 9  | 1                          |  |                               |                       |                  | 9         |                            |                           |                  |          |                       |                  | 9                           |               |                  |                   |
| S-1  | SLO-1   | Historical perspective o<br>diseases  | f infe <mark>ctious</mark>  | Morphology, pathogenicity of Cholera   | Morphology, pathogenicity of HIV   |                            | Morph  | , i                           |                       |                  |           | Malari                     | а                         |                  |          |                       |                  | mune s                      |               |                  |                   |
| 6.3  | SLO-2<br>SLO-1<br>SLO-2                         | Disease outbreak Microbial Toxins Types of microbial toxir  | 18  | Molecular biology of Cholera  Morphology, pathogenicity of Tuberculosis  Molecular biology of Tuberculosis | Molecular biology of AIDS virus  Morphology and lifecycle of Dengue  Molecular biology of Dengue | )                          | Moled<br>Morph<br>Moled                            | nology                        | y and i               | lifecyc          | le of V   |                            | ereria l                  | bancro           | ofti An  | tibiot                | ic resi          | pe me<br>istance<br>resista | mech          |                  |                   |
|  | SLO-1   | Toxin assays  |   | Enteric fever causes   | Morphology, pathogenicity of Rabies virus Morphology, transm<br>Leptospirosis                    |                            |  | nsmiss                        | ion, p                | athog            |           | s of                       | Ev                        | asior            | of ph    | nagocy                | tosis            |                             |               |                  |                   |
|  | SLO-2   | Toxin genes   |   | Molecular biology of Enteric Fever   | Molecular biology of Rabies  |                            | Molec  | ular b                        | piology               | of Le            | ptosp     | <mark>iros</mark> is       | osis Evasion mechanism of |                  |          | of ph                 | agocy            | osis                        |               |                  |                   |
| S-4 -  | SLO-1   | Water borne pathogens   | 3   | Morphology and pathogenesis of Shigella  | Structure and pathogenesis of Hepatitis  |                            |  |                               |                       |                  |           | Antigen Hyper variability  |                           |                  |          |                       |                  |                             |               |                  |                   |
|  |   | Air borne Pathogens   |   | Bacterial signals and cell responses during<br>Shigella entry into epithelial cells                        | Molecular biology of Hepatitis   |                            |  | Molecular biology of Syphilis |                       |                  |           | Antigenic shift and drift  |                           |                  |          |                       |                  |                             |               |                  |                   |
| 1 1  | $\alpha \alpha \alpha$                          | 0 - 11  |   | In a judate just a higher way of Touch a jet Touche  | Dette and a selection of a selfferness of an a   |                            | F  |                               |                       |                  |           |                            |                           |                  |          |                       | -I ·             |                             |               |                  |                   |

Pathogenesis of papilloma virus

Molecular biology of Flu virus

Molecular biology of cervical cancer

Morphology and pathogenesis of Flu virus

Morphology and pathogenesis of Polio

Fungal pathogens

Trypanosomia

Causes of Athletes foot

Molecular biology of Aspergillosis

Molecular biology of Athletes foot

Morphology, transmission, pathogenesis of

Secreted modulators

Interaction with Toll Like receptors

Interference with Cytokines

Complement pathway inhibition

Surface modulators

Insights into biology of Typhoid Toxin

Molecular biology of Gastric ulcer

Genetic and Molecular aspects of Helicobacter

Serovars of Salmonella

General disease symptoms - External Morphology and pathogenesis of botulism

SLO-1 Soil borne pathogens

SLO-2 Pathogens transmitted via animals

Mode of Entry of pathogens

Initiation of diseases

S-5

S-6

SLO-1

SLO-2

SLO-1

|     | SLO-2  | Disease symptoms - Internal        | Mode of action of botulism toxin          | Molecular biology of Polio virus                 | Molecular biology of Sleeping sickness    | Defense against competition      |
|-----|--------|------------------------------------|---|--|---|----------------------------------|
| S-8 | SLO-1  | Virulence factors – Cell bound     | Morphological identification methods      | Genetic screens to understand signaling pathways | Molecular biology of Amoebiasis           | Interfering with cell signaling  |
|     | SLO-2  | Virulence factors - secreted       | Culture based identification methods      | Virus culturing                                  | Molecular biology of Candidiasis          | Examples                         |
|     | QI O 1 | Virulence associated Genes         | Serologic diagnostic methods of bacterial | Serologic diagnostic methods of viral            | Serologic diagnostic methods of parasitic | Pathogen signaling to repress    |
| S-9 |        |                                    | diseases                                  |  |   | antimicrobial compound synthesis |
| 3-9 | SLo-2  | Plasmid borne virulence associated | Molecular diagnostic methods of bacterial | Molecular diagnostic methods of viral            | Molecular diagnostic methods of parasitic | Pathogen structural barriers     |
|     | JLU-Z  | genes                              | diseases                                  | diseases   | diseases                                  | r atriogeri structurai barriers  |

| Learning<br>Resources | <ol> <li>Peter Williams, Julian Ketley &amp; George Salmond, "Methods in Microbiology: Bacterial Pathogenesis, Vol. 27", Academic Press, 1998.</li> <li>Rajan.R., "Medical Microbiology", MJP Publishers, 1st edition, 2007.</li> </ol> |  |
|-----------------------|---|--|
|                       |   |  |

| Learning Asse | essment                |                    |          |               |                   | 100.00            |          |         |          |                                    |          |  |
|---------------|------------------------|--------------------|----------|---------------|-------------------|-------------------|----------|---------|----------|------------------------------------|----------|--|
|               | Bloom's                |                    |          | Contin        | uous Learning Ass | essment (50% weig | htage)   |         |          | Final Examination (50% weightage)  |          |  |
|               | Level of Thinking      | CLA – 1 (10%)      |          | CLA – 2 (15%) |                   | CLA – 3 (15%)     |          | CLA – 4 | (10%)#   | Final Examination (50 % weightage) |          |  |
|               | Level of Thinking      | Theory             | Practice | Theory        | Practice          | Theory            | Practice | Theory  | Practice | Theory                             | Practice |  |
| Level 1       | Remember<br>Understand | 4 <mark>0 %</mark> |          | 30%           | the second pro-   | 30%               |          | 30%     |          | 30%                                | -        |  |
| Level 2       | Apply<br>Analyze       | <mark>40 %</mark>  | 300      | 40%           |                   | 40%               | 1.6      | 40%     | -        | 40%                                | -        |  |
| Level 3       | Evaluate<br>Create     | 20 %               | 7-10     | 30%           |                   | 30%               | WEST C   | 30%     |          | 30%                                | -        |  |
|               | Total                  | tal 100 % 100 %    |          | %             | 100 %             |                   |          | ) %     | 100 %    |                                    |          |  |

<sup>#</sup> CLA – 4 can be from any combination of these: Assignments, Seminars, Tech Talks, Mini-Projects, Case-Studies, Self-Study, MOOCs, Certifications, Conf. Paper etc.,

| Course Designers  |   |                     |  |  |  |  |  |  |  |
|---|---|---------------------|--|--|--|--|--|--|--|
| Experts from Industry   | Experts from Higher Technical Institutions  | Internal Experts    |  |  |  |  |  |  |  |
| Dr.Ayyadurai , Scientist, CLRI , Chennai ayyadu <mark>rai@clri.r</mark> es.in | Dr. G. Mathan, Asst. Professor, Department of Biomedical science, Bharathidasan University, Trichy Email: mathan_cell@yahoo.com | Dr. M.Ramya, SRMIST |  |  |  |  |  |  |  |
| Shalini M, , Scientist I, ITC Lifescienes PVT LTD Email: shalubioc@gmail.com  | Dr. Nishad Fathima Principal scientist, CSIR-Central Leather Research Institute, Chennai Email: nishad.clri@gmail.com           | Dr.Rajnish , SRMIST |  |  |  |  |  |  |  |

| Cou<br>Co  |   | 18BTE425T                       | Course<br>Name                                | MOLECULAR DIAGNOSTIC                         | S Course Categor                         |   | Е  |                          |                  | Prof                 | fessio                     | nal E               | lective  |                                 |                          |               | L<br>3       | T 0          | P<br>0     | C 3        |
|--|---|---------------------------------|---|--|--|---|--|--------------------------|------------------|----------------------|----------------------------|---------------------|--|---------------------------------|--------------------------|---------------|--------------|--------------|------------|------------|
|  | Pre-regi  | uisite Courses                  | Nil   | Co-requisite Courses Nil                     | Progress                                 | ive C   | `nurses  | Nil                      |                  |                      |                            |                     |  |                                 |                          |               |              |              |            |            |
| Course   |   | Department                      | Biotechnology                                 |  | / Codes/Standards Nil                    | JIVC C  | 7001303  | 1 111                    |                  |                      |                            |                     |  |                                 |                          |               |              |              |            |            |
| Ocuro  | , chomig  | Dopartmont                      | Biotodimology                                 | Data Book                                    | 7 Codos Cidinadias 7411                  |   |  |                          |                  |                      |                            |                     |  |                                 |                          |               |              |              |            |            |
| Course<br>(CLR):                                   |   | g Rationale The                 | e purpose of learning this co                 | urse is to:                                  | TI NOT                                   | Le  | earning  |                          |                  |                      | F                          | rogra               | ım Lear  | ning C                          | utcon                    | nes (F        | PLO)         |              |            |            |
| CLR-1  |   |                                 | based methods for diagnos                     | i <mark>s of genetic d</mark> iseases        |  | 1   | 2 3  | 1                        | 2                | 3                    | 4                          | 5                   | 6 7  | 8                               | 9                        | 10            | 11           | 12 1         | 13   1     | 14 15      |
| CLR-2  |   | uss PCR based                   |   |  |  |   | 100  |                          |                  |                      | <u>_</u>                   |                     | .≥   | ۱-                              |                          |               |              |              |            |            |
| CLR-3  |   | uss diagnosis by                | DNA Sequencing                                | 41   |  | E   | 8 9  |                          | ,                |                      | arc                        |                     | lide   |                                 | ٧                        |               |              |              |            |            |
| CLR-4  | Expl  | ain about nucleid               | acid based diagnosi <mark>s of inf</mark>     | ectious diseases                             | - 11 m 1 m                               | 8   | y (9   |                          | Ď.               | ent                  | ese                        |                     | je.  |                                 | Vor                      |               | වූ           |              |            |            |
| CLR-5  |   |                                 | cal diagnosis of infe <mark>ctious di</mark>  |  |  | (B)   | enc  | d                        | S                | md                   | α.                         | age                 | e  |                                 | ٦<br>ا                   |               | Finance      | Б            |            |            |
| CLR-6  | Expl  | ain molecular me                | ethods for molecul <mark>ar diagnos</mark>    | stics  |  | ιĒ  | Proficiency (%)                                  | 2                        | lysi             | le le                | ign                        | US.                 | Culture<br>ant & Su                            |                                 | -ea                      | e e           | ⊗<br>E       | Ē            |            |            |
|  |   |                                 |   | S PROPERTY.                                  |  | of Thinking (Bloom)   | Expected Proficiency (%) Expected Attainment (%) | Froingering Knowledge    | Problem Analysis | Design & Development | Analysis, Design, Research | T Modern Tool Usage | Society & Culture Environment & Sustainability |                                 | ⊤ Individual & Team Work | Communication | t Mgt. 8     | ang Learning | - c        | .3         |
| (CLO):   |   |                                 | he end of this <mark>course, le</mark> arne   |  | 200                                      | Level   | Expected F                                       | Fnoing                   | Proble           | Design               | Analys                     | Moder               | Society & (                                    | Ethics                          | Individ                  |               | Project Mgt. |              | 084        | PSO -      |
| CLO-1  |   | loy hybridization               | based metho <mark>ds for dia</mark> gnos      | is of genetic diseases                       | A STAN STAN STAN STAN STAN STAN STAN STA | 2   | 75 70<br>80 75                                   |                          |                  | Н                    | Н                          |                     | H L  |                                 |                          |               |              |              | $H \mid I$ | $H \mid H$ |
|  | CLO-2: Apply PCR based diagnosis  |                                 |   |  |  |   |  |                          |                  | Н                    | Н                          | Н                   | H M  |                                 | Н                        |               |              |              |            | Н Н        |
| CLO-3 : Design diagnostic method by DNA Sequencing |   |                                 |   |  |  | 3   | 85 80  | N                        |                  | М                    | Н                          | Н                   | H M  |                                 | Н                        |               |              |              |            | Н Н        |
| CLO-4  |   |                                 | ised diagnos <mark>is of infec</mark> tious ( |  | White the same of the same of the same   | 2   | 80 75  | H                        |                  |                      | Н                          | Н                   | M H  |                                 |                          | Н             |              |              |            | Н Н        |
| CLO-5  |   |                                 | cal diagnosi <mark>s of infect</mark> ious d  |  | CALL OF THE PARTY                        | 3   | 85 75  |                          |                  | Н                    | Н                          | М                   | M H  |                                 | Н                        |               |              |              |            | Н Н        |
| CLO-6  | : Anal  | yze genetic and                 | infectious di <mark>seases th</mark> rough    | molecular methods                            | the second second                        | 2   | 80 75  | ] <u></u>                | Н                | Н                    | Н                          | L                   | M M  | М                               | Н                        | Н             | Н            | Н            | H I        | Н Н        |
| Durati   | on (hour)   |                                 | 9   | 9  | 9  |   |  | _                        | 9                | -                    |                            |                     |  |                                 |                          |               | 9            |              |            |            |
|  |   | Introduction to I               |   | Introduction to PCR based diagnostics        | Basics of DNA sequencing                 |   | Ribotypi   | na                       | 3                |                      |                            |                     | Δα   | glutina                         | tion to                  | ot. D         | •            | olo ma       | athod      | 1          |
| S-1  |   | Types of FISH                   | 1011  | End-point PCR                                | Mutation detection by sequencing         |   |  | ions of Ri               | hotyn            | ina                  |                            |                     |  | olicatio                        |                          |               |              |              |            |            |
|  |   | Interphase FISH                 | 4   | ARMS PCR based diagnostics                   | Genome wide association studies          |   |  | eld Gel E                |                  |                      | sis                        |                     |  | ISA's :                         |                          |               |              |              |            | 2.5        |
| S-2  |   | Metaphase FIS                   |   | Allele specific PCR                          | Application in Health care               |   |  | ion of PF                |                  | 311010               | 0,0                        |                     |  | plicatio                        |                          |               |              | o arre       |            |            |
| S-3  | SLO-1 Principles of Multicolor FISH Restriction fragment length polymorphism (RFLP) |                                 |   | Next generation sequencing                   |  |   | PCR for  |                          | nce fa           | actor                |                            | lmi                 | nunofi<br>d types                              | uores                           |                          |               | nciple       | , met        | hod        |            |
|  |   |                                 |   | Application in disease diagnosis             |  |   | ion and li                                       | mitatio                  | ns               |                      |                            |                     | olicatio                                       |                                 | mmui                     | noflu         | oresce       | ence         |            |            |
|  | SLO-1 Application of FISH Multiplex PCR   |                                 |   | Clinical exome sequencing                    |  |   | inase poi  |                          |                  | nplific              | ation                      |                     | stern  |                                 |                          |               |              |              |            |            |
| S-4  | SLO-2 Limitations of FISH  Applications of multiplex PCR                            |                                 |   | Application in Health care                   |  | Applicat<br>RPA   | ion and li                                       | mitatio                  | ns               |                      |                            |                     | olicatio                                       | on of V                         | Veste                    | ern bl        | ot           |              |            |            |
|  | SLO-1   | Principles of ae                | nomic hybridization                           | LAMP PCR                                     |  |   |  | cina for m               | ultidri          | ia res               | istant                     | mark                | ers Cli  | rs Clinical significance of HIV |                          |               |              |              |            |            |
| S-5  |   |                                 |   |  | Linkage analysis for disease diagnosis   |   |  | ions and                 |                  |                      |                            |                     | Ca   | se stu                          | dv: HI                   | V det         | ectio        | n .          |            |            |
| 0.5  | SLO-1 Introduction to DNA chips and Micro-arrays Multiplex ligation probe dependent |                                 |   | Marfan syndrome: Disease gene identification | DNA chips: Principle and method          |   |  | Case study: Tuberculosis |                  |                      |                            |                     |  |                                 |                          |               |              |              |            |            |
| S-6  | SLO-2   | Diagnostics bas<br>Micro-arrays | sed on DNA chips and                          | MLPA in disease diagnosis                    | Case study: Marfan syndrome              | Gene chips for mutation screening in virulence genes  Diagnosis and challen |  |                          |                  | enges                | S                          |                     |  |                                 |                          |               |              |              |            |            |
|  |   | Davin aviadrana                 |   | Dool time DCD                                | Custis fibussis                          |   | Cananat  |                          |                  |                      |                            |                     |  | 4                               |                          |               |              |              |            |            |

Case study: cystic fibrosis

Cystic fibrosis

Real time PCR

SLO-2 Case study: Diagnosis of Down syndrome Application in diagnosis

SLO-1 Down syndrome

Case study: MRSA,

Diagnosis of MRSA

Case study: Flu virus Diagnosis of Flu Virus

| Duration | on (hour) | 9  | 9  | 9   | 9                                    | 9                         |
|----------|-----------|--|--|---|--------------------------------------|---------------------------|
|          | SLO-1     | Digeorge syndrome                              | Sickel cell anaemia                          | Molecular aspects of diabetes                       | Case study: Vibrio cholerae          | Case study: Dengue        |
| S-8      |           | Case study: Diagnosis of Digeorge syndrome     | Case study: Diagnosis of Sickel cell anaemia | Case study: Diagnosis of diabetes                   | Diagnosis of Vibrio cholerae         | Diagnosis of Dengue virus |
|          | SLO-1     | Childhood leukemia                             | Duchenne muscular dystrophy                  | Dibetes: Disease gene identification                | Case study: Acinetobacter boumannii  | Case study: chikungunya   |
| S-9      | SLO-2     | Case study: Diagnosis of Childhood<br>leukemia |  | Clinical application of dibetes gene identification | Diagnosis of Acinetobacter boumannii | Diagnosis of chikungunya  |

| Learning  | 1. Gersen, Keagle, "The Principles of Clinical Cytogenetics" 3 <sup>rd</sup> edition - Springer-Verlag, Inc., 2013.   |
|-----------|---|
| Resources | 2. Donnai, Read, "New Clinical Genetics" 3 <sup>rd</sup> edition – Scion, Inc., 2015. 3. Tang, Statton, "Advanced Techniques in Diagnostic Microbiology" Springer, Inc., 2013 |
|           |   |

| Learning Ass | sessment               |        |          | 100     |                  |                    |          |         |          |                                   |                   |  |
|--------------|------------------------|--------|----------|---------|------------------|--------------------|----------|---------|----------|-----------------------------------|-------------------|--|
| _            | Dloom's                |        |          | Contin  | uous Learning As | sessment (50% weig | htage)   | 471     |          | Final Examination (50% weightage) |                   |  |
|              | Bloom's                | CLA –  | 1 (10%)  | CLA – 2 | (15%)            | CLA -              | 3 (15%)  | CLA – 4 | (10%)#   | Final Examinatio                  | n (50% weightage) |  |
|              | Level of Thinking      | Theory | Practice | Theory  | Practice         | Theory             | Practice | Theory  | Practice | Theory                            | Practice          |  |
| Level 1      | Remember<br>Understand | 40 %   |          | 30%     | Short min        | 30%                | 1        | 30%     | Tale.    | 30%                               | -                 |  |
| Level 2      | Apply<br>Analyze       | 40 %   | N-EN     | 40%     | 160              | 40%                | 15 3.00  | 40%     |          | 40%                               | -                 |  |
| Level 3      | Evaluate<br>Create     | 20 %   | 3 10     | 30%     |                  | 30%                | the n    | 30%     | 11:      | 30%                               | -                 |  |
|              | Total                  | 10     | 0 %      | 100     | %                | 10                 | 0 %      | 100     | ) %      | 10                                | 0 %               |  |

<sup>#</sup> CLA – 4 can be from any combination of these: Assignments, Seminars, Tech Talks, Mini-Projects, Case-Studies, Self-Study, MOOCs, Certifications, Conf. Paper etc.,

| Course Designers   |  |   |
|--|--|---|
| Experts from Industry  | Experts from Higher Technical Institutions                         | Internal Experts  |
| Dr. Kalpana Gowrishankar, Apollo Hospital, Chennai gskalpana@yahoo.com | Dr. Solomon F.D. Paul, SRMC RI, Chennai paul@sriramachandra.edu.in | Dr. M. Jeevan Kumar, SRMIST jeevankm@srmist.edu.in          |
| Dr. Balamurugan Ramadass, AIIMS, Bhubaneswar balaramadass1@gmail.com   | Dr. V.Aravindhan, Dr ALM PG IBMS, Chennai cvaravindhan@gmail.com   | Dr. S. Iyappan <mark>, SRMIST</mark> iyappans@srmist.edu.in |

|                  | urse<br>ode     | 18BTE426T Course Name                           | GENE THER   | APY  | Cours |                  | Е                        |                          |                       |                  | Pi                   | ofess   | ional             | Elec                 | tive                         |        |             |               | ;              | L T               | - F  | ) 3        |
|------------------|-----------------|---|---|--|-------|------------------|--------------------------|--------------------------|-----------------------|------------------|----------------------|---|-------------------|----------------------|------------------------------|--------|-------------|---------------|----------------|-------------------|------|------------|
|                  | Pre-rea         | uisite Courses 18BTC105                         | 5J Co-requisite Courses N   | 1  | Prod  | aress            | ive C                    | ourses                   |                       | Nil              |                      |   |                   |                      |                              |        |             |               |                |                   |      |            |
| Course           |                 | Department Biotechno                            |   | ata Book / Codes/Standards   | Nil   |                  |                          |                          |                       |                  |                      |   |                   |                      |                              |        |             |               |                |                   |      |            |
|                  |                 |   |   | THE RESERVE OF THE PARTY OF THE |       |                  |                          |                          |                       |                  |                      |   |                   |                      |                              |        |             |               |                |                   |      |            |
| Course<br>(CLR): | e Learninç<br>: | Rationale The purpose of learn                  | ing this course is to:  | CONTRACT.  |       | Le               | arnin                    | g                        |                       |                  |                      | F   | Progr             | am L                 | .earni                       | ing Οι | ıtcon       | nes (         | PLO)           | ١                 |      |            |
| CLR-1            | : Prov          | ide basic knowledge on gene ther                | apy and its <mark>importance.</mark>                                    |  |       | 1                | 2                        | 3                        | 1                     | 2                | 3                    | 4   | 5                 | 6                    | 7                            | 8      | 9           | 10            | 11             | 12                | 13 1 | 14 15      |
| CLR-2            | : Iden          | tify an interest to know about the o            | different t <mark>ypes of gene</mark> therapy, its applications         | for diseases.  |       |                  |                          |                          |                       |                  |                      | Ч   |                   |                      | ity                          |        |             |               |                |                   |      |            |
| CLR-3            | : Deve          | elop awareness about the differen               | t metho <mark>ds of gene</mark> delivery and provide knowle             | edge on vectors.   |       | Ê                | (%                       | (9)                      |                       | ,                |                      | Analysis, Design, Research  |                   |                      | Environment & Sustainability |        | ~           |               |                |                   |      |            |
| CLR-4            |                 |   | gen <mark>ome editing</mark> and understand its application             | OS.  |       | 8                | )<br>(                   | t (%                     | 100                   | Š.               | ent                  | ese   |                   |                      | ä                            |        | Vor         |               | 92             |                   |      |            |
| CLR-5            |                 |   | se <mark>s of gene t</mark> herapy in treatment of disease.             |  |       | ) (B             | enc                      | ner                      | O'AV                  | 2                | , Lad                | 굣.  | age               | a                    | nst                          |        | Team Work   |               | Finance        | g                 |      |            |
| CLR-6            | i: Prep         | are engineering students to know                | the recent advancements in gene therapy.                                |  |       | Ĕ.               | ofici                    | ain                      | 70                    |                  | le le                | sign  | Us                | 草                    | ∞ ∞                          |        | ea_         | ы             | ω.<br>L        | Ē                 |      |            |
|                  |                 |   |   | A CALL TO A CALL   |       | Thinking (Bloom) | Pro                      | Att                      | 2                     | S L              | De                   | Des   | 00                | Culture              | ent                          |        | ∽           | cati          | gt.            | Les               |      |            |
|                  |                 |   |   |  |       | of T             | ted                      | ted                      | i.i.                  | 2 2              | ∞ ∞                  | Sis,  | n T               | ∞ >                  | 틸                            |        | la          | Ē             | Ţ              | gu                | ~ C  | 7 6        |
|                  |                 | Outcomes At the and of this cou                 | urse, learners will be able to:   | STATE OF THE STATE | 177.4 | evel             | Expected Proficiency (%) | Sec                      | Engineering Knowledge | Problem Analysis | Design & Development | alys  | Modern Tool Usage | Society &            | ķ.                           | Ethics | ndividual & | Communication | Project Mgt. & | ife Long Learning | o o  | ےٰ ا دٰ    |
| (CLO)            |                 |   |   |  |       |                  |                          | Sexpected Attainment (%) | LI LI                 | P                |                      |   | Mo                | So                   |                              |        | <u>pu</u>   |               | Pro            | _                 |      | PSO<br>PSO |
| CLO-1            |                 | y knowledge about gene thera <mark>py i</mark>  |   | Carlotte and the second  | 7.5   |                  |                          |                          | -                     | -                | Н                    | М   | -                 | -                    | М                            | Н      | -           | Η             | -              |                   |      | H H        |
| CLO-2            |                 |   | of gene therapy and its applications.                                   |  |       |                  |                          | 75                       |                       |                  |                      | М   | -                 | -                    | М                            | Н      | -           | Н             | -              |                   |      | H H        |
| CLO-3            |                 |   | viral vectors and usage of non-viral vectors to                         | correct the genetic defect.  |       |                  | 80                       | 70                       | ŀ                     |                  | Н                    | М   | -                 | -                    | М                            | Н      | -           | Н             | -              |                   |      | H H        |
| CLO-4            |                 | molecular aspects involved i <mark>n gen</mark> |   |  | 45-77 |                  | 80                       | 75                       | ŀ                     |                  | Н                    | М   | -                 | -                    | М                            | Н      | -           | Н             | -              |                   |      | H H        |
| CLO-5            |                 |   | ssed by gene therapy clinical trials.                                   | THE STATE OF THE S |       |                  | 80                       | 70                       | ŀ                     |                  | Н                    | М   | -                 | -                    | М                            | Н      | -           | Н             | -              |                   |      | H H        |
| CLO-6            | S:  Anal        | yze recent advancements in <mark>gene</mark>    | therapy.  | Contract to the latest the latest to the lat |       | 2                | 80                       | 70                       | ŀ                     | / <u>-</u>       | Н                    | М   | -                 | -                    | М                            | Η      | -           | Н             | -              | Н                 | H .  | H H        |
| F=               |                 |   | 23.757  | all the second second  | -     |                  | -                        |                          |                       | _#               |                      |   |                   |                      |                              |        |             |               |                |                   |      |            |
| Durati           | ion (hour)      | 9   | 9   | 9  | 4     | ш                |                          | 9                        |                       | - 74             |                      | 01  |                   |                      |                              |        | 9           | )             |                |                   |      |            |
| S-1              | SLO-1           | Introduction to Gene therapy                    | Embryo somatic gene therapy - Reproductive cloning                      | Gene delivery-An overview  |       |                  |                          | ng-Gen                   |                       |                  |                      | stem  | n cells           | s                    |                              |        |             |               |                |                   |      | poietio    |
|                  | SLO-2           | Genes as drugs                                  | Embryo somatic gene therapy - Therapeutic cloning                       | Methods of gene delivery   |       | nome<br>nd bro   |                          | ng Prod<br>epair         | esse                  | s-Dou            | ble                  | Hem   | natopo            | <mark>oi</mark> etic | Sten                         | n Cell | S           |               |                | e Tran            |      |            |
| 6.0              | SLO-1           | Gene therapy – overview                         | Preimplantation genetic diagnosis-History, Indications and applications | Direct Inoculation of DNAs   | Eng   | ineer            | ed N                     | uclease                  | es                    |                  |                      |   |                   |                      |                              |        |             |               |                | erapy<br>Gene     |      | ncer-      |
| S-2              | SLO-2           | History of Gene Therapy                         | Preimplantation genetic diagnosis –<br>Techniques and ethical issues    | Direct Inoculation of RNAs   | Meg   | ganuc            | lease                    | es                       | 4.                    |                  |                      |   |                   |                      |                              | Cance  |             |               |                |                   |      |            |
|                  | SLO-1           | Types of gene therapy-somatic                   | Prenatal/ fetal gene therapy – Concepts and methods                     | Non-viral methods-Physical methods   | Zinc  | Fing             | er N                     | uclease                  | s                     |                  |                      | Treatment of genetic diseases - neurodegenerati disorders- Gene Therapy of Alzheimer's Disease  |                   |                      |                              |        |             |               |                |                   |      |            |
| S-3              | SLO-2           | Types of gene therapy- germ line                | Prenatal/fetal gene therapy with case study  —Tay Sach's disease        | Non-viral methoods-Chenical methods  | s ZNF | s as             | gene                     | editing                  | tools                 |                  |                      | disorders- Gene Therapy of Alzheimer's Disorders-<br>Treatment of genetic diseases - neurodegen<br>disorders- Gene Therapy of Parkinson's Dis |                   |                      |                              | egene  | rative      |               |                |                   |      |            |

TALENs as gene editing tools

Introduction and Mechanism

**Applications** 

CRISPR/Cas9 as gene editing tools-

CRISPR/Cas9 as gene editing tools-

Gene Therapy of Huntington's Disease

transduction and the Visual Cycle

Gene Therapy of Spinal Muscular Dystrophy

Gene Treatment of genetic diseases - Retinal Photo

Viral Vectors - Retroviral vectors-

Retroviral vectors- Mechanism and

action Adenoviral vectors-Structure,

Adenoviral vectors-Structure, Mechanism

Structure

Mechanism

SLO-1 Methods of gene therapy-Ex vivo Postnatal somatic gene therapy

Methods of Germline gene therapy

SLO-2 Methods of gene therapy- In-vivo Germline gene therapy

SLO-1 Vectors for gene therapy-viral

S-4

S-5

| Duration | on (hour) | 9   | 9  | 9   | 9  | 9  |
|----------|-----------|---|--|---|--|--|
|          | SLO-2     | Vectors for gene therapy-non-<br>viral                            | Germline gene therapy-Drawbacks  | Adenoviral vectors- Advantages and disadvantages                | Precision and efficiency of engineered nucleases   | Gene Treatment of genetic diseases - Congenital Retinal degenerations              |
| S-6      | SLO-1     | Diseases with dominant heredity                                   | Suicide gene therapy – Current strategies  | Adeno associated viral vectors-Structure,<br>Mechanism          | Multiplex automated Genome engineering   | Gene Therapy of Retinal Neovascularization and Retinoblastoma                      |
| 3-0      | SLO-2     | Diseases with recessive heredity                                  | Suicide gene therapy for Cancer  | Adeno associated viral vectors-<br>Advantages and disadvantages | Types of therapeutic genome modifications- Gene disruption   | Treatment of genetic diseases - cardiovascular disorders-                          |
| S-7      |           | Ex vivo gene therapy with case study-SCID (Causes)                | Secretion gene therapy   | Herpes simplex viral vectors –Structure                         | Types of therapeutic genome<br>modifications- Non homologous end<br>joining - NHEJ gene correction | Gene Therapy of Heart Failure  |
| 3-1      | SLO-2     | Ex vivo gene therapy with case study-SCID (Treatment)             |  | Herpes simplex viral vectors –<br>Mechanism and Action          | Types of therapeutic genome modifications- Non homologous end joining - NHEJ gene addiction        | Therapeutic Angiogenesis   |
| S-8      | SLO-1     | In vivo gene therapy with case study- Cystic fibrosis (Causes)    | Gene therapy for infectious diseases-<br>Nucleic acid-based gene therapy (Antisense<br>DNA and RNA, Ribozymes, RNA decoys) | Envelope protein pseudo typing of viral vectors                 | Types of therapeutic genome<br>modifications - Homology directed<br>repair - HDR gene correction   | Gene therapy of HIV infection - Natural History of HIV-1 Infection                 |
| 3-0      |           | In vivo gene therapy with case study- Cystic fibrosis (Treatment) | Protein- based assays for gene therapy   | Replication-competent vectors                                   | Types of therapeutic genome<br>modifications - Homology directed<br>repair - HDR gene addition     | General Considerations Gene Therapy of HIV Infection by Intracellular Immunization |
| S-9      | SLO-1     | Ethical problems in gene the rapy                                 | Target pathogens for antimicrobial gene therapy  | Cis and trans-acting elements                                   | Applications of Genome editing   | The <mark>rapy of H</mark> IV Infection by Immunotherapy                           |
| 3-9      | SLO-2     | Social problems in gene the <mark>rapy</mark>                     | Examples of clinical trials for infectious diseases  | Hybrid vectors  | Prospects and Ilimitations of Genome editing   | Rec <mark>ent advan</mark> ces in gene therapy                                     |


| Learning  |  |
|-----------|--|
| Resources |  |
|           |  |

- 1. Evelyn B. Kelly, "Gene Therapy", Greenwood Press, 2007.
- Mauro Giacca, "Gene Therapy", Springer Milan, 2010.
   Peter J. Quesenberry, "Stem cell biology and gene therapy", John Wiley & Sons, 2002.
- 4. Roland W. Herzog, "A Guide to Human Gene Therapy", World Scientific Publishing Co Pvt. Ltd. 2010.
- 5. David Benjamin Turitz Cox et al "Therapeutic genome editing: prospects and challenges" Nature Medicine, Vol 21(2): 121- 131, 2015.

| Learning Asse | essment             |        | P.CA.    |        | 11/                 |                     |          | The same of |                       |                    |                   |
|---------------|---------------------|--------|----------|--------|---------------------|---------------------|----------|-------------|-----------------------|--------------------|-------------------|
|               | Bloom's             |        |          | Cont   | inuous Learning Ass | sessment (50% weigl | htage)   | 100         |                       | Final Examination  | (E00/ weightege)  |
|               | Level of Thinking   | CLA –  | 1 (10%)  | CLA –  | 2 (15%)             | CLA – :             | 3 (15%)  | CLA -       | <mark>4 (10%)#</mark> | Filiai Examination | i (50% weightage) |
|               | Level of Thirking   | Theory | Practice | Theory | Practice            | Theory              | Practice | Theory      | Practice              | Theory             | Practice          |
| Level 1       | Remember Understand | 40 %   | · 3      | 30%    | DV                  | 30%                 |          | 30%         | -                     | 30%                | -                 |
| Level 2       | Apply<br>Analyze    | 40 %   | . //     | 40%    | the Food            | 40%                 | END      | 40%         | -                     | 40%                |                   |
| Level 3       | Evaluate<br>Create  | 20 %   | -        | 30%    | -                   | 30%                 |          | 30%         | -                     | 30%                | -                 |
|               | Total               | 10     | 0 %      | 10     | 00 %                | 100                 | ) %      | 10          | 00 %                  | 100                | ) %               |

<sup>#</sup> CLA – 4 can be from any combination of these: Assignments, Seminars, Tech Talks, Mini-Projects, Case-Studies, Self-Study, MOOCs, Certifications, Conf. Paper etc.,

| Course Designers  |   |  |
|---|---|--|
| Experts from Industry   | Experts from Higher Technical Institutions  | Internal Experts                                 |
| Ms.Krutika Rajkumar, Life Cell, Senior Manager Corporate Communications       | Dr. Sachin Kumar, Department of Biosciences and Bioengineering, Indian Institute of | Dr. Devi. A, SRM Institute of Science Technology |
| krutika.r@lifecell.in   | Technology Guwahati, Guwahati 781039, Assam, India. sachinku@iitg.ac.in             | devia@srmist.edu.in                              |
| Dr.Sudha Warrier, Associate Professor, Manipal University, Manipal, School of | Dr. B.S.Lakshmi, Associate Professor, Anna University                               | Dr.Swapna Geetanjali A, SRMIST                   |
| Regenerative Medicine, sudha.warrier@manipal.edu                              | lakshmibs@annauniv.edu  | swapnaga@srmist.edu.in                           |



| Course Co            | ode 18BTE                      | Course Name  | FUNCTIONAL G                                 | ENOMICS  | (                         | Course Cat              | tegory                | Е                |                      | Pi                   | rofess            | siona  | l Elec          | tive                   |                  | L<br>3         | T<br>0      | P<br>0         | <u>C</u> |
|----------------------|--------------------------------|--|--|--|---------------------------|-------------------------|-----------------------|------------------|----------------------|----------------------|-------------------|--|-----------------|------------------------|------------------|----------------|-------------|----------------|----------|
|                      | Pre-requisite Co               | ourses Nil   | Co-requisite Courses                         | Nil  |                           |                         | Progr                 | avise            | Сош                  | 242                  | Ni                |  |                 |                        |                  |                |             |                |          |
| Course Off           | fering Department              |  | Co-requisite Courses                         | Data Book / Codes/Standards  |                           | Nil                     | i rogi                | 533110           | Coul                 | 303                  | INI               |  |                 |                        |                  |                |             |                |          |
| OGGIGG OII           | oring Doparation               | Biotodimology                                      |  | Bata Book / Codes/Ctaridards   |                           |                         |                       |                  |                      |                      |                   |  |                 |                        |                  |                |             |                |          |
| Course Lea<br>(CLR): | arning Rationale               | The purpose of learning this coul                  | rse is to:                                   | The North  | Lear                      | ning                    |                       |                  |                      | Pro                  | gram              | Lea  | rning           | Outco                  | mes (I           | PLO)           |             |                |          |
| CLR-1:               | Analyze the ge                 | nome structure, organization and                   | function across life.                        |  | 1 2                       | 3                       | 1                     | 2                | 3                    | 4 5                  | 5 6               | 7  | ' 8             | 9                      | 10               | 11             | 12   1      | 3 14           | 4 15     |
| CLR-2:               | Analyze about                  | the comparative genomics of orga                   | nelles and nuclear genomes across life       |  |                           |                         |                       |                  |                      | _                    |                   | į  | <u>-</u>        |                        |                  |                |             |                |          |
| CLR-3:               |                                |  | expression and whole transcriptome           |  | E 3                       |                         |                       |                  |                      | Kesearch             |                   | 3  |                 |                        |                  |                |             |                |          |
| CLR-4:               |                                | us NGS techniques to stu <mark>dy geno</mark>      |  | and the state of   | 100                       | (%)                     | dge                   |                  | aut                  | Sec                  |                   | 2.   | <u> </u>        | Į Š                    |                  | Finance        |             |                |          |
| CLR-5:               |                                | s of metabolic pathways, transcript                |  | E/0[745]   | <u>a</u>                  | i je                    | Ne Ne                 |                  | E I                  | 풀 (                  | ρ<br>Σ            | .   1  | non             | >                      |                  | ٦g             | Б           |                |          |
| CLR-6:               |                                | plications of functional genomics i                |  |  | ing                       | in                      | l ou                  | ysis             | elo                  | ug 2                 | D I               | 2 0  | 2               | ear                    | 드                | 這              | Ē           |                |          |
|                      |                                |  |  |  | Level of Thinking (Bloom) | Expected Attainment (%) | Engineering Knowledge | Problem Analysis | Design & Development | Analysis, Design, Re | Society & Culture | Coulon a Canal Course Course of Cour |                 | Individual & Team Work | Communication    | Project Mgt. & | ng Learning | -   -          | -3       |
| (CLO):               | arning Outcomes                | At the end of this <mark>course, le</mark> arner   |  |  | Level                     | Expect                  | Engine                | Proble           |                      |                      | Society           |  | Ethics<br>Range | Individ                | Comm             | Project        | Life Long I | - 089<br>- 089 | PSO      |
| CLO-1:               |                                | asics of genome o <mark>rganizatio</mark> n acro   |  | AL AND STATE OF STATE | 1 75                      |                         | М                     |                  |                      | H                    | 1                 |  |                 | Н                      |                  |                |             | 1 F            | H H      |
| CLO-2:               |                                | ienomics of organ <mark>elle and n</mark> uclear   |  |  | 1 75                      |                         | М                     |                  |                      | H F                  | 1                 |  |                 | Н                      |                  |                | H I         |                | Н Н      |
| CLO-3:               |                                |  | ssical methods to study gene expression      | The state of the s | 2 70                      |                         | М                     |                  |                      | H H                  | 1                 |  |                 | Н                      |                  |                | H I         |                | H H      |
| CLO-4:               | Describe about                 | t traditional and N <mark>ext Gene</mark> ration S | Sequencing (NGS)platforms for the study of g | genome, exome and transcriptome  | 2 60                      |                         | Н                     |                  |                      | H   H                | 1                 |  | Н               |                        |                  | Н              |             |                | H H      |
| CLO-5:               | Describe about                 | t genes for metab <mark>olic pathw</mark> ays, tra | anscription factors, genome editing.         | MINERAL BISELIN  | 3 70                      |                         | M                     | Н                | Н                    | H H                  | 1                 |  | Н               | Н                      |                  |                | H I         |                | Н Н      |
| CLO-6:               | Summarize the                  | applications of f <mark>unctional</mark> genomi    | cs in various sectors.                       |  | 3 60                      | 80                      | М                     | Н                | Н                    | H   H                | 1                 | ŀ  | l H             | Н                      |                  | Н              | H I         | 1 F            | H H      |
|                      |                                |  | Philippe Permit Hallen                       |  |                           |                         |                       |                  |                      |                      |                   |  |                 |                        |                  |                |             |                |          |
| Duration (           |                                | 9  | 9  | 9  |                           |                         |                       | 9                |                      |                      |                   |  |                 |                        |                  | 9              |             |                |          |
|                      |                                | rganization in Euk <mark>aryotes</mark>            | Genome size, gene content                    | Transcriptome from Eukaryotes  |                           | DNA Seq                 |                       |                  |                      |                      |                   |  |                 |                        | ne fun           |                |             |                |          |
| - ·   S              |                                | level organization                                 | Gene order                                   | Transcriptome from prokaryotes   |                           | Sanger n                |                       |                  |                      |                      | ing               |  |                 |                        | athway           |                | 3G          |                |          |
|                      | LO-1 Genome o                  | rganization in Euka <mark>ryotes</mark>            | Orthologs                                    | Gene expression studies with mR  | NA                        | Automate                | ed DNA                | Sequ             | ıenci <mark>r</mark> | ng                   |                   |  |                 |                        | า facto          |                |             |                |          |
| S-2 S                | LO-2 Sequence                  | level organization                                 | Paralogs                                     | Gene expression studies with oth   | er RNAs                   | Next Ger                | neration              | ı Sequ           | iencii               | ng (NO               | SS)               |  |                 |                        | scade<br>n facto |                | rolled      | by             |          |
| S-3                  | LO-1 Genome o                  | rganization in Prokaryot <mark>es</mark>           | Comparative genomics                         | Classical methods to study gene expression   |                           | Principle<br>Platforms  |                       | ethodo           | ology                | of NG                | S                 | (  | Genor           | ne edi                 | ting             |                |             |                |          |
|                      | LO-2 Sequence                  | level organization                                 | Comparative genomics of bacteria             | Northern hybridization   |                           | Principle<br>Platforms  |                       | ethodo           | ology                | of NG                | S                 | -  | Targe           | ed ge                  | nome             | Editin         | g           |                |          |
|                      | LO-1 Genetic ele               | ements and their organization in                   | Pangenome-metagenomics                       | Differential Display PCR   | EX                        | Third Gei               |                       | n Seq            | uenci                | ng me                | thods             | 3  | Fools           | for ge                 | nome             | editing        | 1           |                |          |
| S-4<br>S             | Genetic ele                    | ements and regulation of gene<br>n in eukaryotes   | Microbiome                                   | Serial Analysis of Gene Expression (SAGE)  | on                        | Comparis<br>sequenci    |                       | of<br>hods       |                      | gh-thr<br>pplica     |                   | out (  | CRISE           | PR/cas                 | 9 gen            | ome e          | diting      |                |          |
|                      | LO-1 Genetic ele<br>prokaryote | ements and their organization in                   | Horizontal gene transfer                     | Reverse transcriptase PCR (RT-<br>study gene expression  | PCR) to                   | Genome                  |                       |                  |                      | •                    |                   | (  | Genet           | ic vari                | ations           | and d          | isease      | es             |          |
| S-5 S                | Genetic ele                    | ements and regulation on gene<br>n in Prokaryotes  | Organelle genomes                            | Methodology of RT-PCR  |                           | Genome                  | assem                 | bly              |                      |                      |                   | 7  | Tools           | to stud                | dy mer           | ndeliai        | n disea     | ases           |          |
|                      | ,                              |  |  | Quantitative BCP (real time) to st   |                           |                         |                       |                  |                      |                      |                   |  |                 |                        |                  |                |             |                |          |

Quantitative PCR (real time) to study gene

Gene Prediction

Genomics of monogenic disorders

expression

Methods to study organelle genomes

SLO-1 Forward genetics

|     | SLO-2   | Classical Forward genetics                        | Comparative genomics of mitochondrial genomes | Methodology of realtime-PCR                      | High-throughput RNA sequencing                      | Genomics of polygenic disorders                    |
|-----|---------|---|---|--|---|--|
| S-7 | 1 O U-1 | Functional genomic analysis with Forward genetics | Comparative genomics of plastid genomes       | High-throughput methods to study gene expression | RNA sequencing to study genome wide gene expression | Genomics in Diagnostics                            |
| 5-7 | SLO-2   | Methods in Forward genetics                       | Nuclear genomes                               | Study of Gene expression using Microarray        | Differential gene expression analysis with RNAseq   | Population genetics                                |
| S-8 | SLO-1   | Reverse Genetics                                  | Comparative genomics of nuclear genomes       | Principle of Microarray                          | Small RNA sequencing                                | Evolutionary genetics                              |
| 5-0 |         | Functional genomic analysis with reverse genetics | Plant genomes                                 | Methodology of Microarray                        | Targeted sequencing                                 | Applications of functional genomics in agriculture |
|     | SLO-1   | Classical Methods in Reverse genetics             | Animal genomes                                | Study of splice variants                         | Exome sequencing                                    | Applications of functional genomics in healthcare  |
| S-9 | 1510-7  | Current methods in Forward and reverse genetics   | Comparison of plant and animal genomes        | Correlation of mRNA and protein abundance        | Amplicon sequencing                                 | Applications of functional genomics in prokaryotes |

| Lograina              | 1. Pevsner. J., "Bioinformatics and Functional Genomics", 3rd edition, Wiley-Blackwell. 2015.                                  |  |
|-----------------------|--|--|
| Learning<br>Resources | 2. Mount. D, "Bioinformatics: Sequence and Genome Analysis", 2nd Edition, Cold Spring Harbor Laboratory Press, New York. 2004. |  |
| Resources             | 3. Primrose. S.B., Twayman. R.M., "Principles of Gene Manipulation and Genomics" 7th edition, Blackwell publishing. 2006.      |  |

| Learning Ass | essment           |        | 1000     | 100    |                         | Contract of the   | - THE ST.         | 7         |                  |                   |                   |
|--------------|-------------------|--------|----------|--------|-------------------------|-------------------|-------------------|-----------|------------------|-------------------|-------------------|
|              | Dia am'a          |        | 4 :- 1   | Conti  | nuous Learning Ass      | essment (50% weig | htage)            | All Marie |                  | Final Examination | n (FOO) waightaga |
|              | Bloom's           | CLA -  | 1 (10%)  | CLA -  | 2 (15%)                 | CLA -             | 3 (15%)           | CLA – 4   | I (10%)#         | Final Examinatio  | n (50% weightage) |
|              | Level of Thinking | Theory | Practice | Theory | Practice                | Theory            | Practice          | Theory    | Practice         | Theory            | Practice          |
| Level 1      | Remember          | 40 %   |          | 30%    | 1000                    | 30%               |                   | 30%       |                  | 30%               |                   |
| Level I      | Understand        | 40 /0  | -        | 3078   | the same of the same of | 3070              | 5-11-11-1         | 3070      |                  | 3070              | -                 |
| Level 2      | Apply             | 40 %   |          | 40%    |                         | 40%               | The second second | 40%       |                  | 40%               | _                 |
| LCVCI Z      | Analyze           | 40 70  | 100      | 4070   |                         | 4070              |                   | 4070      |                  | 7070              |                   |
| Level 3      | Evaluate          | 20 %   | 1        | 30%    |                         | 30%               |                   | 30%       |                  | 30%               |                   |
| Level 3      | Create            | 20 /0  | -7. X    | 30 /0  |                         | 30 /6             | -                 | 3070      |                  | 30 /0             | -                 |
|              | Total             | 10     | 0 %      | 10     | 0 %                     | 100               | 0 %               | 100       | 0 <mark>%</mark> | 10                | 00 %              |

<sup>#</sup> CLA – 4 can be from any combination of these: Assignments, Seminars, Tech Talks, Mini-Projects, Case-Studies, Self-Study, MOOCs, Certifications, Conf. Paper etc.,

| Course Designers  |  |                              |
|---|--|------------------------------|
| Experts from Industry   | Experts from Higher Technical Institutions   | Internal Experts             |
| Dr. V.L.Ramprasad, MedGenome Labs Ltd, Bengaluru ramprasadv@medgenome.com | Dr. S. Mahalingam,Indian Institute of Technology Madras, Chennai mahalingam@iitm.ac.in     | Dr. N. Purushothaman, SRMIST |
| Dr. N. Mathan, Allianz Biosciences (P) Ltd, Puducherry nm@abpl.co.in      | Dr. M. Raveendran, Tamil Nadu Agricultural University, Coimbatore raveendrantnau@gmail.com | Dr. P. Senthilkumar, SRMIST  |

| Course<br>Code                                 | 1881-4781   | Course<br>Name  | PLANT INTERACT   | IONS                        | Course<br>Category  | Е                        |                          |                         |                       | F                | Profes   | sional  | Electiv  | /e     |        |                        |                                      | L<br>3     | T<br>0  | P C 0 3 |
|--|---|---|--|-----------------------------|---------------------|--------------------------|--------------------------|-------------------------|-----------------------|------------------|----------|---|----------|--------|--------|------------------------|--------------------------------------|------------|---------|---------|
| F  | Pre-requisite Courses   | 18BTC108J   | Co-requisite Courses /   | Vil                         | Progre              | ssive                    | Course                   | Nil                     |                       |                  |          |   |          |        |        |                        |                                      |            |         |         |
|  | Offering Department   | Biotechnology   |  | Data Book / Codes/Standards | Nil                 |                          |                          |                         |                       |                  |          |   |          |        |        |                        |                                      |            |         |         |
| Course L<br>(CLR):                             | earning Rationale The   | e purpose of learning this co   | urse is to:  | SCH                         | $O_{F_{\alpha}}$    | Le                       | earning                  |                         |                       |                  |          | Pro   | gram l   | Learni | ng Ou  | ıtcome                 | es (PL                               | <b>O</b> ) |         |         |
| CLR-1:   | Relate the signaling  | mechanisms in the develop   | o <mark>ment of a pla</mark> nt's root, shoot, leaf  | and flower                  |                     | 1                        | 2 3                      | 3                       | 1                     | 2                | 3        | 4 5   | 6        | 7      | 8      | 9 ′                    | 10 1                                 | 12         | 13      | 14 15   |
| CLR-2:<br>CLR-3:<br>CLR-4:<br>CLR-5:<br>CLR-6: | Explain the mechar Discuss about hype Relate the role of pl Recognize the effor | nisms in plant-microbe in <mark>tera</mark><br>Praccumulators, heavy <mark>metal</mark><br>Prytochemicals in pla <mark>nts beh</mark> a | uli and day-night cycle (circadian r<br>ction, biotic and abiotic stresses<br>tolerance and phytoremediation<br>avior and in facilitating plants grow<br>r their survival and avoidance of s<br>ers will be able to: | rth                         |                     | evel of Thinking (Bloom) | Expected Proficiency (%) | Aperied Attailment (70) | Engineering Knowledge | Problem Analysis | Develop  | Analysis, Design, Research<br>Modern Tool Usage | & Cultur | Ĕ      | Ethics | Individual & Team Work | Communication  Project Met & Finance | ਲੂ ।       | PSO - 1 | PSO - 2 |
| CLO-1:   | Describe the perce  | ption and res <mark>ponses of</mark> plan   | ts to environmental stimuli and str  | ess cues                    | ***                 | 2                        | 85 8                     |                         | М                     | H                |          | M M   | M        | М      | H      |                        | H                                    |            | H       | HH      |
| CLO-2:   | Design transgenic p   | plants (GMOs <mark>) for biotic</mark> and  | abiotic stress tolerance   |                             |                     | 3                        | 85 8                     |                         | М                     | Н                |          | H H   |          | Н      | Н      |                        | H F                                  |            | Н       | H H     |
| CLO-3:   |   | se plasticity f <mark>or improv</mark> ed pro   |  |                             | ST CONTRACT         | 3                        |                          | 5                       | М                     | Н                |          | H H   |          | Н      | Н      |                        | H E                                  |            | Н       | H H     |
| CLO-4:   |   |   | ves and other plants for nutrients a   | and sunlight                | A 15 - 45 - 55      | 2                        | 75 7                     | 0                       | М                     | Н                |          | H H   |          | Н      | Н      |                        | H F                                  |            | Н       | H H     |
| CLO-5:   |   | ts of intercro <mark>pping and</mark> crop  |  |                             | and the same        | 2                        | 80 7                     |                         | М                     | Н                |          | H H   |          |        |        |                        | H F                                  |            | Н       | H H     |
| CLO-6:   | Recall what a plant   | does in the course of its life  | time for better growth and product   | ivity                       |                     | 3                        | 80 7                     | 5                       | М                     | Н                | Н        | H H   | H        | Н      | Н      | М                      | H E                                  | H          | Н       | H H     |
| Duration                                       | (hour)  | 9   | 9  |                             | 9                   |                          |                          |                         |                       | 9                | -        |   |          |        |        |                        | 9                                    |            |         |         |
|  | ` '   | iology of plant <mark>s-an over</mark> view   | Plant response to physical and lig<br>stimuli-an overview  | ght Plant-microbe inter     |                     | w                        | Plant<br>overv           |                         | tion to               |                  | tic stre | es <mark>ses</mark> -A                          | An       | Plan   | t-plan | t inter                | action                               |            |         |         |
|  | SLO-2 Signal transduc   | tion using G pr <mark>oteins</mark>   | Response to gravity-gravitropism   | Plant growth promo          | oting rhizobacteriu | ım                       |                          | ologica                 |                       | moled            | ular r   | e <mark>sp</mark> ons                           | e of     | Plan   | t plas | ticity                 |                                      |            |         |         |

| Durati | on (hour) | 9   | 9  | 9                                  | 9                                  | 9   |
|--------|-----------|---|--|------------------------------------|------------------------------------|---|
| S-7    | SLO-1     | Parts of a monoecious and dioecious flower          | Circadian clock                          | Plant immunity                     | Hyperaccumulators                  | Shoot competition                                   |
|        | SLO-2     | ABC model for flowering-florigenesis                | Molecular mechanisms of light perception | Physical barriers                  | Phytoremediation Phytoremediation  | Root competition                                    |
|        | SLO-1     | Natural fertilization                               | TOC1, LHY and CCA genes                  | Systemic acquired resistance (SAR) | Phenotypic plasticity              | Shade avoidance                                     |
| S-8    | SLO-2     | Artificial fertilization-apomixis and parthenocarpy | Model of circadian clock in Arabidopsis  | Hormones in SAR                    | Root plasticity                    | Effect of phytochromes                              |
| S-9    | SLO-1     | Hormones in seed dormancy                           | Short day plants                         | Induced systemic resistance (ISR)  | Soil physical constraints          | Neighbor signaling as a warning to biotic stresses  |
| 3-9    | SLO-2     | Hormones in seed germination                        | Long day plants                          | Hormones in ISR                    | Plant growth in non-conducive soil | Neighbor signaling as a warning to abiotic stresses |

| Learning  | <ol> <li>Plant Environment Interactions, Sec</li> </ol> | ond edition, by Robert E. Wilkinson | ., Marcel Dekker, Inc., 2000. |
|-----------|---|-------------------------------------|-------------------------------|
| Resources | 2 Principles of plant microbe interaction               | ns by Ben Lugtenberg Springer 2     | 2015                          |

| Learning Ass | essment                |               |          | / PAYOR  | A1. W 130 | 1 1700        |          |                                   |          |                                   |          |
|--------------|------------------------|---------------|----------|--|-----------|---------------|----------|-----------------------------------|----------|-----------------------------------|----------|
|              | Bloom's                |               |          | Continuous Learning Assessment (50% weightage) |           |               |          | Final Examination (F0% weightegs) |          |                                   |          |
|              | Level of Thinking      | CLA – 1 (10%) |          | CLA – 2 (15%)                                  |           | CLA – 3 (15%) |          | CLA – 4 (10%)#                    |          | Final Examination (50% weightage) |          |
|              |                        | Theory        | Practice | Theory   | Practice  | Theory        | Practice | Theory                            | Practice | Theory                            | Practice |
| Level 1      | Remember<br>Understand | 40 %          |          | 30%  |           | 30%           | - NA     | 30%                               |          | 30%                               | -        |
| Level 2      | Apply<br>Analyze       | 40 %          | Z . E    | 40%  |           | 40%           | MES. G   | 40%                               |          | 40%                               | -        |
| Level 3      | Evaluate<br>Create     | 20 %          |          | 30%  |           | 30%           |          | 30%                               |          | 30%                               | -        |
|              | Total                  | 10            | 00 %     | 100  | %         | 10            | 0 %      | 100                               | %        | 10                                | 0 %      |

<sup>#</sup> CLA – 4 can be from any combination of these: Assignments, Seminars, Tech Talks, Mini-Projects, Case-Studies, Self-Study, MOOCs, Certifications, Conf. Paper etc.,

| Course Designers  | The state of the s |   |
|---|--|---|
| Experts from Industry   | Experts from Higher Technical Institutions   | Internal Experts  |
| Dr. P. Sadasivam, Scientist, Du Pont Industrial biosciences, Hyderabad sadha_pbg@yahoo.co.in    | Dr. Sivaprakash Ramalingam, Scientist, IGIB, New Delhi sivaprakash.ramalingam@gmail.com  | Dr. B. Usha, Associate Professor, SRMIST sundaram.usha@gmail.com                  |
| Dr. M. Harikrishnan, Scientist, Pondicherry Biotech Pvt. Ltd, Pondicherry sriharish.m@gmail.com | Prof. Raveendran, Professor, TNAU, TamilNadu raveendrantnau@gmail.com  | Dr. A. Swapna Geetanjali, Associate Professor, SRMIST swapna.geetanjali@gmail.com |